Download Document

1. Effect of Anticoagulation on Hospitalization Costs After Intracranial Hemorrhage in Atrial
Fibrillation: A Registry Study.
Vestergaard AS, Skjøth F, Lip GY, Larsen TB.
Stroke. 2016 Feb 16. pii: STROKEAHA.115.012338. [Epub ahead of print]
2. Diabetes mellitus and risk of ischemic stroke in patients with heart failure and no atrial fibrillation.
Melgaard L, Gorst-Rasmussen A, Søgaard P, Rasmussen LH, Lip GY, Larsen TB.
Int J Cardiol. 2016 Feb 3;209:1-6. doi: 10.1016/j.ijcard.2016.02.004. [Epub ahead of print]
3. Stroke prevention in atrial fibrillation and 'real world' adherence to guidelines in the Balkan
Region: The BALKAN-AF Survey.
Potpara TS, Dan GA, Trendafilova E, Goda A, Kusljugic Z, Manola S, Music L, Musetescu R, Badila E,
Mitic G, Paparisto V, Dimitrova ES, Polovina MM, Petranov SL, Djergo H, Loncar D, Bijedic A, Brusich
S, Lip GY; BALKAN-AF Investigators.
Sci Rep. 2016 Feb 12;6:20432. doi: 10.1038/srep20432.
4. EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation
of patients with atrial fibrillation.
Donal E, Lip GY, Galderisi M, Goette A, Shah D, Marwan M, Lederlin M, Mondillo S, Edvardsen T,
Sitges M, Grapsa J, Garbi M, Senior R, Gimelli A, Potpara TS, Van Gelder IC, Gorenek B, Mabo P,
Lancellotti P, Kuck KH, Popescu BA, Hindricks G, Habib G; Document Reviewers: For EACVI:, Cardim
NM, Cosyns B, Delgado V, Haugaa KH, Muraru D, Nieman K; For EHRA:, Boriani G, Cohen A.
Eur Heart J Cardiovasc Imaging. 2016 Feb 9. pii: jev354. [Epub ahead of print] Review.
5. Non-vitamin K oral anticoagulant drugs for stroke prevention in patients with atrial fibrillation and
chronic kidney disease.
Potpara TS, Jokic V, Dagres N, Larsen TB, Lane DA, Hindricks G, Lip GY.
Curr Med Chem. 2016 Feb 10. [Epub ahead of print].
6. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with
non-valvular atrial fibrillation: part 2.
Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, Ezekowitz MD, Granger CB,
Halperin JL, Hohnloser SH, Hylek EM, Kirchhof P, Lane DA, Verheugt FW, Veltkamp R, Lip GY.
Eur Heart J. 2016 Feb 4. pii: ehw069. [Epub ahead of print] Review.
7.Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with
non-valvular atrial fibrillation: part 1.
Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, Ezekowitz MD, Granger CB,
Halperin JL, Hohnloser SH, Hylek EM, Kirchhof P, Lane DA, Verheugt FW, Veltkamp R, Lip GY.
Eur Heart J. 2016 Feb 4. pii: ehv643. [Epub ahead of print] Review.
8.Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve
bioprosthesis. The Loire Valley Atrial Fibrillation Project.
Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Angoulvant D, Babuty D, Lip GY,
Fauchier L.
Thromb Haemost. 2016 Feb 4;115(5). [Epub ahead of print]
9.Atrial fibrillation and risk of stroke: a nationwide cohort study.
Christiansen CB, Gerds TA, Olesen JB, Kristensen SL, Lamberts M, Lip GY, Gislason GH, Køber L, TorpPedersen C. Europace. 2016 Feb 2. pii: euv401. [Epub ahead of print]
1
10.Monitoring the Effects and Antidotes of the Non-vitamin K Oral Anticoagulants.
Rahmat NA, Lip GY.
Arrhythm Electrophysiol Rev. 2015 Aug;4(2):90-5. doi: 10.15420/aer.2015.04.02.90.
11.Anticoagulant therapy after venous thromboembolism and 10-year mortality.
Larsen TB, Lip GY, Gorst-Rasmussen A.
Int J Cardiol. 2016 Jan 18;208:72-78. doi: 10.1016/j.ijcard.2016.01.190. [Epub ahead of print]
12.'Real-world' management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial
fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EORP-AF)
General Pilot Registry.
Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH, Dan GA, Kalarus Z,
Tavazzi L, Maggioni AP, Lip GY.
Europace. 2016 Jan 29. pii: euv390. [Epub ahead of print]
13.β-Blockers in Atrial Fibrillation Patients With or Without Heart Failure: Association With Mortality
in a Nationwide Cohort Study.
Nielsen PB, Larsen TB, Gorst-Rasmussen A, Skjøth F, Lip GY.
Circ Heart Fail. 2016 Feb;9(2):e002597. doi: 10.1161/CIRCHEARTFAILURE.115.002597.
14.The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE.
A real-life inception cohort study.
Palareti G, Antonucci E, Lip GY, Testa S, Guazzaloca G, Falanga A, Pengo V, Poli D; START-Register
Participants.
Thromb Haemost. 2016 Jan 28;115(6). [Epub ahead of print]
15.Relation of female sex to left atrial diameter and cardiovascular death in atrial fibrillation: The
AFFIRM Trial.
Proietti M, Raparelli V, Basili S, Olshansky B, Lip GY.
Int J Cardiol. 2016 Mar 15;207:258-63. doi: 10.1016/j.ijcard.2016.01.169. Epub 2016 Jan 11.
16.Pulmonary Embolism As a Consequence of Ultrasonographic Examination of Extremities for
Suspected Venous Thrombosis: A Systematic Review.
Mehdipoor G, Shabestari AA, Lip GY, Bikdeli B.
Semin Thromb Hemost. 2016 Jan 25. [Epub ahead of print]
17.Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart
Failure - Subanalysis of the WARCEF Trial.
Kato TS, Di Tullio MR, Qian M, Wu M, Thompson JL, Mann DL, Sacco RL, Pullicino PM, Freudenberger
RS, Teerlink JR, Graham S, Lip GY, Levin B, Mohr JP, Labovitz AJ, Estol CJ, Lok DJ, Ponikowski P, Anker
SD, Homma S; WARCEF Investigators. [Epub ahead of print]
Circ J. 2016 Jan 22.
18.CHA2DS2-VASc Score for Predicting Stroke and Thromboembolism in Patients With AF
and Biological Valve Prosthesis.
Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Angoulvant D, Babuty D, Lip GY,
Fauchier L.
J Am Coll Cardiol. 2016 Jan 26;67(3):343-4. doi: 10.1016/j.jacc.2015.10.061.No abstract available.
19.Authors' reply to Beales.
Staerk L, Lip GY.
2
BMJ. 2016 Jan 20;532:i266. doi: 10.1136/bmj.i266. No abstract available.
20.Heart failure and risk of venous thromboembolism: a systematic review and meta-analysis.
Tang L, Wu YY, Lip GY, Yin P, Hu Y.
Lancet Haematol. 2016 Jan;3(1):e30-44. doi: 10.1016/S2352-3026(15)00228-8. Epub 2015 Dec 4.
21. From clinical trials to real-world clinical practice: observations on the direct oral anticoagulants.
Lip GY.
Lancet Haematol. 2016 Jan;3(1):e2-3. doi: 10.1016/S2352-3026(15)00282-3. Epub 2015 Dec 8. No
abstract available.
22.Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with
cryptogenic stroke.
Diamantopoulos A, Sawyer LM, Lip GY, Witte KK, Reynolds MR, Fauchier L, Thijs V, Brown B, Quiroz
Angulo ME, Diener HC.
Int J Stroke. 2016 Jan 6. pii: 1747493015620803. [Epub ahead of print]
23.Long-Term Predictors of Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients
Undergoing Electrical Cardioversion.
García-Fernández A, Marín F, Roldán V, Gómez-Sansano JM, Hernández-Romero D, Valdés M,
Martinez-Martinez JG, Sogorb-Garri F, Lip GY.
Circ J. 2016 Jan 14. [Epub ahead of print]
24.Association of Smoking, Alcohol, and Obesity with Cardiovascular Death and Ischemic Stroke in
Atrial Fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study and Cardiovascular Health
Study (CHS).
Kwon Y, Norby FL, Jensen PN, Agarwal SK, Soliman EZ, Lip GY, Longstreth WT Jr, Alonso A, Heckbert
SR, Chen LY.
PLoS One. 2016 Jan 12;11(1):e0147065. doi: 10.1371/journal.pone.0147065. eCollection 2016.
25.Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and metaanalysis of randomized controlled trials.
Serban MC, Sahebkar A, Mikhailidis DP, Toth PP, Jones SR, Muntner P, Blaha MJ, Andrica F, Martin SS,
Borza C, Lip GY, Ray KK, Rysz J, Hazen SL, Banach M.
Sci Rep. 2016 Jan 12;6:19188. doi: 10.1038/srep19188.
26.Ankle-Brachial Index and cardiovascular events in atrial fibrillation. The ARAPACIS Study.
Violi F, Davì G, Proietti M, Pastori D, Hiatt WR, Corazza GR, Perticone F, Pignatelli P, Farcomeni A,
Vestri AR, Lip GY, Basili S; ARAPACIS (Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence
Assessment-Collaborative Italian Study) STUDY Investigators.
Thromb Haemost. 2016 Jan 7;115(4). [Epub ahead of print]
27. Volume and functional outcome of intracerebral hemorrhage according to oral anticoagulant
type.
Wilson D, Charidimou A, Shakeshaft C, Ambler G, White M, Cohen H, Yousry T, Al-Shahi Salman R,Lip
GY, Brown MM, Jäger HR, Werring DJ; CROMIS-2 collaborators.
Neurology. 2016 Jan 26;86(4):360-6. doi: 10.1212/WNL.0000000000002310. Epub 2015 Dec 30.
3
28.Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of
available evidence and recommendations for clinical management-a joint position paper of the
European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European
Society of Cardiology Working Group on Thrombosis.
Niessner A, Tamargo J, Morais J, Koller L, Wassmann S, Husted SE, Torp-Pedersen C, Kjeldsen K, Lewis
BS, Drexel H, Kaski JC, Atar D, Storey RF, Lip GY, Verheugt FW, Agewall S.
Eur Heart J. 2015 Dec 24. pii: ehv676. Epub ahead of print] Review. No abstract available.
29.Risk of Ischemic Stroke after Intracranial Hemorrhage in Patients with Atrial Fibrillation.
Lerario MP, Gialdini G, Lapidus DM, Shaw MM, Navi BB, Merkler AE, Lip GY, Healey JS, Kamel H.
PLoS One. 2015 Dec 23;10(12):e0145579. doi: 10.1371/journal.pone.0145579. eCollection 2015.
30. Editors' Choice 2015 papers in Thrombosis and Haemostasis.
Weber C, Lip GY.
Thromb Haemost. 2015 Dec 22;115(1):230-2. doi: 10.1160/TH15-11-0911. No abstract available.
31. May your New Year be happy and prosperous with "Thrombosis and Haemostasis".
Lip GY, Weber C.
Thromb Haemost. 2015 Dec 22;115(1):1-2. doi: 10.1160/TH15-11-0912. No abstract available.
32.Stroke prevention in atrial fibrillation: Where are we now?
Lip GY.
Indian Heart J. 2015 Dec;67 Suppl 2:S1-3. doi: 10.1016/j.ihj.2015.11.002. Epub 2015 Nov 28.
33. Switching from a vitamin K antagonist to a NOAC.
Senoo K, Lip GY.
Lancet Haematol. 2015 Apr;2(4):e132-3. doi: 10.1016/S2352-3026(15)00041-1. Epub 2015 Apr 1. No
abstract available.
34.Usefulness of the SAME-TT2R2 score to predict anticoagulation control on VKA in patients with
atrial fibrillation and obstructive sleep apnea.
Szymanski FM, Lip GY, Filipiak KJ, Platek AE, Karpinski G.
Int J Cardiol. 2016 Feb 1;204:200-5. doi: 10.1016/j.ijcard.2015.11.158. Epub 2015 Nov 23.
35.Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation:
Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient
subgroups.
Lip GY, Mitchell SA, Liu X, Liu LZ, Phatak H, Kachroo S, Batson S.
Int J Cardiol. 2016 Feb 1;204:88-94. doi: 10.1016/j.ijcard.2015.11.084. Epub 2015 Nov 17.
36.Difficult situations in anticoagulation after stroke: between Scylla and Charybdis.
Ntaios G, Lip GY.
Curr Opin Neurol. 2016 Feb;29(1):42-8. doi: 10.1097/WCO.0000000000000283.
37.The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review
and meta-analysis of randomised placebo-controlled trials.
Sahebkar A, Serban C, Ursoniu S, Mikhailidis DP, Undas A, Lip GY, Bittner V, Ray K, Watts GF, Hovingh
GK, Rysz J, Kastelein JJ, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC)
Group.
Thromb Haemost. 2015 Dec 3;115(3). [Epub ahead of print]
4
38.Body Mass Index and Adverse Outcomes in Elderly Patients With Atrial Fibrillation: The AMADEUS
Trial.
Senoo K, Lip GY.
Stroke. 2016 Feb;47(2):523-6. doi: 10.1161/STROKEAHA.115.011876. Epub 2015 Dec 1.
39. Antithrombotic management in patients with atrial fibrillation undergoing coronary stent
implantation: What is the impact of guideline adherence?
Ancedy Y, Lecoq C, Saint Etienne C, Ivanes F, Angoulvant D, Babuty D, Lip GY, Fauchier L.
Int J Cardiol. 2016 Jan 15;203:987-94. doi: 10.1016/j.ijcard.2015.11.090. Epub 2015 Nov 17.
40.Response to Letter Regarding Article, "Risk of Stroke in Chronic Heart Failure Patients Without
Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure
(CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart
Failure (GISSI-HF) Trials.".
Abdul-Rahim AH, Perez AC, Fulton RL, Jhund PS, Latini R, Tognoni G, Wikstrand J, Kjekshus J, Lip GY,
Maggioni AP, Tavazzi L, Lees KR, McMurray JJ.
Circulation. 2015 Dec 1;132(22):e358. doi: 10.1161/CIRCULATIONAHA.115.018395.No abstract
available.
41. Matching the NOAC to the Patient: Remember the Modifiable Bleeding Risk Factors.
Lip GY, Lane DA.
J Am Coll Cardiol. 2015 Dec 1;66(21):2282-4. doi: 10.1016/j.jacc.2015.07.086.No abstract available.
42. Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients
With Atrial Fibrillation and Recent Acute Heart Failure.
Andreu-Cayuelas JM, Pastor-Pérez FJ, Puche CM, Mateo-Martínez A, García-Alberola A, Flores-Blanco
PJ, Valdés M, Lip GY, Roldán V, Manzano-Fernández S.
Rev Esp Cardiol (Engl Ed). 2016 Feb;69(2):134-40. doi: 10.1016/j.rec.2015.06.021. Epub 2015 Oct 23.
43.Management of atrial fibrillation in specific patient populations.
Szymański FM, Lip GY, Filipiak KJ.
Kardiol Pol. 2016;74(1):1-8. doi: 10.5603/KP.a2015.0223. Epub 2015 Nov 24.
44. A decisional model to individualize warfarin recommendations: Expected impact on treatment
and outcome rates in a real-world population with atrial fibrillation.
Marcucci M, Skjøth F, Lip GY, Iorio A, Larsen TB.
Int J Cardiol. 2016 Jan 15;203:785-90. doi: 10.1016/j.ijcard.2015.11.035. Epub 2015 Nov 6.
45.From malignant hypertension to hypertension-MOD: a modern definition for an old but still
dangerous emergency.
Cremer A, Amraoui F, Lip GY, Morales E, Rubin S, Segura J, Van den Born BJ, Gosse P.
J Hum Hypertens. 2015 Nov 19. doi: 10.1038/jhh.2015.112. [Epub ahead of print] Review.
46. Atrial fibrillation and heart failure due to reduced versus preserved ejection fraction: A systematic
review and meta-analysis of death and adverse outcomes.
Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY.
Int J Cardiol. 2016 Jan 15;203:660-6. doi: 10.1016/j.ijcard.2015.10.220. Epub 2015 Oct 28.
47. Association between peripheral plasma markers and left atrial anatomy in patients with atrial
fibrillation.
Nedios S, Seewöster T, Lip GH, Husser D, Hindricks G, Bollmann A, Kornej J.
5
Int J Cardiol. 2016 Jan 15;203:621-3. doi: 10.1016/j.ijcard.2015.11.022. Epub 2015 Nov 10. No
abstract available.
48. Stroke and recurrent haemorrhage associated with antithrombotic treatment after
gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study.
Staerk L, Lip GY, Olesen JB, Fosbøl EL, Pallisgaard JL, Bonde AN, Gundlund A, Lindhardt TB, Hansen
ML, Torp-Pedersen C, Gislason GH.
BMJ. 2015 Nov 16;351:h5876. doi: 10.1136/bmj.h5876.
49. The SAMe-TT2R2 score and decision-making between a vitamin K antagonist or a non-vitamin K
antagonist oral anticoagulant in patients with atrial fibrillation.
Esteve-Pastor MA, Roldán V, Valdés M, Lip GY, Marín F.
Expert Rev Cardiovasc Ther. 2016 Feb;14(2):177-87. doi: 10.1586/14779072.2016.1116941. Epub
2015 Dec 9.
50. Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular
atrial fibrillation.
Dzeshka MS, Lip GY.
Expert Opin Pharmacother. 2015 Dec;16(17):2661-78. doi: 10.1517/14656566.2015.1104301.Epub
2015 Nov 11.
51. The first prognostic model for stroke and death in patients with systolic heart failure.
Freudenberger RS, Cheng B, Mann DL, Thompson JL, Sacco RL, Buchsbaum R, Sanford A, Pullicino PM,
Levin B, Teerlink JR, Graham S, Mohr JP, Labovitz AJ, Di Tullio MR, Lip GY, Estol CJ, Lok DJ, Ponikowski
P, Anker SD, Homma S; WARCEF Investigators.
J Cardiol. 2015 Nov 5. pii: S0914-5087(15)00309-3. doi: 10.1016/j.jjcc.2015.09.014. [Epub ahead of
print]
52. Intracerebral haemorrhage, atrial fibrillation, and anticoagulation.
Wilson D, Al-Shahi Salman R, Klijn CJ, Lip GY, Werring DJ.
Lancet. 2015 Oct 31;386(10005):1736-7. doi: 10.1016/S0140-6736(15)00695-9.
53. Predictors for Stroke and Death in Non-Anticoagulated Asian Patients with Atrial Fibrillation: The
Fushimi AF Registry.
Hamatani Y, Yamashita Y, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GY, Akao M.
PLoS One. 2015 Nov 5;10(11):e0142394. doi: 10.1371/journal.pone.0142394. eCollection 2015.
54. Polypharmacy and major adverse events in atrial fibrillation: observations from the AFFIRM trial.
Proietti M, Raparelli V, Olshansky B, Lip GY.
Clin Res Cardiol. 2015 Nov 2. [Epub ahead of print]
55. Reply to: "Inadequate anticoagulation by vitamin K antagonists and major adverse cardiovascular
events other than stroke".
Pastori D, Pignatelli P, Saliola M, Carnevale R, Vicario T, Cangemi R, Barillà F, Lip GY, Violi F.
Int J Cardiol. 2016 Jan 1;202:934-5. doi: 10.1016/j.ijcard.2015.10.122. Epub 2015 Oct 17. No abstract
available.
6
56. Incidence of Stroke or Systemic Embolism in Paroxysmal Versus Sustained Atrial Fibrillation: The
Fushimi Atrial Fibrillation Registry.
Takabayashi K, Hamatani Y, Yamashita Y, Takagi D, Unoki T, Ishii M, Iguchi M, Masunaga N, Ogawa H,
Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GY, Akao M.
Stroke. 2015 Dec;46(12):3354-61. doi: 10.1161/STROKEAHA.115.010947. Epub 2015 Oct 29.
57. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing
peritoneal dialysis.
Chan PH, Huang D, Yip PS, Hai J, Tse HF, Chan TM, Lip GY, Lo WK, Siu CW.
Europace. 2015 Oct 25. pii: euv289. [Epub ahead of print]
58. An update on atrial fibrillation: focus on stroke risk reduction strategies.
Potpara T, Jokic V, Medic B, Prostran M, Lip G.
Minerva Med. 2015 Oct;106(5):259-273. Epub 2015 Oct 23.
59. Evaluation of the HAS-BLED, ATRIA and ORBIT bleeding risk scores in atrial fibrillation patients on
warfarin.
Senoo K, Proietti M, Lane DA, Lip GY.
Am J Med. 2015 Oct 16. pii: S0002-9343(15)00926-2. doi: 10.1016/j.amjmed.2015.10.001. [Epub
ahead of print]
60. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth
Atrial Fibrillation Network/European Heart Rhythm Association consensus conference.
Kirchhof P, Breithardt G, Bax J, Benninger G, Blomstrom-Lundqvist C, Boriani G, Brandes A, Brown H,
Brueckmann M, Calkins H, Calvert M, Christoffels V, Crijns H, Dobrev D, Ellinor P, Fabritz L, Fetsch T,
Freedman SB, Gerth A, Goette A, Guasch E, Hack G, Haegeli L, Hatem S, Haeusler KG, Heidbüchel H,
Heinrich-Nols J, Hidden-Lucet F, Hindricks G, Juul-Möller S, Kääb S, Kappenberger L, Kespohl S,
Kotecha D, Lane DA, Leute A, Lewalter T, Meyer R, Mont L, Münzel F, Nabauer M, Nielsen JC, Oeff M,
Oldgren J, Oto A, Piccini JP, Pilmeyer A, Potpara T, Ravens U, Reinecke H, Rostock T, Rustige J,
Savelieva I, Schnabel R, Schotten U, Schwichtenberg L, Sinner MF, Steinbeck G, Stoll M, Tavazzi L,
Themistoclakis S, Tse HF, Van Gelder IC, Vardas PE, Varpula T, Vincent A, Werring D, Willems S,
Ziegler A, Lip GY, Camm AJ.
Europace. 2016 Jan;18(1):37-50. doi: 10.1093/europace/euv304. Epub 2015 Oct 18. Review.
61. Patterns in atrial fibrillation management and ‘real-world’ adherence to guidelines in the Balkan
Region: an overview of the Balkan–atrial fibrillation survey.
Potpara TS; Balkan-AF Investigators, Lip GY.
Eur Heart J. 2015 Aug 7;36(30):1943-4. No abstract available.
62. Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular
Atrial Fibrillation.
Lip GY, Lanitis T, Kongnakorn T, Phatak H, Chalkiadaki C, Liu X, Kuznik A, Lawrence J, Dorian P.
Clin Ther. 2015 Nov 1;37(11):2476-2488.e27. doi: 10.1016/j.clinthera.2015.09.005. Epub 2015 Oct 23.
63. Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score.
Pastori D, Farcomeni A, Poli D, Antonucci E, Angelico F, Del Ben M, Cangemi R, Tanzilli G, Lip GY,
Pignatelli P, Violi F.
Intern Emerg Med. 2015 Oct 15. [Epub ahead of print]
64. Relationship of Age With Stroke and Death in Anticoagulated Patients With Nonvalvular Atrial
Fibrillation: AMADEUS Trial.
7
Senoo K, Lip GY.
Stroke. 2015 Nov;46(11):3202-7. doi: 10.1161/STROKEAHA.115.010614. Epub 2015 Oct 13.
65. Oxidised LDL lipids, statins and a blood-brain barrier.
Griffiths H, Irundika D, Lip G, Spickett C, Polidori C.
Free Radic Biol Med. 2014 Oct;75 Suppl 1:S15-6. doi: 10.1016/j.freeradbiomed.2014.10.591. Epub
2014 Dec 10.
66. Stroke Risk Factors Beyond the CHA₂DS₂-VASc Score: Can We Improve Our Identification of "High
Stroke Risk" Patients With Atrial Fibrillation?
Szymanski FM, Lip GY, Filipiak KJ, Platek AE, Hrynkiewicz-Szymanska A, Opolski G.
Am J Cardiol. 2015 Dec 1;116(11):1781-8. doi: 10.1016/j.amjcard.2015.08.049. Epub 2014 Dec 10.
Review.
67. Preventing Thrombosis to Improve Outcomes in Heart Failure Patients.
Shantsila E, Lip GY.
Prog Cardiovasc Dis. 2015 Oct 1. pii: S0033-0620(15)30018-9. doi: 10.1016/j.pcad.2015.09.005. Epub
2015 Sep 11. Review.
68. CD4(+) T cell surface alpha enolase is lower in older adults.
Bennett SJ, Augustyniak EM, Dunston CR, Brown RA, Shantsila E, Lip GY, Torrao RD, Pararasa C,
Remtulla AH, Ladouce R, Friguet B, Griffiths HR.
Mech Ageing Dev. 2015 Dec;152:56-62. doi: 10.1016/j.mad.2015.09.005. Epub 2015 Oct 1.
69. Oral anticoagulation and the risk of stroke or death in patients with atrial fibrillation and one
additional stroke risk factor: the Loire Valley Atrial Fibrillation Project.
Fauchier L, Lecoq C, Clementy N, Bernard A, Angoulvant D, Ivanes F, Babuty D, Lip GY.
Chest. 2015 Oct 1. doi: 10.1378/chest.15-1622. [Epub ahead of print]
70. Assessing Bleeding Risk With the HAS-BLED Score: Balancing Simplicity, Practicality, and
Predictive Value in Bleeding-Risk Assessment.
Lip GY.
Clin Cardiol. 2015 Sep;38(9):562-4. doi: 10.1002/clc.22436.
71. Composite end point analyses of non-vitamin K antagonist oral anticoagulants compared with
warfarin in patients with atrial fibrillation.
Madzak A, Larsen TB, Lane DA, Lip GY, Nielsen PB.
Expert Rev Cardiovasc Ther. 2015 Oct;13(10):1155-63. doi: 10.1586/14779072.2015.1086643.
72. LDL-lipids from patients with hypercholesterolaemia and Alzheimer's disease are inflammatory to
microvascular endothelial cells: mitigation by statin intervention.
Dias HK, Brown CL, Polidori MC, Lip GY, Griffiths HR.
Clin Sci (Lond). 2015 Dec;129(12):1195-206. doi: 10.1042/CS20150351. Epub 2015 Sep 23.
73. Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in
patients with atrial fibrillation.
Pastori D, Pignatelli P, Farcomeni A, Cangemi R, Hiatt WR, Bartimoccia S, Nocella C, Vicario T, Bucci T,
Carnevale R, Lip GY, Violi F.
Am Heart J. 2015 Sep;170(3):490-7.e1. doi: 10.1016/j.ahj.2015.05.011. Epub 2015 May 22.
8
74. Age Threshold for Increased Stroke Risk Among Patients With Atrial Fibrillation: A Nationwide
Cohort Study From Taiwan.
Chao TF, Wang KL, Liu CJ, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Liao JN, Chen TJ, Chiang
CE, Lip GY, Chen SA.
J Am Coll Cardiol. 2015 Sep 22;66(12):1339-47. doi: 10.1016/j.jacc.2015.07.026.
75. Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population:
A modelling analysis based on a nationwide cohort study.
Blann AD, Banerjee A, Lane DA, Torp-Pedersen C, Lip GY.
Int J Cardiol. 2015 Dec 15;201:693-8. doi: 10.1016/j.ijcard.2015.08.07. Epub 2015 Aug 10.
76. The CHA₂DS₂-VASc score for stroke risk stratification in patients with atrial fibrillation: a brief
history.
Lip GY.
Eur Heart J. 2015 Nov 7;36(42):2880-5. No abstract available.
77. Recalibration of the HAS-BLED score - should haemorrhagic stroke account for 1 or 2 points?
Nielsen PB, Larsen TB, Lip GY.
Chest. 2015 Sep 10. doi: 10.1378/chest.15-1509. [Epub ahead of print]
78. Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in
patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of
observational studies.
Bavishi C, Koulova A, Bangalore S, Sawant A, Chatterjee S, Ather S, Valencia J, Sarafoff N, Rubboli A,
Airaksinen JK, Lip GY, Tamis-Holland JE.
Catheter Cardiovasc Interv. 2015 Sep 10. doi: 10.1002/ccd.26234. [Epub ahead of print]
79. Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical
application requires focus on the reversible bleeding risk factors.
Lip GY, Lane DA.
Eur Heart J. 2015 Dec 7;36(46):3265-7. doi: 10.1093/eurheartj/ehv415. Epub 2015 Sep 8. No abstract
available.
80. Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial
fibrillation and heart failure: a systemic review and meta-analysis of randomized trials.
Xiong Q, Lau YC, Senoo K, Lane DA, Hong K, Lip GY. Epub 2015 Sep 3.
Eur J Heart Fail. 2015 Nov;17(11):1192-200. doi: 10.1002/ejhf.343.
81. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of
the ISTH: comment.
Husted S, Lip GY, De Caterina R.
J Thromb Haemost. 2015 Nov;13(11):2130-2. doi: 10.1111/jth.13124. Epub 2015 Sep 30. No abstract
available.
82. Assessing Eligibility for Anticoagulation After Diagnosis of Atrial Fibrillation--Reply.
Lip GY, Lane DA.
JAMA. 2015 Sep 1;314(9):949-50. doi: 10.1001/jama.2015.8995. No abstract available.
83. Multiple risk factors and ischaemic stroke in the elderly Asian population with and without atrial
fibrillation. An analysis of 425,600 Chinese individuals without prior stroke.
Guo Y, Wang H, Tian Y, Wang Y, Lip GY.
9
Thromb Haemost. 2015 Dec 22;115(1):184-92. doi: 10.1160/TH15-07-0577. Epub 2015 Aug 31.
84. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic
treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot
Registry.
Lip GY, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA, Kalarus Z, Crijns HJ, Oliveira
MM, Tavazzi L, Maggioni AP, Boriani G.
Europace. 2015 Dec;17(12):1777-86. doi: 10.1093/europace/euv269. Epub 2015 Aug 31.
85. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and
controlled trial data.
Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, Steeds RP, Townend J, Kotecha D.
BMJ. 2015 Aug 30;351:h4451. doi: 10.1136/bmj.h4451. Review
86. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint
Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of
Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European
Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung
Transplantation (ISHLT).
Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk
Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P,
Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M, Aboyans V, Vaz Carneiro
A, Achenbach S, Agewall S, Allanore Y, Asteggiano R, Paolo Badano L, Albert Barberà J, Bouvaist H,
Bueno H, Byrne RA, Carerj S, Castro G, Erol Ç, Falk V, Funck-Brentano C, Gorenflo M, Granton J, Iung
B, Kiely DG, Kirchhof P, Kjellstrom B, Landmesser U, Lekakis J, Lionis C, Lip GY, Orfanos SE, Park MH,
Piepoli MF, Ponikowski P, Revel MP, Rigau D, Rosenkranz S, Völler H, Luis Zamorano J.
Eur Heart J. 2016 Jan 1;37(1):67-119. doi: 10.1093/eurheartj/ehv317. Epub 2015 Aug 29
87. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force
for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology
(ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS).
Adler Y, Charron P, Imazio M, Badano L, Barón-Esquivias G, Bogaert J, Brucato A, Gueret P, Klingel K,
Lionis C, Maisch B, Mayosi B, Pavie A, Ristić AD, Sabaté Tenas M, Seferovic P, Swedberg K, Tomkowski
W, Achenbach S, Agewall S, Al-Attar N, Angel Ferrer J, Arad M, Asteggiano R, Bueno H, Caforio AL,
Carerj S, Ceconi C, Evangelista A, Flachskampf F, Giannakoulas G, Gielen S, Habib G, Kolh P,
Lambrinou E, Lancellotti P, Lazaros G, Linhart A, Meurin P, Nieman K, Piepoli MF, Price S, RoosHesselink J, Roubille F, Ruschitzka F, Sagristà Sauleda J, Sousa-Uva M, Uwe Voigt J, Luis Zamorano J;
European Society of Cardiology (ESC).
Eur Heart J. 2015 Nov 7;36(42):2921-64. doi: 10.1093/eurheartj/ehv318. Epub 2015 Aug 29.
88. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting
without persistent ST-segment elevation: Task Force for the Management of Acute Coronary
Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society
of Cardiology (ESC).
Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew
DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF,
Windecker S, Baumgartner H, Gaemperli O, Achenbach S, Agewall S, Badimon L, Baigent C, Bueno H,
Bugiardini R, Carerj S, Casselman F, Cuisset T, Erol Ç, Fitzsimons D, Halle M, Hamm C, Hildick-Smith D,
Huber K, Iliodromitis E, James S, Lewis BS, Lip GY, Piepoli MF, Richter D, Rosemann T, Sechtem U,
Steg PG, Vrints C, Luis Zamorano J.
10
Eur Heart J. 2016 Jan 14;37(3):267-315. doi: 10.1093/eurheartj/ehv320. Epub 2015 Aug 29.
86. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the
Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by:
European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear
Medicine (EANM).
Authors/Task Force Members, Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti
F, Dulgheru R, El Khoury G, Erba PA, Iung B, Miro JM, Mulder BJ, Plonska-Gosciniak E, Price S, RoosHesselink J, Snygg-Martin U, Thuny F, Tornos Mas P, Vilacosta I, Zamorano JL; Document Reviewers,
Erol Ç, Nihoyannopoulos P, Aboyans V, Agewall S, Athanassopoulos G, Aytekin S, Benzer W, Bueno H,
Broekhuizen L, Carerj S, Cosyns B, De Backer J, De Bonis M, Dimopoulos K, Donal E, Drexel H,
Flachskampf FA, Hall R, Halvorsen S, Hoen B, Kirchhof P, Lainscak M, Leite-Moreira AF, Lip GY,
Mestres CA, Piepoli MF, Punjabi PP, Rapezzi C, Rosenhek R, Siebens K, Tamargo J, Walker DM.
Eur Heart J. 2015 Nov 21;36(44):3075-128. doi: 10.1093/eurheartj/ehv319. Epub 2015 Aug 29.
87. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the
prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular
Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology
(ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).
Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons
D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekvål
TM, Spaulding C, Van Veldhuisen DJ; Authors/Task Force Members; Document Reviewers.
Eur Heart J. 2015 Nov 1;36(41):2793-867. doi: 10.1093/eurheartj/ehv316. Epub 2015 Aug 29.
88. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the
prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular
Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology
(ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).
Authors/Task Force Members, Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M,
Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, HernandezMadrid A, Nikolaou N, Norekvål TM, Spaulding C, Van Veldhuisen DJ.
Europace. 2015 Nov;17(11):1601-87. doi: 10.1093/europace/euv319. Epub 2015 Aug 29.
89. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and
Death in Patients With Heart Failure With and Without Atrial Fibrillation.
Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY.
JAMA. 2015 Sep 8;314(10):1030-8. doi: 10.1001/jama.2015.10725.
90. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse
Cardiovascular Events in patients with atrial fibrillation.
Pastori D, Pignatelli P, Saliola M, Carnevale R, Vicario T, Del Ben M, Cangemi R, Barillà F, Lip GY, Violi
F.
Int J Cardiol. 2015 Dec 15;201:513-6. doi: 10.1016/j.ijcard.2015.08.054.
91. Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial
Fibrillation Patients.
Lip GY, Lanitis T, Mardekian J, Kongnakorn T, Phatak H, Dorian P.
Stroke. 2015 Oct;46(10):2830-7. doi: 10.1161/STROKEAHA.115.009995
92. Erectile dysfunction in atrial fibrillation: A risk factor for stroke or a reflection of stroke risk
factors?
Brown RA, Lip GY.
11
Cardiol J. 2015;22(4):359-61. doi: 10.5603/CJ.2015.0049
93. Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Asian Patients With
Nonvalvular Atrial Fibrillation: Meta-Analysis.
Wang KL, Lip GY, Lin SJ, Chiang CE.
Stroke. 2015 Sep;46(9):2555-61. doi: 10.1161/STROKEAHA.115.009947.
94. Recurrent Stroke: The Value of the CHA2DS2VASc Score and the Essen Stroke Risk Score in a
Nationwide Stroke Cohort.
Andersen SD, Gorst-Rasmussen A, Lip GY, Bach FW, Larsen TB.
Stroke. 2015 Sep;46(9):2491-7. doi: 10.1161/STROKEAHA.115.009912
95. Stroke in atrial fibrillation and improving the identification of 'high-risk' patients: the crossroads
of immunity and thrombosis.
Shantsila E, Lip GY.
J Thromb Haemost. 2015 Nov;13(11):1968-70. doi: 10.1111/jth.13121. Epub 2015 Sep 21.
96. Sex differences in clinical characteristics and inpatient outcomes among 2442 hospitalized
Chinese patients with nonvalvular atrial fibrillation: The Nanchang Atrial Fibrillation Project.
Xiong Q, Shantsila A, Lane DA, Zhou Q, Liu Y, Shen Y, Cheng X, Hong K, Lip GY.
Int J Cardiol. 2015 Dec 15;201:195-9. doi: 10.1016/j.ijcard.2015.08.076.
97. European Heart Rhythm Association/Heart Failure Association joint consensus document on
arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart
Rhythm Society.
Lip GY, Heinzel FR, Gaita F, Juanatey JR, Le Heuzey JY, Potpara T, Svendsen JH, Vos MA, Anker SD,
Coats AJ, Haverkamp W, Manolis AS, Chung MK, Sanders P, Pieske B; Document Reviewers:, Gorenek
B, Lane D, Boriani G, Linde C, Hindricks G, Tsutsui H, Homma S, Brownstein S, Nielsen JC, Lainscak M,
Crespo-Leiro M, Piepoli M, Seferovic P, Savelieva I.
Europace. 2016 Jan;18(1):12-36. doi: 10.1093/europace/euv191.
98. Cardiac Fibrosis in Patients With Atrial Fibrillation: Mechanisms and Clinical Implications.
Dzeshka MS, Lip GY, Snezhitskiy V, Shantsila E.
J Am Coll Cardiol. 2015 Aug 25;66(8):943-59. doi: 10.1016/j.jacc.2015.06.1313.
99. European Heart Rhythm Association/Heart Failure Association joint consensus document on
arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart
Rhythm Society.
Lip GY, Heinzel FR, Gaita F, Juanatey JR, Le Heuzey JY, Potpara T, Svendsen JH, Vos MA, Anker SD,
Coats AJ, Haverkamp W, Manolis AS, Chung MK, Sanders P, Pieske B.
Eur J Heart Fail. 2015 Sep;17(9):848-74. doi: 10.1002/ejhf.338. Epub 2015 Aug 21.
100. Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation.
Xiong Q, Lau YC, Lip GY.
J Comp Eff Res. 2015;4(4):367-76. doi: 10.2217/cer.15.15.
101. Non-VKA Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients with
Atrial Fibrillation: a Meta-analysis of Randomized Controlled Trials.
Kumar S, Danik SB, Altman RK, Barrett CD, Lip GY, Chatterjee S, Roubin GS, Natale A, Danik JS.
Cardiol Rev. 2015 Aug 11.
12
102. Patients With Ischemic Stroke and Incident Atrial Fibrillation: A Nationwide Cohort Study.
Fauchier L, Clementy N, Pelade C, Collignon C, Nicolle E, Lip GY.
Stroke. 2015 Sep;46(9):2432-7. doi: 10.1161/STROKEAHA.115.010270.
103. Benefit of Anticoagulation Therapy in Hyperthyroidism-Related Atrial Fibrillation.
Chan PH, Hai J, Yeung CY, Lip GY, Lam KS, Tse HF, Siu CW.
Clin Cardiol. 2015 Aug;38(8):476-82. doi: 10.1002/clc.22427.
104. Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation
undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy.
Capodanno D, Rossini R, Musumeci G, Lettieri C, Senni M, Valsecchi O, Angiolillo DJ, Lip GY.
Int J Cardiol. 2015 Nov 15;199:319-25. doi: 10.1016/j.ijcard.2015.07.064.
105. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial
Fibrillation: The GLORIA-AF Registry, Phase II.
Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener HC, Dubner SJ, Halperin JL, Ma C, Zint K,
Elsaesser A, Bartels DB, Lip GY; GLORIA-AF Investigators.
Am J Med. 2015 Dec;128(12):1306-1313.e1. doi: 10.1016/j.amjmed.2015.07.013.
106. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a
specialist atrial fibrillation clinic.
Lee SI, Sayers M, Lip GY, Lane DA.
Int J Clin Pract. 2015 Nov;69(11):1341-8. doi: 10.1111/ijcp.12712.
107. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy.
Lip GY, Skjøth F, Nielsen PB, Larsen TB.
Thromb Haemost. 2015 Oct;114(4):826-34. doi: 10.1160/TH15-07-0565.
108. Can venous thromboembolism navigate the prevention of cardiovascular complications?
Shantsila A, Lip GY.
Ann Transl Med. 2015 Jun;3(9):116. doi: 10.3978/j.issn.2305-5839.2015.04.10.
109. Net Clinical Benefit for Oral Anticoagulation, Aspirin, or No Therapy in Nonvalvular Atrial
Fibrillation Patients With 1 Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex).
Lip GY, Skjøth F, Rasmussen LH, Nielsen PB, Larsen TB.
J Am Coll Cardiol. 2015 Jul 28;66(4):488-90. doi: 10.1016/j.jacc.2015.05.044.
110. Residual Risk of Stroke and Death in Anticoagulated Patients According to the Type of Atrial
Fibrillation: AMADEUS Trial.
Senoo K, Lip GY, Lane DA, Büller HR, Kotecha D.
Stroke. 2015 Sep;46(9):2523-8. doi: 10.1161/STROKEAHA.115.009487.
111. Safety and efficacy of abciximab in older adults undergoing percutaneous coronary intervention.
Brown RA, Shantsila E, Varma C, Lip GY.
Int J Clin Pract. 2015 Nov;69(11):1334-40. doi: 10.1111/ijcp.12702.
112. Nonsteroidal anti-inflammatory drugs and bleeding risk in anticoagulated patients with atrial
fibrillation.
Lip GY.
Expert Rev Cardiovasc Ther. 2015;13(9):963-5. doi: 10.1586/14779072.2015.1071665.
13
113. Statin therapy and plasma coenzyme Q10 concentrations--A systematic review and metaanalysis of placebo-controlled trials.
Banach M, Serban C, Ursoniu S, Rysz J, Muntner P, Toth PP, Jones SR, Rizzo M, Glasser SP, Watts GF,
Blumenthal RS, Lip GY, Mikhailidis DP, Sahebkar A; Lipid and Blood Pressure Meta-analysis
Collaboration (LBPMC) Group.
Pharmacol Res. 2015 Sep;99:329-36. doi: 10.1016/j.phrs.2015.07.008.
114. Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With
Reduced Ejection Fraction Treated With Warfarin or Aspirin.
Ye S, Cheng B, Lip GY, Buchsbaum R, Sacco RL, Levin B, Di Tullio MR, Qian M, Mann DL, Pullicino PM,
Freudenberger RS, Teerlink JR, Mohr JP, Graham S, Labovitz AJ, Estol CJ, Lok DJ, Ponikowski P, Anker
SD, Thompson JL, Homma S; WARCEF Investigators.
Am J Cardiol. 2015 Sep 15;116(6):904-12. doi: 10.1016/j.amjcard.2015.06.016.
115. CD36 expression and lipid metabolism following an oral glucose challenge in South Asians.
Patel JV, Banerjee A, Montoro-Garcia S, Shantsila E, Alam M, Flinders P, Houlton KA, Hughes EA,Lip
GY, Gill PS.
World J Diabetes. 2015 Jul 10;6(7):983-9. doi: 10.4239/wjd.v6.i7.983.
116. Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation.
Proietti M, Marra AM, Tassone EJ, De Vuono S, Corrao S, Gobbi P, Perticone F, Corazza GR, Basili
S, Lip GY, Violi F, Raparelli V; ARAPACIS Study Investigators; GIS Group.
Am J Cardiol. 2015 Sep 15;116(6):877-82. doi: 10.1016/j.amjcard.2015.05.060.
117. Clinical characteristics and outcomes in extreme elderly (age ≥85) Japanese patients with atrial
fibrillation: The Fushimi AF Registry.
Yamashita Y, Hamatani Y, Esato M, Chun YH, Tsuji H, Wada H, Hasegawa K, Abe M, Lip GY, Akao M.
Chest. 2015 Jul 16. doi: 10.1378/chest.15-1095.
118.Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes.
Comprehensive network meta-analysis of 42 randomised trials involving 117,353 patients.
Navarese EP, Andreotti F, Kołodziejczak M, Schulze V, Wolff G, Dias S, Claessen B, Brouwer M,
Tarantini G, Iliceto S, Brockmeyer M, Kowalewski M, Lin Y, Eikelboom J, Musumeci G, Lee L, Lip GY,
Valgimigli M, Berti S, Kelm M.
Thromb Haemost. 2015 Nov;114(5):933-44. doi: 10.1160/TH14-12-1066.
119. Exposure-response for biomarkers of anticoagulant effects by the oral direct thrombin inhibitor
AZD0837 in patients with atrial fibrillation.
Lip GY, Rasmussen LH, Olsson SB, Jensen E, Hamrén B, Eriksson UG, Wåhlander K.
Br J Clin Pharmacol. 2015 Dec;80(6):1362-73. doi: 10.1111/bcp.12719.
120. Risk and prediction of dementia in patients with atrial fibrillation--a nationwide populationbased cohort study.
Liao JN, Chao TF, Liu CJ, Wang KL, Chen SJ, Tuan TC, Lin YJ, Chang SL, Lo LW, Hu YF, Chung FP, Tsao
HM, Chen TJ, Lip GY, Chen SA.
Int J Cardiol. 2015 Nov 15;199:25-30. doi: 10.1016/j.ijcard.2015.06.170.
121. moking, atrial fibrillation, and ischemic stroke: a confluence of epidemics.
Albertsen IE, Overvad TF, Lip GY, Larsen TB.
Curr Opin Cardiol. 2015 Sep;30(5):512-7. doi: 10.1097/HCO.0000000000000205.
14
122. Antithrombotic therapy in the elderly: expert position paper of the European Society of
Cardiology Working Group on Thrombosis.
Andreotti F, Rocca B, Husted S, Ajjan RA, Ten Berg J, Cattaneo M, Collet JP, De Caterina R, Fox KA,
Halvorsen S, Huber K, Hylek EM, Lip GY, Montalescot G, Morais J, Patrono C, Verheugt FW, Wallentin
L, Weiss TW, Storey RF; ESC Thrombosis Working Group.
Eur Heart J. 2015 Dec 7;36(46):3238-49. doi: 10.1093/eurheartj/ehv304. Epub 2015 Jul 9. Review.
123. Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
Potpara TS, Lip GY.
Prog Cardiovasc Dis. 2015 Sep-Oct;58(2):177-94. doi: 10.1016/j.pcad.2015.07.003.
124. Influence of age on respiratory modulation of muscle sympathetic nerve activity, blood pressure
and baroreflex function in humans.
Shantsila A, McIntyre DB, Lip GY, Fadel PJ, Paton JF, Pickering AE, Fisher JP.
Exp Physiol. 2015 Sep;100(9):1039-51. doi: 10.1113/EP085071.
125. Duration of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation:
Nationwide Cohort Study.
Overvad TF, Skjøth F, Lip GY, Lane DA, Albertsen IE, Rasmussen LH, Larsen TB.
Stroke. 2015 Aug;46(8):2168-74. doi: 10.1161/STROKEAHA.115.009371.
126. Atrial flutter and thromboembolic risk: a systematic review.
Vadmann H, Nielsen PB, Hjortshøj SP, Riahi S, Rasmussen LH, Lip GY, Larsen TB.
Heart. 2015 Sep;101(18):1446-55. doi: 10.1136/heartjnl-2015-307550.
127. Metabolic syndrome, atrial fibrillation, and stroke: Tackling an emerging epidemic.
Hajhosseiny R, Matthews GK, Lip GY.
Heart Rhythm. 2015 Nov;12(11):2332-43. doi: 10.1016/j.hrthm.2015.06.038.
128. Thromboembolic risk stratification of patients hospitalized with heart failure in sinus rhythm: a
nationwide cohort study.
Wolsk E, Lamberts M, Hansen ML, Blanche P, Køber L, Torp-Pedersen C, Lip GY, Gislason G.
Eur J Heart Fail. 2015 Aug;17(8):828-36. doi: 10.1002/ejhf.309.
129. Lights and shadows in the management of old and new oral anticoagulants in the real world of
atrial fibrillation by Italian internists. A survey from the Atrial Fibrillation Registry for Ankle-Brachial
Index Prevalence Assessment-Collaborative Italian Study.
Pignatelli P, Pastori D, Perticone F, Corazza GR, Violi F; ARAPACIS (Atrial Fibrillation Registry for AnkleBrachial Index Prevalence Assessment-Collaborative Italian Study) Study group.
Eur J Intern Med. 2015 Oct;26(8):e31-3. doi: 10.1016/j.ejim.2015.06.007.
130. Blood pressure and prognosis in patients with incident heart failure: the Diet, Cancer and Health
(DCH) cohort study.
Lip GY, Skjøth F, Overvad K, Rasmussen LH, Larsen TB.
Clin Res Cardiol. 2015 Dec;104(12):1088-96. doi: 10.1007/s00392-015-0878-4.
131. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical
devices: clinical significance and implications for decision making-a position paper of the European
Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm
Society.
15
Boriani G, Savelieva I, Dan GA, Deharo JC, Ferro C, Israel CW, Lane DA, La Manna G, Morton J, Mitjans
AM, Vos MA, Turakhia MP, Lip GY; Document reviewers.
Europace. 2015 Aug;17(8):1169-96. doi: 10.1093/europace/euv202
132. Cardiac tachyarrhythmias and patient values and preferences for their management: the
European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm
Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de
Estimulación Cardíaca y Electrofisiología (SOLEACE).
Lane DA, Aguinaga L, Blomström-Lundqvist C, Boriani G, Dan GA, Hills MT, Hylek EM, LaHaye SA,Lip
GY, Lobban T, Mandrola J, McCabe PJ, Pedersen SS, Pisters R, Stewart S, Wood K, Potpara TS;
Document Reviewers, Gorenek B, Conti JB, Keegan R, Power S, Hendriks J, Ritter P, Calkins H, Violi F,
Hurwitz J.
Europace. 2015 Dec;17(12):1747-69. doi: 10.1093/europace/euv233.
133. Antithrombotic management in patients undergoing electrophysiological procedures: a
European Heart Rhythm Association (EHRA) position document endorsed by the ESC Working Group
Thrombosis, Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society (APHRS).
Sticherling C, Marin F, Birnie D, Boriani G, Calkins H, Dan GA, Gulizia M, Halvorsen S, Hindricks G, Kuck
KH, Moya A, Potpara T, Roldan V, Tilz R, Lip GY; Document reviewers.
Europace. 2015 Aug;17(8):1197-214. doi: 10.1093/europace/euv190.
134. New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin Kantagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint.
Rubboli A, Agewall S, Huber K, Lip GY.
Int J Cardiol. 2015 Oct 1;196:133-8. doi: 10.1016/j.ijcard.2015.06.006.
135. The SAMe-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective
'Real-world' Inception Cohort Study.
Roldán V, Cancio S, Gálvez J, Valdés M, Vicente V, Marín F, Lip GY.
Am J Med. 2015 Nov;128(11):1237-43. doi: 10.1016/j.amjmed.2015.05.036.
136. Impact of advanced age on management and prognosis in atrial fibrillation: insights from a
population-based study in general practice.
Wolff A, Shantsila E, Lip GY, Lane DA.
Age Ageing. 2015 Sep;44(5):874-8. doi: 10.1093/ageing/afv071
137. sST2 levels are associated with all-cause mortality in anticoagulated patients with atrial
fibrillation.
Vílchez JA, Pérez-Cuellar M, Marín F, Gallego P, Manzano-Fernández S, Valdés M, Vicente V, NogueraVelasco JA, Lip GY, Ordóñez-Llanos J, Roldán V.
Eur J Clin Invest. 2015 Sep;45(9):899-905. doi: 10.1111/eci.12482.
138. Statins and the risk of dementia in patients with atrial fibrillation: A nationwide populationbased cohort study.
Chao TF, Liu CJ, Chen SJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Lip GY, Chiang CE,
Chen SA.
Int J Cardiol. 2015 Oct 1;196:91-7. doi: 10.1016/j.ijcard.2015.05.159.
139. Antidotes to non-vitamin K oral anticoagulants: necessary or not?
Proietti M, Lip GY.
Expert Opin Pharmacother. 2015;16(11):1573-6. doi: 10.1517/14656566.2015.1057119.
16
140. Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized
controlled trials.
Sahebkar A, Kotani K, Serban C, Ursoniu S, Mikhailidis DP, Jones SR, Ray KK, Blaha MJ, Rysz J, Toth PP,
Muntner P, Lip GY, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group.
Atherosclerosis. 2015 Aug;241(2):433-42. doi: 10.1016/j.atherosclerosis.2015.05.022.
141. Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial
fibrillation. An indirect comparison analysis.
Blann AD, Skjøth F, Rasmussen LH, Larsen TB, Lip GY.
Thromb Haemost. 2015 Aug;114(2):403-9. doi: 10.1160/TH15-05-0383.
142. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial
Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study.
Nielsen PB, Larsen TB, Skjøth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY.
Circulation. 2015 Aug 11;132(6):517-25. doi: 10.1161/CIRCULATIONAHA.115.015735.
143. A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and
tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the
oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2).
Lip GY, Halperin JL, Petersen P, Rodgers GM, Pall D, Renfurm RW.
J Thromb Haemost. 2015 Aug;13(8):1405-13. doi: 10.1111/jth.13025
144. The CHADS2 and CHA2DS2-VASc scores for predicting ischemic stroke among East Asian patients
with atrial fibrillation: A systemic review and meta-analysis.
Xiong Q, Chen S, Senoo K, Proietti M, Hong K, Lip GY.
Int J Cardiol. 2015 Sep 15;195:237-42. doi: 10.1016/j.ijcard.2015.05.115.
145. Recent scientific documents from the European Heart Rhythm Association (EHRA).
Gorenek B, Lip GY.
Europace. 2015 Aug;17(8):1161-3. doi: 10.1093/europace/euv193.
146. Renal Impairment and Prognosis of Patients with Atrial Fibrillation Undergoing Coronary
Intervention - The AFCAS Trial.
Lahtela HM, Kiviniemi TO, Puurunen MK, Schlitt A, Rubboli A, Ylitalo A, Valencia J, Lip GY, Airaksinen
KE.
PLoS One. 2015 Jun 1;10(6):e0128492. doi: 10.1371/journal.pone.0128492.
147. Symptom-to-door times in patients presenting with ST elevation myocardial infarction-do ethnic
or gender differences exist?
Brown RA, Shantsila E, Varma C, Lip GY.
QJM. 2015 May 28. pii: hcv112
148.Association between statin use and plasma D-dimer levels. A systematic review and metaanalysis of randomised controlled trials.
Sahebkar A, Serban C, Mikhailidis DP, Undas A, Lip GY, Muntner P, Bittner V, Ray KK, Watts GF,
Hovingh GK, Rysz J, Kastelein JJ, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration
(LBPMC) Group.
Thromb Haemost. 2015 Aug 31;114(3):546-57. doi: 10.1160/TH14-11-0937.
149. Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with
atrial fibrillation: a prospective multicentre cohort study.
17
Violi F, Pastori D, Perticone F, Hiatt WR, Sciacqua A, Basili S, Proietti M, Corazza GR, Lip GY, Pignatelli
P; ARAPACIS (Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative
Italian Study) STUDY group.
BMJ Open. 2015 May 21;5(5):e008026. doi: 10.1136/bmjopen-2015-008026.
150. Relationship between Mediterranean diet and time in therapeutic range in atrial fibrillation
patients taking vitamin K antagonists.
Pignatelli P, Pastori D, Vicario T, Bucci T, Del Ben M, Russo R, Tanzilli A, Nardoni ML, Bartimoccia S,
Nocella C, Ferro D, Saliola M, Cangemi R, Lip GY, Violi F.
Europace. 2015 Aug;17(8):1223-8. doi: 10.1093/europace/euv127.
151. Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients
with atrial fibrillation: a nationwide cohort study.
Staerk L, Gislason GH, Lip GY, Fosbøl EL, Hansen ML, Lamberts M, Bonde AN, Torp-Pedersen C,
Olesen JB.
Europace. 2015 Aug;17(8):1215-22. doi: 10.1093/europace/euv119.
152. Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial fibrillation' and
valvular heart disease: the Loire Valley Atrial Fibrillation Project.
Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Babuty D, Angoulvant D, Lip GY,
Fauchier L.
Eur Heart J. 2015 Jul 21;36(28):1822-30. doi: 10.1093/eurheartj/ehv163.
153. Atrial fibrillation (chronic).
Lane DA, Boos CJ, Lip GY.
BMJ Clin Evid. 2015 May 20;2015. pii: 0217.
154. Stroke prevention in atrial fibrillation: a systematic review.
Lip GY, Lane DA.
JAMA. 2015 May 19;313(19):1950-62. doi: 10.1001/jama.2015.4369. Review. Erratum in: JAMA. 2015
Aug 25;314(8):837.
155. Ethnic-Specific Normative Reference Values for Echocardiographic LA and LV Size, LV Mass, and
Systolic Function: The EchoNoRMAL Study.
Echocardiographic Normal Ranges Meta-Analysis of the Left Heart Collaboration.
JACC Cardiovasc Imaging. 2015 Jun;8(6):656-65. doi: 10.1016/j.jcmg.2015.02.014.
156. Asymptomatic versus symptomatic atrial fibrillation: A systematic review of age/gender
differences and cardiovascular outcomes.
Xiong Q, Proietti M, Senoo K, Lip GY.
Int J Cardiol. 2015 Jul 15;191:172-7. doi: 10.1016/j.ijcard.2015.05.011. Epub 2015 May 7. Review.
157. A systematic review and meta-analysis of the effect of statins on plasma asymmetric
dimethylarginine concentrations.
Serban C, Sahebkar A, Ursoniu S, Mikhailidis DP, Rizzo M, Lip GY, Kees Hovingh G, Kastelein JJ,
Kalinowski L, Rysz J, Banach M.
Sci Rep. 2015 May 13;5:9902. doi: 10.1038/srep09902.
158.A prospective evaluation of edoxaban compared to warfarin in subjects undergoing
cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of
Atrial Fibrillation (ENSURE-AF) study.
18
Lip GY, Merino J, Ezekowitz M, Ellenbogen K, Zamoryakhin D, Lanz H, Jin J, Al-Saadi N, Mercuri M,
Goette A.
Am Heart J. 2015 May;169(5):597-604.e5. doi: 10.1016/j.ahj.2015.02.009.
159. Optimizing atrial fibrillation management: from ICU and beyond.
Walkey AJ, Hogarth DK, Lip GY.
Chest. 2015 Oct;148(4):859-64. doi: 10.1378/chest.15-0358.
160. Using the CHA2DS2-VASc Score for Stroke Prevention in Atrial Fibrillation: A Focus on Vascular
Disease, Women, and Simple Practical Application.
Nielsen PB, Skjøth F, Rasmussen LH, Larsen TB, Lip GY.
Can J Cardiol. 2015 Jun;31(6):820.e9-10. doi: 10.1016/j.cjca.2015.01.034.
161. isk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with
atrial fibrillation in Taiwan: a nationwide cohort study.
Chen PC, Lip GY, Yeh G, Lin HJ, Chien KL.
PLoS One. 2015 Apr 29;10(4):e0125257. doi: 10.1371/journal.pone.0125257.
162. Low volume-high intensity interval exercise elicits antioxidant and anti-inflammatory effects in
humans.
Wadley AJ, Chen YW, Lip GY, Fisher JP, Aldred S.
J Sports Sci. 2016 Jan;34(1):1-9. doi: 10.1080/02640414.2015.1035666.
163. Randomized trial of atrial arrhythmia monitoring to guide anticoagulation in patients with
implanted defibrillator and cardiac resynchronization devices.
Martin DT, Bersohn MM, Waldo AL, Wathen MS, Choucair WK, Lip GY, Ip J, Holcomb R, Akar JG,
Halperin JL; IMPACT Investigators.
Eur Heart J. 2015 Jul 7;36(26):1660-8. doi: 10.1093/eurheartj/ehv115. Epub 2015 Apr 23.
PMID:
164. The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of
Major Bleeding Complications during the First Six Months of Anticoagulant Treatment.
Kooiman J, van Hagen N, Iglesias Del Sol A, Planken EV, Lip GY, van der Meer FJ, Cannegieter SC, Klok
FA, Huisman MV.
PLoS One. 2015 Apr 23;10(4):e0122520. doi: 10.1371/journal.pone.0122520.
165. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors-Results from a systematic review and meta-analysis of randomized controlled trials.
Sahebkar A, Serban C, Ursoniu S, Wong ND, Muntner P, Graham IM, Mikhailidis DP, Rizzo M, Rysz J,
Sperling LS, Lip GY, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration Group.
Int J Cardiol. 2015;189:47-55. doi: 10.1016/j.ijcard.2015.04.008.
166. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with
drug eluting stents: meta-analysis of randomised controlled trials.
Navarese EP, Andreotti F, Schulze V, Kołodziejczak M, Buffon A, Brouwer M, Costa F, Kowalewski M,
Parati G, Lip GY, Kelm M, Valgimigli M.
BMJ. 2015 Apr 16;350:h1618. doi: 10.1136/bmj.h1618.
167. Development and validation of a new assay for assessing clot integrity.
Ranjit P, Lau Y, Lip GY, Blann AD.
Vascul Pharmacol. 2015 Aug;71:102-7. doi: 10.1016/j.vph.2015.02.013.
19
168. Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with
edoxaban compared to warfarin in Germany.
Krejczy M, Harenberg J, Wehling M, Obermann K, Lip GY.
Biomed Res Int. 2015;2015:876923. doi: 10.1155/2015/876923.
169. Quality of anticoagulation control in preventing adverse events in patients with heart failure in
sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy.
Homma S, Thompson JL, Qian M, Ye S, Di Tullio MR, Lip GY, Mann DL, Sacco RL, Levin B, Pullicino PM,
Freudenberger RS, Teerlink JR, Graham S, Mohr JP, Labovitz AJ, Buchsbaum R, Estol CJ, Lok DJ,
Ponikowski P, Anker SD; WARCEF Investigators.
Circ Heart Fail. 2015 May;8(3):504-9. doi: 10.1161/CIRCHEARTFAILURE.114.001725.
170. Ethnic differences in the diurnal variation of symptom onset time for acute ST elevation
myocardial infarction - An observational cohort study.
Brown RA, Lip GY, Varma C, Shantsila E.
Int J Cardiol. 2015;187:414-6. doi: 10.1016/j.ijcard.2015.03.371.
171. Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from
patients and physicians leads to better outcomes.
Potpara TS, Lane DA, Lip GY.
Europace. 2015 Apr;17(4):507-8. doi: 10.1093/europace/euv041.
172. The SAMe-TT2R2 score and quality of anticoagulation in atrial fibrillation: a simple aid to
decision-making on who is suitable (or not) for vitamin K antagonists.
Fauchier L, Angoulvant D, Lip GY.
Europace. 2015 May;17(5):671-3. doi: 10.1093/europace/euv088.
173. Free Light Chains in patients with acute coronary syndromes: Relationships to inflammation and
renal function.
Shantsila E, Tapp LD, Lip GY.
Int J Cardiol. 2015 Apr 15;185:322-7. doi: 10.1016/j.ijcard.2015.03.105.
174. Simultaneous computerised activation of the primary percutaneous coronary intervention
pathway reduces out-of-hours door-to-balloon time but not mortality.
Brown RA, Varma C, Connolly DL, Ahmad R, Shantsila E, Lip GY.
Int J Cardiol. 2015;186:226-30. doi: 10.1016/j.ijcard.2015.03.172.
175. Small-size Microparticles as Indicators of Acute Decompensated State in Ischemic Heart Failure.
Montoro-García S, Shantsila E, Wrigley BJ, Tapp LD, Abellán Alemán J, Lip GY.
Rev Esp Cardiol (Engl Ed). 2015 Nov;68(11):951-8. doi: 10.1016/j.rec.2014.11.016.
176. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of
rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial
fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).
Gibson CM, Mehran R, Bode C, Halperin J, Verheugt F, Wildgoose P, van Eickels M, Lip GY, Cohen M,
Husted S, Peterson E, Fox K.
Am Heart J. 2015 Apr;169(4):472-8.e5. doi: 10.1016/j.ahj.2014.12.006.
177. Rationale and design of a study exploring the efficacy of once-daily oral rivaroxaban (X-TRA) on
the outcome of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation or atrial
flutter and a retrospective observational registry providing baseline data (CLOT-AF).
20
Lip GY, Hammerstingl C, Marin F, Cappato R, Meng IL, Kirsch B, Morandi E, van Eickels M, Cohen A.
Am Heart J. 2015 Apr;169(4):464-71.e2. doi: 10.1016/j.ahj.2014.12.020.
178. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants.
Enriquez A, Lip GY, Baranchuk A.
Europace. 2015 Mar 26. pii: euv030.
179. Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With
Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project.
Angoulvant D, Villejoubert O, Bejan-Angoulvant T, Ivanes F, Saint Etienne C, Lip GY, Fauchier L.
Chest. 2015 Aug;148(2):491-8. doi: 10.1378/chest.14-3006.
PMID:
180. Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the
Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo
Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.
Abdul-Rahim AH, Perez AC, Fulton RL, Jhund PS, Latini R, Tognoni G, Wikstrand J, Kjekshus J, Lip GY,
Maggioni AP, Tavazzi L, Lees KR, McMurray JJ; Investigators of the Controlled Rosuvastatin
Multinational Study in Heart Failure (CORONA); GISSI-Heart Failure (GISSI-HF) Committees and
Investigators.
Circulation. 2015 Apr 28;131(17):1486-94; discussion 1494. doi:
10.1161/CIRCULATIONAHA.114.013760. Epub 2015 Mar 25.
181. Pharmacodynamic profile and drug interactions with non-vitamin K antagonist oral
anticoagulants: implications for patients with atrial fibrillation.
Xiong Q, Lau YC, Lip GY.
Expert Opin Drug Metab Toxicol. 2015 Jun;11(6):937-48. doi: 10.1517/17425255.2015.1027683.
182. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke
risk factor based on the CHA2DS2-VASc score.
Lip GY, Skjøth F, Rasmussen LH, Larsen TB.
J Am Coll Cardiol. 2015 Apr 14;65(14):1385-94. doi: 10.1016/j.jacc.2015.01.044.
183. Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke
prevention in atrial fibrillation.
Shields AM, Lip GY.
J Intern Med. 2015 Jul;278(1):1-18. doi: 10.1111/joim.12360.
184. Not all thromboembolism comes from the left atrial appendage in atrial fibrillation.
Senoo K, Lip GY.
Heart. 2015 Jun;101(11):830-1. doi: 10.1136/heartjnl-2015-307451.
185. Gender differences in stroke prevention in atrial fibrillation in general practice: using the GRASPAF audit tool.
Shantsila E, Wolff A, Lip GY, Lane DA.
Int J Clin Pract. 2015 Aug;69(8):840-5. doi: 10.1111/ijcp.12625.
186. Catheter ablation of atrial fibrillation and thromboembolic risk.
Kornej J, Hindricks G, Lip GY, Bollmann A.
Circ J. 2015;79(2):444. doi: 10.1253/circj.CJ-14-1006.
21
187. Effects of Body Mass Index on the Lipid Profile and Biomarkers of Inflammation and a
Fibrinolytic and Prothrombotic State.
Orenes-Piñero E, Pineda J, Roldán V, Hernández-Romero D, Marco P, Tello-Montoliu A, Sogorb F,
Valdés M, Lip GY, Marín F.
J Atheroscler Thromb. 2015;22(6):610-7. doi: 10.5551/jat.26161.
188. Optimising stroke prevention in patients with atrial fibrillation.
Lane DA, Wolff A, Shantsila E, Lip GY.
Br J Gen Pract. 2015 Mar;65(632):117. doi: 10.3399/bjgp15X683905.
189. Female gender and atrial fibrillation: An association with worse prognosis and outcomes.
Kornej J, Bollmann A, Hindricks G, Lip GY.
Int J Cardiol. 2015 Apr 1;184:321-2. doi: 10.1016/j.ijcard.2015.02.062.
190. Female sex is associated with a lower risk of stroke in patients with heart failure.
Melgaard L, Gorst-Rasmussen A, Lip GY, Rasmussen LH, Larsen TB.
Am Heart J. 2015 Mar;169(3):396-403.e2. doi: 10.1016/j.ahj.2014.12.004.
191. Heart failure in patients with atrial fibrillation in Europe: a report from the EURObservational
Research Programme Pilot survey on Atrial Fibrillation.
Lip GY, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA, Kalarus Z, Crijns HJ, Oliveira
MM, Tavazzi L, Maggioni AP, Boriani G.
Eur J Heart Fail. 2015 Jun;17(6):570-82. doi: 10.1002/ejhf.254.
192. Renal, endothelial function, warfarin management, and the CHADS2, CHA2DS2VASc and HASBLED scores inpredicting MACE in AF.
Blann AD, Lip GY.
Thromb Haemost. 2015 May;113(5):1155-7. doi: 10.1160/TH14-11-0932.
193. Safety and efficacy of well managed warfarin. A report from the Swedish quality register
Auricula.
Sjögren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ, Själander A.
Thromb Haemost. 2015 Jun;113(6):1370-7. doi: 10.1160/TH14-10-0859.
1. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The
prospective global anticoagulant registry in the FIELD-Atrial Fibrillation.
Lip GY, Rushton-Smith SK, Goldhaber SZ, Fitzmaurice DA, Mantovani LG, Goto S, Haas S, Bassand JP,
Camm AJ, Ambrosio G, Janský P, Al Mahmeed W, Oh S, van Eickels M, Raatikainen P, Steffel J, Oto A,
Kayani G, Accetta G, Kakkar AK; GARFIELD-AF Investigators.
Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2 Suppl 1):S12-20. doi:
10.1161/CIRCOUTCOMES.114.001556.
195. Sex-related predictors for thromboembolic events after catheter ablation of atrial fibrillation:
The Leipzig Heart Center AF Ablation Registry.
Kornej J, Kosiuk J, Hindricks G, Arya A, Sommer P, Rolf S, Husser D, Lip GY, Bollmann A.
Clin Res Cardiol. 2015 Jul;104(7):603-10. doi: 10.1007/s00392-015-0823-6.
196. Development of recommendations to continue anticoagulation with one of the two types of oral
anticoagulants based on the identification of patients' preference.
Zolfaghari S, Harenberg J, Frölich L, Weiss C, Wehling M, Wild P, Prochaska J, Beyer-Westendorf J,
Koscielny J, Lip GY.
Semin Thromb Hemost. 2015 Mar;41(2):166-77. doi: 10.1055/s-0035-1546467.
22
197. Leukoaraiosis and stroke recurrence risk in patients with and without atrial fibrillation.
Ntaios G, Lip GY, Lambrou D, Papavasileiou V, Manios E, Milionis H, Spengos K, Makaritsis K, Vemmos
K.
Neurology. 2015 Mar 24;84(12):1213-9. doi: 10.1212/WNL.0000000000001402.
198. Developing an Atrial Fibrillation Guideline Support Tool (AFGuST) for shared decision making.
Eckman MH, Wise RE, Naylor K, Arduser L, Lip GY, Kissela B, Flaherty M, Kleindorfer D, Khan F,
Schauer DP, Kues J, Costea A.
Curr Med Res Opin. 2015 Apr;31(4):603-14. doi: 10.1185/03007995.2015.1019608.
199. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients
with nonvalvular atrial fibrillation.
Senoo K, Lip GY.
Semin Thromb Hemost. 2015 Mar;41(2):146-53. doi: 10.1055/s-0035-1544156.
200. Difficult decision making in the management of patients with atrial fibrillation and acute
coronary syndrome or invasive cardiovascular interventions: new recommendations for daily
practice.
Boriani G, Lane DA, Windecker S, Huber K, Kirchhof P, Lip GY.
Europace. 2015 Sep;17(9):1319-22. doi: 10.1093/europace/euu303.
201. ld atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond
sex) receive oral anticoagulation?
Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Lip GY, Chen SA.
J Am Coll Cardiol. 2015 Feb 24;65(7):635-42. doi: 10.1016/j.jacc.2014.11.046.
202. Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention
of Stroke among Persons with Atrial Fibrillation.
Xiong Q, Lip GY.
Curr Treat Options Neurol. 2015 Feb;17(2):331. doi: 10.1007/s11940-014-0331-4.
203. Bridging therapy with low molecular weight heparin in patients with atrial fibrillation
undergoing percutaneous coronary intervention with stent implantation: the AFCAS study.
Kiviniemi T, Airaksinen KE, Rubboli A, Biancari F, Valencia J, Lip GY, Karjalainen PP, Weber M, Laine M,
Kirchhof P, Schlitt A; AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary
Artery Stenting) study group.
Int J Cardiol. 2015 Mar 15;183:105-10. doi: 10.1016/j.ijcard.2015.01.056.
204. Use of psychotropic drugs following venous thromboembolism in youth. A nationwide cohort
study.
Højen AA, Gorst-Rasmussen A, Lip GY, Lane DA, Rasmussen LH, Sørensen EE, Larsen TB.
Thromb Res. 2015 Apr;135(4):643-7. doi: 10.1016/j.thromres.2015.01.024.
205. Triple therapy for atrial fibrillation and ACS with or without PCI: don't drop aspirin just yet.
Capodanno D, Lip GY.
J Am Coll Cardiol. 2015 Feb 10;65(5):515-6. doi: 10.1016/j.jacc.2014.10.063.
206. Dabigatran and myocardial infarction.
Hohnloser SH, Lip GY.
Chest. 2015 Feb;147(2):e70-1. doi: 10.1378/chest.14-2534.
23
207. Non-vitamin K antagonist oral anticoagulants in the cardioversion of patients with atrial
fibrillation: systematic review and meta-analysis.
Caldeira D, Costa J, Ferreira JJ, Lip GY, Pinto FJ.
Clin Res Cardiol. 2015 Jul;104(7):582-90. doi: 10.1007/s00392-015-0821-8.
208. Increased stroke risk in atrial fibrillation patients with heart failure: does ejection fraction
matter?
Kotecha D, Banerjee A, Lip GY.
Stroke. 2015 Mar;46(3):608-9. doi: 10.1161/STROKEAHA.114.008421.
209. Fondaparinux in atrial fibrillation – old dog, new tricks?
Lau YC, Brown RA, Lip GY.
Arch Cardiovasc Dis. 2015 Feb;108(2):85-7. doi: 10.1016/j.acvd.2014.12.001.
210. Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or
undergoing percutaneous coronary intervention or transcatheter aortic valve replacement.
Capodanno D, Lip GY, Windecker S, Huber K, Kirchhof P, Boriani G, Lane D, Gilard M, Collet JP,
Valgimigli M, Byrne RA.
EuroIntervention. 2015 Jan;10(9):1015-21. doi: 10.4244/EIJV10I9A174.
211. Increased pre-surgical numbers of endothelial progenitor cells and circulating endothelial cells in
colorectal cancer fail to predict outcome.
Ramcharan KS, Lip GY, Stonelake PS, Blann AD.
Int J Colorectal Dis. 2015 Mar;30(3):315-21. doi: 10.1007/s00384-014-2116-3.
212. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a
nationwide cohort study.
Gorst-Rasmussen A, Skjøth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA.
J Thromb Haemost. 2015 Apr;13(4):495-504. doi: 10.1111/jth.12845.
213. Editors' Choice papers in Thrombosis and Haemostasis.
Weber C, Lip GY.
Thromb Haemost. 2015 Jan;113(1):217-20.
214. A happy new year from Thrombosis and Haemostasis. A 5 year reflection from the editorial
team.
Lip GY, Weber C.
Thromb Haemost. 2015 Jan;113(1):1-2.
215. Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF
audit tool in a UK general practice cohort.
Shantsila E, Wolff A, Lip GY, Lane DA.
Br J Gen Pract. 2015 Jan;65(630):e16-23. doi: 10.3399/bjgp15X683113.
216. Cardiovascular risk prediction: balancing complexity against simple practicality.
Dzeshka MS, Gill PS, Lip GY.
Br J Gen Pract. 2015 Jan;65(630):4-5. doi: 10.3399/bjgp15X683005.
217. Misperceptions of aspirin efficacy and safety may perpetuate anticoagulant underutilization in
atrial fibrillation.
Ben Freedman S, Gersh BJ, Lip GY.
24
Eur Heart J. 2015 Mar 14;36(11):653-6. doi: 10.1093/eurheartj/ehu494.
218. Monitoring changes in thioredoxin and over-oxidised peroxiredoxin in response to exercise in
humans.
Wadley AJ, Chen YW, Bennett SJ, Lip GY, Turner JE, Fisher JP, Aldred S.
Free Radic Res. 2015 Mar;49(3):290-8. doi: 10.3109/10715762.2014.1000890.
219. Atrial fibrillation patients categorized as "not for anticoagulation" according to the 2014
Canadian Cardiovascular Society algorithm are not "low risk".
Lip GY, Nielsen PB, Skjøth F, Rasmussen LH, Larsen TB.
Can J Cardiol. 2015 Jan;31(1):24-8. doi: 10.1016/j.cjca.2014.10.018.
220. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF
Pilot General Registry.
Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH, Sinagra G, Petrescu L,
Tavazzi L, Maggioni AP, Lip GY.
Am J Med. 2015 May;128(5):509-18.e2. doi: 10.1016/j.amjmed.2014.11.026.
221. nts with atrial fibrillation undergoing percutaneous coronary intervention. Current concepts and
concerns: part I.
Dzeshka MS, Brown RA, Lip GY.
Pol Arch Med Wewn. 2015;125(1-2):73-81.
222. Patients with atrial fibrillation undergoing percutaneous coronary intervention: current
concepts and concerns: part II.
Dzeshka MS, Brown RA, Lip GY.
Pol Arch Med Wewn. 2015;125(3):172-80.
223. Stroke risk reduction with oral anticoagulation using CHA2DS2-VASc in a Japanese AF
population: A modeling analysis.
Senoo K, Lane DA, Lip GY.
Int J Cardiol. 2015 Feb 15;181:247-54. doi: 10.1016/j.ijcard.2014.11.196
224. Erratum to: medication prescription and adherence disparities in non valvular atrial fibrillation
patients: an Italian portrait from the ARAPACIS study.
Raparelli V, Proietti M, Buttà C, Di Giosia P, Sirico D, Gobbi P, Corrao S, Davì G, Vestri AR, Perticone F,
Corazza GR, Violi F, Basili S; ARAPACIS Study Investigators; GIS Group.
Intern Emerg Med. 2015 Mar;10(2):261-5. doi: 10.1007/s11739-014-1166-4.
225. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation and venous thromboembolism:
where are we now?
Hajhosseiny R, Sabir I, Lip GY.
Hosp Pract (1995). 2014 Oct;42(4):153-62. doi: 10.3810/hp.2014.10.1152.
226. Efficacy and safety of non-vitamin K antagonist oral anticoagulants vs. warfarin in Japanese
patients with atrial fibrillation – meta-analysis.
Senoo K, Lau YC, Dzeshka M, Lane D, Okumura K, Lip GY.
Circ J. 2015;79(2):339-45. doi: 10.1253/circj.CJ-14-1042.
227. Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With
New-Onset Atrial Fibrillation.
Guo Y, Wang H, Tian Y, Wang Y, Lip GY.
Chest. 2015 Jul;148(1):62-72. doi: 10.1378/chest.14-2018.
25
228. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic
kidney disease: a nationwide observational cohort study.
Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, Hansen ML, Gislason GH, TorpPedersen C, Olesen JB.
J Am Coll Cardiol. 2014 Dec 16;64(23):2471-82. doi: 10.1016/j.jacc.2014.09.051.
229. Statin treatment is associated with improved prognosis in patients with AF-related stroke.
Ntaios G, Papavasileiou V, Makaritsis K, Milionis H, Manios E, Michel P, Lip GY, Vemmos K.
Int J Cardiol. 2014 Nov 15;177(1):129-33. doi: 10.1016/j.ijcard.2014.09.031. Epub 2014 Sep 28.
PMID:
230. Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in
cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes.
Larsen TB, Nielsen PB, Skjøth F, Rasmussen LH, Lip GY.
PLoS One. 2014 Dec 5;9(12):e114445. doi: 10.1371/journal.pone.0114445. eCollection 2014.
231. Post myocardial infarction and atrial fibrillation: Thromboprophylaxis and risk stratification using
the CHA2DS2-VASc score.
Lau YC, Lip GY.
Cardiol J. 2014;21(5):451-3. doi: 10.5603/CJ.2014.0075.
232. Risk of major bleeding in different indications for new oral anticoagulants: insights from a metaanalysis of approved dosages from 50 randomized trials.
Sardar P, Chatterjee S, Lavie CJ, Giri JS, Ghosh J, Mukherjee D, Lip GY.
Int J Cardiol. 2015 Jan 20;179:279-87. doi: 10.1016/j.ijcard.2014.11.101.
233. Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic
review and meta-analysis of 7 studies with 2420 patients.
Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, Rysz J, Muntner P, Toth PP, Jones SR, Rizzo M,
Kees Hovingh G, Farnier M, Moriarty PM, Bittner VA, Lip GY, Banach M; Lipid and Blood Pressure
Meta-analysis Collaboration (LBPMC) Group.
Int J Cardiol. 2015 Jan 15;178:111-6. doi: 10.1016/j.ijcard.2014.10.118.
234. Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients
with atrial fibrillation: time for a reappraisal.
Lip GY, Wang KL, Chiang CE.
Int J Cardiol. 2015 Feb 1;180:246-54. doi: 10.1016/j.ijcard.2014.11.182.
235. Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart
Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington,
DC, December 9-10, 2013.
Van Wagoner DR, Piccini JP, Albert CM, Anderson ME, Benjamin EJ, Brundel B, Califf RM, Calkins H,
Chen PS, Chiamvimonvat N, Darbar D, Eckhardt LL, Ellinor PT, Exner DV, Fogel RI, Gillis AM, Healey J,
Hohnloser SH, Kamel H, Lathrop DA, Lip GY, Mehra R, Narayan SM, Olgin J, Packer D, Peters NS,
Roden DM, Ross HM, Sheldon R, Wehrens XH.
Heart Rhythm. 2015 Jan;12(1):e5-e29. doi: 10.1016/j.hrthm.2014.11.011.
236. Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants
in patients with atrial fibrillation.
Manzano-Fernández S, Andreu-Cayuelas JM, Marín F, Orenes-Piñero E, Gallego P, Valdés M, Vicente
V, Lip GY, Roldán V.
26
Rev Esp Cardiol (Engl Ed). 2015 Jun;68(6):497-504. doi: 10.1016/j.rec.2014.06.026.
237. Association of quality of life with anticoagulant control in patients with heart failure: the
Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial.
Shaffer JA, Thompson JL, Cheng B, Ye S, Lip GY, Mann DL, Sacco RL, Pullicino PM, Freudenberger RS,
Graham S, Mohr JP, Labovitz AJ, Estol CJ, Lok DJ, Ponikowski P, Anker SD, Di Tullio MR, Homma S;
WARCEF Investigators.
Int J Cardiol. 2014 Dec 15;177(2):715-7.
238. Clinical risk factors and subclinical target organ damage as predictors of new-onset of atrial
fibrillation: the Catanzaro atrial fibrillation project.
Perticone F, Sciacqua A, Perticone M, Tassone EJ, Sesti G, Violi F, Lip GY.
Int J Cardiol. 2014 Dec 15;177(2):666-8. doi: 10.1016/j.ijcard.2014.09.169.
239. Antithrombotic and anticoagulant therapy for atrial fibrillation.
Dzeshka MS, Lip GY.
Cardiol Clin. 2014 Nov;32(4):585-99. doi: 10.1016/j.ccl.2014.07.009.
240. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled
trials.
Banach M, Serban C, Sahebkar A, Ursoniu S, Rysz J, Muntner P, Toth PP, Jones SR, Rizzo M, Glasser
SP, Lip GY, Dragan S, Mikhailidis DP; Lipid and Blood Pressure Meta-analysis Collaboration Group.
Mayo Clin Proc. 2015 Jan;90(1):24-34. doi: 10.1016/j.mayocp.2014.08.021.
241. Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?
Dzeshka MS, Lip GY.
Trends Cardiovasc Med. 2015 May;25(4):315-36. doi: 10.1016/j.tcm.2014.10.017.
242. Atrial fibrillation (acute onset).
Lip GY, Apostolakis S.
BMJ Clin Evid. 2014 Nov 27;2014. pii: 0210.
243. Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation
taking anticoagulants: relation to atherosclerotic risk factors.
Pastori D, Pignatelli P, Angelico F, Farcomeni A, Del Ben M, Vicario T, Bucci T, Raparelli V, Cangemi R,
Tanzilli G, Lip GY, Violi F.
Chest. 2015 Jun;147(6):1644-50. doi: 10.1378/chest.14-2414.
244. Cognitive function in ambulatory patients with systolic heart failure: insights from the warfarin
versus aspirin in reduced cardiac ejection fraction (WARCEF) trial.
Graham S, Ye S, Qian M, Sanford AR, Di Tullio MR, Sacco RL, Mann DL, Levin B, Pullicino PM,
Freudenberger RS, Teerlink JR, Mohr JP, Labovitz AJ, Lip GY, Estol CJ, Lok DJ, Ponikowski P, Anker SD,
Thompson JL, Homma S; WARCEF Investigators.
PLoS One. 2014 Nov 26;9(11):e113447. doi: 10.1371/journal.pone.0113447. eCollection 2014.
245. Stroke and major bleeding risk in elderly patients aged ≥75 years with atrial fibrillation: the Loire
Valley atrial fibrillation project.
Lip GY, Clementy N, Pericart L, Banerjee A, Fauchier L.
Stroke. 2015 Jan;46(1):143-50. doi: 10.1161/STROKEAHA.114.007199.
246. Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and
efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis.
27
Nielsen PB, Lane DA, Rasmussen LH, Lip GY, Larsen TB.
Clin Res Cardiol. 2015 May;104(5):418-29. doi: 10.1007/s00392-014-0797-9.
247. Intracranial hemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: a
nationwide cohort study.
Brønnum Nielsen P, Larsen TB, Gorst-Rasmussen A, Skjøth F, Rasmussen LH, Lip GY.
Chest. 2015 Jun;147(6):1651-8. doi: 10.1378/chest.14-2099.
248. The impact of associated diabetic retinopathy on stroke and severe bleeding risk in diabetic
patients with atrial fibrillation: the loire valley atrial fibrillation project.
Lip GY, Clementy N, Pierre B, Boyer M, Fauchier L.
Chest. 2015 Apr;147(4):1103-10. doi: 10.1378/chest.14-2096.
249. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of
quality of anticoagulation control.
Ho CW, Ho MH, Chan PH, Hai JJ, Cheung E, Yeung CY, Lau KK, Chan KH, Lau CP, Lip GY, Leung GK, Tse
HF, Siu CW.
Stroke. 2015 Jan;46(1):23-30. doi: 10.1161/STROKEAHA.114.006476.
250. Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk
in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study.
Lamberts M, Lip GY, Hansen ML, Lindhardsen J, Olesen JB, Raunsø J, Olsen AM, Andersen PK, Gerds
TA, Fosbøl EL, Torp-Pedersen C, Gislason GH.
Ann Intern Med. 2014 Nov 18;161(10):690-8. doi: 10.7326/M13-1581.
251. Serum NOX2 and urinary isoprostanes predict vascular events in patients with atrial fibrillation.
Pignatelli P, Pastori D, Carnevale R, Farcomeni A, Cangemi R, Nocella C, Bartimoccia S, Vicario T,
Saliola M, Lip GY, Violi F.
Thromb Haemost. 2015 Mar;113(3):617-24. doi: 10.1160/TH14-07-0571.
252. Effects of radiofrequency catheter ablation of atrial fibrillation on soluble P-selectin, von
Willebrand factor and IL-6 in the peripheral and cardiac circulation.
Kornej J, Dinov B, Blann AD, Rolf S, Arya A, Schmidl J, Husser D, Hindricks G, Bollmann A, Lip GY.
PLoS One. 2014 Nov 12;9(11):e111760. doi: 10.1371/journal.pone.0111760. eCollection 2014.
253. Interaction between digoxin and dronedarone in the PALLAS trial.
Hohnloser SH, Halperin JL, Camm AJ, Gao P, Radzik D, Connolly SJ; PALLAS investigators.
Circ Arrhythm Electrophysiol. 2014 Dec;7(6):1019-25. doi: 10.1161/CIRCEP.114.002046.
254. Atrial fibrillation during sepsis: a determinant of long-term outcomes?
Lau YC, Lip GY.
Chest. 2014 Nov;146(5):1138-40. doi: 10.1378/chest.14-0986.
255. Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial
fibrillation.
Dzeshka MS, Lip GY.
Expert Opin Drug Saf. 2015 Jan;14(1):45-62. doi: 10.1517/14740338.2015.973847.
256. Using the CHA2DS2-VASc score for refining stroke risk stratification in 'low-risk' Asian patients
with atrial fibrillation.
Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Lip GY, Chen SA.
28
J Am Coll Cardiol. 2014 Oct 21;64(16):1658-65. doi: 10.1016/j.jacc.2014.06.1203.
257. Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a
Bayesian meta-analysis approach.
Verdecchia P, Angeli F, Bartolini C, De Filippo V, Aita A, Di Giacomo L, Poltronieri C, Lip GY, Reboldi G.
Expert Opin Drug Saf. 2015 Jan;14(1):7-20. doi: 10.1517/14740338.2014.971009.
258. The reply.
Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjøth F, Rosenzweig M, Lane DA, Lip GY.
Am J Med. 2014 Oct;127(10):e21. doi: 10.1016/j.amjmed.2014.06.018.
259. Plasma CX3CL1 levels and long term outcomes of patients with atrial fibrillation: the West
Birmingham Atrial Fibrillation Project.
Guo Y, Apostalakis S, Blann AD, Lip GY.
Cerebrovasc Dis. 2014;38(3):204-11. doi: 10.1159/000365841
260. Recurrent stroke in the warfarin versus aspirin in reduced cardiac ejection fraction (WARCEF)
trial.
Pullicino PM, Qian M, Sacco RL, Freudenberger R, Graham S, Teerlink JR, Mann D, Di Tullio MR,
Ponikowski P, Lok DJ, Anker SD, Lip GY, Estol CJ, Levin B, Mohr JP, Thompson JL, Homma S; WARCEF
Investigators.
Cerebrovasc Dis. 2014;38(3):176-81. doi: 10.1159/000365502. Epub 2014 Oct 9.
261. he optimal management of patients on oral anticoagulation undergoing coronary artery
stenting. The 10th Anniversary Overview.
Rubboli A, Faxon DP, Juhani Airaksinen KE, Schlitt A, Marín F, Bhatt DL, Lip GY.
Thromb Haemost. 2014 Dec;112(6):1080-7. doi: 10.1160/TH14-08-0681.
262. Bare-metal vs. drug-eluting stents in patients with atrial fibrillation undergoing percutaneous
coronary intervention.
Kiviniemi T, Puurunen M, Schlitt A, Rubboli A, Karjalainen P, Nammas W, Kirchhof P, Biancari F, Lip
GY, Airaksinen KJ.
Circ J. 2014;78(11):2674-81.
263. New biomarkers and risk stratification in atrial fibrillation: simplicity and practicality matter.
Griffiths HR, Lip GY.
Circulation. 2014 Nov 18;130(21):1837-9. doi: 10.1161/CIRCULATIONAHA.114.012870.
264. Changes in renal function after catheter ablation of atrial fibrillation are associated with CHADS2
and CHA2DS2-VASc scores and arrhythmia recurrences.
Kornej J, Hindricks G, Banerjee A, Arya A, Sommer P, Rolf S, Husser D, Lip GY, Bollmann A.
Heart. 2015 Jan;101(2):126-31. doi: 10.1136/heartjnl-2014-306013.
265. Stroke and bleeding risk in atrial fibrillation.
Senoo K, Lane D, Lip GY.
Korean Circ J. 2014 Sep;44(5):281-90. doi: 10.4070/kcj.2014.44.5.281.
266. A brief history of 'lone' atrial fibrillation: from 'a peculiar pulse irregularity' to a modern public
health concern.
Potpara TS, Lip GY.
Curr Pharm Des. 2015;21(5):679-96.
29
267. Free light chains in patients with acute heart failure secondary to atherosclerotic coronary
artery disease.
Shantsila E, Wrigley B, Lip GY.
Am J Cardiol. 2014 Oct 15;114(8):1243-8. doi: 10.1016/j.amjcard.2014.07.049.
268. Impact of non-vitamin k antagonist oral anticoagulants on intracranial bleeding in Asian patients
with non-valvular atrial fibrillation.
Yasaka M, Lip GY.
Circ J. 2014;78(10):2367-72. Epub 2014 Sep 10.
269. Laboratory monitoring of the non-vitamin K oral anticoagulants.
Blann AD, Lip GY.
J Am Coll Cardiol. 2014 Sep 16;64(11):1140-2. doi: 10.1016/j.jacc.2014.07.010.
270. Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and
endothelial cells in colorectal cancer.
Ramcharan KS, Lip GY, Stonelake PS, Blann AD.
Br J Cancer. 2014 Oct 28;111(9):1742-9. doi: 10.1038/bjc.2014.491.
271. Integrating real-time clinical information to provide estimates of net clinical benefit of
antithrombotic therapy for patients with atrial fibrillation.
Eckman MH, Wise RE, Speer B, Sullivan M, Walker N, Lip GY, Kissela B, Flaherty ML, Kleindorfer D,
Khan F, Kues J, Baker P, Ireton R, Hoskins D, Harnett BM, Aguilar C, Leonard A, Prakash R, Arduser L,
Costea A.
Circ Cardiovasc Qual Outcomes. 2014 Sep;7(5):680-6. doi: 10.1161/CIRCOUTCOMES.114.001163.
272. Atrial fibrillation in cryptogenic stroke: look harder, look longer, but just keep looking.
Lau YC, Lane DA, Lip GY.
Stroke. 2014 Nov;45(11):3184-5. doi: 10.1161/STROKEAHA.114.006862.
27O3. ral anticoagulants for stroke prevention in atrial fibrillation.
Senoo K, Lane DA, Lip GY.
Curr Probl Cardiol. 2014 Sep;39(9):319-44. doi: 10.1016/j.cpcardiol.2014.07.001.
274. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient
data meta-analysis.
Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY, Coats AJ, Andersson B,
Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD; Beta-Blockers in
Heart Failure Collaborative Group.
Lancet. 2014 Dec 20;384(9961):2235-43. doi: 10.1016/S0140-6736(14)61373-8.
275. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a
nationwide cohort study.
Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjøth F, Lane DA, Lip GY.
Am J Med. 2014 Dec;127(12):1172-8.e5. doi: 10.1016/j.amjmed.2014.07.023
276. Hormone replacement therapy and adverse outcomes in women with atrial fibrillation: an
analysis from the atrial fibrillation follow-up investigation of rhythm management trial.
Apostolakis S, Sullivan RM, Olshansky B, Lip GY.
Stroke. 2014 Oct;45(10):3076-9. doi: 10.1161/STROKEAHA.114.006668.
30
277. The association of CHA2DS2-VASc score and blood biomarkers with ischemic stroke outcomes:
the Belgrade stroke study.
Potpara TS, Polovina MM, Djikic D, Marinkovic JM, Kocev N, Lip GY.
PLoS One. 2014 Sep 3;9(9):e106439. doi: 10.1371/journal.pone.0106439.
278. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias.
Pedersen CT, Kay GN, Kalman J, Borggrefe M, Della-Bella P, Dickfeld T, Dorian P, Huikuri H, Kim YH,
Knight B, Marchlinski F, Ross D, Sacher F, Sapp J, Shivkumar K, Soejima K, Tada H, Alexander ME,
Triedman JK, Yamada T, Kirchhof P, Lip GY, Kuck KH, Mont L, Haines D, Indik J, Dimarco J, Exner D,
Iesaka Y, Savelieva I; EP-Europace,UK.
Heart Rhythm. 2014 Oct;11(10):e166-96. doi: 10.1016/j.hrthm.2014.07.024.
279. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year followup of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase
(EORP-AF Pilot registry).
Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L, Darabantiu D, Crijns HJ,
Kirchhof P, Vardas P, Tavazzi L, Maggioni AP, Boriani G.
Eur Heart J. 2014 Dec 14;35(47):3365-76. doi: 10.1093/eurheartj/ehu374.
280. Best practice for atrial fibrillation patient education.
Lane DA, Barker RV, Lip GY.
Curr Pharm Des. 2015;21(5):533-43.
281. Endothelial (dys)function in lone atrial fibrillation.
Polovina MM, Lip GY, Potpara TS.
Curr Pharm Des. 2015;21(5):622-45.
282. 'Lone' atrial fibrillation: no longer lone or even alone.
Potpara TS, Lip GY.
Curr Pharm Des. 2015;21(5):531-2.
283. Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or
malignant gastrointestinal lesions?
Clemens A, Strack A, Noack H, Konstantinides S, Brueckmann M, Lip GY.
Ann Med. 2014 Dec;46(8):672-8. doi: 10.3109/07853890.2014.952327.
284. Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA,
and EAPCI task force.
Gorenek B, Blomström Lundqvist C, Brugada Terradellas J, Camm AJ, Hindricks G, Huber K, Kirchhof P,
Kuck KH, Kudaiberdieva G, Lin T, Raviele A, Santini M, Tilz RR, Valgimigli M, Vos MA, Vrints C, Zeymer
U, Lip GY, Potpara T, Fauchier L, Sticherling C, Roffi M, Widimsky P, Mehilli J, Lettino M, Schiele F,
Sinnaeve P, Boriani G, Lane D, Savelieva I; European Heart Rhythm Association; Acute Cardiovascular
Care Association; European Association of Percutaneous Cardiovascular Interventions.
Europace. 2014 Nov;16(11):1655-73. doi: 10.1093/europace/euu208
285. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion.
Meier B, Blaauw Y, Khattab AA, Lewalter T, Sievert H, Tondo C, Glikson M; Document Reviewers.
Europace. 2014 Oct;16(10):1397-416. doi: 10.1093/europace/euu174.
286. EHRA/HRS/APHRS expert consensus on ventricular arrhythmias.
31
Pedersen CT, Kay GN, Kalman J, Borggrefe M, Della-Bella P, Dickfeld T, Dorian P, Huikuri H, Kim YH,
Knight B, Marchlinski F, Ross D, Sacher F, Sapp J, Shivkumar K, Soejima K, Tada H, Alexander ME,
Triedman JK, Yamada T, Kirchhof P; Document Reviewers:, Lip GY, Kuck KH, Mont L, Haines D, Indik J,
Dimarco J, Exner D, Iesaka Y, Savelieva I.
Europace. 2014 Sep;16(9):1257-83. doi: 10.1093/europace/euu194.
287. Cardiovascular risk in patients with sleep apnoea with or without continuous positive airway
pressure therapy: follow-up of 4.5 million Danish adults.
Lamberts M, Nielsen OW, Lip GY, Ruwald MH, Christiansen CB, Kristensen SL, Torp-Pedersen C,
Hansen ML, Gislason GH.
J Intern Med. 2014 Dec;276(6):659-66. doi: 10.1111/joim.12302
288. Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms
(CHADS2 , CHA2 DS2 -VASc, R2 CHADS2 , HAS-BLED, ATRIA, and more).
Dzeshka MS, Lane DA, Lip GY.
Clin Cardiol. 2014 Oct;37(10):634-44. doi: 10.1002/clc.22294.
289. Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke
prevention and current therapeutic approaches?
Lip GY, Al-Khatib SM, Cosio FG, Banerjee A, Savelieva I, Ruskin J, Blendea D, Nattel S, De Bono J,
Conroy JM, Hess PL, Guasch E, Halperin JL, Kirchhof P, Cosio MD, Camm AJ.
J Am Heart Assoc. 2014 Aug 27;3(4). pii: e001179. doi: 10.1161/JAHA.114.001179.
290. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute
coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint
consensus document of the European Society of Cardiology Working Group on Thrombosis, European
Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular
Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart
Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS).
Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG, Boriani G, Capodanno
D, Gilard M, Zeymer U, Lane D; Document Reviewers, Storey RF, Bueno H, Collet JP, Fauchier L,
Halvorsen S, Lettino M, Morais J, Mueller C, Potpara TS, Rasmussen LH, Rubboli A, Tamargo J,
Valgimigli M, Zamorano JL.
Eur Heart J. 2014 Dec 1;35(45):3155-79. doi: 10.1093/eurheartj/ehu298
291. Autonomic function and rheumatoid arthritis: a systematic review.
Adlan AM, Lip GY, Paton JF, Kitas GD, Fisher JP.
Semin Arthritis Rheum. 2014 Dec;44(3):283-304. doi: 10.1016/j.semarthrit.2014.06.003. Epub 2014
Jul 22. Review.
292. Regional differences in presentation and treatment of patients with atrial fibrillation in Europe:
a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General
Registry.
Lip GY, Laroche C, Boriani G, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Oliveira MM, Mairesse G,
Crijns HJ, Simantirakis E, Atar D, Maggioni AP, Tavazzi L.
Europace. 2015 Feb;17(2):194-206. doi: 10.1093/europace/euu201.
293. The impact of heart failure and left ventricular dysfunction in predicting stroke,
thromboembolism, and mortality in atrial fibrillation patients: a systematic review.
Agarwal M, Apostolakis S, Lane DA, Lip GY.
Clin Ther. 2014 Sep 1;36(9):1135-44. doi: 10.1016/j.clinthera.2014.07.015.
32
294. Response to Ansell et al. "Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new
or novel". (Thromb Haemost 2014; 112: 841).
Husted S, Lip GY; ESC Working Group on Thrombosis Task Force on Anticoagulants in Heart Disease.
Thromb Haemost. 2014 Oct;112(4):842. doi: 10.1160/TH14-06-0564
295. New advances in the treatment of atrial fibrillation: focus on stroke prevention.
Lau YC, Lip GY.
Expert Opin Pharmacother. 2014 Oct;15(15):2193-204. doi: 10.1517/14656566.2014.948418.
296. My Approach to the use of NOACs for stroke prevention in patients with atrial fibrillation.
Lip GY.
Trends Cardiovasc Med. 2014 Aug;24(6):265-6. doi: 10.1016/j.tcm.2014.05.012.
297. Acute myocardial infarction in patients with atrial fibrillation with a CHA2DS2-VASc score of 0 or
1: a nationwide cohort study.
Chao TF, Huang YC, Liu CJ, Chen SJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Hsieh
MH, Lip GY, Chen SA.
Heart Rhythm. 2014 Nov;11(11):1941-7. doi: 10.1016/j.hrthm.2014.08.003.
298. Response to letter regarding article, "warfarin versus aspirin for prevention of cognitive decline
in atrial fibrillation: randomized controlled trial (birmingham atrial fibrillation treatment of the aged
study)".
Mavaddat N, Roalfe A, Fletcher K, Lip GY, Hobbs FD, Fitzmaurice D, Mant J.
Stroke. 2014 Sep;45(9):e192. doi: 10.1161/STROKEAHA.114.006301.
299. Early cerebral thromboembolic complications after radiofrequency catheter ablation of atrial
fibrillation: incidence, characteristics, and risk factors.
Kosiuk J, Kornej J, Bollmann A, Piorkowski C, Myrda K, Arya A, Sommer P, Richter S, Rolf S, Husser D,
Gaspar T, Lip GY, Hindricks G.
Heart Rhythm. 2014 Nov;11(11):1934-40. doi: 10.1016/j.hrthm.2014.07.039.
300. The value of the European society of cardiology guidelines for refining stroke risk stratification in
patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in
atrial fibrillation stroke score: a nationwide cohort study.
Lip GY, Nielsen PB, Skjøth F, Lane DA, Rasmussen LH, Larsen TB.
Chest. 2014 Nov;146(5):1337-46. doi: 10.1378/chest.14-0533.
301. Anticoagulant drugs: a perspective.
Vílchez JA, Gallego P, Lip GY.
Ther Adv Drug Saf. 2014 Feb;5(1):8-20. doi: 10.1177/2042098613507945.
302. Ventricular-arterial coupling in obstructive sleep apnea.
Shantsila A, Shantsila E, Butt M, Khair OA, Dwivedi G, Lip GY.
J Am Soc Hypertens. 2014 Sep;8(9):624-9. doi: 10.1016/j.jash.2014.05.013.
303. Updated NICE guideline: management of atrial fibrillation (2014).
Senoo K, Lau YC, Lip GY.
Expert Rev Cardiovasc Ther. 2014 Sep;12(9):1037-40. doi: 10.1586/14779072.2014.943189.
33
304. Female sex as a risk factor for thromboembolism and death in patients with incident atrial
fibrillation. The prospective Danish Diet, Cancer and Health study.
Overvad TF, Rasmussen LH, Skjøth F, Overvad K, Albertsen IE, Lane DA, Lip GY, Larsen TB.
Thromb Haemost. 2014 Oct;112(4):789-95. doi: 10.1160/TH14-06-0545.
305. Oxidized LDL lipids increase β-amyloid production by SH-SY5Y cells through glutathione
depletion and lipid raft formation.
Dias IH, Mistry J, Fell S, Reis A, Spickett CM, Polidori MC, Lip GY, Griffiths HR.
Free Radic Biol Med. 2014 Oct;75:48-59. doi: 10.1016/j.freeradbiomed.2014.07.012.
306. Which drug should we use for stroke prevention in atrial fibrillation?
Lau YC, Lip GY.
Curr Opin Cardiol. 2014 Jul;29(4):293-300. doi: 10.1097/HCO.0000000000000065.
307. An "unlikely" Wells rule score (≤ 1) plus a negative D-dimer result excluded DVT in noncancer
patients.
Brown RA, Lip GY.
Ann Intern Med. 2014 Jul 15;161(2):JC9. doi: 10.7326/0003-4819-161-2-201407150-02009.
308. The atrial fibrillation epidemic: a validated diagnosis, or not?
Olesen JB, Lip GY, Fauchier L.
Europace. 2014 Dec;16(12):1701-2. doi: 10.1093/europace/euu173.
309. Exercise-induced changes in inflammatory processes: Implications for thrombogenesis in
cardiovascular disease.
Chen YW, Apostolakis S, Lip GY.
Ann Med. 2014 Nov;46(7):439-55. doi: 10.3109/07853890.2014.927713
310. Expression of monocyte subsets and angiogenic markers in relation to carotid plaque
neovascularization in patients with pre-existing coronary artery disease and carotid stenosis.
Jaipersad AS, Shantsila A, Lip GY, Shantsila E.
Ann Med. 2014 Nov;46(7):530-8. doi: 10.3109/07853890.2014.931101.
311. Modern management of atrial fibrillation requires initial identification of "low-risk" patients
using the CHA2DS2-VASc score, and not focusing on "high-risk" prediction.
Lip GY, Lane DA.
Circ J. 2014;78(8):1843-5.
312. Thrombotic complications in heart failure: an underappreciated challenge.
Shantsila E, Lip GY.
Circulation. 2014 Jul 29;130(5):387-9. doi: 10.1161/CIRCULATIONAHA.114.011353.
313. Prediction of stroke in patients without atrial fibrillation using the CHADS2 and CHA2DS2-VASc
scores: a justification for more widespread thromboprophylaxis?
Senoo K, Lip GY.
Heart. 2014 Oct;100(19):1485-6. doi: 10.1136/heartjnl-2014-306161.
314. Specific risk scores for specific purposes: use CHA2DS2-VASc for assessing stroke risk, and use
HAS-BLED for assessing bleeding risk in atrial fibrillation.
Dzeshka MS, Lip GY.
Thromb Res. 2014 Aug;134(2):217-8. doi: 10.1016/j.thromres.2014.06.003.
34
315. Sex-related differences in presentation, treatment, and outcome of patients with atrial
fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on
Atrial Fibrillation.
Lip GY, Laroche C, Boriani G, Cimaglia P, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Popescu MI,
Tica O, Hellum CF, Mortensen B, Tavazzi L, Maggioni AP.
Europace. 2015 Jan;17(1):24-31. doi: 10.1093/europace/euu155.
316. Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed
placebo analysis and multiple treatment comparisons.
Verdecchia P, Angeli F, Lip GY, Reboldi G.
PLoS One. 2014 Jun 23;9(6):e100478. doi: 10.1371/journal.pone.0100478.
317. Incidence and prediction of ischemic stroke among atrial fibrillation patients with end-stage
renal disease requiring dialysis.
Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Liao JN, Chen TJ, Lip GY,
Chen SA.
Heart Rhythm. 2014 Oct;11(10):1752-9. doi: 10.1016/j.hrthm.2014.06.021
318. Measurement of rivaroxaban and apixaban in serum samples of patients.
Harenberg J, Krämer S, Du S, Zolfaghari S, Schulze A, Krämer R, Weiss C, Wehling M, Lip GY.
Eur J Clin Invest. 2014 Aug;44(8):743-52. doi: 10.1111/eci.12291.
319. Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation
Project.
Banerjee A, Clementy N, Haguenoer K, Fauchier L, Lip GY.
Am J Med. 2014 Oct;127(10):972-8. doi: 10.1016/j.amjmed.2014.05.035.
320. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global
burden of atrial fibrillation.
Guo Y, Tian Y, Wang H, Si Q, Wang Y, Lip GY.
Chest. 2015 Jan;147(1):109-19. doi: 10.1378/chest.14-0321.
321. Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients
with atrial fibrillation: a secondary analysis of the AVERROES study.
Lip GY, Eikelboom J, Yusuf S, Shestakovska O, Hart RG, Connolly S; AVERROES Investigators.
Stroke. 2014 Jul;45(7):2127-30. doi: 10.1161/STROKEAHA.114.005746.
322. Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects
meta-analysis with predefined heterogeneity quality criteria.
Clemens A, Noack H, Brueckmann M, Lip GY.
PLoS One. 2014 Jun 9;9(6):e99276. doi: 10.1371/journal.pone.0099276. eCollection 2014. Erratum in:
PLoS One. 2014;9(9):e109437.
323. Adverse cardiovascular outcomes in relation to suboptimal antithrombotic therapy use in
patients undergoing peripheral artery disease angioplasty: lost opportunities?
Bodansky DM, Allon IR, Apostolakis S, Lip GY.
Int J Clin Pract. 2015 Feb;69(2):162-8. doi: 10.1111/ijcp.12470
324. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with
atrial fibrillation.
Gallego P, Roldán V, Marin F, Gálvez J, Valdés M, Vicente V, Lip GY.
35
Am J Med. 2014 Nov;127(11):1083-8. doi: 10.1016/j.amjmed.2014.05.023.
325. Primary prevention of ischaemic stroke in atrial fibrillation: new oral anticoagulant drugs for all?
Foley J, Kirchhof P, Lip GY.
Curr Vasc Pharmacol. 2014 May;12(3):373-83. Review.
326. ACP Journal Club. Ablation reduced recurrent atrial tachyarrhythmia more than antiarrhythmic
drugs in paroxysmal AF.
Lau YC, Lip GY.
Ann Intern Med. 2014 May 20;160(10):JC5. doi: 10.7326/0003-4819-160-10-201405200-02005.
327. Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro
Heart Survey.
Marcucci M, Lip GY, Nieuwlaat R, Pisters R, Crijns HJ, Iorio A.
Am J Med. 2014 Oct;127(10):979-986.e2. doi: 10.1016/j.amjmed.2014.05.003.
328.Impact of anaemia on clinical outcome in patients with atrial fibrillation undergoing
percutaneous coronary intervention: insights from the AFCAS registry.
Puurunen M, Kiviniemi T, Nammas W, Schlitt A, Rubboli A, Nyman K, Karjalainen P, Kirchhof P, Lip GY,
Airaksinen JK.
BMJ Open. 2014 May 13;4(5):e004700. doi: 10.1136/bmjopen-2013-004700.
329Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent
chronic kidney disease.
Kooiman J, van Rein N, Spaans B, van Beers KA, Bank JR, van de Peppel WR, del Sol AI, Cannegieter
SC, Rabelink TJ, Lip GY, Klok FA, Huisman MV.
PLoS One. 2014 May 9;9(5):e94420. doi: 10.1371/journal.pone.0094420. eCollection 2014.
330. Stroke/thromboembolism and intracranial hemorrhage in a real-world atrial fibrillation
population: the Complications of Atrial Fibrillation in the Bologna Area (CAFBO) study.
Palareti G, Salomone L, Cavazza M, Guidi M, Muscari A, Boriani G, Di Micoli A, Guizzardi G,
Procaccianti G, Guidetti A, Binetti N, Malservisi S, Masina M, Viola A, Bua V, Ongari M, Diaspri G,Lip
GY.
Chest. 2014 Oct;146(4):1073-80. doi: 10.1378/chest.13-2443.
331. Edoxaban: a focused review of its clinical pharmacology.
Lip GY, Agnelli G.
Eur Heart J. 2014 Jul 21;35(28):1844-55. doi: 10.1093/eurheartj/ehu181.
332. Non-vitamin K antagonist oral anticoagulants: an appeal for consensus on terminology.
Lip GY, Camm AJ, Hylek EM, Halperin JL, Weitz JI.
Chest. 2014 May;145(5):1177-8. doi: 10.1378/chest.13-2951.
333. Antithrombotic treatment in patients with heart failure and associated atrial fibrillation and
vascular disease: a nationwide cohort study.
Lamberts M, Lip GY, Ruwald MH, Hansen ML, Özcan C, Kristensen SL, Køber L, Torp-Pedersen C,
Gislason GH.
J Am Coll Cardiol. 2014 Jun 24;63(24):2689-98. doi: 10.1016/j.jacc.2014.03.039.
334. Performance of bleeding risk-prediction scores in patients with atrial fibrillation undergoing
percutaneous coronary intervention.
36
Kiviniemi T, Puurunen M, Schlitt A, Rubboli A, Karjalainen P, Vikman S, Niemelä M, Lahtela H, Lip GY,
Airaksinen KE.
Am J Cardiol. 2014 Jun 15;113(12):1995-2001. doi: 10.1016/j.amjcard.2014.03.038.
335. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials.
Sardar P, Chatterjee S, Chaudhari S, Lip GY.
J Am Geriatr Soc. 2014 May;62(5):857-64. doi: 10.1111/jgs.12799.
336. Assess bleeding risk with HAS-BLED and assess stroke risk with CHA2DS2-VASc in patients with
atrial fibrillation.
Lau YC, Lip GY, Gallego P.
Hypertens Res. 2014 Jul;37(7):699-700. doi: 10.1038/hr.2014.63.
337. he Potential Role of Edoxaban in Stroke Prevention Guidelines.
Plunkett O, Lip GY.
Arrhythm Electrophysiol Rev. 2014 May;3(1):40-3. doi: 10.15420/aer.2011.3.1.40.
338. Interleukin-6 and high-sensitivity C-reactive protein for the prediction of outcomes in non-STsegment elevation acute coronary syndromes.
López-Cuenca Á, Manzano-Fernández S, Lip GY, Casas T, Sánchez-Martínez M, Mateo-Martínez A,
Pérez-Berbel P, Martínez J, Hernández-Romero D, Romero Aniorte AI, Valdés M, Marín F.
Rev Esp Cardiol (Engl Ed). 2013 Mar;66(3):185-92. doi: 10.1016/j.rec.2012.07.019.
339. Small-size platelet microparticles trigger platelet and monocyte functionality and modulate
thrombogenesis via P-selectin.
Montoro-García S, Shantsila E, Hernández-Romero D, Jover E, Valdés M, Marín F, Lip GY.
Br J Haematol. 2014 Aug;166(4):571-80. doi: 10.1111/bjh.12913.
340. Stroke prevention in Asian patients with atrial fibrillation.
Yasaka M, Lip GY.
Stroke. 2014 Jun;45(6):1608-9. doi: 10.1161/STROKEAHA.114.005339.
341. Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong.
Siu CW, Lip GY, Lam KF, Tse HF.
Heart Rhythm. 2014 Aug;11(8):1401-8. doi: 10.1016/j.hrthm.2014.04.021.
342. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant
bleeding, and mortality in patients with atrial fibrillation.
Lip GY, Haguenoer K, Saint-Etienne C, Fauchier L.
Chest. 2014 Sep;146(3):719-26. doi: 10.1378/chest.13-2976.
343. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the
Swedish Atrial Fibrillation Cohort study.
Friberg L, Benson L, Lip GY.
Eur Heart J. 2015 Feb 1;36(5):297-306. doi: 10.1093/eurheartj/ehu139.
344. Warfarin versus aspirin for prevention of cognitive decline in atrial fibrillation: randomized
controlled trial (Birmingham Atrial Fibrillation Treatment of the Aged Study).
Mavaddat N, Roalfe A, Fletcher K, Lip GY, Hobbs FD, Fitzmaurice D, Mant J.
Stroke. 2014 May;45(5):1381-6. doi: 10.1161/STROKEAHA.113.004009
37
345. Anticoagulation versus placebo for heart failure in sinus rhythm.
Lip GY, Shantsila E.
Cochrane Database Syst Rev. 2014 Mar 28;3:CD003336. doi: 10.1002/14651858.CD003336.pub3.
Review.
346. Use of the HAS-BLED bleeding score in real-life settings.
Lane DA, Lip GY.
Thromb Res. 2014 Jul;134(1):202. doi: 10.1016/j.thromres.2014.03.027.
347. Age dependence of risk factors for stroke and death in young patients with atrial fibrillation: a
nationwide study.
Melgaard L, Rasmussen LH, Skjøth F, Lip GY, Larsen TB.
Stroke. 2014 May;45(5):1331-7. doi: 10.1161/STROKEAHA.114.004903
348. Atrial fibrillation …. more than simply being irregularly irregular.
Lip GY.
Int J Clin Pract. 2014 Apr;68(4):408-9. doi: 10.1111/ijcp.12416.
349. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel.
Husted S, de Caterina R, Andreotti F, Arnesen H, Bachmann F, Huber K, Jespersen J, Kristensen SD, Lip
GY, Morais J, Rasmussen LH, Siegbahn A, Storey RF, Weitz JI; ESC Working Group on Thrombosis Task
Force on Anticoagulants in Heart Disease.
Thromb Haemost. 2014 May 5;111(5):781-2. doi: 10.1160/TH14-03-0228.
350. A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients
who will have good anticoagulation control on warfarin.
Poli D, Antonucci E, Testa S, Lip GY.
Intern Emerg Med. 2014 Jun;9(4):443-7. doi: 10.1007/s11739-014-1065-8.
351. Atrial fibrillation and stroke prevention: brief observations on the last decade.
Lip GY.
Expert Rev Cardiovasc Ther. 2014 Apr;12(4):403-6. doi: 10.1586/14779072.2014.896196. Review.
Erratum in: Expert Rev Cardiovasc Ther. 2014 May;12(5):635.
352. Atrial fibrillation and retinal vein or artery occlusion: looking beyond the eye.
Plunkett O, Lip PL, Lip GY.
Br J Ophthalmol. 2014 Sep;98(9):1141-3. doi: 10.1136/bjophthalmol-2013-304646.
353. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A
systematic review and meta-analysis.
Wagstaff AJ, Overvad TF, Lip GY, Lane DA.
QJM. 2014 Dec;107(12):955-67. doi: 10.1093/qjmed/hcu054
354. Vernakalant hydrochloride to treat atrial fibrillation.
Brown RA, Lau YC, Lip GY.
Expert Opin Pharmacother. 2014 Apr;15(6):865-72. doi: 10.1517/14656566.2014.898751.
355. Prognostic value of two polymorphisms in non-sarcomeric genes for the development of atrial
fibrillation in patients with hypertrophic cardiomyopathy.
38
Orenes-Piñero E, Hernández-Romero D, Romero-Aniorte AI, Martínez M, García-Honrubia A,
Caballero L, Garrigos-Gómez N, Andreu-Cayuelas JM, González J, Feliu E, Climent V, Nicolás-Ruiz F, De
La Morena G, Valdés M, Lip GY, Marín F.
QJM. 2014 Aug;107(8):613-21. doi: 10.1093/qjmed/hcu046.
356. Dabigatran etexilate for venous thromboembolism: a safety evaluation.
Brown R, Lip GY, Gallego P.
Expert Opin Drug Saf. 2014 May;13(5):639-47. doi: 10.1517/14740338.2014.895321.
357. Monocyte subsets in coronary artery disease and their associations with markers of
inflammation and fibrinolysis.
Shantsila E, Tapp LD, Wrigley BJ, Pamukcu B, Apostolakis S, Montoro-García S, Lip GY.
Atherosclerosis. 2014 May;234(1):4-10. doi: 10.1016/j.atherosclerosis.2014.02.009.
358. Comparing the 'new' R2CHADS2 with the 'old' CHA2DS2-VASc scores for predicting
thromboembolism in patients undergoing atrial fibrillation ablation: new does not mean better.
Kornej J, Lip GY.
Can J Cardiol. 2014 Apr;30(4):385-7. doi: 10.1016/j.cjca.2013.12.015.
359. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for
stroke prevention in atrial fibrillation. An indirect comparison analysis.
Skjøth F, Larsen TB, Rasmussen LH, Lip GY.
Thromb Haemost. 2014 May 5;111(5):981-8. doi: 10.1160/TH14-02-0118.
360. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients
with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in
patients with atrial fibrillation.
Huisman MV, Lip GY, Diener HC, Dubner SJ, Halperin JL, Ma CS, Rothman KJ, Teutsch C, Zint K,
Ackermann D, Clemens A, Bartels DB.
Am Heart J. 2014 Mar;167(3):329-34. doi: 10.1016/j.ahj.2013.12.006. Epub 2013 Dec 19.
PMID:
361. Contemporary real life cardioversion of atrial fibrillation: Results from the multinational
RHYTHM-AF study.
Crijns HJ, Weijs B, Fairley AM, Lewalter T, Maggioni AP, Martín A, Ponikowski P, Rosenqvist M,
Sanders P, Scanavacca M, Bash LD, Chazelle F, Bernhardt A, Gitt AK, Lip GY, Le Heuzey JY.
Int J Cardiol. 2014 Apr 1;172(3):588-94. doi: 10.1016/j.ijcard.2014.01.099.
362. Circulating microparticles: challenges and perspectives of flow cytometric assessment.
Shantsila E, Montoro-García S, Gallego P, Lip GY.
Thromb Haemost. 2014 Jun;111(6):1009-14. doi: 10.1160/TH13-11-0937.
363. Bivalirudin use during percutaneous coronary intervention in patients on chronic warfarin
therapy.
Kiviniemi T, Karjalainen P, Niemelä M, Rubboli A, Lip GY, Schlitt A, Nammas W, Airaksinen KE.
Thromb Res. 2014 Apr;133(4):695-6. doi: 10.1016/j.thromres.2014.01.038.
364. Early management of atrial fibrillation to prevent cardiovascular complications.
Nattel S, Guasch E, Savelieva I, Cosio FG, Valverde I, Halperin JL, Conroy JM, Al-Khatib SM, Hess PL,
Kirchhof P, De Bono J, Lip GY, Banerjee A, Ruskin J, Blendea D, Camm AJ.
Eur Heart J. 2014 Jun 7;35(22):1448-56. doi: 10.1093/eurheartj/ehu028.
39
365. Bleeding events among new starters and switchers to dabigatran compared with warfarin in
atrial fibrillation.
Larsen TB, Gorst-Rasmussen A, Rasmussen LH, Skjøth F, Rosenzweig M, Lip GY.
Am J Med. 2014 Jul;127(7):650-656.e5. doi: 10.1016/j.amjmed.2014.01.031.
366. Atrial fibrillation and heart failure: a bad combination.
Lau YC, Lane DA, Lip GY.
Am J Cardiol. 2014 Apr 1;113(7):1196-7. doi: 10.1016/j.amjcard.2014.01.002. Epub 2014 Jan 16. No
abstract available.
367. Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in
anticoagulated patients with atrial fibrillation.
Roldán V, Vílchez JA, Manzano-Fernández S, Jover E, Gálvez J, Puche CM, Valdés M, Vicente V,Lip GY,
Marín F.
Stroke. 2014 Mar;45(3):696-701. doi: 10.1161/STROKEAHA.113.003338.
368. Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients
with atrial fibrillation.
Dorian P, Kongnakorn T, Phatak H, Rublee DA, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L,Lip GY.
Eur Heart J. 2014 Jul 21;35(28):1897-906. doi: 10.1093/eurheartj/ehu006.
369. Reply: A persisting dilemma for triple antithrombotic therapy: are we close to finding the correct
answer?
Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A, Christensen
CB, Lip GY, Køber L, Torp-Pedersen C, Hansen ML.
J Am Coll Cardiol. 2014 Jul 15;64(2):231-2. doi: 10.1016/j.jacc.2013.11.049.
370. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in
atrial fibrillation.
Lip GY, Kongnakorn T, Phatak H, Kuznik A, Lanitis T, Liu LZ, Iloeje U, Hernandez L, Dorian P.
Clin Ther. 2014 Feb 1;36(2):192-210.e20. doi: 10.1016/j.clinthera.2013.12.011.
371. Stroke prevention in atrial fibrillation: an Asian perspective.
Chiang CE, Wang KL, Lip GY.
Thromb Haemost. 2014 May 5;111(5):789-97. doi: 10.1160/TH13-11-0948.
372. Response.
Apostolakis S, Sullivan RM, Olshansky B, Lip GY.
Chest. 2014 Feb;145(2):419-20. doi: 10.1378/chest.13-2775.
373. Aspirin versus vitamin K antagonist treatment guided by transoesophageal echocardiography in
patients with atrial fibrillation: a pilot study.
Dinh T, Baur LH, Pisters R, Kamp O, Verheugt FW, Smeets JL, Cheriex EC, Lindeboom JE, Heesen WF,
Tieleman RG, Prins MH, Crijns HJ; TIARA investigators.
Heart. 2014 Apr;100(7):563-8. doi: 10.1136/heartjnl-2013-305017.
374. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.
Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Ioachim PM, Tica O, Boriani G,
Cimaglia P, Diemberger I, Hellum CF, Mortensen B, Maggioni AP.
Am J Med. 2014 Jun;127(6):519-29.e1. doi: 10.1016/j.amjmed.2013.12.022.
40
375. One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an
analysis of the AFCAS registry.
Rubboli A, Schlitt A, Kiviniemi T, Biancari F, Karjalainen PP, Valencia J, Laine M, Kirchhof P, Niemelä
M, Vikman S, Lip GY, Airaksinen KE; AFCAS Study Group.
Clin Cardiol. 2014 Jun;37(6):357-64. doi: 10.1002/clc.22254.
376. Management of acute coronary syndrome in patients with non-valvular atrial fibrillation: results
of the European Heart Rhythm Association Survey.
Potpara TS, Lip GY, Dagres N, Estner HL, Larsen TB, Blomström-Lundqvist C; Conducted by the
Scientific Initiatives Committee, European Heart Rhythm Association.
Europace. 2014 Feb;16(2):293-8. doi: 10.1093/europace/euu008.
377. Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and
bleeding risk with oral anticoagulation.
Lane DA, Lip GY.
Thromb Haemost. 2014 Mar 3;111(3):381-3. doi: 10.1160/TH14-01-0063.
378. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral
anticoagulant: a nationwide cohort study.
Lamberts M, Gislason GH, Lip GY, Lassen JF, Olesen JB, Mikkelsen AP, Sørensen R, Køber L, TorpPedersen C, Hansen ML.
Circulation. 2014 Apr 15;129(15):1577-85. doi: 10.1161/CIRCULATIONAHA.113.004834.
379. CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial
fibrillation undergoing percutaneous coronary intervention.
Puurunen MK, Kiviniemi T, Schlitt A, Rubboli A, Dietrich B, Karjalainen P, Nyman K, Niemelä M, Lip GY,
Airaksinen KE.
Thromb Res. 2014 Apr;133(4):560-6. doi: 10.1016/j.thromres.2014.01.007.
380. Composite risk scores and composite endpoints in the risk prediction of outcomes in
anticoagulated patients with atrial fibrillation. The Loire Valley Atrial Fibrillation Project.
Banerjee A, Fauchier L, Bernard-Brunet A, Clementy N, Lip GY.
Thromb Haemost. 2014 Mar 3;111(3):549-56. doi: 10.1160/TH13-12-1033.
381. Use of novel oral anticoagulants in patients with heart failure.
Shantsila E, Lip GY.
Curr Treat Options Cardiovasc Med. 2014 Feb;16(2):285. doi: 10.1007/s11936-013-0285-y.
382. A very happy new year 2014 from Thrombosis and Haemostasis! Reflections on the past, the
present and the future.
Lip GY, Weber C.
Thromb Haemost. 2014 Jan;111(1):1-2.
383. Response.
Apostolakis S, Sullivan RM, Olshansky B, Lip GY.
Chest. 2014 Jan;145(1):188-9. doi: 10.1378/chest.13-2641.
384. Biomarkers in atrial fibrillation: an overview.
Vílchez JA, Roldán V, Hernández-Romero D, Valdés M, Lip GY, Marín F.
Int J Clin Pract. 2014 Apr;68(4):434-43. doi: 10.1111/ijcp.12304.
41
385. Lone atrial fibrillation - an overview.
Potpara TS, Lip GY.
Int J Clin Pract. 2014 Apr;68(4):418-33. doi: 10.1111/ijcp.12281.
386. Myocardial ischemic events in 'real world' patients with atrial fibrillation treated with dabigatran
or warfarin.
Larsen TB, Rasmussen LH, Gorst-Rasmussen A, Skjøth F, Rosenzweig M, Lane DA, Lip GY.
Am J Med. 2014 Apr;127(4):329-336.e4. doi: 10.1016/j.amjmed.2013.12.005.
387. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial
fibrillation: the Loire Valley Atrial Fibrillation Project.
Banerjee A, Fauchier L, Vourc'h P, Andres CR, Taillandier S, Halimi JM, Lip GY.
Chest. 2014 Jun;145(6):1370-82. doi: 10.1378/chest.13-2103.
388. Patent foramen ovale and migraine attacks: a systematic review.
Lip PZ, Lip GY.
Am J Med. 2014 May;127(5):411-20. doi: 10.1016/j.amjmed.2013.12.006.
389. A prospective survey in European Society of Cardiology member countries of atrial fibrillation
management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF)
Pilot General Registry.
Lip GY, Laroche C, Dan GA, Santini M, Kalarus Z, Rasmussen LH, Oliveira MM, Mairesse G, Crijns HJ,
Simantirakis E, Atar D, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP.
Europace. 2014 Mar;16(3):308-19. doi: 10.1093/europace/eut373.
390. Remote monitoring of cardiac implantable electronic devices in Europe: results of the European
Heart Rhythm Association survey.
Hernández-Madrid A, Lewalter T, Proclemer A, Pison L, Lip GY, Blomstrom-Lundqvist C; Scientific
Initiatives Committee, European Heart Rhythm Association.
Europace. 2014 Jan;16(1):129-32. doi: 10.1093/europace/eut414.
391. ACP Journal Club. PCI in noninfarction arteries reduced cardiac events in acute STEMI with
multivessel coronary disease.
Brown R, Lip GY.
Ann Intern Med. 2013 Dec 17;159(12):JC3. doi: 10.7326/0003-4819-159-12-201312170-02003.
392. Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial
fibrillation (the RHYTHM-AF study).
Lip GY, Gitt AK, Le Heuzey JY, Bash LD, Morabito CJ, Bernhardt AA, Sisk CM, Chazelle F, Crijns HJ;
RHYTHM-AF Scientific Committee.
Am J Cardiol. 2014 Feb 1;113(3):480-4. doi: 10.1016/j.amjcard.2013.10.036.
393. Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY
database.
Lip GY, Clemens A, Noack H, Ferreira J, Connolly SJ, Yusuf S.
Thromb Haemost. 2014 May 5;111(5):933-42. doi: 10.1160/TH13-09-0734.
394. Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in
the REACH Registry.
Ruff CT, Bhatt DL, Steg PG, Gersh BJ, Alberts MJ, Hoffman EB, Ohman EM, Eagle KA, Lip GY, Goto S;
REACH Registry Investigators.
Int J Cardiol. 2014 Jan 1;170(3):413-8. doi: 10.1016/j.ijcard.2013.11.030.
42
395. Reply: ankle-brachial index in patients with nonvalvular atrial fibrillation.
Violi F, Davì G, Hiatt W, Lip GY, Corazza GR, Perticone F, Proietti M, Pignatelli P, Vestri AR, Basili S;
ARAPACIS Study Investigators.
J Am Coll Cardiol. 2014 Apr 15;63(14):1457-8. doi: 10.1016/j.jacc.2013.11.011.
396. Warfarin or novel oral anticoagulants for atrial fibrillation?
Larsen TB, Lip GY.
Lancet. 2014 Mar 15;383(9921):931-3. doi: 10.1016/S0140-6736(13)62376-4.
397. Left ventricular geometry and outcomes in patients with atrial fibrillation: the AFFIRM Trial.
Apostolakis S, Sullivan RM, Olshansky B, Lip GY.
Int J Cardiol. 2014 Jan 1;170(3):303-8. doi: 10.1016/j.ijcard.2013.11.002.
398. Comparison of clinical risk stratification for predicting stroke and thromboembolism in atrial
fibrillation.
Aakre CA, McLeod CJ, Cha SS, Tsang TS, Lip GY, Gersh BJ.
Stroke. 2014 Feb;45(2):426-31. doi: 10.1161/STROKEAHA.113.002585.
399. Treatment of hypertension in peripheral arterial disease.
Lane DA, Lip GY.
Cochrane Database Syst Rev. 2013 Dec 4;12:CD003075. doi: 10.1002/14651858.CD003075.pub3.
Review.
400. No effect of clopidogrel activity or cessation on vascular function or markers of inflammation.
Kuzniatsova N, Balakrishnan B, Lip GY, Blann AD.
Int J Angiol. 2012 Dec;21(4):195-200. doi: 10.1055/s-0032-1328777.
401. Acetylsalicylic acid for stroke prevention in atrial fibrillation: a conspiracy that needs to end?
Lau YC, Lip GY.
Europace. 2014 May;16(5):619-20. doi: 10.1093/europace/eut356.
402. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position
paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease.
De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K,
Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI.
Thromb Haemost. 2013 Dec;110(6):1087-107. doi: 10.1160/TH13-06-0443.
403. Balancing bleeding and thrombotic risk with new oral anticoagulants in patients with atrial
fibrillation.
Overvad TF, Larsen TB, Albertsen IE, Rasmussen LH, Lip GY.
Expert Rev Cardiovasc Ther. 2013 Dec;11(12):1619-29. doi: 10.1586/14779072.2013.839214. Review.
404. Inflammatory Biomarkers and Atrial Fibrillation: Potential Role of Inflammatory Pathways in the
Pathogenesis of Atrial Fibrillation-induced Thromboembolism.
Guo Y, Lip GY, Apostolakis S.
Curr Vasc Pharmacol. 2015;13(2):192-201. Review.
405. Rhythm outcomes after catheter ablation of atrial fibrillation. Clinical implication of biomarkers.
Kornej J, Husser D, Bollmann A, Lip GY.
Hamostaseologie. 2014;34(1):9-19. doi: 10.5482/HAMO-13-09-0051.
43
406 High-sensitivity troponin T as a biomarker for the development of atrial fibrillation after cardiac
surgery.
Hernández-Romero D, Vílchez JA, Lahoz Á, Romero-Aniorte AI, Orenes-Piñero E, Caballero L, JaraRubio R, Arribas JM, García-Alberola A, Valdés M, Lip GY, Marín F.
Eur J Cardiothorac Surg. 2014 Apr;45(4):733-8. doi: 10.1093/ejcts/ezt488.
407. Psychological interventions for depression in adolescent and adult congenital heart disease.
Lane DA, Millane TA, Lip GY.
Cochrane Database Syst Rev. 2013 Oct 28;10:CD004372. doi: 10.1002/14651858.CD004372.pub2.
Review.
408. The role of monocytes in angiogenesis and atherosclerosis.
Jaipersad AS, Lip GY, Silverman S, Shantsila E.
J Am Coll Cardiol. 2014 Jan 7-14;63(1):1-11. doi: 10.1016/j.jacc.2013.09.019. Epub 2013 Oct 16.
Review.
409. Using the CHADS2 and CHA2DS2-VASc scores for stroke risk prediction as well as the
identification of stroke outcomes and cardiac complications in patients with and without atrial
fibrillation.
Lip GY.
Cerebrovasc Dis. 2013;36(4):281-2. doi: 10.1159/000355981.
410. The effect of statin therapy withdrawal on monocyte subsets.
Jaipersad AS, Shantsila E, Blann A, Lip GY.
Eur J Clin Invest. 2013 Dec;43(12):1307-13. doi: 10.1111/eci.12183.
411. Predictive value of atrial high-rate episodes for arterial stiffness and endothelial dysfunction in
dual-chamber pacemaker patients.
Krishnamoorthy S, Khoo CW, Lim HS, Lip GY.
Eur J Clin Invest. 2014 Jan;44(1):13-21. doi: 10.1111/eci.12182.
412. Anticoagulation management in nonvalvular atrial fibrillation: current and future directions.
Kornej J, Potpara T, Lip GY.
Pol Arch Med Wewn. 2013;123(11):623-34.
413. Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in
patients with atrial fibrillation.
Gallego P, Roldan V, Marín F, Romera M, Valdés M, Vicente V, Lip GY.
Thromb Haemost. 2013 Dec;110(6):1189-98. doi: 10.1160/TH13-07-0556.
414. The impact of smoking on thromboembolism and mortality in patients with incident atrial
fibrillation: insights from the Danish Diet, Cancer, and Health study.
Albertsen IE, Rasmussen LH, Lane DA, Overvad TF, Skjøth F, Overvad K, Lip GY, Larsen TB.
Chest. 2014 Mar 1;145(3):559-66. doi: 10.1378/chest.13-1740.
415. Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel
oral anticoagulants.
Kasmeridis C, Apostolakis S, Ehlers L, Rasmussen LH, Boriani G, Lip GY.
Pharmacoeconomics. 2013 Nov;31(11):971-80. doi: 10.1007/s40273-013-0090-1. Review.
416. Potential value of targeting von Willebrand factor in atherosclerotic cardiovascular disease.
44
Montoro-García S, Shantsila E, Lip GY.
Expert Opin Ther Targets. 2014 Jan;18(1):43-53. doi: 10.1517/14728222.2013.840585.
417. Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European
Heart Rhythm Association survey.
Lip GY, Bongiorni MG, Dobreanu D, Lewalter T, Hastrup Svendsen J, Blomström-Lundqvist C; Scientific
Initiative Committee, European Heart Rhythm Association.
Europace. 2013 Oct;15(10):1526-32. doi: 10.1093/europace/eut292.
418. Coronary artery diseases in Japanese patients with nonvalvular atrial fibrillation.
Senoo K, Suzuki S, Sagara K, Otsuka T, Matsuno S, Uejima T, Oikawa Y, Yajima J, Nagashima K, Kirigaya
H, Sawada H, Aizawa T, Lip GY, Yamashita T.
J Cardiol. 2014 Feb;63(2):123-7. doi: 10.1016/j.jjcc.2013.08.007.
419. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or
CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V, Marín F, Manzano-Fernández S, Gallego P, Vílchez JA, Valdés M, Vicente V, Lip GY.
J Am Coll Cardiol. 2013 Dec 10;62(23):2199-204. doi: 10.1016/j.jacc.2013.08.1623.
420. Stroke prevention in atrial fibrillation in heart failure.
Shantsila E, Lip GY.
Heart Fail Clin. 2013 Oct;9(4):427-35, viii. doi: 10.1016/j.hfc.2013.07.008. Review.
421. Antithrombotic therapy in atrial fibrillation and stent implantation: treatment or threats by the
use of triple or dual antithrombotic therapy.
Marín F, Huber K, Lip GY.
Thromb Haemost. 2013 Oct;110(4):623-5. doi: 10.1160/TH13-08-0677.
422. Comparison of the CHADS2, CHA2DS2-VASc and HAS-BLED scores for the prediction of clinically
relevant bleeding in anticoagulated patients with atrial fibrillation: the AMADEUS trial.
Apostolakis S, Lane DA, Buller H, Lip GY.
Thromb Haemost. 2013 Nov;110(5):1074-9. doi: 10.1160/TH13-07-0552.
423. Renal dysfunction, stroke risk scores (CHADS2, CHA2DS2-VASc, and R2CHADS2), and the risk
of thromboembolic events after catheter ablation of atrial fibrillation: the Leipzig Heart Center AF
Ablation Registry.
Kornej J, Hindricks G, Kosiuk J, Arya A, Sommer P, Husser D, Rolf S, Richter S, Piorkowski C, Gaspar
T, Lip GY, Bollmann A.
Circ Arrhythm Electrophysiol. 2013 Oct;6(5):868-74. doi: 10.1161/CIRCEP.113.000869.
424. Educational intervention improves anticoagulation control in atrial fibrillation patients: the
TREAT randomised trial.
Clarkesmith DE, Pattison HM, Lip GY, Lane DA.
PLoS One. 2013 Sep 9;8(9):e74037. doi: 10.1371/journal.pone.0074037. eCollection 2013.
425. Novel oral anticoagulants in cardiovascular disease.
Gallego P, Roldán V, Lip GY.
J Cardiovasc Pharmacol Ther. 2014 Jan;19(1):34-44. doi: 10.1177/1074248413501392.
426. Anticoagulant treatment is effective in atrial fibrillation.
Robson JP, Lip GY.
BMJ. 2013 Sep 12;347:f5429. doi: 10.1136/bmj.f5429.
45
427. Patient preferences at ten years following initial diagnosis of atrial fibrillation: the Belgrade
Atrial Fibrillation Study.
Potpara TS, Polovina MM, Mujovic NM, Kocijancic AM, Lip GY.
Patient Prefer Adherence. 2013 Aug 26;7:835-42. doi: 10.2147/PPA.S50990. eCollection 2013.
.
428. Development of a novel composite stroke and bleeding risk score in patients with atrial
fibrillation: the AMADEUS Study.
Lip GY, Lane DA, Buller H, Apostolakis S.
Chest. 2013 Dec;144(6):1839-47. doi: 10.1378/chest.13-1635.
429. Subclinical thyroid dysfunction and cardiac function amongst minority ethnic groups in the UK: a
cross sectional study.
Gill PS, Patel JV, Chackathayil J, Webster C, Davis RC, Hughes E, Lip GY.
Int J Cardiol. 2013 Oct 15;168(6):5218-20. doi: 10.1016/j.ijcard.2013.08.030.
430. Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for
stroke prevention in atrial fibrillation.
Myat A, Ahmad Y, Haldar S, Tantry US, Redwood SR, Gurbel PA, Lip GY.
Expert Rev Cardiovasc Ther. 2013 Aug;11(8):1029-49. doi: 10.1586/14779072.2013.815423. Review.
431. Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation
competence NETwork/European Heart Rhythm Association consensus conference.
Kirchhof P, Breithardt G, Aliot E, Al Khatib S, Apostolakis S, Auricchio A, Bailleul C, Bax J, Benninger G,
Blomstrom-Lundqvist C, Boersma L, Boriani G, Brandes A, Brown H, Brueckmann M, Calkins H,
Casadei B, Clemens A, Crijns H, Derwand R, Dobrev D, Ezekowitz M, Fetsch T, Gerth A, Gillis A, Gulizia
M, Hack G, Haegeli L, Hatem S, Georg Häusler K, Heidbüchel H, Hernandez-Brichis J, Jais P,
Kappenberger L, Kautzner J, Kim S, Kuck KH, Lane D, Leute A, Lewalter T, Meyer R, Mont L, Moses G,
Mueller M, Münzel F, Näbauer M, Nielsen JC, Oeff M, Oto A, Pieske B, Pisters R, Potpara T,
Rasmussen L, Ravens U, Reiffel J, Richard-Lordereau I, Schäfer H, Schotten U, Stegink W, Stein K,
Steinbeck G, Szumowski L, Tavazzi L, Themistoclakis S, Thomitzek K, Van Gelder IC, von Stritzky B,
Vincent A, Werring D, Willems S, Lip GY, Camm AJ.
Europace. 2013 Nov;15(11):1540-56. doi: 10.1093/europace/eut232.
432. β-Trace protein and prognosis in patients with atrial fibrillation receiving anticoagulation
treatment.
Vílchez JA, Roldán V, Manzano-Fernández S, Fernández H, Avilés-Plaza F, Martínez-Hernández P,
Vicente V, Valdés M, Marín F, Lip GY.
Chest. 2013 Nov;144(5):1564-70. doi: 10.1378/chest.13-0922.
433. Monocytes in coronary artery disease and atherosclerosis: where are we now?
Ghattas A, Griffiths HR, Devitt A, Lip GY, Shantsila E.
J Am Coll Cardiol. 2013 Oct 22;62(17):1541-51. doi: 10.1016/j.jacc.2013.07.043.
434. Sequential changes in renal function and the risk of stroke and death in patients with atrial
fibrillation.
Guo Y, Wang H, Zhao X, Zhang Y, Zhang D, Ma J, Wang Y, Lip GY.
Int J Cardiol. 2013 Oct 12;168(5):4678-84. doi: 10.1016/j.ijcard.2013.07.179.
435. Renal function and outcomes in anticoagulated patients with non-valvular atrial fibrillation: the
AMADEUS trial.
Apostolakis S, Guo Y, Lane DA, Buller H, Lip GY.
46
Eur Heart J. 2013 Dec;34(46):3572-9. doi: 10.1093/eurheartj/eht328.
436. The emerging role of biomarkers in atrial fibrillation.
Kornej J, Apostolakis S, Bollmann A, Lip GY.
Can J Cardiol. 2013 Oct;29(10):1181-93. doi: 10.1016/j.cjca.2013.04.016.
437. Prognostic role of plasma von Willebrand factor and soluble E-selectin levels for future
cardiovascular events in a 'real-world' community cohort of patients with atrial fibrillation.
Krishnamoorthy S, Khoo CW, Lim HS, Lane DA, Pignatelli P, Basili S, Violi F, Lip GY.
Eur J Clin Invest. 2013 Oct;43(10):1032-8. doi: 10.1111/eci.12140.
438. New oral anticoagulants in heart failure.
Van Gelder IC, Van Veldhuisen DJ, Lip GY.
Eur J Heart Fail. 2013 Sep;15(9):966-73. doi: 10.1093/eurjhf/hft135.
439. A comparison of clinical characteristics and long-term prognosis in asymptomatic and
symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study.
Potpara TS, Polovina MM, Marinkovic JM, Lip GY.
Int J Cardiol. 2013 Oct 12;168(5):4744-9. doi: 10.1016/j.ijcard.2013.07.234.
440. Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation:
implications for risk and therapy.
Violi F, Daví G, Hiatt W, Lip GY, Corazza GR, Perticone F, Proietti M, Pignatelli P, Vestri AR, Basili S;
ARAPACIS Study Investigators.
J Am Coll Cardiol. 2013 Dec 10;62(23):2255-6. doi: 10.1016/j.jacc.2013.07.035.
441. Novel oral anticoagulants in non-valvular atrial fibrillation.
Potpara TS, Lip GY.
Best Pract Res Clin Haematol. 2013 Jun;26(2):115-29. doi: 10.1016/j.beha.2013.07.008.
442. Finding atrial fibrillation: just keep looking, just keep looking … (but remember stroke
prevention).
Lip GY.
J Intern Med. 2013 Nov;274(5):457-60. doi: 10.1111/joim.12118.
443.
Ambulatory blood pressure in atrial fibrillation: an irregular conundrum of rate and rhythm.
Kotecha D, Lip GY.
Hypertens Res. 2013 Oct;36(10):854-5. doi: 10.1038/hr.2013.59.
444. Projections on the number of individuals with atrial fibrillation in the European Union, from
2000 to 2060.
Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, Witteman JC, Stricker BH, Heeringa J.
Eur Heart J. 2013 Sep;34(35):2746-51. doi: 10.1093/eurheartj/eht280.
445. Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm: a
subgroup analysis of WARCEF, a randomized controlled trial.
Homma S, Thompson JL, Sanford AR, Mann DL, Sacco RL, Levin B, Pullicino PM, Freudenberger RS,
Teerlink JR, Graham S, Mohr JP, Massie BM, Labovitz AJ, Di Tullio MR, Gabriel AP, Lip GY, Estol CJ, Lok
DJ, Ponikowski P, Anker SD; WARCEF Investigators.
Circ Heart Fail. 2013 Sep 1;6(5):988-97. doi: 10.1161/CIRCHEARTFAILURE.113.000372.
47
446. Current practice for diagnosis and management of silent atrial fibrillation: results of the
European Heart Rhythm Association survey.
Dobreanu D, Svendsen JH, Lewalter T, Hernández-Madrid A, Lip GY, Blomström-Lundqvist C; Scientific
Initiatives Committee, European Heart Rhythm Association.
Europace. 2013 Aug;15(8):1223-5. doi: 10.1093/europace/eut227.
447. Low stroke risk after elective cardioversion of atrial fibrillation: an analysis of the Flec-SL trial.
Apostolakis S, Haeusler KG, Oeff M, Treszl A, Andresen D, Borggrefe M, Lip GY, Meinertz T, Parade U,
Samol A, Steinbeck G, Wegscheider K, Breithardt G, Kirchhof P.
Int J Cardiol. 2013 Oct 9;168(4):3977-81. doi: 10.1016/j.ijcard.2013.06.090.
448. Monocytes circulate in constant reversible interaction with platelets in a [Ca2+]-dependent
manner.
Shantsila E, Montoro-Garcia S, Lip GY.
Platelets. 2014;25(3):197-201. doi: 10.3109/09537104.2013.784248.
449. Antiplatelet therapy and anticoagulants.
Schlitt A, Rubboli A, Airaksinen KE, Lip GY.
Lancet. 2013 Jul 6;382(9886):24-5. doi: 10.1016/S0140-6736(13)61521-4.
450. Response to letter regarding article, "Bridging evidence-based practice and practice-based
evidence in periprocedural anticoagulation".
Gallego P, Apostolakis S, Lip GY.
Circulation. 2013 May 14;127(19):e617.
451. Reply: Dabigatran's 'real-world' data about risk of myocardial infarction and gastrointestinal
bleeding contradicts with randomized trials.
Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, Lip GY.
J Am Coll Cardiol. 2013 Sep 3;62(10):946-7. doi: 10.1016/j.jacc.2013.05.067.
452. Recent developments in understanding epidemiology and risk determinants of atrial fibrillation
as a cause of stroke.
Ahmad Y, Lip GY, Lane DA.
Can J Cardiol. 2013 Jul;29(7 Suppl):S4-S13. doi: 10.1016/j.cjca.2013.03.009. Review.
PMID:
453. Bridging therapy: a challenging area in the management of patients with atrial fibrillation.
Guo Y, Lip GY, Apostolakis S.
Am J Cardiovasc Drugs. 2013 Aug;13(4):259-61. doi: 10.1007/s40256-013-0032-5.
454.
Alcohol intake and prognosis of atrial fibrillation.
Overvad TF, Rasmussen LH, Skjøth F, Overvad K, Albertsen IE, Lane DA, Lip GY, Larsen TB.
Heart. 2013 Aug;99(15):1093-9. doi: 10.1136/heartjnl-2013-304036.
455. The management of patients with atrial fibrillation undergoing percutaneous coronary
intervention with stent implantation: in-hospital-data from the Atrial Fibrillation undergoing
Coronary Artery Stenting study.
Schlitt A, Rubboli A, Lip GY, Lahtela H, Valencia J, Karjalainen PP, Weber M, Laine M, Kirchhof P,
Niemelä M, Vikman S, Buerke M, Airaksinen KE; AFCAS (Management of patients with Atrial
Fibrillation undergoing Coronary Artery Stenting Study Group).
48
Catheter Cardiovasc Interv. 2013 Dec 1;82(7):E864-70. doi: 10.1002/ccd.25064.
456 Warfarin for stroke prevention in atrial fibrillation: time to switch?
Ahmad Y, Lip GY.
Int J Clin Pract. 2013 Jul;67(7):603-5. doi: 10.1111/ijcp.12157.
457. Pharmacokinetic considerations for antithrombotic therapies in stroke.
Apostolakis S, Lip GY, Shantsila E.
Expert Opin Drug Metab Toxicol. 2013 Oct;9(10):1335-47. doi: 10.1517/17425255.2013.808331.
458. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction
and coronary intervention.
Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A, Christensen
CB, Lip GY, Køber L, Torp-Pedersen C, Hansen ML.
J Am Coll Cardiol. 2013 Sep 10;62(11):981-9. doi: 10.1016/j.jacc.2013.05.029.
459. Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation.
Ng KP, Edwards NC, Lip GY, Townend JN, Ferro CJ.
Am J Kidney Dis. 2013 Sep;62(3):615-32. doi: 10.1053/j.ajkd.2013.02.381.
460. Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute
coronary syndromes.
Huber K, Lip GY.
Thromb Haemost. 2013 Jul;110(1):11-3. doi: 10.1160/TH13-06-0453. Epub 2013 Jun 7.
461. Increased expression of cell adhesion molecule receptors on monocyte subsets in ischaemic
heart failure.
Wrigley BJ, Shantsila E, Tapp LD, Lip GY.
Thromb Haemost. 2013 Jul;110(1):92-100. doi: 10.1160/TH13-02-0088.
462 Atrial fibrillation as a risk factor for cognitive impairment: a semi-systematic review.
Udompanich S, Lip GY, Apostolakis S, Lane DA.
QJM. 2013 Sep;106(9):795-802. doi: 10.1093/qjmed/hct129.
463. Cardioversion for atrial fibrillation in current European practice: results of the European Heart
Rhythm Association survey.
Hernández-Madrid A, Svendsen JH, Lip GY, Van Gelder IC, Dobreanu D, Blomstrom-Lundqvist C;
Scientific Initiatives Committee, European Heart Rhythm Association (EHRA).
Europace. 2013 Jun;15(6):915-8. doi: 10.1093/europace/eut143.
464. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at
risk of stroke: perspectives from the international, observational, prospective GARFIELD registry.
Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GY,
Mantovani LG, Turpie AG, van Eickels M, Misselwitz F, Rushton-Smith S, Kayani G, Wilkinson P,
Verheugt FW; GARFIELD Registry Investigators.
PLoS One. 2013 May 21;8(5):e63479. doi: 10.1371/journal.pone.0063479. Print 2013.
465. Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in
heart failure: background, aims and design of the RACE 3 study.
Alings M, Smit MD, Moes ML, Crijns HJ, Tijssen JG, Brügemann J, Hillege HL, Lane DA, Lip GY, Smeets
JR, Tieleman RG, Tukkie R, Willems FF, Vermond RA, Van Veldhuisen DJ, Van Gelder IC.
Neth Heart J. 2013 Jul;21(7-8):354-63. doi: 10.1007/s12471-013-0428-5.
49
466. Angiogenin outperforms VEGF, EPCs and CECs in predicting Dukes' and AJCC stage in colorectal
cancer.
Ramcharan SK, Lip GY, Stonelake PS, Blann AD.
Eur J Clin Invest. 2013 Aug;43(8):801-8. doi: 10.1111/eci.12108.
467. Receptors to interleukin-6 and adhesion molecules on circulating monocyte subsets in acute
myocardial infarction.
Shantsila E, Tapp LD, Wrigley BJ, Montoro-García S, Lip GY.
Thromb Haemost. 2013 Aug;110(2):340-8. doi: 10.1160/TH13-02-0085.
468. Thrombocytopenia in patients with atrial fibrillation on oral anticoagulation undergoing
percutaneous coronary intervention.
Kiviniemi T, Karjalainen P, Rubboli A, Schlitt A, Tuomainen P, Niemelä M, Laine M, Biancari F, Lip GY,
Airaksinen KE.
Am J Cardiol. 2013 Aug 15;112(4):493-8. doi: 10.1016/j.amjcard.2013.04.007.
469. Conventional and new oral anticoagulants in the treatment of chest disease and its
complications.
Gallego P, Roldan V, Lip GY.
Am J Respir Crit Care Med. 2013 Aug 15;188(4):413-21. doi: 10.1164/rccm.201301-0141PP.
470. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on
warfarin: the SAMe-TT₂R₂ score.
Apostolakis S, Sullivan RM, Olshansky B, Lip GY.
Chest. 2013 Nov;144(5):1555-63. doi: 10.1378/chest.13-0054.
471. Retinal vein and artery occlusions: a risk factor for stroke in atrial fibrillation.
Christiansen CB, Lip GY, Lamberts M, Gislason G, Torp-Pedersen C, Olesen JB.
J Thromb Haemost. 2013 Aug;11(8):1485-92. doi: 10.1111/jth.12297.
PMID:
472. Pacemaker or defibrillator surgery without interruption of anticoagulation.
Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, Simpson CS, Ayala-Paredes F, Coutu B,
Leiria TL, Essebag V; BRUISE CONTROL Investigators.
N Engl J Med. 2013 May 30;368(22):2084-93. doi: 10.1056/NEJMoa1302946.
473. Stroke prevention with oral anticoagulation therapy in patients with atrial fibrillation--focus on
the elderly.
Lip GY, Lane DA.
Circ J. 2013;77(6):1380-8.
474. Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on
anticoagulation.
Ahmad Y, Lip GY.
Contrib Nephrol. 2013;179:81-91. doi: 10.1159/000346726.
475. Cholesterol-adjusted vitamin E serum levels are associated with cardiovascular events in
patients with non-valvular atrial fibrillation.
Cangemi R, Pignatelli P, Carnevale R, Corazza GR, Pastori D, Farcomeni A, Basili S, Davì G, Ferro D,
Hiatt WR, Licata G, Lip GY, Loffredo L, Mannucci PM, Vestri A, Violi F; ARA PACIS study group.
Int J Cardiol. 2013 Oct 9;168(4):3241-7. doi: 10.1016/j.ijcard.2013.04.142.
50
476. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study.
Sørensen R, Gislason G, Torp-Pedersen C, Olesen JB, Fosbøl EL, Hvidtfeldt MW, Karasoy D, Lamberts
M, Charlot M, Køber L, Weeke P, Lip GY, Hansen ML.
BMJ Open. 2013 May 3;3(5). pii: e002758. doi: 10.1136/bmjopen-2013-002758.
477. Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position
paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease.
De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K,
Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI;
European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart
Disease.
Thromb Haemost. 2013 May;109(5):769-86. doi: 10.1160/TH12-06-0403.
478. Current strategy for treatment of patients with Wolff-Parkinson-White syndrome and
asymptomatic preexcitation in Europe: European Heart Rhythm Association survey.
Svendsen JH, Dagres N, Dobreanu D, Bongiorni MG, Marinskis G, Blomström-Lundqvist C; Scientific
Initiatives Committee, European Heart Rhythm Association.
Europace. 2013 May;15(5):750-3. doi: 10.1093/europace/eut094.
479. EUR Observational research programme: atrial fibrillation general registry pilot phase.
Lip GY.
Eur Heart J. 2013 Mar;34(11):794. No abstract available.
480. The unmet need of stroke prevention in atrial fibrillation in the far East and South East Asia.
Guo Y, Lip GY, Apostolakis S.
Malays J Med Sci. 2012 Jul;19(3):1-7.
481. Body mass index and adverse events in patients with incident atrial fibrillation.
Overvad TF, Rasmussen LH, Skjøth F, Overvad K, Lip GY, Larsen TB.
Am J Med. 2013 Jul;126(7):640.e9-17. doi: 10.1016/j.amjmed.2012.11.024. Epub 2013 Apr 17.
482. Heart failure in East Asia.
Guo Y, Lip GY, Banerjee A.
Curr Cardiol Rev. 2013 May;9(2):112-22. Review.
483. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc
stroke stratification risk scores for atrial fibrillation?
Roldán V, Marín F, Manzano-Fernandez S, Fernández H, Gallego P, Valdés M, Vicente V, Lip GY.
Thromb Haemost. 2013 May;109(5):956-60. doi: 10.1160/TH13-01-0054.
484. Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial
fibrillation: a prospective nationwide cohort study.
Larsen TB, Rasmussen LH, Skjøth F, Due KM, Callréus T, Rosenzweig M, Lip GY.
J Am Coll Cardiol. 2013 Jun 4;61(22):2264-73. doi: 10.1016/j.jacc.2013.03.020.
485.
Atrial fibrillation: Anticoagulation for AF: can we GRASP-AF patients?
Lane DA, Lip GY.
Nat Rev Cardiol. 2013 May;10(5):241-2. doi: 10.1038/nrcardio.2013.47. Epub 2013 Apr 2. No abstract
available.
51
486. Bleeding risk during oral anticoagulation therapy for atrial fibrillation.
Gallego P, Lip GY, Lane DA.
Europace. 2013 Jun;15(6):773-4. doi: 10.1093/europace/eut061. Epub 2013 Mar 28. No abstract
available.
487.
Inflammation does not influence arterial stiffness and pulse-wave velocity in patients with coronary
artery disease.
Blann AD, Kuzniatsova N, Lip GY.
J Hum Hypertens. 2013 Oct;27(10):629-34. doi: 10.1038/jhh.2013.17.
488. Current practice of antiarrhythmic drug therapy for prevention of atrial fibrillation in Europe:
The European Heart Rhythm Association survey.
Dagres N, Lewalter T, Lip GY, Pison L, Proclemer A, Blomström-Lundqvist C; Scientific Initiatives
Committee, European Heart Rhythm Association.
Europace. 2013 Apr;15(4):478-81. doi: 10.1093/europace/eut063.
488. Awareness and treatment of atrial fibrillation in older adults: the present and the future.
Lip GY.
QJM. 2013 May;106(5):393-4. doi: 10.1093/qjmed/hct074. Epub 2013 Mar 23. No abstract available.
490. Renal impairment and ischemic stroke risk assessment in patients with atrial fibrillation: the
Loire Valley Atrial Fibrillation Project.
Banerjee A, Fauchier L, Vourc'h P, Andres CR, Taillandier S, Halimi JM, Lip GY.
J Am Coll Cardiol. 2013 May 21;61(20):2079-87. doi: 10.1016/j.jacc.2013.02.035. Epub 2013 Mar 21.
491. Cardiovascular Risk Profiles amongst Women in a Multiethnic Population in Inner City Britain: A
Potential Impact of Anaemia.
Chackathayil J, Patel JV, Gill PS, Potluri R, Natalwala A, Uppal H, Lavu D, Heun R, Hughes EA, Lip GY.
Int J Endocrinol. 2013;2013:303859. doi: 10.1155/2013/303859.
492.Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a
systematic review and meta-analysis.
Albertsen IE, Rasmussen LH, Overvad TF, Graungaard T, Larsen TB, Lip GY.
Stroke. 2013 May;44(5):1329-36. doi: 10.1161/STROKEAHA.113.000883.
493.Assessment of stroke risk in Middle Eastern patients with atrial fibrillation: the Gulf SAFE
registry.
Apostolakis S, Zubaid M, Rashed WA, Alsheikh-Ali AA, Almahmeed W, Shehab A, Sulaiman K,
Alqudaimi A, Asaad N, Amin H, Lane DA, Lip GY; Gulf Survey of Atrial Fibrillation Events Investigators.
Int J Cardiol. 2013 Sep 30;168(2):1644-6. doi: 10.1016/j.ijcard.2013.02.003.
494. Using the CHA(2)DS(2)-VASc score for stroke risk stratification in atrial fibrillation: a clinical
perspective.
Lip GY.
Expert Rev Cardiovasc Ther. 2013 Mar;11(3):259-62. doi: 10.1586/erc.13.13.
495. Bleeding risk assessment in patients with atrial fibrillation who are taking oral anticoagulants.
Guo Y, Lip GY, Apostolakis S.
Hosp Pract (1995). 2013 Feb;41(1):71-8. doi: 10.3810/hp.2013.02.1012. Review.
52
496. A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
Kasmeridis C, Lip GY, Apostolakis S.
Hosp Pract (1995). 2013 Feb;41(1):61-70. doi: 10.3810/hp.2013.02.1011. Review.
497. Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on
atrial fibrillation: a commentary.
Lip GY.
J Thromb Haemost. 2013 Apr;11(4):615-26. doi: 10.1111/jth.12140.
498. General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of
the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease.
De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K,
Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI;
European Society of Cardiology Working Group on Thrombosis Task Force on Anticoagulants in Heart
Disease.
Thromb Haemost. 2013 Apr;109(4):569-79. doi: 10.1160/TH12-10-0772.
499. The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and
mortality in atrial fibrillation patients: a systematic review.
Anandasundaram B, Lane DA, Apostolakis S, Lip GY.
J Thromb Haemost. 2013 May;11(5):975-87. doi: 10.1111/jth.12177. Review.
500. Upper limb arterial thromboembolism: a systematic review on incidence, risk factors, and
prognosis, including a meta-analysis of risk-modifying drugs.
Andersen LV, Lip GY, Lindholt JS, Frost L.
J Thromb Haemost. 2013 May;11(5):836-44. doi: 10.1111/jth.12181. Review.
501. Questionable levels of evidence in new atrial fibrillation guidelines? Reply.
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P.
Europace. 2013 Mar;15(3):461-2. doi: 10.1093/europace/eus394.
502. 'Patient choice' concept in AF ESC Guidelines: is the clinician giving up? Reply.
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P.
Europace. 2013 Mar;15(3):460-1. doi: 10.1093/europace/eus386.
503. Localized retinal nerve fiber layer defects and arterial hypertension: insights into
pathophysiology and perhaps an eye for detail?
Kalitzeos AA, Heitmar R, Lip GY.
Am J Hypertens. 2013 Apr;26(4):454-5. doi: 10.1093/ajh/hpt013. Epub 2013 Feb 21.
504. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular
disease and antithrombotic therapy.
Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GY, Verheugt FW, Huber K, Grove EL, Morais J,
Husted S, Wassmann S, Rosano G, Atar D, Pathak A, Kjeldsen K, Storey RF; ESC Working Group on
Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis.
Eur Heart J. 2013 Jun;34(23):1708-13, 1713a-1713b. doi: 10.1093/eurheartj/eht042.
505. A happy new year 2013 for Thrombosis and Haemostasis.
Weber C, Lip GY.
Thromb Haemost. 2013 Jan;109(1):1-2.
53
506.
Small-size circulating microparticles in acute coronary syndromes: relevance to fibrinolytic status,
reparative markers and outcomes.
Montoro-García S, Shantsila E, Tapp LD, López-Cuenca A, Romero AI, Hernández-Romero D, OrenesPiñero E, Manzano-Fernández S, Valdés M, Marín F, Lip GY.
Atherosclerosis. 2013 Apr;227(2):313-22. doi: 10.1016/j.atherosclerosis.2013.01.028.
507. CHADS₂, CHA₂S₂DS₂-VASc, and long-term stroke outcome in patients without atrial fibrillation.
Ntaios G, Lip GY, Makaritsis K, Papavasileiou V, Vemmou A, Koroboki E, Savvari P, Manios E, Milionis
H, Vemmos K.
Neurology. 2013 Mar 12;80(11):1009-17. doi: 10.1212/WNL.0b013e318287281b. Epub 2013 Feb 13.
.
508. Does obesity influence target organ damage and outcomes in patients with malignant phase
hypertension? The West Birmingham Malignant Hypertension Project.
Shantsila A, Lane DA, Beevers DG, Lip GY.
Hypertens Res. 2013 Jun;36(6):546-9. doi: 10.1038/hr.2012.222.
509. Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
Lip GY, Connolly S, Yusuf S, Shestakovska O, Flaker G, Hart R, Lanas F, Xavier D, Eikelboom J; ERROES
Investigators.
Circ Arrhythm Electrophysiol. 2013 Feb;6(1):31-8. doi: 10.1161/CIRCEP.112.975847.
510. The CHADS2 and CHA 2DS 2-VASc scores predict new occurrence of atrial fibrillation and
ischemic stroke.
Zuo ML, Liu S, Chan KH, Lau KK, Chong BH, Lam KF, Chan YH, Lau YF, Lip GY, Lau CP, Tse HF, Siu CW.
J Interv Card Electrophysiol. 2013 Jun;37(1):47-54. doi: 10.1007/s10840-012-9776-0.
511. X-ray exposure hazards for physicians performing ablation procedures and device implantation:
results of the European Heart Rhythm Association survey.
Marinskis G, Bongiorni MG, Dagres N, Lewalter T, Pison L, Blomstrom-Lundqvist C; Scientific Initiative
Committee, European Heart Rhythm Association.
Europace. 2013 Mar;15(3):444-6. doi: 10.1093/europace/eut022.
512. Recent advances in management of atrial fibrillation in patients with heart failure.
Shantsila E, Lip GY.
Curr Opin Cardiol. 2013 Mar;28(2):197-208. doi: 10.1097/HCO.0b013e32835bd465.
513. Relation of renal dysfunction to the increased risk of stroke and death in female patients with
atrial fibrillation.
Guo Y, Wang H, Zhao X, Zhang Y, Zhang D, Ma J, Wang Y, Lip GY.
Int J Cardiol. 2013 Sep 30;168(2):1502-8. doi: 10.1016/j.ijcard.2012.12.099.
514. Estimated glomerular filtration rate is associated with major bleeding complications but not
thromboembolic events, in anticoagulated patients taking warfarin.
Wieloch M, Jönsson KM, Själander A, Lip GY, Eriksson N, Svensson PJ.
Thromb Res. 2013 Jun;131(6):481-6. doi: 10.1016/j.thromres.2013.01.006.
515. Do open label blinded outcome studies of novel anticoagulants versus warfarin have equivalent
validity to those carried out under double-blind conditions?
54
O'Neil WM, Welner SA, Lip GY.
Thromb Haemost. 2013 Mar;109(3):497-503. doi: 10.1160/TH12-10-0715.
516. Reply: To PMID 22858389.
Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY.
J Am Coll Cardiol. 2013 Jan 29;61(4):482-3. doi: 10.1016/j.jacc.2012.10.033. No abstract available.
517. Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation
(implications for thromboembolism and bleeding).
Roldán V, Marín F, Fernández H, Manzano-Fernández S, Gallego P, Valdés M, Vicente V, Lip GY.
Am J Cardiol. 2013 Apr 15;111(8):1159-64. doi: 10.1016/j.amjcard.2012.12.045. Epub 2013 Jan 18.
518. Comparative assessment of the HAS-BLED score with other published bleeding risk scoring
schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: the Chin-Shan
Community Cohort Study.
Lip GY, Lin HJ, Hsu HC, Su TC, Chen MF, Lee YT, Chien KL.
Int J Cardiol. 2013 Oct 3;168(3):1832-6. doi: 10.1016/j.ijcard.2012.12.076. Epub 2013 Jan 19.
519. Current practice in Europe: how do we manage patients with ventricular tachycardia? European
Heart Rhythm Association survey.
Proclemer A, Dagres N, Marinskis G, Pison L, Lip GY, Blomstrom-Lundqvist C; Scientific Initiative
Committee, European Heart Rhythm Association.
Europace. 2013 Feb;15(2):167-9. doi: 10.1093/europace/eus436.
520. Atrial fibrillation and thrombosis: the missing molecular links.
Blann AD, Lip GY.
J Am Coll Cardiol. 2013 Feb 26;61(8):861-2. doi: 10.1016/j.jacc.2012.11.047. Epub 2013 Jan 16. No
abstract available.
521. Left ventricular fibrosis in atrial fibrillation.
Shantsila E, Shantsila A, Blann AD, Lip GY.
Am J Cardiol. 2013 Apr 1;111(7):996-1001. doi: 10.1016/j.amjcard.2012.12.005. Epub 2013 Jan 17.
522. Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.
Adlan AM, Lip GY.
Drug Saf. 2013 Feb;36(2):93-110. doi: 10.1007/s40264-012-0012-8. Review.
523. Predictors and prognostic implications of incident heart failure following the first diagnosis of
atrial fibrillation in patients with structurally normal hearts: the Belgrade Atrial Fibrillation Study.
Potpara TS, Polovina MM, Licina MM, Marinkovic JM, Lip GY.
Eur J Heart Fail. 2013 Apr;15(4):415-24. doi: 10.1093/eurjhf/hft004.
524. Aspirin and aspirin resistance in coronary artery disease.
Kasmeridis C, Apostolakis S, Lip GY.
Curr Opin Pharmacol. 2013 Apr;13(2):242-50. doi: 10.1016/j.coph.2012.12.004. Epub 2013 Jan 5.
Review.
525. Which is the optimal antihypertensive combination in different diseases, a renin- angiotensinaldosterone system inhibitor with a diuretic or with a calcium channel blocker?
Riva N, Lip GY.
55
Curr Pharm Des. 2013;19(21):3753-65. Review.
526. The prognostic role of the adiponectin levels in atrial fibrillation.
Hernández-Romero D, Jover E, Marín F, Vilchez JA, Manzano-Fernandez S, Romera M, Vicente V,
Valdés M, Lip GY, Roldán V.
Eur J Clin Invest. 2013 Feb;43(2):168-73. doi: 10.1111/eci.12028. Epub 2012 Dec 20. Erratum in: Eur J
Clin Invest. 2013 Apr;43(4):428.
527 Reply: To PMID 22575324.
Lip GY, Larsen TB, Skjøth F, Rasmussen LH.
J Am Coll Cardiol. 2013 Feb 5;61(5):596. doi: 10.1016/j.jacc.2012.10.034. Epub 2012 Dec 26. No
abstract available.
.
528. Risk of stroke and oral anticoagulant use in atrial fibrillation: a cross-sectional survey.
Holt TA, Hunter TD, Gunnarsson C, Khan N, Cload P, Lip GY.
Br J Gen Pract. 2012 Oct;62(603):e710-7. doi: 10.3399/bjgp12X656856.
529. Stroke risk stratification scores in atrial fibrillation: current recommendations for clinical
practice and future perspectives.
Durrant J, Lip GY, Lane DA.
Expert Rev Cardiovasc Ther. 2013 Jan;11(1):77-90. doi: 10.1586/erc.12.161. Review.
530. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?
Lip GY.
Eur Heart J. 2013 Apr;34(14):1041-9. doi: 10.1093/eurheartj/ehs435. Epub 2012 Dec 20. Review.
531. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart
failure, diabetes mellitus and paroxysmal atrial fibrillation.
Ahmad Y, Lip GY, Apostolakis S.
Expert Rev Cardiovasc Ther. 2012 Dec;10(12):1471-80. doi: 10.1586/erc.12.148. Review.
532 Performance of the HEMORR 2 HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in
nonwarfarin anticoagulated atrial fibrillation patients.
Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY.
J Am Coll Cardiol. 2013 Jan 22;61(3):386-7. doi: 10.1016/j.jacc.2012.10.010. Epub 2012 Dec 12. No
abstract available.
533. Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to
real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the
General Practice Research Database.
Lee S, Monz BU, Clemens A, Brueckmann M, Lip GY.
BMJ Open. 2012 Dec 14;2(6). pii: e001768. doi: 10.1136/bmjopen-2012-001768. Print 2012.
534. CD14++CD16+ monocytes in patients with acute ischaemic heart failure.
Wrigley BJ, Shantsila E, Tapp LD, Lip GY.
Eur J Clin Invest. 2013 Feb;43(2):121-30. doi: 10.1111/eci.12023. Epub 2012 Dec 14.
535. Left atrial appendage occlusion for stroke prevention in atrial fibrillation in Europe: results of
the European Heart Rhythm Association survey.
Lip GY, Dagres N, Proclemer A, Svendsen JH, Pison L, Blomstrom-Lundqvist C; Scientific Initiative
Committee, European Heart Rhythm Association.
56
Europace. 2013 Jan;15(1):141-3. doi: 10.1093/europace/eus413.
536. Reduction of stroke and mortality in patients with atrial fibrillation by catheter ablation? Finally,
tackling the hard endpoints.
Kornej J, Lip GY, Bollmann A.
Europace. 2013 May;15(5):620-2. doi: 10.1093/europace/eus389. Epub 2012 Dec 11. No abstract
available.
537. Safety and efficacy of new anticoagulants in patients with heart failure.
Pisters R, Lip GY.
Curr Heart Fail Rep. 2013 Mar;10(1):18-25. doi: 10.1007/s11897-012-0125-5. Review.
538. CXCR4 positive and angiogenic monocytes in myocardial infarction.
Shantsila E, Tapp LD, Wrigley BJ, Montoro-García S, Lip GY.
Thromb Haemost. 2013 Feb;109(2):255-62. doi: 10.1160/TH12-06-0395. Epub 2012 Dec 6.
539. The membrane expression of P-selectin, but not monocyte-platelet aggregates, is influenced by
variability in response to aspirin in patients with coronary artery disease.
Kuzniatsova N, Shantsila E, Lip GY, Blann AD.
Platelets. 2014;25(2):142-3. doi: 10.3109/09537104.2012.739720. Epub 2012 Dec 5. No abstract
available.
540. Atherosclerosis and thromboembolic risk in atrial fibrillation: focus on peripheral vascular
disease.
Jover E, Marín F, Roldán V, Montoro-García S, Valdés M, Lip GY.
Ann Med. 2013 May;45(3):274-90. doi: 10.3109/07853890.2012.732702.
541. The challenge of antiplatelet therapy in patients with atrial fibrillation and heart failure.
Guo Y, Lip GY, Apostolakis S.
J Cardiovasc Transl Res. 2013 Jun;6(3):388-97. doi: 10.1007/s12265-012-9427-y. Epub 2012 Dec 4.
Review.
542. Differences between indirect comparison studies of the oral anticoagulants for stroke
prevention in atrial fibrillation: where do we go next?
Harenberg J, Lip GY.
QJM. 2013 Jan;106(1):95-6. doi: 10.1093/qjmed/hcs224. Epub 2012 Dec 1. No abstract available.
543. Oral anticoagulation for heart failure in sinus rhythm: from evidence to clinical
recommendations, or not?
Marín F, Lip GY.
Eur J Heart Fail. 2013 Jan;15(1):3-4. doi: 10.1093/eurjhf/hfs198.
544. Vascular and platelet responses to aspirin in patients with coronary artery disease.
Blann AD, Kuzniatsova N, Lip GY.
Eur J Clin Invest. 2013 Jan;43(1):91-9. doi: 10.1111/eci.12021.
545. Inflammation in atrial fibrillation.
Guo Y, Lip GY, Apostolakis S.
J Am Coll Cardiol. 2012 Dec 4;60(22):2263-70. doi: 10.1016/j.jacc.2012.04.063. Review.
57
546. Sympathetic nerve activity during non-sustained ventricular tachycardia in chronic heart failure.
Adlan AM, Lip GY, Fadel PJ, Fisher JP.
Int J Cardiol. 2013 May 10;165(2):e15-7. doi: 10.1016/j.ijcard.2012.10.088. Epub 2012 Nov 22. No
abstract available.
547.Potential net clinical benefit of population-wide implementation of apixaban and dabigatran
among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey.
Pisters R, Nieuwlaat R, Lane DA, Crijns HJ, Lip GY.
Thromb Haemost. 2013 Feb;109(2):328-36. doi: 10.1160/TH12-08-0539.
548. Validation of contemporary stroke and bleeding risk stratification scores in non-anticoagulated
Chinese patients with atrial fibrillation.
Guo Y, Apostolakis S, Blann AD, Wang H, Zhao X, Zhang Y, Zhang D, Ma J, Wang Y, Lip GY.
Int J Cardiol. 2013 Sep 30;168(2):904-9. doi: 10.1016/j.ijcard.2012.10.052.
549. Increased formation of monocyte-platelet aggregates in ischemic heart failure.
Wrigley BJ, Shantsila E, Tapp LD, Lip GY.
Circ Heart Fail. 2013 Jan;6(1):127-35. doi: 10.1161/CIRCHEARTFAILURE.112.968073.
550. Retinal vessel tortuosity measures and their applications.
Kalitzeos AA, Lip GY, Heitmar R.
Exp Eye Res. 2013 Jan;106:40-6. doi: 10.1016/j.exer.2012.10.015. Epub 2012 Nov 9.
551. Is the higher risk of cardiovascular disease amongst South Asian populations linked to
abnormalities of haemoglobin? A preliminary case control study.
Patel JV, Chackathayil J, Gammon B, Tracey I, Lovick A, Gill PS, Banerjee A, Scarff CA, Scrivens JH,Lip
GY, Hughes EA.
Atherosclerosis. 2013 Jan;226(1):198-200. doi: 10.1016/j.atherosclerosis.2012.09.017. Epub 2012 Oct
25.
552. Vitamin D deficiency amongst minority ethnic groups in the UK: a cross sectional study.
Patel JV, Chackathayil J, Hughes EA, Webster C, Lip GY, Gill PS.
Int J Cardiol. 2013 Sep 1;167(5):2172-6. doi: 10.1016/j.ijcard.2012.05.081. Epub 2012 Nov 7.
553. Performing magnetic resonance imaging in patients with implantable pacemakers and
defibrillators: results of a European Heart Rhythm Association survey.
Marinskis G, Bongiorni MG, Dagres N, Dobreanu D, Lewalter T, Blomström-Lundqvist C; Scientific
Initiative Committee, European Heart Rhythm Association.
Europace. 2012 Dec;14(12):1807-9. doi: 10.1093/europace/eus379.
554. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in
atrial fibrillation: indirect comparison analysis.
Rasmussen LH, Larsen TB, Graungaard T, Skjøth F, Lip GY.
BMJ. 2012 Nov 5;345:e7097. doi: 10.1136/bmj.e7097.
555. TLR4 expression on monocyte subsets in myocardial infarction.
Tapp LD, Shantsila E, Wrigley BJ, Montoro-Garcia S, Lip GY.
J Intern Med. 2013 Mar;273(3):294-305. doi: 10.1111/joim.12011. Epub 2012 Dec 28.
.
556. Prior aspirin therapy and cardiovascular implantable electronic device infections.
Gallego P, Marin F, Lip GY.
58
Europace. 2013 Feb;15(2):163-4. doi: 10.1093/europace/eus346. Epub 2012 Nov 1. No abstract
available.
557. Pre and post-operative treatments for prevention of atrial fibrillation after cardiac surgery.
Orenes-Piñero E, Montoro-García S, Banerjee A, Valdés M, Lip GY, Marín F.
Mini Rev Med Chem. 2012 Nov;12(13):1419-31. Review.
'
558. How European centres diagnose, treat, and prevent CIED infections: results of an European
Heart Rhythm Association survey.
Bongiorni MG, Marinskis G, Lip GY, Svendsen JH, Dobreanu D, Blomström-Lundqvist C; Scientific
Initiative Committee, European Heart Rhythm Association.
Europace. 2012 Nov;14(11):1666-9. doi: 10.1093/europace/eus350.
559. Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: would
the novel oral anticoagulants have an impact?
Guo Y, Pisters R, Apostolakis S, Blann AD, Wang H, Zhao X, Zhang Y, Zhang D, Ma J, Wang Y, Lip GY.
Int J Cardiol. 2013 Sep 20;168(1):515-22. doi: 10.1016/j.ijcard.2012.09.187. Epub 2012 Oct 23.
560. Antithrombotic management and type of stent in atrial fibrillation patients undergoing
percutaneous coronary intervention.
Ruiz-Nodar JM, Marín F, Lip GY.
Rev Esp Cardiol (Engl Ed). 2013 Jan;66(1):12-6. doi: 10.1016/j.recesp.2012.07.018.
561. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive
summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working
Group on Thrombosis.
Lip GY, Piotrponikowski P, Andreotti F, Anker SD, Filippatos G, Homma S, Morais J, Pullicino P,
Rasmussen LH, Marín F, Lane DA; Heart Failure Association (EHFA) of the European Society of
Cardiology (ESC) and the ESC Working Group on Thrombosis.
Thromb Haemost. 2012 Dec;108(6):1009-22. doi: 10.1160/TH12-08-0578. Epub 2012 Oct 23.
562. Comparative assessment of published atrial fibrillation stroke risk stratification schemes for
predicting stroke, in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study.
Lip GY, Lin HJ, Chien KL, Hsu HC, Su TC, Chen MF, Lee YT.
Int J Cardiol. 2013 Sep 20;168(1):414-9. doi: 10.1016/j.ijcard.2012.09.148.
563. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and
meta-analysis of the literature.
Dentali F, Riva N, Crowther M, Turpie AG, Lip GY, Ageno W.
Circulation. 2012 Nov 13;126(20):2381-91. doi: 10.1161/CIRCULATIONAHA.112.115410.
564. Role of microRNAs in cardiac remodelling: new insights and future perspectives.
Orenes-Piñero E, Montoro-García S, Patel JV, Valdés M, Marín F, Lip GY.
Int J Cardiol. 2013 Sep 1;167(5):1651-9. doi: 10.1016/j.ijcard.2012.09.120. Epub 2012 Oct 9. Review.
565. Ankle brachial index as an independent predictor of mortality in anticoagulated atrial fibrillation.
Gallego P, Roldán V, Marín F, Jover E, Manzano-Fernández S, Valdés M, Vicente V, Lip GY.
Eur J Clin Invest. 2012 Dec;42(12):1302-8. doi: 10.1111/eci.12004.
566. The immunological axis in heart failure: importance of the leukocyte differential.
Vaduganathan M, Greene SJ, Butler J, Sabbah HN, Shantsila E, Lip GY, Gheorghiade M.
59
Heart Fail Rev. 2013 Nov;18(6):835-45. doi: 10.1007/s10741-012-9352-9. Review.
.
567. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation
unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation
patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial.
Flaker GC, Eikelboom JW, Shestakovska O, Connolly SJ, Kaatz S, Budaj A, Husted S, Yusuf S, Lip GY,
Hart RG.
Stroke. 2012 Dec;43(12):3291-7. doi: 10.1161/STROKEAHA.112.664144.
568. RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and
characteristics of participating centers.
Crijns HJ, Bash LD, Chazelle F, Le Heuzey JY, Lewalter T, Lip GY, Maggioni AP, Martín A, Ponikowski P,
Rosenqvist M, Sanders P, Scanavacca M, Bernhardt AA, Unniachan S, Phatak HM, Gitt AK.
BMC Cardiovasc Disord. 2012 Oct 2;12:85. doi: 10.1186/1471-2261-12-85.
569. The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of
1 who are unlikely to benefit from oral anticoagulant therapy.
Coppens M, Eikelboom JW, Hart RG, Yusuf S, Lip GY, Dorian P, Shestakovska O, Connolly SJ.
Eur Heart J. 2013 Jan;34(3):170-6. doi: 10.1093/eurheartj/ehs314.
570. Bridging Therapy: A Challenging Area in the Management of Patients with Atrial Fibrillation.
Guo Y, Lip GY, Apostolakis S.
Am J Cardiovasc Drugs. 2012 Sep 28. doi: 10.2165/11634490-000000000-00000. [Epub ahead of
print] No abstract available.
571. Atrial fibrillation ablation techniques.
Lewalter T, Dobreanu D, Proclemer A, Marinskis G, Pison L, Blomström-Lundqvist C; Scientific
Initiative Committee-European Heart Rhythm Association.
Europace. 2012 Oct;14(10):1515-7.
572 Bridging evidence-based practice and practice-based evidence in periprocedural anticoagulation.
Gallego P, Apostolakis S, Lip GY.
Circulation. 2012 Sep 25;126(13):1573-6. No abstract available.
573. Stroke and thromboembolism in atrial fibrillation.
Pisters R, Lane DA, Marin F, Camm AJ, Lip GY.
Circ J. 2012;76(10):2289-304. Epub 2012 Sep 19. Review.
574. Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to
differences in warfarin anticoagulation control (from AFFIRM).
Sullivan RM, Zhang J, Zamba G, Lip GY, Olshansky B.
Am J Cardiol. 2012 Dec 15;110(12):1799-802. doi: 10.1016/j.amjcard.2012.08.014. Epub 2012 Sep 18.
575. Oral anticoagulation improves the prognosis of octogenarian patients with atrial fibrillation
undergoing percutaneous coronary intervention and stenting.
Caballero L, Ruiz-Nodar JM, Marín F, Roldán V, Hurtado JA, Valencia J, Manzano-Fernandez S, Sogorb
F, Valdes M, Lip GY.
Age Ageing. 2013 Jan;42(1):70-5. doi: 10.1093/ageing/afs121. Epub 2012 Sep 14.
576. A proposal for new clinical concepts in the management of atrial fibrillation.
60
Camm AJ, Al-Khatib SM, Calkins H, Halperin JL, Kirchhof P, Lip GY, Nattel S, Ruskin J, Banerjee A,
Blendea D, Guasch E, Needleman M, Savelieva I, Viles-Gonzalez J, Williams ES.
Am Heart J. 2012 Sep;164(3):292-302.e1. doi: 10.1016/j.ahj.2012.05.017. Epub 2012 Aug 3. Review.
577. Evaluation of carotid plaque neovascularization using contrast ultrasound.
Jaipersad AS, Shantsila A, Silverman S, Lip GY, Shantsila E.
Angiology. 2013 Aug;64(6):447-50. doi: 10.1177/0003319712457013. Epub 2012 Aug 23.
578. Seasonality, incidence and prognosis in atrial fibrillation and stroke in Denmark and New
Zealand.
Christensen AL, Rasmussen LH, Baker MG, Lip GY, Dethlefsen C, Larsen TB.
BMJ Open. 2012 Aug 24;2(4). pii: e001210. doi: 10.1136/bmjopen-2012-001210. Print 2012.
579. Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation
project.
Lip GY, Banerjee A, Lagrenade I, Lane DA, Taillandier S, Fauchier L.
Circ Arrhythm Electrophysiol. 2012 Oct;5(5):941-8. doi: 10.1161/CIRCEP.112.972869. Epub 2012 Aug
24.
580. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update
of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special
contribution of the European Heart Rhythm Association.
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC
Committee for Practice Guidelines-CPG; Document Reviewers.
Europace. 2012 Oct;14(10):1385-413. Epub 2012 Aug 24. No abstract available.
581. Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on
the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the
European Association for Cardio-Thoracic Surgery (EACTS).
Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, Borger MA, Carrel
TP, De Bonis M, Evangelista A, Falk V, Lung B, Lancellotti P, Pierard L, Price S, Schäfers HJ, Schuler G,
Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M; ESC
Committee for Practice Guidelines (CPG); Joint Task Force on the Management of Valvular Heart
Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic
Surgery (EACTS).
Eur J Cardiothorac Surg. 2012 Oct;42(4):S1-44. doi: 10.1093/ejcts/ezs455. Epub 2012 Aug 25. No
abstract available.
582. Guidelines on the management of valvular heart disease (version 2012).
Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology
(ESC); European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F,
Antunes MJ, Barón-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A,
Falk V, Iung B, Lancellotti P, Pierard L, Price S, Schäfers HJ, Schuler G, Stepinska J, Swedberg K,
Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, Zembala M.
Eur Heart J. 2012 Oct;33(19):2451-96. doi: 10.1093/eurheartj/ehs109. Epub 2012 Aug 24. No abstract
available.
583. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update
of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special
contribution of the European Heart Rhythm Association.
61
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC
Committee for Practice Guidelines (CPG).
Eur Heart J. 2012 Nov;33(21):2719-47. doi: 10.1093/eurheartj/ehs253. Epub 2012 Aug 24. No
abstract available. Erratum in: Eur Heart J. 2013 Mar;34(10):790. Eur Heart J. 2013 Sep;34(36):28501.
584 Stroke prevention in atrial fibrillation: concepts and controversies.
Ahmad Y, Lip GY.
Curr Cardiol Rev. 2012 Nov;8(4):290-301. Review.
585.Antiplatelet therapy in stroke prevention.
Apostolakis S, Marín F, Lip GY.
Adv Cardiol. 2012;47:141-54. doi: 10.1159/000338050. Epub 2012 Aug 9. Review.
586. Insights from the RCPE UK Consensus Conference on approaching the comprehensive
management of atrial fibrillation.
Lip GY, Ramsay SG.
Expert Rev Cardiovasc Ther. 2012 Jun;10(6):697-700. doi: 10.1586/erc.12.48.
587. Stroke and bleeding in atrial fibrillation with chronic kidney disease.
Olesen JB, Lip GY, Kamper AL, Hommel K, Køber L, Lane DA, Lindhardsen J, Gislason GH, TorpPedersen C.
N Engl J Med. 2012 Aug 16;367(7):625-35. doi: 10.1056/NEJMoa1105594. Erratum in: N Engl J Med.
2012 Dec 6;367(23):2262.
588. Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for
thromboprophylaxis in nonvalvular atrial fibrillation.
Lane DA, Lip GY.
Circulation. 2012 Aug 14;126(7):860-5. doi: 10.1161/CIRCULATIONAHA.111.060061. No abstract
available.
589. Prevention of venous thromboembolism with new oral anticoagulants versus standard
pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.
Albertsen IE, Larsen TB, Rasmussen LH, Overvad TF, Lip GY.
Drugs. 2012 Sep 10;72(13):1755-64. doi: 10.2165/11635630-000000000-00000. Review.
590. Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in
patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of
SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study.
Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY.
J Am Coll Cardiol. 2012 Aug 28;60(9):861-7. doi: 10.1016/j.jacc.2012.06.019
591. Current practice in out-of-hospital cardiac arrest management: a European heart rhythm
association EP network survey.
Proclemer A, Dobreanu D, Pison L, Lip GY, Svendsen JH, Lundqvist CB; Scientific Initiative CommitteeEuropean Heart Rhythm Association.
Europace. 2012 Aug;14(8):1195-8. doi: 10.1093/europace/eus232.
592. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task
Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European
Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.
62
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G,
Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM,
Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA,
Zannad F, Zeiher A; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure
2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C,
Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C,
Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S,
McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P,
Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN,
Nielsen OW, Orn S, Parissis JT, Ponikowski P; ESC Committee for Practice Guidelines.
Eur J Heart Fail. 2012 Aug;14(8):803-69. doi: 10.1093/eurjhf/hfs105. No abstract available. Erratum
in: Eur J Heart Fail. 2013 Mar;15(3):361-2.
593. Periprocedural antithrombotic management of patients undergoing ablation for atrial
fibrillation: what we currently do...and what should we do?
Pisters R, Lip GY.
Can J Cardiol. 2013 Feb;29(2):139-41. doi: 10.1016/j.cjca.2012.05.016. Epub 2012 Jul 20. No abstract
available.
594. Renal function and aspirin resistance in patients with coronary artery disease.
Blann AD, Kuzniatsova N, Velu S, Lip GY.
Thromb Res. 2012 Sep;130(3):e103-6. doi: 10.1016/j.thromres.2012.06.026. Epub 2012 Jul 17.
595. Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study.
Mikkelsen AP, Lindhardsen J, Lip GY, Gislason GH, Torp-Pedersen C, Olesen JB.
J Thromb Haemost. 2012 Sep;10(9):1745-51. doi: 10.1111/j.1538-7836.2012.04853.x.
596. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with
atrial fibrillation using network meta-analysis.
Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.
Int Angiol. 2012 Aug;31(4):330-9. Review.
597. Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project.
Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY, Fauchier L.
Int J Cardiol. 2013 Sep 10;167(6):2682-7. doi: 10.1016/j.ijcard.2012.06.118. Epub 2012 Jul 15.
598. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation
undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?
Ruiz-Nodar JM, Marín F, Roldán V, Valencia J, Manzano-Fernández S, Caballero L, Hurtado JA, Sogorb
F, Valdés M, Lip GY.
Circ Cardiovasc Interv. 2012 Aug 1;5(4):459-66. doi: 10.1161/CIRCINTERVENTIONS.112.968792. Epub
2012 Jul 10.
599. Edoxaban in Japanese patients with nonvalvular atrial fibrillation: not the same dose for
everybody.
Roldán V, Marín F, Lip GY.
Circ J. 2012;76(8):1826-7. Epub 2012 Jul 29. No abstract available.
600. Stroke and mortality in patients with incident heart failure: the Diet, Cancer and Health (DCH)
cohort study.
Lip GY, Rasmussen LH, Skjøth F, Overvad K, Larsen TB.
63
BMJ Open. 2012 Jul 7;2(4). pii: e000975. doi: 10.1136/bmjopen-2012-000975. Print 2012.
601. Eosinophil count predicts mortality following percutaneous coronary intervention.
Toor IS, Jaumdally R, Lip GY, Millane T, Varma C.
Thromb Res. 2012 Oct;130(4):607-11. doi: 10.1016/j.thromres.2012.05.033. Epub 2012 Jul 6.
.
602. Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical
investigation.
Ahrens I, Peter K, Lip GY, Bode C.
Discov Med. 2012 Jun;13(73):445-50. Review.
603. Development and clinical applications of novel oral anticoagulants. Part I. Clinically approved
drugs.
Ahrens I, Peter K, Lip GY, Bode C.
Discov Med. 2012 Jun;13(73):433-43. Review.
604 An innovative flow cytometric approach for small-size platelet microparticles: influence of
calcium.
Montoro-García S, Shantsila E, Orenes-Piñero E, Lozano ML, Lip GY.
Thromb Haemost. 2012 Aug;108(2):373-83. doi: 10.1160/TH12-02-0120. Epub 2012 Jun 28.
605. New anticoagulant treatments to protect against stroke in atrial fibrillation.
Potpara TS, Lip GY, Apostolakis S.
Heart. 2012 Sep;98(18):1341-7. doi: 10.1136/heartjnl-2012-301841. Epub 2012 Jun 22. Review.
606. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a
"real-world" population with atrial fibrillation receiving anticoagulant therapy.
Roldán V, Marín F, Fernández H, Manzano-Fernandez S, Gallego P, Valdés M, Vicente V, Lip GY.
Chest. 2013 Jan;143(1):179-84.
607. Subclinical atherosclerotic endothelial damage as predictor for bleeding in anticoagulated atrial
fibrillation patients.
Hernández-Romero D, Marín F, Roldán V, Lip GY.
J Intern Med. 2012 Oct;272(4):409. doi: 10.1111/j.1365-2796.2012.02565.x. Epub 2012 Jul 27. No
abstract available.
608. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation:
NICE guidance.
Ahmad Y, Lip GY.
Heart. 2012 Oct;98(19):1404-6. doi: 10.1136/heartjnl-2012-302101. Epub 2012 Jun 14. No abstract
available.
609. Anticoagulation versus placebo for heart failure in sinus rhythm.
Lip GY, Wrigley BJ, Pisters R.
Cochrane Database Syst Rev. 2012 Jun 13;6:CD003336. doi: 10.1002/14651858.CD003336.pub2.
Review. Update in: Cochrane Database Syst Rev. 2014;3:CD003336.
610. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.
Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.
64
611. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and
mortality in anticoagulated patients with atrial fibrillation.
Roldán V, Marín F, Díaz J, Gallego P, Jover E, Romera M, Manzano-Fernández S, Casas T, Valdés M,
Vicente V, Lip GY.
J Thromb Haemost. 2012 Aug;10(8):1500-7. doi: 10.1111/j.1538-7836.2012.04812.x.
612. A contemporary view on endothelial function in heart failure.
Shantsila E, Wrigley BJ, Blann AD, Gill PS, Lip GY.
Eur J Heart Fail. 2012 Aug;14(8):873-81. doi: 10.1093/eurjhf/hfs066. Epub 2012 Jun 7. Review.
613. Role of the CHADS2 score in acute coronary syndromes: with or without atrial fibrillation.
Adlan AM, Lip GY.
Chest. 2012 Jun;141(6):1375-6. doi: 10.1378/chest.11-2780. No abstract available.
614. Bleeding risk assessment and management in atrial fibrillation patients. Key messages for
clinical practice from the European Heart Rhythm Association position statement.
Guo Y, Lip GY, Apostolakis S.
Pol Arch Med Wewn. 2012;122(5):235-42. Review.
615. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide
retrospective cohort study.
Friberg L, Benson L, Rosenqvist M, Lip GY.
BMJ. 2012 May 30;344:e3522. doi: 10.1136/bmj.e3522.
616. How early is early enough to prevent stroke in atrial fibrillation?
Guo Y, Lip GY, Apostolakis S.
Expert Rev Cardiovasc Ther. 2012 May;10(5):585-8. doi: 10.1586/erc.12.36.
617. Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban.
Apostolakis S, Lip GY.
Expert Opin Investig Drugs. 2012 Jul;21(7):1057-64. doi: 10.1517/13543784.2012.689286. Epub 2012
May 23. Review.
618. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task
Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European
Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G,
Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM,
Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA,
Zannad F, Zeiher A; ESC Committee for Practice Guidelines.
Eur Heart J. 2012 Jul;33(14):1787-847. doi: 10.1093/eurheartj/ehs104. Epub 2012 May 19. No
abstract available. Erratum in: Eur Heart J. 2013 Jan;34(2):158.
619. Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint
consensus document from the ESC Heart Failure Association and the ESC Working Group on
Thrombosis.
Lip GY, Ponikowski P, Andreotti F, Anker SD, Filippatos G, Homma S, Morais J, Pullicino P, Rasmussen
LH, Marin F, Lane DA; ESC Task Force.
Eur J Heart Fail. 2012 Jul;14(7):681-95. doi: 10.1093/eurjhf/hfs073. Epub 2012 May 19. Review.
.
65
620. Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke
despite oral anticoagulation.
Jover E, Roldán V, Gallego P, Hernández-Romero D, Valdés M, Vicente V, Lip GY, Marín F.
Rev Esp Cardiol (Engl Ed). 2012 Jul;65(7):627-33. doi: 10.1016/j.recesp.2012.02.017.
621. A cross-sectional study of quality of life in an elderly population (75 years and over) with atrial
fibrillation: secondary analysis of data from the Birmingham Atrial Fibrillation Treatment of the Aged
study.
Roalfe AK, Bryant TL, Davies MH, Hackett TG, Saba S, Fletcher K, Lip GY, Hobbs FD, Mant J; BAFTA
investigators.
Europace. 2012 Oct;14(10):1420-7. Epub 2012 May 10.
622. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study.
Olesen JB, Lip GY, Lane DA, Køber L, Hansen ML, Karasoy D, Hansen CM, Gislason GH, Torp-Pedersen
C.
Am J Med. 2012 Aug;125(8):826.e13-23. doi: 10.1016/j.amjmed.2011.11.024. Epub 2012 May 10.
623. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for
stroke prevention in atrial fibrillation.
Lip GY, Larsen TB, Skjøth F, Rasmussen LH.
J Am Coll Cardiol. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. Epub 2012 May 9.
624. Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable?
Marín F, Roldán V, Lip GY.
Expert Opin Pharmacother. 2012 Jun;13(8):1087-90. doi: 10.1517/14656566.2012.688954. Epub
2012 May 9. No abstract available.
.
625. Warfarin and aspirin in patients with heart failure and sinus rhythm.
Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, Ammon SE, Graham S,
Sacco RL, Mann DL, Mohr JP, Massie BM, Labovitz AJ, Anker SD, Lok DJ, Ponikowski P, Estol CJ, Lip GY,
Di Tullio MR, Sanford AR, Mejia V, Gabriel AP, del Valle ML, Buchsbaum R; WARCEF Investigators.
N Engl J Med. 2012 May 17;366(20):1859-69. doi: 10.1056/NEJMoa1202299. Epub 2012 May 2.
626. Resource utilization and outcomes in patients with atrial fibrillation: a case control study.
Boggon R, Lip GY, Gallagher AM, van Staa TP.
Appl Health Econ Health Policy. 2012 Jul 1;10(4):249-59. doi: 10.2165/11599940-000000000-00000.
.
627. Hospital delay in South Asian patients with acute ST-elevation myocardial infarction in the UK.
Kendall H, Marley A, Patel JV, Khan JM, Blann AD, Lip GY, Dwivedi G.
Eur J Prev Cardiol. 2013 Oct;20(5):737-42. doi: 10.1177/2047487312447844. Epub 2012 Apr 26.
628. Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical
features and pathophysiological pathways.
Shantsila E, Montoro-García S, Tapp LD, Apostolakis S, Wrigley BJ, Lip GY.
Thromb Haemost. 2012 Jul;108(1):32-40. doi: 10.1160/TH12-01-0011. Epub 2012 Apr 27.
629. Added predictive ability of the CHA2DS2VASc risk score for stroke and death in patients with
atrial fibrillation: the prospective Danish Diet, Cancer, and Health cohort study.
Larsen TB, Lip GY, Skjøth F, Due KM, Overvad K, Hvilsted Rasmussen L.
66
Circ Cardiovasc Qual Outcomes. 2012 May;5(3):335-42. doi: 10.1161/CIRCOUTCOMES.111.964023.
Epub 2012 Apr 24.
630. Population health status of South Asian and African-Caribbean communities in the United
Kingdom.
Calvert M, Duffy H, Freemantle N, Davis R, Lip GY, Gill P.
BMC Health Serv Res. 2012 Apr 25;12:101. doi: 10.1186/1472-6963-12-101.
631. Periprocedural anticoagulation therapy for devices and atrial fibrillation ablation.
Lip GY, Proclemer A, Dagres N, Bongiorni MG, Lewalter T, Blomström-Lundqvist C; Scientific Initiative
Committee, European Heart Rhythm Association.
Europace. 2012 May;14(5):741-4. doi: 10.1093/europace/eus105.
632. What is the most effective and safest delivery of thromboprophylaxis in atrial fibrillation?
Lip GY.
J R Coll Physicians Edinb. 2012;42 Suppl 18:35-44. doi: 10.4997/JRCPE.2012.S04.
633. Monocyte-derived and CD34+/KDR+ endothelial progenitor cells in heart failure.
Shantsila E, Wrigley BJ, Shantsila A, Tapp LD, Gill PS, Lip GY.
J Thromb Haemost. 2012 Jul;10(7):1252-61. doi: 10.1111/j.1538-7836.2012.04753.x.
634. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial
fibrillation cohort study.
Friberg L, Rosenqvist M, Lip GY.
Circulation. 2012 May 15;125(19):2298-307. doi: 10.1161/CIRCULATIONAHA.111.055079. Epub 2012
Apr 18.
.
635. Do the current atrial fibrillation guidelines for stroke prevention need to be changed with the
availability of new data on the new oral anticoagulants?
Foley J, Lip GY.
Int J Clin Pract. 2012 May;66(5):422-4. doi: 10.1111/j.1742-1241.2011.02815.x. No abstract available.
636. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group
on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.
De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K,
Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI;
Coordinating Committee.
J Am Coll Cardiol. 2012 Apr 17;59(16):1413-25. doi: 10.1016/j.jacc.2012.02.008. Review.
637. Lack of impact of pulse pressure on outcomes in patients with malignant phase hypertension:
the West Birmingham Malignant Hypertension study.
Shantsila A, Lane DA, Beevers DG, Lip GY.
J Hypertens. 2012 May;30(5):974-9. doi: 10.1097/HJH.0b013e3283526e47.
638. Ethnic/racial differences in circulating markers of angiogenesis and their association with
cardiovascular risk factors and cardiovascular disease.
Bennett PC, Gill PS, Silverman S, Blann AD, Balakrishnan B, Lip GY.
Int J Cardiol. 2013 Aug 20;167(4):1247-50. doi: 10.1016/j.ijcard.2012.03.158. Epub 2012 Apr 9.
639. Prevalence of atrial fibrillation in the general population and in high-risk groups: the ECHOES
study.
67
Davis RC, Hobbs FD, Kenkre JE, Roalfe AK, Iles R, Lip GY, Davies MK.
Europace. 2012 Nov;14(11):1553-9. doi: 10.1093/europace/eus087. Epub 2012 Apr 5.
640. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial
fibrillation with a CHADS2 score 0-1: a nationwide cohort study.
Olesen JB, Torp-Pedersen C, Hansen ML, Lip GY.
Thromb Haemost. 2012 Jun;107(6):1172-9. doi: 10.1160/TH12-03-0175. Epub 2012 Apr 3.
641. Angiotensin receptor blockers and tumorigenesis: something to be (or not to be) concerned
about?
Tchaikovski V, Lip GY.
Curr Hypertens Rep. 2012 Jun;14(3):183-92. doi: 10.1007/s11906-012-0263-x. Review.
.
642. Comparison of frequency of major adverse events in patients with atrial fibrillation receiving
bare-metal versus drug-eluting stents in their coronary arteries.
Fauchier L, Pellegrin C, Bernard A, Clementy N, Angoulvant D, Lip GY, Babuty D.
Am J Cardiol. 2012 Jul 1;110(1):7-12. doi: 10.1016/j.amjcard.2012.02.042. Epub 2012 Mar 29.
643. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of
atrial fibrillation in regions outside North America and Europe.
Lip GY, Brechin CM, Lane DA.
Chest. 2012 Dec;142(6):1489-98. doi: 10.1378/chest.11-2888. Review.
644 Monitoring in the management of atrial fibrillation.
Lewalter T, Morgan J, Halimi F, Lip G, Dagres N, Blomström-Lundqvist C; Scientific Initiative
Committee, European Heart Rhythm Association.
Europace. 2012 Apr;14(4):591-2. doi: 10.1093/europace/eus073.
645. Heparin bridging vs. uninterrupted oral anticoagulation in patients with Atrial Fibrillation
undergoing Coronary Artery Stenting. Results from the AFCAS registry.
Lahtela H, Rubboli A, Schlitt A, Karjalainen PP, Niemelä M, Vikman S, Puurunen M, Weber M, Valencia
J, Biancari F, Lip GY, Airaksinen KE; AFCAS (Management of patients with Atrial Fibrillation
undergoing Coronary Artery Stenting) study group.
Circ J. 2012;76(6):1363-8. Epub 2012 Mar 9.
646. Anthropometric discriminators of the risk of high blood pressure amongst public schoolchildren
in Gujarat, India.
Patel JV, Lip GY, Prabharkaran D, Reddy KS, Gill PS, Hughes EA.
Int J Clin Pract. 2012 Apr;66(4):418-20. doi: 10.1111/j.1742-1241.2011.02875.x. No abstract available.
647. Matrix metalloproteinases and their tissue inhibitors in hypertension-related pregnancy
complications.
Karthikeyan VJ, Lane DA, Beevers DG, Lip GY, Blann AD.
J Hum Hypertens. 2013 Feb;27(2):72-8. doi: 10.1038/jhh.2012.8. Epub 2012 Mar 15. Review.
648. Left ventricular systolic and diastolic function in obstructive sleep apnea: impact of continuous
positive airway pressure therapy.
Butt M, Dwivedi G, Shantsila A, Khair OA, Lip GY.
Circ Heart Fail. 2012 Mar 1;5(2):226-33. doi: 10.1161/CIRCHEARTFAILURE.111.964106. Epub 2012
Mar 13.
68
649. Stroke Prevention in Atrial Fibrillation: Where are We Now?
Ahmad Y, Lip GY.
Clin Med Insights Cardiol. 2012;6:65-78. doi: 10.4137/CMC.S8976. Epub 2012 Feb 23.
650.Highlights of the American Heart Association Scientific Sessions 2011: a focus on ATLAS-TIMI 51,
TRACER and PALLAS.
Shantsila A, Lip GY.
Expert Rev Cardiovasc Ther. 2012 Mar;10(3):305-7. doi: 10.1586/erc.11.192.
651. A contemporary viewpoint on 'aspirin resistance'.
Kuzniatsova N, Shantsila E, Blann A, Lip GY.
Ann Med. 2012 Dec;44(8):773-83. doi: 10.3109/07853890.2011.605388. Epub 2012 Mar 1. Review.
652. Improving thromboprophylaxis using atrial fibrillation diagnostic capabilities in implantable
cardioverter-defibrillators: the multicentre Italian ANGELS of AF Project.
Boriani G, Santini M, Lunati M, Gasparini M, Proclemer A, Landolina M, Padeletti L, Botto GL, Capucci
A, Bianchi S, Biffi M, Ricci RP, Vimercati M, Grammatico A, Lip GY; Italian ClinicalService Project.
Circ Cardiovasc Qual Outcomes. 2012 Mar 1;5(2):182-8. doi: 10.1161/CIRCOUTCOMES.111.964205.
Epub 2012 Feb 28.
653. Vascular ventricular coupling in patients with malignant phase hypertension: the West
Birmingham malignant hypertension project.
Shantsila A, Dwivedi G, Shantsila E, Steeds RP, Beevers G, Lip GY.
Hypertens Res. 2012 Jul;35(7):725-8. doi: 10.1038/hr.2012.18. Epub 2012 Feb 23.
654. The effects of exercise and diurnal variation on monocyte subsets and monocyte-platelet
aggregates.
Shantsila E, Tapp LD, Wrigley BJ, Montoro-Garcia S, Ghattas A, Jaipersad A, Lip GY.
Eur J Clin Invest. 2012 Aug;42(8):832-9. doi: 10.1111/j.1365-2362.2012.02656.x. Epub 2012 Feb 22.
655. Practices of cardiac implantable electronic device follow-up: results of the European Heart
Rhythm Association survey.
Marinskis G, van Erven L, Bongiorni MG, Lip GY, Pison L, Blomström-Lundqvist C; Scientific Initiative
Committee, European Heart Rhythm Association.
Europace. 2012 Mar;14(3):423-5. doi: 10.1093/europace/eus020.
656. A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for
long-term prevention of thromboembolic complications in patients with atrial fibrillation?
Riva N, Lip GY.
Pol Arch Med Wewn. 2012;122(1-2):45-53. Review.
657. Comments on the Spanish Society of Cardiology critical review of the ESC 2010 clinical practice
guidelines on atrial fibrillation.
Lip GY, Camm AJ.
Rev Esp Cardiol (Engl Ed). 2012 Apr;65(4):390-1; author reply 391-2. doi:
10.1016/j.recesp.2011.12.007. Epub 2012 Feb 18. No abstract available.
658. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of
Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice
Guidelines.
69
You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes
M, Spencer FA, Manning WJ, Halperin JL, Lip GY; American College of Chest Physicians.
Chest. 2012 Feb;141(2 Suppl):e531S-75S. doi: 10.1378/chest.11-2304.
659. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and
mortality in anticoagulated patients with atrial fibrillation.
Gallego P, Roldán V, Torregrosa JM, Gálvez J, Valdés M, Vicente V, Marín F, Lip GY.
Circ Arrhythm Electrophysiol. 2012 Apr;5(2):312-8. doi: 10.1161/CIRCEP.111.967000. Epub 2012 Feb
7.
660. Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with
"lone" atrial fibrillation: the Belgrade atrial fibrillation study.
Potpara TS, Polovina MM, Licina MM, Marinkovic JM, Prostran MS, Lip GY.
Circ Arrhythm Electrophysiol. 2012 Apr;5(2):319-26. doi: 10.1161/CIRCEP.111.966713. Epub 2012 Feb
8.
661. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving
uncertainties in routine practice.
Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A.
Thromb Haemost. 2012 May;107(5):838-47. doi: 10.1160/TH11-10-0718. Epub 2012 Feb 8. Review.
662. Metabolic syndrome and renal disease.
Gluba A, Mikhailidis DP, Lip GY, Hannam S, Rysz J, Banach M.
Int J Cardiol. 2013 Apr 5;164(2):141-50. doi: 10.1016/j.ijcard.2012.01.013. Epub 2012 Feb 2. Review.
663. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient
ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.
Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, O'Donnell M, Hohnloser SH, Hankey
GJ, Shestakovska O, Yusuf S; AVERROES Steering Committee and Investigators.
Lancet Neurol. 2012 Mar;11(3):225-31. doi: 10.1016/S1474-4422(12)70017-0. Epub 2012 Feb 1.
664. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire
Valley Atrial Fibrillation Project.
Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY, Fauchier L.
Eur J Heart Fail. 2012 Mar;14(3):295-301. doi: 10.1093/eurjhf/hfs005. Epub 2012 Jan 30.
665. Pharmacological modulation of microparticle release: new strategies for the management of
atherothrombotic vascular disorders.
Montoro-García S, Orenes-Piñero E, Marín F, Mariano, Valdés, Lip GY, Shantsila E.
Curr Pharm Des. 2012;18(6):840-9. Review.
666. Antiplatelet therapy in atherothrombotic cardiovascular diseases for primary and secondary
prevention: a focus on old and new antiplatelet agents.
Pamukcu B, Huber K, Lip GY.
Curr Pharm Des. 2012;18(6):850-60.
667. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based
cohort study.
Taillandier S, Olesen JB, Clémenty N, Lagrenade I, Babuty D, Lip GY, Fauchier L.
J Cardiovasc Electrophysiol. 2012 Jul;23(7):708-13. doi: 10.1111/j.1540-8167.2011.02257.x. Epub
2012 Jan 23.
70
.
668. Outpatient evaluation and management of patients with ventricular premature beats or nonsustained ventricular tachycardia.
Svendsen JH, Goette A, Dobreanu D, Marinskis G, Mabo P, Blomström-Lundqvist C; Scientific
Initiative Committee, European Heart Rhythm Association.
Europace. 2012 Feb;14(2):294-6. doi: 10.1093/europace/eus009.
669. Can we predict stroke in atrial fibrillation?
Lip GY.
Clin Cardiol. 2012 Jan;35 Suppl 1:21-7. doi: 10.1002/clc.20969. Review.
670. Atrial fibrillation and vascular disease--a bad combination.
Olesen JB, Gislason GH, Torp-Pedersen C, Lip GY.
Clin Cardiol. 2012 Jan;35 Suppl 1:15-20. doi: 10.1002/clc.20955. Review.
671. Bleeding risk assessment and management in atrial fibrillation patients.
Lip GY.
Eur Heart J. 2012 Jan;33(2):147-9. doi: 10.1093/eurheartj/ehr431. No abstract available.
672. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients
with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.
Friberg L, Rosenqvist M, Lip GY.
Eur Heart J. 2012 Jun;33(12):1500-10. doi: 10.1093/eurheartj/ehr488. Epub 2012 Jan 13.
673. Blood leukocytes in heart failure with preserved ejection fraction: impact on prognosis.
Shantsila E, Bialiuk N, Navitski D, Pyrochkin A, Gill PS, Pyrochkin V, Snezhitskiy V, Lip GY.
Int J Cardiol. 2012 Mar 8;155(2):337-8. doi: 10.1016/j.ijcard.2011.12.048. Epub 2012 Jan 9. No
abstract available.
674. The CD14++CD16+ monocyte subset and monocyte-platelet interactions in patients with STelevation myocardial infarction.
Tapp LD, Shantsila E, Wrigley BJ, Pamukcu B, Lip GY.
J Thromb Haemost. 2012 Jul;10(7):1231-41. doi: 10.1111/j.1538-7836.2011.04603.x.
675. Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke: a 10year follow-up study.
Vemmos K, Ntaios G, Savvari P, Vemmou AM, Koroboki E, Manios E, Kounali A, Lip GY.
Eur J Heart Fail. 2012 Feb;14(2):211-8. doi: 10.1093/eurjhf/hfr172. Epub 2011 Dec 26.
676. A comprehensive assessment of cardiac structure and function in patients with treated
malignant phase hypertension: the West Birmingham Malignant Hypertension project.
Shantsila A, Dwivedi G, Shantsila E, Butt M, Beevers DG, Lip GY.
Int J Cardiol. 2013 Jul 15;167(1):67-72. doi: 10.1016/j.ijcard.2011.11.077. Epub 2011 Dec 20.
677. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no
treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide
cohort study.
Banerjee A, Lane DA, Torp-Pedersen C, Lip GY.
Thromb Haemost. 2012 Mar;107(3):584-9. doi: 10.1160/TH11-11-0784. Epub 2011 Dec 21.
71
678. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position
paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of
Hypertension.
Manolis AJ, Rosei EA, Coca A, Cifkova R, Erdine SE, Kjeldsen S, Lip GY, Narkiewicz K, Parati G, Redon J,
Schmieder R, Tsioufis C, Mancia G.
J Hypertens. 2012 Feb;30(2):239-52. doi: 10.1097/HJH.0b013e32834f03bf. Review.
679. Atrial fibrillation in 2011: Stroke prevention in AF.
Lip GY.
Nat Rev Cardiol. 2011 Dec 20;9(2):71-3. doi: 10.1038/nrcardio.2011.203. Review.
680. International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global
Anticoagulant Registry in the FIELD (GARFIELD).
Kakkar AK, Mueller I, Bassand JP, Fitzmaurice DA, Goldhaber SZ, Goto S, Haas S, Hacke W, Lip GY,
Mantovani LG, Verheugt FW, Jamal W, Misselwitz F, Rushton-Smith S, Turpie AG.
Am Heart J. 2012 Jan;163(1):13-19.e1. doi: 10.1016/j.ahj.2011.09.011. Epub 2011 Nov 20.
681. Treatment pathways for atrial fibrillation: simplifying the approach to thromboprophylaxis.
Potpara TS, Lip GY.
Int J Clin Pract. 2012 Jan;66(1):4-6. doi: 10.1111/j.1742-1241.2011.02816.x. No abstract available.
682. Oral antithrombotic therapy and gastrointestinal bleeding: the good, the bad and the ugly.
Riva N, Apostolakis S, Lip GY.
Int J Clin Pract. 2012 Jan;66(1):2-4. doi: 10.1111/j.1742-1241.2011.02828.x. No abstract available.
683. Atrial fibrillation.
Lip GY, Tse HF, Lane DA.
Lancet. 2012 Feb 18;379(9816):648-61. doi: 10.1016/S0140-6736(11)61514-6. Epub 2011 Dec 11.
Review.
684. Antiplatelet agents and anticoagulants for hypertension.
Lip GY, Felmeden DC, Dwivedi G.
Cochrane Database Syst Rev. 2011 Dec 7;(12):CD003186. doi: 10.1002/14651858.CD003186.pub3.
Review.
685. Dronedarone: a new hope for stroke prevention in atrial fibrillation?
Shantsila A, Lip GY.
Am J Cardiovasc Drugs. 2011 Dec 1;11(6):355-6. doi: 10.2165/11595330-000000000-00000. No
abstract available.
686 Stroke prevention in atrial fibrillation: do we still need warfarin?
Diener HC, Weber R, Lip GY, Hohnloser SH.
Curr Opin Neurol. 2012 Feb;25(1):27-35. doi: 10.1097/WCO.0b013e32834e604a. Review.
.
687. Diabetes Health, Residence & Metabolism in Asians: the DHRMA study, research into foods from
the Indian subcontinent - a blinded, randomised, placebo controlled trial.
Patel JV, Hughes EA, Lip GY, Gill PS.
BMC Cardiovasc Disord. 2011 Dec 2;11:70. doi: 10.1186/1471-2261-11-70.
688. Idiopathic atrial fibrillation revisited in a large longitudinal clinical cohort.
72
Weijs B, Pisters R, Nieuwlaat R, Breithardt G, Le Heuzey JY, Vardas PE, Limantoro I, Schotten U,Lip GY,
Crijns HJ.
Europace. 2012 Feb;14(2):184-90. doi: 10.1093/europace/eur379. Epub 2011 Dec 1.
689. Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic
review and meta-analysis.
Marchesi C, Dentali F, Nicolini E, Maresca AM, Tayebjee MH, Franz M, Guasti L, Venco A, Schiffrin
EL, Lip GY, Grandi AM.
J Hypertens. 2012 Jan;30(1):3-16. doi: 10.1097/HJH.0b013e32834d249a. Review.
690. Prevalence of heart failure and atrial fibrillation in minority ethnic subjects: the EthnicEchocardiographic Heart of England Screening Study (E-ECHOES).
Gill PS, Calvert M, Davis R, Davies MK, Freemantle N, Lip GY.
PLoS One. 2011;6(11):e26710. doi: 10.1371/journal.pone.0026710. Epub 2011 Nov 16.
691. Systolic heart failure in South Asians.
Shantsila E, Lip GY, Gill PS.
Int J Clin Pract. 2011 Dec;65(12):1274-82. doi: 10.1111/j.1742-1241.2011.02796.x. Review.
692. Differences between South Asians and White Europeans in five year outcome following
percutaneous coronary intervention.
Toor IS, Jaumdally R, Lip GY, Pagano D, Dimitri W, Millane T, Varma C.
Int J Clin Pract. 2011 Dec;65(12):1259-66. doi: 10.1111/j.1742-1241.2011.02776.x.
693. Dronedarone in high-risk permanent atrial fibrillation.
Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum Á, Blomström P,
Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacrétaz E, Di Pasquale
G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbüchel H, Kautzner
J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A,
Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsányi J, Torp-Pedersen C, Tse HF, Vardas
P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S,
Afzal R, Hohnloser SH; PALLAS Investigators.
N Engl J Med. 2011 Dec 15;365(24):2268-76. doi: 10.1056/NEJMoa1109867. Epub 2011 Nov 14.
Erratum in: N Engl J Med. 2012 Feb 16;366(7):672.
694. Atrial fibrillation (chronic).
Lane DA, Apostolakis S, Boos CJ, Lip GY.
BMJ Clin Evid. 2011 Nov 10;2011. pii: 0217. Review.
695. Lone atrial fibrillation: where are we now?
Potpara TS, Lip GY.
Hosp Pract (1995). 2011 Oct;39(4):17-31. doi: 10.3810/hp.2011.10.919. Review.
696. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a
Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European
Society of Cardiology [ESC] Working Group on Thrombosis.
Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marín F, Palareti G,
Kirchhof P; European Heart Rhythm Association.
Thromb Haemost. 2011 Dec;106(6):997-1011. doi: 10.1160/TH11-10-0690. Epub 2011 Nov 2.
73
697. Comprehensive risk reduction in patients with atrial fibrillation: Emerging diagnostic and
therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA consensus
conference.
Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kääb S, Schotten U, Wegscheider K, Boriani G,
Ezekowitz M, Diener H, Heidbuchel H, Lane D, Mont L, Willems S, Dorian P, Vardas P, Breithardt G,
Camm AJ.
Thromb Haemost. 2011 Dec;106(6):1012-9. doi: 10.1160/TH11-07-0517. Epub 2011 Nov 2.
698. Silent cerebral embolism after catheter ablation of atrial fibrillation.
Shantsila A, Lip GY.
Int J Clin Pract. 2012 Feb;66(2):118-20. doi: 10.1111/j.1742-1241.2011.02820.x. Epub 2011 Oct 21.
No abstract available.
699. Ischemic stroke and atrial fibrillation--a deadly serious combination.
Potpara TS, Lip GY.
Cerebrovasc Dis. 2011;32(5):461-2. doi: 10.1159/000332030. Epub 2011 Oct 14. No abstract
available.
700.A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants,
antiarrhythmic drugs, and devices.
Banerjee A, Marín F, Lip GY.
Stroke. 2011 Nov;42(11):3316-22. doi: 10.1161/STROKEAHA.111.617886. Epub 2011 Oct 13. Review.
701. impact of dilated left atrium on rhythm control in patients with newly diagnosed persistent
atrial fibrillation: the Belgrade atrial fibrillation project.
Potpara TS, Polovina MM, Licina MM, Mujovic NM, Marinkovic JM, Petrovic M, Vujisic-Tesic B, Lip GY.
Int J Clin Pract. 2011 Nov;65(11):1202-3. doi: 10.1111/j.1742-1241.2011.02772.x. No abstract
available.
702. An observational study of endothelial function in early arthritis.
Foster W, Lip GY, Raza K, Carruthers D, Blann AD.
Eur J Clin Invest. 2012 May;42(5):510-6. doi: 10.1111/j.1365-2362.2011.02607.x. Epub 2011 Oct 10.
703. Nebivolol for the treatment of heart failure.
Riva N, Lip GY.
Expert Opin Investig Drugs. 2011 Dec;20(12):1733-46. doi: 10.1517/13543784.2011.625011. Epub
2011 Oct 8. Review.
704. Intracardiac expression of markers of endothelial damage/dysfunction, inflammation,
thrombosis, and tissue remodeling, and the development of postoperative atrial fibrillation.
Kaireviciute D, Lip GY, Balakrishnan B, Uzdavinys G, Norkunas G, Kalinauskas G, Sirvydis V, Aidietis A,
Zanetto U, Sihota H, Maheshwari M, Blann AD.
J Thromb Haemost. 2011 Dec;9(12):2345-52. doi: 10.1111/j.1538-7836.2011.04523.x.
705 The role of monocytes and inflammation in the pathophysiology of heart failure.
Wrigley BJ, Lip GY, Shantsila E.
Eur J Heart Fail. 2011 Nov;13(11):1161-71. doi: 10.1093/eurjhf/hfr122. Epub 2011 Sep 27. Review.
706. Advancing age and bleeding risk are the strongest barriers to anticoagulant prescription in atrial
fibrillation.
Riva N, Smith DE, Lip GY, Lane DA.
74
Age Ageing. 2011 Nov;40(6):653-5. doi: 10.1093/ageing/afr128. Epub 2011 Sep 27. No abstract
available.
707.The management of patients on oral anticoagulation undergoing coronary stent implantation: a
survey among interventional cardiologists from eight European countries.
Rubboli A, Dewilde W, Huber K, Eeckhout E, Herzfeld I, Valencia J, Windecker S, Airaksinen KE, Lip GY.
J Interv Cardiol. 2012 Apr;25(2):163-9. doi: 10.1111/j.1540-8183.2011.00683.x. Epub 2011 Sep 26.
PMID:
708. Stroke prevention in non-valvular atrial fibrillation: can warfarin do better?
Apostolakis S, Lip GY.
Thromb Haemost. 2011 Nov;106(5):753-4. doi: 10.1160/TH11-08-0580. Epub 2011 Sep 22. No
abstract available.
709. New anticoagulation drugs for atrial fibrillation.
Potpara TS, Lip GY.
Clin Pharmacol Ther. 2011 Oct;90(4):502-6. doi: 10.1038/clpt.2011.180. Epub 2011 Aug 10. Review.
710. The role of echocardiography in stroke risk assessment in patients with atrial fibrillation: is it
additive or does it simply echo clinical risk factors?
Pisters R, Olesen JB, Lip GY.
Europace. 2012 Jan;14(1):1-2. doi: 10.1093/europace/eur310. Epub 2011 Sep 20. No abstract
available.
711. Looking through the PRISM: new insights for young patients with atrial fibrillation and stroke.
Banerjee A, Lip GY.
Cerebrovasc Dis. 2011;32(4):383-4. doi: 10.1159/000331464. Epub 2011 Sep 15. No abstract
available.
712. Ethnic differences in macrovascular and microvascular function in systolic heart failure.
Shantsila E, Wrigley B, Shantsila A, Tapp LD, Blann AD, Gill PS, Lip GY.
Circ Heart Fail. 2011 Nov;4(6):754-62. doi: 10.1161/CIRCHEARTFAILURE.111.962365. Epub 2011 Sep
13.
713. Improving the diagnosis and prognosis of atrial fibrillation in stroke: quo vadis?
Banerjee A, Lip GY.
Eur J Neurol. 2012 Feb;19(2):187-8. doi: 10.1111/j.1468-1331.2011.03516.x. Epub 2011 Sep 14. No
abstract available.
713. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting:
similarities and dissimilarities between North America and Europe.
Huber K, Airaksinen KJ, Cuisset T, Marín F, Rubboli A, Lip GY.
Thromb Haemost. 2011 Oct;106(4):569-71. doi: 10.1160/TH11-08-0602. Epub 2011 Sep 12. No
abstract available.
715. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the
novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome.
Steg PG, Mehta SR, Jukema JW, Lip GY, Gibson CM, Kovar F, Kala P, Garcia-Hernandez A, Renfurm
RW, Granger CB; RUBY-1 Investigators.
Eur Heart J. 2011 Oct;32(20):2541-54. doi: 10.1093/eurheartj/ehr334. Epub 2011 Aug 30.
75
716. Strategies to improve oral anticoagulation management.
Smith DE, Lip GY, Lane DA.
Chest. 2011 Aug;140(2):281-2. doi: 10.1378/chest.11-0418. No abstract available.
717. Stroke in atrial fibrillation: epidemiology and thromboprophylaxis.
Lip GY.
J Thromb Haemost. 2011 Jul;9 Suppl 1:344-51. doi: 10.1111/j.1538-7836.2011.04302.x. Review.
718. Is plasminogen activator inhibitor-1 (PAI-1) a surrogate marker of vascular damage?
Montoro-García S, Marín F, Roldán V, Lip GY.
Thromb Res. 2011 Dec;128(6):601-2. doi: 10.1016/j.thromres.2011.07.005. Epub 2011 Jul 30. No
abstract available.
719. Intracerebral hemorrhage and warfarin: perceived versus actual risk.
Banerjee A, Lip GY.
Stroke. 2011 Sep;42(9):2383-4. doi: 10.1161/STROKEAHA.111.626739. Epub 2011 Jul 28. No abstract
available.
720. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and
therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart
Rhythm Association consensus conference.
Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, Schotten U, Wegscheider K, Boriani G,
Brandes A, Ezekowitz M, Diener H, Haegeli L, Heidbuchel H, Lane D, Mont L, Willems S, Dorian P,
Aunes-Jansson M, Blomstrom-Lundqvist C, Borentain M, Breitenstein S, Brueckmann M, Cater N,
Clemens A, Dobrev D, Dubner S, Edvardsson NG, Friberg L, Goette A, Gulizia M, Hatala R, Horwood J,
Szumowski L, Kappenberger L, Kautzner J, Leute A, Lobban T, Meyer R, Millerhagen J, Morgan J,
Muenzel F, Nabauer M, Baertels C, Oeff M, Paar D, Polifka J, Ravens U, Rosin L, Stegink W, Steinbeck
G, Vardas P, Vincent A, Walter M, Breithardt G, Camm AJ.
Europace. 2012 Jan;14(1):8-27. doi: 10.1093/europace/eur241. Epub 2011 Jul 26. Review.
721. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial
fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study.
Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunsø J, Tolstrup JS, Hansen PR,
Gislason GH, Torp-Pedersen C.
Thromb Haemost. 2011 Oct;106(4):739-49. doi: 10.1160/TH11-05-0364. Epub 2011 Jul 20.
.
722. The role of aspirin for stroke prevention in atrial fibrillation.
Lip GY.
Nat Rev Cardiol. 2011 Jul 26;8(10):602-6. doi: 10.1038/nrcardio.2011.112.
723. Myocardial perfusion by myocardial contrast echocardiography and endothelial dysfunction in
obstructive sleep apnea.
Butt M, Khair OA, Dwivedi G, Shantsila A, Shantsila E, Lip GY.
Hypertension. 2011 Sep;58(3):417-24. doi: 10.1161/HYPERTENSIONAHA.111.170910. Epub 2011 Jul
11.
724. Dronedarone: an overview.
Kozlowski D, Budrejko S, Lip GY, Mikhailidis DP, Rysz J, Raczak G, Banach M.
Ann Med. 2012 Feb;44(1):60-72. doi: 10.3109/07853890.2011.594808. Epub 2011 Jul 11. Review.
725. Atrial fibrillation and upper limb thromboembolectomy: a national cohort study.
76
Andersen LV, Mortensen LS, Lip GY, Lindholt JS, Faergeman O, Henneberg EW, Frost L.
J Thromb Haemost. 2011 Sep;9(9):1738-43. doi: 10.1111/j.1538-7836.2011.04435.x.
726. Atrial fibrillation, arrhythmia burden and thrombogenesis.
Khoo CW, Krishnamoorthy S, Lim HS, Lip GY.
Int J Cardiol. 2012 Jun 14;157(3):318-23. doi: 10.1016/j.ijcard.2011.06.088. Epub 2011 Jul 2. Review.
727. Atrial fibrillation (acute onset).
Lip GY, Apostolakis S.
BMJ Clin Evid. 2011 Feb 15;2011. pii: 0210.
728. Angiogenin and apoptosis in hypertension in pregnancy.
Karthikeyan VJ, Lip GY, Lane DA, Blann AD.
Pregnancy Hypertens. 2011 Jul-Oct;1(3-4):191-6. doi: 10.1016/j.preghy.2011.07.002. Epub 2011 Jul
19. Review.
729. Influence of cardiac resynchronization therapy on indices of inflammation, the prothrombotic
state and tissue remodeling in systolic heart failure: a pilot study.
Marín F, Roldán V, Martínez JG, Hernández-Madrid A, Hernández-Romero D, Ortego M, Ibáñez A,
Marín-Marín I, Navarro X, Lip GY, Moro C.
Thromb Res. 2011 Oct;128(4):391-4. doi: 10.1016/j.thromres.2011.05.022. Epub 2011 Jun 26. No
abstract available.
730. Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review
and meta-analysis of randomized trials and observational studies.
Biancari F, Airaksinen KE, Lip GY.
J Thorac Cardiovasc Surg. 2012 Mar;143(3):665-675.e4. doi: 10.1016/j.jtcvs.2011.01.069. Epub 2011
Jun 24. Review.
731. Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin:
comparative cohort study from BAFTA trial.
Hobbs FD, Roalfe AK, Lip GY, Fletcher K, Fitzmaurice DA, Mant J; Birmingham Atrial Fibrillation in the
Aged Investigators and Midland Research Practices Consortium Network.
BMJ. 2011 Jun 23;342:d3653. doi: 10.1136/bmj.d3653.
732. Circulating microparticles: new insights into the biochemical basis of microparticle release and
activity.
Montoro-García S, Shantsila E, Marín F, Blann A, Lip GY.
Basic Res Cardiol. 2011 Nov;106(6):911-23. doi: 10.1007/s00395-011-0198-4. Epub 2011 Jun 21.
733. The improved but unfinished business of stroke risk stratification in atrial fibrillation.
Banerjee A, Marín F, Lip GY.
Rev Esp Cardiol. 2011 Aug;64(8):639-41. doi: 10.1016/j.recesp.2011.04.005. Epub 2011 Jun 17.
English, Spanish. No abstract available.
734. Safety of coronary artery bypass surgery during therapeutic oral anticoagulation.
Airaksinen KE, Biancari F, Karjalainen P, Mikkola R, Kuttila K, Porela P, Laitio T, Lip GY.
Thromb Res. 2011 Nov;128(5):435-9. doi: 10.1016/j.thromres.2011.05.021. Epub 2011 Jun 17.
735. Risk factors for stroke and thromboembolism in relation to age among patients with atrial
fibrillation: the Loire Valley Atrial Fibrillation Project.
77
Olesen JB, Fauchier L, Lane DA, Taillandier S, Lip GY.
Chest. 2012 Jan;141(1):147-53. doi: 10.1378/chest.11-0862. Epub 2011 Jun 16.
736 .Bleeding risk with oral anticoagulation--new frontiers and new questions.
Banerjee A, Lane DA, Lip GY.
Int J Clin Pract. 2011 Jul;65(7):719-21. doi: 10.1111/j.1742-1241.2011.02716.x. No abstract available.
737. Peripheral artery disease and atrial fibrillation: a potentially dangerous combination.
Violi F, Lip GY, Basili S.
Intern Emerg Med. 2012 Jun;7(3):213-8. doi: 10.1007/s11739-011-0637-0. Epub 2011 Jun 11. Review.
738. Validation of the Edinburgh Claudication Questionnaire in 1st generation Black AfricanCaribbean and South Asian UK migrants: a sub-study to the Ethnic-Echocardiographic Heart of
England Screening (E-ECHOES) study.
Bennett PC, Lip GY, Silverman S, Blann AD, Gill PS.
BMC Med Res Methodol. 2011 Jun 3;11:85. doi: 10.1186/1471-2288-11-85.
739. The nuclear factor--kappa B pathway in atherosclerosis: a potential therapeutic target for
atherothrombotic vascular disease.
Pamukcu B, Lip GY, Shantsila E.
Thromb Res. 2011 Aug;128(2):117-23. doi: 10.1016/j.thromres.2011.03.025. Epub 2011 Jun 1.
Review.
740. Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established
bleeding prediction schemes in a nationwide cohort.
Olesen JB, Lip GY, Hansen PR, Lindhardsen J, Ahlehoff O, Andersson C, Weeke P, Hansen ML, Gislason
GH, Torp-Pedersen C.
J Thromb Haemost. 2011 Aug;9(8):1460-7. doi: 10.1111/j.1538-7836.2011.04378.x.
741. A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications
of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study.
Potpara TS, Stankovic GR, Beleslin BD, Polovina MM, Marinkovic JM, Ostojic MC, Lip GY.
Chest. 2012 Feb;141(2):339-47. doi: 10.1378/chest.11-0340. Epub 2011 May 26.
742. Endothelial damage/dysfunction and hypertension in pregnancy.
Karthikeyan VJ, Lip GY.
Front Biosci (Elite Ed). 2011 Jun 1;3:1100-8. Review.
743. Volume status and diuretic therapy in systolic heart failure and the detection of early
abnormalities in renal and tubular function.
Damman K, Ng Kam Chuen MJ, MacFadyen RJ, Lip GY, Gaze D, Collinson PO, Hillege HL, van Oeveren
W, Voors AA, van Veldhuisen DJ.
J Am Coll Cardiol. 2011 May 31;57(22):2233-41. doi: 10.1016/j.jacc.2010.10.065.
744. Atorvastatin and its collateral effects on microparticles.
Montoro-García S, Lip GY, Shantsila E.
Thromb Haemost. 2011 Aug;106(2):185-6. doi: 10.1160/TH11-05-0335. Epub 2011 May 26. No
abstract available.
745. Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients.
Ogilvie IM, Welner SA, Cowell W, Lip GY.
78
Thromb Haemost. 2011 Jul;106(1):34-44. doi: 10.1160/TH10-10-0674. Epub 2011 May 26. Review.
746. Angiogenin and hemoxygenase in pregnancy: influence of hypertension.
Karthikeyan VJ, Lip GY, Baghdadi S, Lane DA, Beevers DG, Blann AD.
Angiology. 2012 Apr;63(3):194-8. doi: 10.1177/0003319711410308. Epub 2011 May 20.
747. Aortic coarctation and twin pregnancy.
Beevers DG, Lip GY.
J Paediatr Child Health. 2011 May;47(5):316. doi: 10.1111/j.1440-1754.2011.02092.x. No abstract
available.
748. An epidemic of atrial fibrillation?
Olesen JB, Lip GY, Lane DA.
Europace. 2011 Aug;13(8):1059-60. doi: 10.1093/europace/eur141. Epub 2011 May 18. No abstract
available.
749.
Gender-related differences in presentation, treatment and long-term outcome in patients with firstdiagnosed atrial fibrillation and structurally normal heart: the Belgrade atrial fibrillation study.
Potpara TS, Marinkovic JM, Polovina MM, Stankovic GR, Seferovic PM, Ostojic MC, Lip GY.
Int J Cardiol. 2012 Nov 1;161(1):39-44. doi: 10.1016/j.ijcard.2011.04.022. Epub 2011 May 12.
750. Interactions between clopidogrel and proton pump inhibitors: a review of evidence.
Muñoz-Esparza C, Jover E, Hernández-Romero D, Saura D, Valdés M, Lip GY, Marín F.
Curr Med Chem. 2011;18(16):2386-400. Review.
751. Short-term effects of screening for cardiovascular risk in the deaf community: a pilot study.
Patel JV, Gill PS, Chackathayil J, Ojukwu H, Stemman P, Sheldon L, Meelu S, Lane DA, Tracey I,Lip GY,
Hughes EA.
Cardiol Res Pract. 2011 Apr 4;2011:493546. doi: 10.4061/2011/493546.
752. Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: a
comparison with plasma vascular markers.
Blann AD, Balakrishnan B, Shantsila E, Ryan P, Lip GY.
Prostate. 2011 Jul;71(10):1047-53. doi: 10.1002/pros.21319. Epub 2010 Dec 28.
753. Soluble Fas and Fas ligand in pregnancy: influence of hypertension.
Karthikeyan VJ, Lip GY, Baghdadi S, Lane DA, Beevers DG, Blann AD.
Angiology. 2012 Jan;63(1):35-8. doi: 10.1177/0003319711406901. Epub 2011 May 8.
754. Characterization of the proportion of untreated and antiplatelet therapy treated patients with
atrial fibrillation.
Ogilvie IM, Welner SA, Cowell W, Lip GY.
Am J Cardiol. 2011 Jul 1;108(1):151-61. doi: 10.1016/j.amjcard.2011.02.353. Epub 2011 May 3.
Review.
755. Coronary stent implantation in patients committed to long-term oral anticoagulation therapy:
successfully navigating the treatment options.
Rubboli A, Kovacic JC, Mehran R, Lip GY.
Chest. 2011 May;139(5):981-7. doi: 10.1378/chest.10-2719.
79
756. Impact of vascular disease in predicting stroke and death in patients with atrial fibrillation: the
Danish Diet, Cancer and Health cohort study.
Rasmussen LH, Larsen TB, Due KM, Tjønneland A, Overvad K, Lip GY.
J Thromb Haemost. 2011 Jul;9(7):1301-7. doi: 10.1111/j.1538-7836.2011.04308.x.
757. What are the costs of atrial fibrillation?
Blomstrom Lundqvist C, Lip GY, Kirchhof P.
Europace. 2011 May;13 Suppl 2:ii9-12. doi: 10.1093/europace/eur087.
758. Bleeding risk assessment and management in atrial fibrillation patients: a position document
from the European Heart Rhythm Association, endorsed by the European Society of Cardiology
Working Group on Thrombosis.
Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane DA, Levi M, Marin F, Palareti G,
Kirchhof P; Document reviewers:, Collet JP, Rubboli A, Poli D, Camm J.
Europace. 2011 May;13(5):723-46. doi: 10.1093/europace/eur126.
759. Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial
fibrillation.
Jowett S, Bryan S, Mant J, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Hobbs FD.
Stroke. 2011 Jun;42(6):1717-21. doi: 10.1161/STROKEAHA.110.600767. Epub 2011 Apr 21.
760. Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with
atrial fibrillation.
Poli D, Testa S, Antonucci E, Grifoni E, Paoletti O, Lip GY.
Chest. 2011 Oct;140(4):918-24. doi: 10.1378/chest.10-3024. Epub 2011 Apr 21. Erratum in: Chest.
2013 Aug;144(2):721.
761. The angiome: a new concept in cancer biology.
Blann AD, Ramcharan KS, Stonelake PS, Luesley D, Lip GY.
J Clin Pathol. 2011 Jul;64(7):637-43. doi: 10.1136/jcp.2011.088948. Epub 2011 Apr 20. Review.
762. Impact of polymorphisms in the renin-angiotensin-aldosterone system on hypertrophic
cardiomyopathy.
Orenes-Piñero E, Hernández-Romero D, Jover E, Valdés M, Lip GY, Marín F.
J Renin Angiotensin Aldosterone Syst. 2011 Dec;12(4):521-30. doi: 10.1177/1470320311405247.
Epub 2011 Apr 20. Review.
763. Plasma von Willebrand factor levels are an independent risk factor for adverse events including
mortality and major bleeding in anticoagulated atrial fibrillation patients.
Roldán V, Marín F, Muiña B, Torregrosa JM, Hernández-Romero D, Valdés M, Vicente V, Lip GY.
J Am Coll Cardiol. 2011 Jun 21;57(25):2496-504. doi: 10.1016/j.jacc.2010.12.033. Epub 2011 Apr 14.
764. Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients
with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring.
Boriani G, Botto GL, Padeletti L, Santini M, Capucci A, Gulizia M, Ricci R, Biffi M, De Santo T, Corbucci
G, Lip GY; Italian AT-500 Registry Investigators.
Stroke. 2011 Jun;42(6):1768-70. doi: 10.1161/STROKEAHA.110.609297. Epub 2011 Apr 14.
765. Altered blood vessel responses in the eye and finger in coronary artery disease.
Heitmar R, Cubbidge RP, Lip GY, Gherghel D, Blann AD.
Invest Ophthalmol Vis Sci. 2011 Aug 3;52(9):6199-205. doi: 10.1167/iovs.10-6628.
80
766. Impact of high-dose atorvastatin on endothelial, platelet, and angiogenic indices: effect of
ethnicity, cardiovascular disease, and diabetes.
Jaumdally RJ, Lip GY, Varma C, Blann AD.
Angiology. 2011 Oct;62(7):571-8. doi: 10.1177/0003319711401904. Epub 2011 Apr 5.
767. The 2010 European Society of Cardiology Guidelines on the management of atrial fibrillation: an
evolution or revolution?
Lip GY, Halperin JL, Tse HF.
Chest. 2011 Apr;139(4):738-41. doi: 10.1378/chest.10-2763. No abstract available.
768. Mitral annular calcification predicts cardiovascular morbidity and mortality in middle-aged
patients with atrial fibrillation: the Belgrade Atrial Fibrillation Study.
Potpara TS, Vasiljevic ZM, Vujisic-Tesic BD, Marinkovic JM, Polovina MM, Stepanovic JM, Stankovic
GR, Ostojic MC, Lip GY.
Chest. 2011 Oct;140(4):902-10. doi: 10.1378/chest.10-2963. Epub 2011 Mar 24.
769. Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation
and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the
Loire Valley Atrial Fibrillation Project.
Gorin L, Fauchier L, Nonin E, Charbonnier B, Babuty D, Lip GY.
Chest. 2011 Oct;140(4):911-7. doi: 10.1378/chest.10-2436. Epub 2011 Mar 24.
770. Bleeding risk in patients with atrial fibrillation: the AMADEUS study.
Lane DA, Kamphuisen PW, Minini P, Büller HR, Lip GY.
Chest. 2011 Jul;140(1):146-55. doi: 10.1378/chest.10-3270. Epub 2011 Mar 17.
771. Severe renal impairment and stroke prevention in atrial fibrillation: implications for
thromboprophylaxis and bleeding risk.
Marinigh R, Lane DA, Lip GY.
J Am Coll Cardiol. 2011 Mar 22;57(12):1339-48. doi: 10.1016/j.jacc.2010.12.013. Review.
772. Irbesartan in patients with atrial fibrillation.
ACTIVE I Investigators, Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, Hohnloser SH,
Joyner CD, Pfeffer MA, Connolly SJ.
N Engl J Med. 2011 Mar 10;364(10):928-38. doi: 10.1056/NEJMoa1008816.
773. Immunophenotypic characterization of human monocyte subsets: possible implications for
cardiovascular disease pathophysiology.
Shantsila E, Wrigley B, Tapp L, Apostolakis S, Montoro-Garcia S, Drayson MT, Lip GY.
J Thromb Haemost. 2011 May;9(5):1056-66. doi: 10.1111/j.1538-7836.2011.04244.x.
774. Soluble vascular endothelial growth factor receptor (VEGFR)-2 in macular oedema--a
mechanism for regulating angiogenesis?
Montoro-García S, Lip PL, Chan CC, Lip GY.
Br J Ophthalmol. 2011 Jun;95(6):757-8. doi: 10.1136/bjo.2010.198002. Epub 2011 Feb 16. No
abstract available.
775. Peri-operative management of ophthalmic patients taking antithrombotic therapy.
Lip GY, Durrani OM, Roldan V, Lip PL, Marin F, Reuser TQ.
Int J Clin Pract. 2011 Mar;65(3):361-71. doi: 10.1111/j.1742-1241.2010.02538.x. Review.
81
776. Apixaban in patients with atrial fibrillation.
Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH,
Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH,
Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL,
Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and
Investigators.
N Engl J Med. 2011 Mar 3;364(9):806-17. doi: 10.1056/NEJMoa1007432. Epub 2011 Feb 10.
777. Review article: proton pump inhibitors with clopidogrel--evidence for and against a clinicallyimportant interaction.
Disney BR, Watson RD, Blann AD, Lip GY, Anderson MR.
Aliment Pharmacol Ther. 2011 Apr;33(7):758-67. doi: 10.1111/j.1365-2036.2011.04585.x. Epub 2011
Feb 8. Review.
778. The risk of thromboembolism in heart failure: does it merit anticoagulation therapy?
Shantsila E, Lip GY.
Am J Cardiol. 2011 Feb 15;107(4):558-60. doi: 10.1016/j.amjcard.2010.10.029. No abstract available.
779. Optimal antithrombotic therapy in patients receiving long-term oral anticoagulation requiring
percutaneous coronary intervention: "triple therapy" or "triple threat".
Tapp LD, Lip GY, Lane DA.
Chest. 2011 Feb;139(2):240-2. doi: 10.1378/chest.10-1102. No abstract available.
780. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients
with atrial fibrillation: nationwide cohort study.
Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM,
Gislason GH, Torp-Pedersen C.
BMJ. 2011 Jan 31;342:d124. doi: 10.1136/bmj.d124.
781. Antithrombotic therapy after percutaneous coronary intervention in anticoagulated patients: a
fine balance between thrombosis and bleeding.
Ghattas A, Shantsila E, Lip GY.
Ther Adv Cardiovasc Dis. 2011 Feb;5(1):5-9. doi: 10.1177/1753944710397225. No abstract available.
782. Monocytes: possible mediators of benefits and harms from physical activity?
Shantsila E, Lip GY.
Thromb Haemost. 2011 Mar;105(3):387-9. doi: 10.1160/TH11-01-0009. Epub 2011 Jan 25. No
abstract available.
783. Increased levels of plasma haemoxygenase-1 in prostate cancer.
Blann AD, Balakrishnan B, Ryan P, Lip GY.
Prostate Cancer Prostatic Dis. 2011 Jun;14(2):114-7. doi: 10.1038/pcan.2010.56. Epub 2011 Jan 25.
784. Persistent macrovascular and microvascular dysfunction in patients with malignant
hypertension.
Shantsila A, Dwivedi G, Shantsila E, Butt M, Beevers DG, Lip GY.
Hypertension. 2011 Mar;57(3):490-6. doi: 10.1161/HYPERTENSIONAHA.110.166314. Epub 2011 Jan
24.
82
785. Clinical and basic science articles from Thrombosis and Haemostasis.
Lip GY, Weber C.
Thromb Haemost. 2011 Jan;105(1):202-5. No abstract available.
786. Combined antiplatelet therapy and oral anticoagulation: is a balance between
thromboembolism and bleeding possible?
Kuzniatsova N, Lip GY.
Int J Cardiol. 2011 Apr 1;148(1):1-3. doi: 10.1016/j.ijcard.2010.12.098. Epub 2011 Jan 17. No abstract
available.
787. The CD40-CD40L system in cardiovascular disease.
Pamukcu B, Lip GY, Snezhitskiy V, Shantsila E.
Ann Med. 2011 Aug;43(5):331-40. doi: 10.3109/07853890.2010.546362. Epub 2011 Jan 18. Review.
788. Renin-angiotensin blockade in diabetic retinopathy.
Ghattas A, Lip PL, Lip GY.
Int J Clin Pract. 2011 Feb;65(2):113-6. doi: 10.1111/j.1742-1241.2010.02592.x. No abstract available.
789. Hemostatic cardiovascular risk factors, common carotid-intima medial thickness and peripheral
arterial disease in South Asians and African Caribbeans: a substudy to the Ethnic-Echocardiographic
Heart of England Screening (E-ECHOES) study.
Bennett PC, Gill PS, Silverman S, Blann AD, Chackathayil J, Lip GY.
J Thromb Haemost. 2011 Apr;9(4):645-52. doi: 10.1111/j.1538-7836.2011.04190.x.
790. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial
fibrillation?
Ahrens I, Lip GY, Peter K.
Thromb Haemost. 2011 Apr;105(4):574-8. doi: 10.1160/TH10-12-0808. Epub 2011 Jan 12. No
abstract available.
791. Karthikeyan VJ, Blann AD, Baghdadi S, Lane DA, Gareth Beevers D, Lip GY.
Clin Res Cardiol. 2011 Jun;100(6):531-7. doi: 10.1007/s00392-010-0277-9. Epub 2011 Jan 9.
792.Lone atrial fibrillation: what is known and what is to come.
Potpara TS, Lip GY.
Int J Clin Pract. 2011 Apr;65(4):446-57. doi: 10.1111/j.1742-1241.2010.02618.x. Epub 2011 Jan 11.
Review.
793. Can we IMPROVE bleeding risk assessment for acutely ill, hospitalized medical patients?
Tay KH, Lip GY, Lane DA.
Chest. 2011 Jan;139(1):10-3. doi: 10.1378/chest.10-1127. No abstract available.
794. Time-trends in treatment and cardiovascular events in patients with heart failure: a
pharmacosurveillance study.
de Peuter OR, Lip GY, Souverein PC, Klungel OH, de Boer A, Büller HR, Kamphuisen PW.
Eur J Heart Fail. 2011 May;13(5):489-95. doi: 10.1093/eurjhf/hfq228. Epub 2010 Dec 29.
795. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in
patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are
appropriate for but unable or unwilling to take vitamin K antagonist therapy.
83
Lip GY, Rasmussen LH, Olsson SB, Zetterstrand S, Stahre C, Bylock A, Aunes-Jansson M, Eriksson U,
Wåhlander K; Steering Committee.
Thromb Res. 2011 Feb;127(2):91-9. doi: 10.1016/j.thromres.2010.11.012. Epub 2010 Dec 18.
796. The endotheliome: a new concept in vascular biology.
Ramcharan KS, Lip GY, Stonelake PS, Blann AD.
Thromb Res. 2011 Jul;128(1):1-7. doi: 10.1016/j.thromres.2010.11.019. Epub 2010 Dec 18. Review.
797.Endothelium-dependent and endothelium-independent vasodilatation of the cutaneous
circulation in sickle cell disease.
Mohan JS, Lip GY, Blann AD, Bareford D, Marshall JM.
Eur J Clin Invest. 2011 May;41(5):546-51. doi: 10.1111/j.1365-2362.2010.02444.x. Epub 2010 Dec 15.
798. What is the role of the cardiologist in future management of stroke prevention in atrial
fibrillation?
Velu S, Lip GY.
Adv Ther. 2011 Jan;28(1):1-12. doi: 10.1007/s12325-010-0091-9. Epub 2010 Dec 6. Review.
799. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial
fibrillation.
Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, Aikens TH, Yang S, Reilly
PA, Lip GY, Yusuf S; RE-LY Steering Committee and Investigators.
Circulation. 2010 Nov 30;122(22):2246-53. doi: 10.1161/CIRCULATIONAHA.110.973735.
.
800. Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and
future developments.
Schirmer SH, Baumhäkel M, Neuberger HR, Hohnloser SH, van Gelder IC, Lip GY, Böhm M.
J Am Coll Cardiol. 2010 Dec 14;56(25):2067-76. doi: 10.1016/j.jacc.2010.09.017. Review.
801. Chronic renal disease and stroke in atrial fibrillation: balancing the prevention of
thromboembolism and bleeding risk.
Lip GY.
Europace. 2011 Feb;13(2):145-8. doi: 10.1093/europace/euq427. Epub 2010 Dec 7. No abstract
available.
802. Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics,
pharmacodynamics and clinical practice.
Pamukcu B, Lip GY.
Expert Opin Pharmacother. 2011 Jan;12(1):131-40. doi: 10.1517/14656566.2011.540800. Epub 2010
Dec 2. Review.
803. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers safe in
pregnancy: a report of ninety-one pregnancies.
Karthikeyan VJ, Ferner RE, Baghdadi S, Lane DA, Lip GY, Beevers DG.
J Hypertens. 2011 Feb;29(2):396-9. doi: 10.1097/HJH.0b013e328341885d.
804. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated
patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke,
Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score.
Lip GY, Frison L, Halperin JL, Lane DA.
84
J Am Coll Cardiol. 2011 Jan 11;57(2):173-80. doi: 10.1016/j.jacc.2010.09.024. Epub 2010 Nov 24.
805. The assessment of stroke and bleeding risk in atrial fibrillation: where are we now?
Pamukcu B, Lane DA, Lip GY.
Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1703-10. doi: 10.1586/erc.10.153. Review.
806. New concepts and approaches to stroke prevention in the new European Society of Cardiology
guidelines for the management of atrial fibrillation.
Kuzniatsova N, Lip GY.
Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1643-7. doi: 10.1586/erc.10.150. No abstract available.
807. Recent progress in antithrombotic therapy for atrial fibrillation.
Velu S, Lip GY.
J Atheroscler Thromb. 2011;18(4):257-73. Epub 2010 Nov 13. Review.
808. Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk.
Lane DA, Lip GY.
Lancet Neurol. 2010 Dec;9(12):1140-2. doi: 10.1016/S1474-4422(10)70275-1. Epub 2010 Nov 6. No
abstract available.
809. Dronedarone or amiodarone for rhythm control for atrial fibrillation: implications from the
DIONYSOS study.
Pamukcu B, Lip GY.
Expert Opin Pharmacother. 2010 Dec;11(17):2775-8. doi: 10.1517/14656566.2010.517196.
810. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in
general practice.
Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY.
J Thromb Haemost. 2011 Jan;9(1):39-48. doi: 10.1111/j.1538-7836.2010.04085.x.
811. Thrombogenesis in lone atrial fibrillation: a role for soluble P-selectin?
Montoro-García S, Marín F, Lip GY.
Europace. 2011 Jan;13(1):3-4. doi: 10.1093/europace/euq376. Epub 2010 Oct 25. No abstract
available.
812. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect
comparisons versus dabigatran etexilate.
Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM.
Thromb Haemost. 2010 Dec;104(6):1106-15. doi: 10.1160/TH10-10-0642. Epub 2010 Oct 21.
813. Identifying patients at high risk for stroke despite anticoagulation: a comparison of
contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort.
Lip GY, Frison L, Halperin JL, Lane DA.
Stroke. 2010 Dec;41(12):2731-8. doi: 10.1161/STROKEAHA.110.590257. Epub 2010 Oct 21.
814. Ethnic differences in common carotid intima-media thickness, and the relationship to
cardiovascular risk factors and peripheral arterial disease: the Ethnic-Echocardiographic Heart of
England Screening Study.
Bennett PC, Gill PS, Silverman S, Blann AD, Lip GY.
QJM. 2011 Mar;104(3):245-54. doi: 10.1093/qjmed/hcq187. Epub 2010 Oct 18.
85
815. Insights from the new European Society of Cardiology guidelines for the medical management of
atrial fibrillation.
Pamukcu B, Lip GY.
Int J Clin Pract. 2010 Nov;64(12):1587-90. doi: 10.1111/j.1742-1241.2010.02522.x. No abstract
available.
816. Percutaneous coronary intervention in anticoagulated patients and balancing the risk of stroke
and bleeding: to interrupt or not to interrupt?
Wrigley BJ, Shantsila E, Lip GY.
Chest. 2010 Oct;138(4):771-4. doi: 10.1378/chest.10-0789. No abstract available.
817.Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial
fibrillation.
Lip GY.
Am J Med. 2011 Feb;124(2):111-4. doi: 10.1016/j.amjmed.2010.05.007. Epub 2010 Sep 29.
818. How to manage antithrombotic treatment during percutaneous coronary interventions in
patients receiving long-term oral anticoagulation: to "bridge" or not to "bridge"?
Airaksinen KE, Schlitt A, Rubboli A, Karjalainen P, Lip GY.
EuroIntervention. 2010 Sep;6(4):520-6. doi: 10.4244/EIJ30V6I4A86. Review.
819. Guidelines for the management of atrial fibrillation: the Task Force for the Management of
Atrial Fibrillation of the European Society of Cardiology (ESC).
European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ,
Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast
B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A,
Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH; ESC Committee for
Practice Guidelines.
Europace. 2010 Oct;12(10):1360-420. doi: 10.1093/europace/euq350. No abstract available. Erratum
in: Europace. 2011 Jul;13(7):1058. Dosage error in article text.
820. Platelet reactivity in prolonged stress disorders--a link with cardiovascular disease?
Montoro-García S, Shantsila E, Lip GY.
Psychoneuroendocrinology. 2011 Feb;36(2):159-60. doi: 10.1016/j.psyneuen.2010.08.010. Epub
2010 Sep 28. No abstract available.
821. An evaluation of the CHADS₂ stroke risk score in patients with atrial fibrillation who undergo
percutaneous coronary revascularization.
Ruiz-Nodar JM, Marín F, Manzano-Fernández S, Valencia-Martín J, Hurtado JA, Roldán V, Pineda J,
Pinar E, Sogorb F, Valdés M, Lip GY.
Chest. 2011 Jun;139(6):1402-9. doi: 10.1378/chest.10-1408. Epub 2010 Sep 23.
822. Endothelial dysfunction: methods of assessment & implications for cardiovascular diseases.
Butt M, Dwivedi G, Blann A, Khair O, Lip GY.
Curr Pharm Des. 2010;16(31):3442-54. Review.
823. Current therapeutic strategies and future perspectives for the prevention of arterial
thromboembolism: focus on atrial fibrillation.
Potpara TS, Lip GY.
Curr Pharm Des. 2010;16(31):3455-71. Review.
86
824. Plasma haemoxygenase-1 in coronary artery disease. A comparison with angiogenin, matrix
metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and vascular endothelial growth factor.
Idriss NK, Lip GY, Balakrishnan B, Jaumdally R, Boos CJ, Blann AD.
Thromb Haemost. 2010 Nov;104(5):1029-37. doi: 10.1160/TH09-11-0802. Epub 2010 Sep 13.
825. Soluble fms-like tyrosine kinase-1 – a novel marker for atherosclerotic progression? –.
Pamukcu B, Shantsila E, Lip GY.
Circ J. 2010 Oct;74(10):2064-5. Epub 2010 Sep 11. No abstract available.
826. Assessment of left atrial volume: a focus on echocardiographic methods and clinical
implications.
Khoo CW, Krishnamoorthy S, Lim HS, Lip GY.
Clin Res Cardiol. 2011 Feb;100(2):97-105. doi: 10.1007/s00392-010-0222-y. Epub 2010 Sep 7. Review.
827. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis.
Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA.
J Am Coll Cardiol. 2010 Sep 7;56(11):827-37. doi: 10.1016/j.jacc.2010.05.028. Review.
828. How do we get better at identifying patients with atrial fibrillation who are at 'truly low risk' or
'truly high risk' of stroke?
Kuzniatsova N, Lip GY.
J Neurol Sci. 2010 Nov 15;298(1-2):21-2. doi: 10.1016/j.jns.2010.08.015. Epub 2010 Sep 1. Review.
No abstract available.
829. Guidelines for the management of atrial fibrillation: the Task Force for the Management of
Atrial Fibrillation of the European Society of Cardiology (ESC).
European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ,
Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast
B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A,
Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH.
Eur Heart J. 2010 Oct;31(19):2369-429. doi: 10.1093/eurheartj/ehq278. Epub 2010 Aug 29. No
abstract available. Erratum in: Eur Heart J. 2011 May;32(9):1172.
830. Quality of anticoagulation control in atrial fibrillation.
Lane DA, Lip GY.
Lancet. 2010 Sep 18;376(9745):935-7. doi: 10.1016/S0140-6736(10)61305-0. No abstract available.
831. Stroke prevention in atrial fibrillation patients.
Marinigh R, Lip GY, Lane DA.
Expert Opin Pharmacother. 2010 Oct;11(14):2331-50. doi: 10.1517/14656566.2010.498819. Review.
832. Rhythm control agents and adverse events in patients with atrial fibrillation.
Marín F, Lip GY.
Int J Clin Pract. 2010 Sep;64(10):1329-31. doi: 10.1111/j.1742-1241.2010.02473.x. No abstract
available.
833 Statins and prophylaxis of venous thrombosis - a further link between arterial and venous
thrombosis.
Shantsila A, Lip GY.
87
Int J Clin Pract. 2010 Sep;64(10):1326-8. doi: 10.1111/j.1742-1241.2010.02461.x. No abstract
available.
834. Circulating microparticles in cardiovascular disease: implications for atherogenesis and
atherothrombosis.
Shantsila E, Kamphuisen PW, Lip GY.
J Thromb Haemost. 2010 Nov;8(11):2358-68. doi: 10.1111/j.1538-7836.2010.04007.x. Review.
835. Antithrombotic therapy in anticoagulated patients with atrial fibrillation presenting with acute
coronary syndromes and/or undergoing percutaneous coronary intervention/stenting.
Wrigley BJ, Tapp LD, Shantsila E, Lip GY.
Pol Arch Med Wewn. 2010 Jul;120(7-8):290-3. Review. Erratum in: Pol Arch Med Wewn. 2010
Sep;120(9):374.
836. Atrial fibrillation and mortality: the impact of antithrombotic therapy.
Lane DA, Lip GY.
Eur Heart J. 2010 Sep;31(17):2075-6. doi: 10.1093/eurheartj/ehp486. Epub 2010 Aug 4. No abstract
available.
837. Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and
thromboembolic risk.
López-Cuenca A, Marín F, Roldán V, González-Conejero R, Hernández-Romero D, Valdés M, Lip GY.
Ann Med. 2010 Dec;42(8):562-75. doi: 10.3109/07853890.2010.507601. Epub 2010 Aug 4. Review.
838. Dronedarone: NICE enough?
Khoo CW, Lim HS, Lip GY.
Expert Rev Cardiovasc Ther. 2010 Aug;8(8):1049-51. doi: 10.1586/erc.10.83. No abstract available.
839. Atrial fibrillation: Blockade of the renin-angiotensin system in atrial fibrillation.
Kuzniatsova N, Shantsila E, Lip GY.
Nat Rev Cardiol. 2010 Aug;7(8):428-30. doi: 10.1038/nrcardio.2010.103. No abstract available.
.
840. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?
Lip GY, Lane DA.
Am J Med. 2010 Sep;123(9):785-9. doi: 10.1016/j.amjmed.2010.01.031. Epub 2010 Jul 23. Review.
841. Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population.
Poli D, Lip GY, Antonucci E, Grifoni E, Lane D.
J Cardiovasc Electrophysiol. 2011 Jan;22(1):25-30. doi: 10.1111/j.1540-8167.2010.01858.x.
842. Levosimendan - a calcium sensitising agent with potential anti-arrhythmic properties.
Kowalczyk M, Banach M, Lip GY, Kozłowski D, Mikhailidis DP, Rysz J.
Int J Clin Pract. 2010 Jul;64(8):1148-54. doi: 10.1111/j.1742-1241.2010.02396.x. Review.
843. Malignant hypertension: a rare problem or is it underdiagnosed?
Shantsila A, Shantsila E, Lip GY.
Curr Vasc Pharmacol. 2010 Nov;8(6):775-9. Review.
844. Underuse of oral anticoagulants in atrial fibrillation: a systematic review.
Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY.
88
Am J Med. 2010 Jul;123(7):638-645.e4. doi: 10.1016/j.amjmed.2009.11.025. Review.
845. Safety and efficacy of oral anticoagulation therapy in Chinese patients with concomitant atrial
fibrillation and hypertension.
Ho LY, Siu CW, Yue WS, Lau CP, Lip GY, Tse HF.
J Hum Hypertens. 2011 May;25(5):304-10. doi: 10.1038/jhh.2010.57. Epub 2010 Jul 1.
846. Synergism between factor XII -4C>T and factor XIII Val34Leu polymorphisms in fibrinolytic
therapy in acute myocardial infarction.
Hernández-Romero D, Marín F, Lee KW, Roldán V, Caturla J, Corral J, Valdés M, Lip GY, Vicente V,
González-Conejero R.
Thromb Haemost. 2010 Sep;104(3):650-2. doi: 10.1160/TH10-01-0022. Epub 2010 Jun 29. No
abstract available.
847. Novel oral anticoagulants: the potential relegation of vitamin K antagonists in clinical practice.
Wrigley BJ, Lip GY, Shantsila E.
Int J Clin Pract. 2010 Jun;64(7):835-8. doi: 10.1111/j.1742-1241.2010.02351.x. No abstract available.
848. Peripheral artery disease: appreciating the asymptomatic - yet lethal - epidemic.
Jaipersad AS, Silverman SH, Lip GY.
Int J Clin Pract. 2010 Jun;64(7):832-5. doi: 10.1111/j.1742-1241.2010.02393.x. No abstract available.
'
The contribution of cardiovascular risk factors to peripheral arterial disease in South Asians and
Blacks: a sub-study to the Ethnic-Echocardiographic Heart of England Screening (E-ECHOES) study.
Bennett PC, Lip GY, Silverman S, Blann AD, Gill PS.
QJM. 2010 Sep;103(9):661-9. doi: 10.1093/qjmed/hcq102. Epub 2010 Jun 24.
850. Improving stroke risk stratification in atrial fibrillation.
Lip GY, Halperin JL.
Am J Med. 2010 Jun;123(6):484-8. doi: 10.1016/j.amjmed.2009.12.013. Review.
851. The role of monocytes in atherosclerotic coronary artery disease.
Pamukcu B, Lip GY, Devitt A, Griffiths H, Shantsila E.
Ann Med. 2010 Sep;42(6):394-403. doi: 10.3109/07853890.2010.497767. Review.
852. Omega-3 polyunsaturated acids and cardiovascular disease: notable ethnic differences or
unfulfilled promise?
Patel JV, Tracey I, Hughes EA, Lip GY.
J Thromb Haemost. 2010 Oct;8(10):2095-104. doi: 10.1111/j.1538-7836.2010.03956.x. Review.
853. The quest for new anticoagulants: from clinical development to clinical practice.
Apostolakis S, Lip GY, Lane DA, Shantsila E.
Cardiovasc Ther. 2011 Dec;29(6):e12-22. doi: 10.1111/j.1755-5922.2010.00160.x. Epub 2010 Jun 14.
Review.
854. New oral anticoagulant drugs in cardiovascular disease.
Ahrens I, Lip GY, Peter K.
Thromb Haemost. 2010 Jul;104(1):49-60. doi: 10.1160/TH09-05-0327. Epub 2010 Jun 10. Review.
855. Complement activation, endothelial dysfunction, insulin resistance and chronic heart failure.
Bjerre M, Kistorp C, Hansen TK, Faber J, Lip GY, Hildebrandt P, Flyvbjerg A.
89
Scand Cardiovasc J. 2010 Oct;44(5):260-6. doi: 10.3109/14017431.2010.484506. Epub 2010 Jun 7.
856. Circulating progenitor cells in patients with atrial fibrillation and their relation with serum
markers of inflammation and angiogenesis.
Watson T, Shantsila E, Blann A, Lip GY.
Thromb Haemost. 2010 Aug;104(2):327-34. doi: 10.1160/TH10-01-0024. Epub 2010 May 27.
857.Simplifying stroke risk stratification in atrial fibrillation patients: implications of the CHA2DS2VASc risk stratification scores.
Pamukcu B, Lip GY, Lane DA.
Age Ageing. 2010 Sep;39(5):533-5. doi: 10.1093/ageing/afq059. Epub 2010 May 26. No abstract
available. Erratum in: Age Ageing. 2011 Jan;40(1):141.
858. TRial of an Educational intervention on patients' knowledge of Atrial fibrillation and
anticoagulant therapy, INR control, and outcome of Treatment with warfarin (TREAT).
Smith DE, Xuereb CB, Pattison HM, Lip GY, Lane DA.
BMC Cardiovasc Disord. 2010 May 20;10:21. doi: 10.1186/1471-2261-10-21.
859. Characterisation and validity of inflammatory biomarkers in the prediction of post-operative
atrial fibrillation in coronary artery disease patients.
Kaireviciute D, Blann AD, Balakrishnan B, Lane DA, Patel JV, Uzdavinys G, Norkunas G, Kalinauskas G,
Sirvydis V, Aidietis A, Lip GY.
Thromb Haemost. 2010 Jul;104(1):122-7. doi: 10.1160/TH09-12-0837. Epub 2010 May 10.
860. Antithrombotic management of atrial fibrillation patients presenting with acute coronary
syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the
European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart
Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular
Interventions (EAPCI).
Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, Kirchhof P, Marín F; Consensus
Document of European Society of Cardiology Working Group on Thrombosis.
Eur Heart J. 2010 Jun;31(11):1311-8. doi: 10.1093/eurheartj/ehq117. Epub 2010 May 6.
<
861. Continuous retinal vessel diameter measurements: the future in retinal vessel assessment?
Heitmar R, Blann AD, Cubbidge RP, Lip GY, Gherghel D.
Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5833-9. doi: 10.1167/iovs.09-5136. Epub 2010 Apr 30.
862. Circulating monocytes and atherogenesis: from animal experiments to human studies.
Shantsila E, Devitt A, Lip GY.
Thromb Haemost. 2010 Aug;104(2):191-3. doi: 10.1160/TH10-03-0176. Epub 2010 Apr 29. No
abstract available.
863. An international survey of physician and patient understanding, perception, and attitudes to
atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality.
Aliot E, Breithardt G, Brugada J, Camm J, Lip GY, Vardas PE, Wagner M; Atrial Fibrillation AWareness
And Risk Education group; Atrial Fibrillation Association; European Heart Rhythm Association; Stroke
Alliance for Europe; World Heart Federation.
Europace. 2010 May;12(5):626-33. doi: 10.1093/europace/euq109.
864. Assessment of endothelial dysfunction.
Freestone B, Krishnamoorthy S, Lip GY.
90
Expert Rev Cardiovasc Ther. 2010 Apr;8(4):557-71. doi: 10.1586/erc.09.184. Review.
865. Thrombosis and cardiovascular disease: Exciting perspectives in cardiovascular prevention and
therapy.
Peter K, Lip GY.
Thromb Haemost. 2010 May;103(5):875-6. doi: 10.1160/TH10-03-0205. Epub 2010 Apr 13. No
abstract available.
866. Guidelines for antithrombotic therapy in atrial fibrillation: understanding the reasons for nonadherence and moving forwards with simplifying risk stratification for stroke and bleeding.
Fauchier L, Lip GY.
Europace. 2010 Jun;12(6):761-3. doi: 10.1093/europace/euq102. Epub 2010 Apr 12. No abstract
available. Erratum in: Europace. 2010 Sep;12(9):1349.
867. The impact of new and emerging clinical data on treatment strategies for atrial fibrillation.
Prystowsky EN, Camm J, Lip GY, Allessie M, Bergmann JF, Breithardt G, Brugada J, Crijns H, Ellinor PT,
Mark D, Naccarelli G, Packer D, Tamargo J.
J Cardiovasc Electrophysiol. 2010 Aug 1;21(8):946-58. doi: 10.1111/j.1540-8167.2010.01770.x. Epub
2010 Apr 8. Review.
868. Impact of symptom control on health-related quality of life in atrial fibrillation patients: the
psychologist's viewpoint.
Smith D, Lip GY, Lane DA.
Europace. 2010 May;12(5):608-10. doi: 10.1093/europace/euq083. Epub 2010 Mar 30. No abstract
available.
869. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with
atrial fibrillation: the Euro Heart Survey.
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY.
Chest. 2010 Nov;138(5):1093-100. doi: 10.1378/chest.10-0134. Epub 2010 Mar 18.
870. Endothelial progenitor cells: what use for the cardiologist?
Siddique A, Shantsila E, Lip GY, Varma C.
J Angiogenes Res. 2010 Feb 22;2:6. doi: 10.1186/2040-2384-2-6.
871. Anger rumination, social support, and cardiac symptoms in patients undergoing angiography.
Closa León T, Nouwen A, Sheffield D, Jaumdally R, Lip GY.
Br J Health Psychol. 2010 Nov;15(Pt 4):841-57. doi: 10.1348/135910710X491360. Epub 2010 Mar 4.
872. Coronary atherosclerosis in rheumatoid arthritis: could endothelial progenitor cells be the
missing link?
Wrigley BJ, Lip GY, Shantsila E.
J Rheumatol. 2010 Mar;37(3):479-81. doi: 10.3899/jrheum.091341. No abstract available.
873. Role of ticagrelor in clopidogrel nonresponders: resistance is futile?
Tapp L, Shantsila E, Lip GY.
Circulation. 2010 Mar 16;121(10):1169-71. doi: 10.1161/CIR.0b013e3181d8d929. Epub 2010 Mar 1.
No abstract available.
874. Anti-platelet therapy: is it all over in peripheral artery disease?
91
Jaipersad AS, Silverman SH, Lip GY.
Thromb Haemost. 2010 Apr;103(4):689-91. doi: 10.1160/TH10-01-0053. Epub 2010 Feb 19. No
abstract available.
875 Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels.
Barbalic M, Dupuis J, Dehghan A, Bis JC, Hoogeveen RC, Schnabel RB, Nambi V, Bretler M, Smith NL,
Peters A, Lu C, Tracy RP, Aleksic N, Heeriga J, Keaney JF Jr, Rice K, Lip GY, Vasan RS, Glazer NL, Larson
MG, Uitterlinden AG, Yamamoto J, Durda P, Haritunians T, Psaty BM, Boerwinkle E, Hofman A, Koenig
W, Jenny NS, Witteman JC, Ballantyne C, Benjamin EJ.
Hum Mol Genet. 2010 May 1;19(9):1863-72. doi: 10.1093/hmg/ddq061. Epub 2010 Feb 18.
876. Inflammation and microvascular and macrovascular endothelial dysfunction in rheumatoid
arthritis: effect of treatment.
Foster W, Carruthers D, Lip GY, Blann AD.
J Rheumatol. 2010 Apr;37(4):711-6. doi: 10.3899/jrheum.090699. Epub 2010 Feb 15.
877 Aspirin--a drug whose time has gone?
Tapp L, Shantsila E, Lip GY.
Am J Cardiol. 2010 Feb 15;105(4):577-8. doi: 10.1016/j.amjcard.2009.10.026. No abstract available.
878. Bleeding after coronary stenting in patients on oral anticoagulation: who is guilty?
Rubboli A, Schlitt A, Airaksinen J, Lip GY.
EuroIntervention. 2010 Jan;5(6):649-50; author reply 651. No abstract available.
879. Changing the scope of preventative and therapeutic approaches in atherothrombosis.
Peter K, Lip GY.
Thromb Haemost. 2010 Mar;103(3):487-8. doi: 10.1160/TH10-01-0063. Epub 2010 Feb 2. No abstract
available.
880. Anticoagulation therapy and the risk of stroke in patients with atrial fibrillation at 'moderate
risk' [CHADS2 score=1]: simplifying stroke risk assessment and thromboprophylaxis in real-life clinical
practice.
Lip GY.
Thromb Haemost. 2010 Apr;103(4):683-5. doi: 10.1160/TH10-01-0038. Epub 2010 Feb 2. No abstract
available.
881. The additive value of biomarkers to clinical risk scores in acute coronary syndrome. Are
biomarkers really ready for real world usage?
Tello-Montoliu A, Marín F, Roldán V, Lip GY.
Heart. 2010 Feb;96(3):227-8; author reply 228. doi: 10.1136/hrt.2009.182105. No abstract available.
882.The effects of exercise stress testing, diurnal variation and temporal decline on circulating
progenitor cells.
Watson T, Shantsila E, Karthikeyan VJ, Jessani S, Goon PK, Lip GY.
Thromb Haemost. 2010 Feb;103(2):419-25. doi: 10.1160/TH09-06-0386. Epub 2009 Nov 13.
883. Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial.
Khoo CW, Lip GY.
Expert Opin Pharmacother. 2010 Mar;11(4):685-7. doi: 10.1517/14656560903530691.
92
884.Apolipoproteins in the discrimination of atherosclerotic burden and cardiac function in patients
with stable coronary artery disease.
Patel JV, Abraheem A, Creamer J, Gunning M, Hughes EA, Lip GY.
Eur J Heart Fail. 2010 Mar;12(3):254-9. doi: 10.1093/eurjhf/hfp202. Epub 2010 Jan 19.
885. Towards (cost)effective cardiovascular risk management: using new drugs vs. the better use of
available ones.
Shantsila A, Lip GY.
Int J Clin Pract. 2010 Jan;64(2):138-40. doi: 10.1111/j.1742-1241.2009.02233.x. No abstract available.
886. Anticoagulation for atrial fibrillation patients with CHADS score of 1.
Lane DA, Lip GY.
J Cardiovasc Electrophysiol. 2010 May;21(5):508-10. doi: 10.1111/j.1540-8167.2009.01687.x. Epub
2010 Jan 15. No abstract available.
887. Anticoagulation intensity for elderly atrial fibrillation patients: should we use a conventional INR
target (2.0 to 3.0) or a lower range?
Lane DA, Lip GY.
Thromb Haemost. 2010 Feb;103(2):254-6. doi: 10.1160/TH09-12-0843. Epub 2010 Jan 13. No
abstract available.
888. Moving forward with a new editorial team for Thrombosis and Haemostasis.
Weber C, Lip GY.
Thromb Haemost. 2010 Jan;103(1):1-2. Epub 2010 Jan 7. No abstract available.
889.Management of antithrombotic therapy in atrial fibrillation patients presenting with acute
coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting.
Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen KJ, Cuisset T, Kirchhof P, Marín F; European
Society of Cardiology Working Group on Thrombosis.
Thromb Haemost. 2010 Jan;103(1):13-28. doi: 10.1160/TH09-08-0580. Epub 2009 Sep 30. Review.
Erratum in: Thromb Haemost. 2010 Sep;104(3):653. Dosage error in article text.
890.The metabolic syndrome is associated with subclinical atherosclerosis independent of insulin
resistance: the Guangzhou Biobank Cohort Study-CVD.
Xu L, Jiang CQ, Lam TH, Lin JM, Yue XJ, Cheng KK, Liu B, Jin YL, Zhang WS, Thomas GN; Guangzhou
Biobank Cohort Study-CVD.
Clin Endocrinol (Oxf). 2010 Aug;73(2):181-8. doi: 10.1111/j.1365-2265.2009.03760.x. Epub 2009 Dec
18.
891. Comparison of sequential rosuvastatin doses in hypercholesterolaemia: a meta-analysis of
randomised controlled trials.
Gray J, Edwards SJ, Lip GY.
Curr Med Res Opin. 2010 Mar;26(3):537-47. doi: 10.1185/03007990903513980. Review.
892. Impaired glucose tolerance and endothelial damage, as assessed by levels of von Willebrand
factor and circulating endothelial cells, following acute myocardial infarction.
Jessani SS, Lane DA, Shantsila E, Watson T, Millane TA, Lip GY.
Ann Med. 2009;41(8):608-18. doi: 10.1080/07853890903159256.
893. Balancing thromboembolism and bleeding risks: insights from anticoagulation for prosthetic
heart valves.
93
Tay KH, Lane DA, Lip GY.
Chest. 2009 Dec;136(6):1451-2. doi: 10.1378/chest.09-1187. No abstract available.
.
894. Plasma YKL-40 levels are elevated in patients with chronic heart failure.
Rathcke CN, Kistorp C, Raymond I, Hildebrandt P, Gustafsson F, Lip GY, Faber J, Vestergaard H.
Scand Cardiovasc J. 2010 Apr;44(2):92-9. doi: 10.3109/14017430903402218.
.
895. Relationship of circulating endothelial progenitor cells to the recurrence of atrial fibrillation
after successful conversion and maintenance of sinus rhythm.
Siu CW, Watson T, Lai WH, Lee YK, Chan YH, Ng KM, Lau CP, Lip GY, Tse HF.
Europace. 2010 Apr;12(4):517-21. doi: 10.1093/europace/eup382. Epub 2009 Nov 30.
896. Vernakalant hydrochloride for the treatment of atrial fibrillation.
Kozlowski D, Budrejko S, Lip GY, Mikhailidis DP, Rysz J, Raczak G, Banach M.
Expert Opin Investig Drugs. 2009 Dec;18(12):1929-37. doi: 10.1517/13543780903386246.
897. Triglycerides and small dense low density lipoprotein in the discrimination of coronary heart
disease risk in South Asian populations.
Patel JV, Caslake MJ, Vyas A, Cruickshank JK, Prabhakaran D, Bhatnagar D, Reddy KS, Lip GY,
Mackness MI, Hughes EA, Durrington PN.
Atherosclerosis. 2010 Apr;209(2):579-84. doi: 10.1016/j.atherosclerosis.2009.10.010. Epub 2009 Oct
13.
898. The role of monocytes in thrombotic disorders. Insights from tissue factor, monocyte-platelet
aggregates and novel mechanisms.
Shantsila E, Lip GY.
Thromb Haemost. 2009 Nov;102(5):916-24. doi: 10.1160/TH09-01-0023. Review.
899. Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation".
Apostolakis S, Shantsila E, Lip GY, Lane DA.
Thromb Haemost. 2009 Nov;102(5):914-5. doi: 10.1160/TH09-08-0563. No abstract available.
900. Vascular damage in impaired glucose tolerance: an unappreciated phenomenon?
Jessani S, Millane T, Lip GY.
Curr Pharm Des. 2009;15(29):3417-32. Review.
901. Pathophysiological insights into atrial fibrillation following cardiac surgery: implications for
current pharmaceutical design.
Kaireviciute D, Aidietis A, Lip GY.
Curr Pharm Des. 2009;15(29):3367-83. Review.
902. Relationship of indices of inflammation and thrombogenesis to arrhythmia burden in
paroxysmal atrial fibrillation.
Watson T, Arya A, Sulke N, Lip GY.
Chest. 2010 Apr;137(4):869-76. doi: 10.1378/chest.09-1426. Epub 2009 Oct 26.
903. Treatment of hypertension in peripheral arterial disease.
Lane DA, Lip GY.
94
Cochrane Database Syst Rev. 2009 Oct 7;(4):CD003075. doi: 10.1002/14651858.CD003075.pub2.
Review. Update in: Cochrane Database Syst Rev. 2013;12:CD003075.
904. Vascular imaging as a cardiovascular risk stratification tool in systemic lupus erythematosus.
Apostolakis S, Shantsila E, Lip GY.
J Rheumatol. 2009 Oct;36(10):2141-3. doi: 10.3899/jrheum.090640. No abstract available.
905. Systemic inflammation as a driver of vascular calcification: a proof of concept.
Shantsila E, Lip GY.
J Intern Med. 2009 Nov;266(5):453-6. doi: 10.1111/j.1365-2796.2009.02138.x. No abstract available.
906. Omega-3 polyunsaturated fatty acids: a necessity for a comprehensive secondary prevention
strategy.
Patel JV, Tracey I, Hughes EA, Lip GY.
Vasc Health Risk Manag. 2009;5:801-10. Epub 2009 Sep 24. Review.
907. Monocytes in heart failure: relationship to a deteriorating immune overreaction or a desperate
attempt for tissue repair?
Apostolakis S, Lip GY, Shantsila E.
Cardiovasc Res. 2010 Mar 1;85(4):649-60. doi: 10.1093/cvr/cvp327. Epub 2009 Oct 4. Review.
908. New anticoagulants for the prevention of deep venous thrombosis: time to consider cost
effectiveness?
Apostolakis S, Shantsila E, Lip GY.
Pharmacoeconomics. 2009;27(10):793-5. doi: 10.2165/11313780-000000000-00000. No abstract
available.
909. Review: combining 2 classes of blood pressure-lowering drugs has an approximately additive
effect on systolic blood pressure.
Shantsila A, Lip GY.
Evid Based Med. 2009 Oct;14(5):142. doi: 10.1136/ebm.14.5.142. No abstract available.
.
910. Rationale and study design of a cross sectional study documenting the prevalence of Heart
Failure amongst the minority ethnic communities in the UK: the E-ECHOES Study (Ethnic-Echocardiographic Heart of England Screening Study).
Gill PS, Davis R, Davies M, Freemantle N, Lip GY.
BMC Cardiovasc Disord. 2009 Sep 30;9:47. doi: 10.1186/1471-2261-9-47.
911. Acute coronary syndromes: oral factor Xa inhibitors in acute coronary syndromes.
Tapp L, Wrigley B, Lip GY.
Nat Rev Cardiol. 2009 Oct;6(10):619-20. doi: 10.1038/nrcardio.2009.160. No abstract available.
912. Left atrial remodelling in hypertrophic cardiomyopathy: relation with exercise capacity and
biochemical markers of tissue strain and remodelling.
Saura D, Marín F, Climent V, González J, Roldán V, Hernández-Romero D, Oliva MJ, Sabater M, de la
Morena G, Lip GY, Valdés M.
Int J Clin Pract. 2009 Oct;63(10):1465-71. doi: 10.1111/j.1742-1241.2009.02127.x.
913. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation
using a novel risk factor-based approach: the euro heart survey on atrial fibrillation.
95
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ.
Chest. 2010 Feb;137(2):263-72. doi: 10.1378/chest.09-1584. Epub 2009 Sep 17.
914. [Management of acute myocardial infarction in patients presenting with persistent ST-segment
elevation].
Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K,
Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; Task Force per il
Trattamento dell'Infarto Miocardico Acuto con; Sopraslivellamento del Tratto ST della Società
Europea di Cardiologia, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, FunckBrentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P,
Zamorano JL, Silber S, Aguirre FV, Al-Attar N, Alegria E, Andreotti F, Benzer W, Breithardt O, Danchin
N, Di Mario C, Dudek D, Gulba D, Halvorsen S, Kaufmann P, Kornowski R, Lip GY, Rutten F, Societá
Europea di Cardiologia.
G Ital Cardiol (Rome). 2009 Jul;10(7):450-89. Italian. No abstract available.
915. Effects of atorvastatin on circulating CD34+/CD133+/ CD45- progenitor cells and indices of
angiogenesis (vascular endothelial growth factor and the angiopoietins 1 and 2) in atherosclerotic
vascular disease and diabetes mellitus.
Jaumdally RJ, Goon PK, Varma C, Blann AD, Lip GY.
J Intern Med. 2010 Apr;267(4):385-93. doi: 10.1111/j.1365-2796.2009.02151.x. Epub 2009 Jul 16.
916. Can the WATCHMAN device truly PROTECT from stroke in atrial fibrillation?
Wrigley BJ, Lip GY.
Lancet Neurol. 2009 Oct;8(10):877-8. doi: 10.1016/S1474-4422(09)70244-3. No abstract available.
917. Antithrombotic therapy for heart failure in sinus rhythm.
Subramaniam V, Davis RC, Shantsila E, Lip GY.
Fundam Clin Pharmacol. 2009 Dec;23(6):705-17. doi: 10.1111/j.1472-8206.2009.00776.x. Epub 2009
Sep 4. Review.
918. Lone atrial fibrillation: what do we know?
Kozlowski D, Budrejko S, Lip GY, Rysz J, Mikhailidis DP, Raczak G, Banach M.
Heart. 2010 Apr;96(7):498-503. doi: 10.1136/hrt.2009.176321. Epub 2009 Aug 26. Review.
919. Combination anticoagulant and antiplatelet therapy in atrial fibrillation patients.
Lip GY, Lane DA.
Rev Esp Cardiol. 2009 Sep;62(9):972-5. English, Spanish. No abstract available.
920. Assessment of endothelial (dys)function in atrial fibrillation.
Krishnamoorthy S, Lim SH, Lip GY.
Ann Med. 2009;41(8):576-90. doi: 10.1080/07853890903160726. Review.
921. Multicenter randomized study of anticoagulation guided by remote rhythm monitoring in
patients with implantable cardioverter-defibrillator and CRT-D devices: Rationale, design, and clinical
characteristics of the initially enrolled cohort The IMPACT study.
Ip J, Waldo AL, Lip GY, Rothwell PM, Martin DT, Bersohn MM, Choucair WK, Akar JG, Wathen MS,
Rohani P, Halperin JL; IMPACT Investigators.
Am Heart J. 2009 Sep;158(3):364-370.e1. doi: 10.1016/j.ahj.2009.07.002.
922. Alcohol and illicit drug use as precipitants of atrial fibrillation in young adults: a case series and
literature review.
96
Krishnamoorthy S, Lip GY, Lane DA.
Am J Med. 2009 Sep;122(9):851-856.e3. doi: 10.1016/j.amjmed.2009.02.012. Review.
923. Improving survival of malignant hypertension patients over 40 years.
Lane DA, Lip GY, Beevers DG.
Am J Hypertens. 2009 Nov;22(11):1199-204. doi: 10.1038/ajh.2009.153. Epub 2009 Aug 20.
924. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in
patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study
of four doses of AZD0837 vs. vitamin K antagonists.
Lip GY, Rasmussen LH, Olsson SB, Jensen EC, Persson AL, Eriksson U, Wåhlander KF; Steering
Committee.
Eur Heart J. 2009 Dec;30(23):2897-907. doi: 10.1093/eurheartj/ehp318. Epub 2009 Aug 18.
925. ACP Journal Club. Review: Combining 2 classes of blood pressure-lowering drugs has an
approximately additive effect on systolic blood pressure.
Shantsila A, Lip GY.
Ann Intern Med. 2009 Aug 18;151(4):JC2-11. No abstract available.
926. The endothelium and thrombotic risk in heart failure.
Shantsila E, Lip GY.
Thromb Haemost. 2009 Aug;102(2):185-7. doi: 10.1160/TH09-06-0344. No abstract available.
927. Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to
endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic
Index.
Goon PK, Lip GY, Stonelake PS, Blann AD.
Neoplasia. 2009 Aug;11(8):771-9.
928. Angiopoietins and preeclampsia: new perspectives in the quest for markers.
Apostolakis S, Shantsila E, Lip GY.
Am J Hypertens. 2009 Aug;22(8):820. doi: 10.1038/ajh.2009.108. No abstract available.
929. Can the NICE guidelines on the management of atrial fibrillation improve its management?
Khoo CW, Lip GY.
Clin Med (Lond). 2009 Jun;9(3):207-9. No abstract available.
930. Angiopoietins in arterial hypertension: a mechanism of adaptation or a target for treatment?
Shantsila E, Lip GY.
J Hypertens. 2009 Aug;27(8):1524-6. doi: 10.1097/HJH.0b013e32832dd5c4. No abstract available.
931. Atrial fibrillation in primary aldosteronism.
Watson T, Karthikeyan VJ, Lip GY, Beevers DG.
J Renin Angiotensin Aldosterone Syst. 2009 Dec;10(4):190-4. doi: 10.1177/1470320309342734. Epub
2009 Jul 17.
932. Novel antiarrhythmic drugs in atrial fibrillation: focus on tedisamil.
Krishnamoorthy S, Lip GY.
Expert Opin Investig Drugs. 2009 Aug;18(8):1191-6. doi: 10.1517/13543780903114150. Review.
97
933. Inflammatory cytokines, endothelial markers and adhesion molecules in rheumatoid arthritis:
effect of intensive anti-inflammatory treatment.
Foster W, Carruthers D, Lip GY, Blann AD.
J Thromb Thrombolysis. 2010 May;29(4):437-42. doi: 10.1007/s11239-009-0370-y.
934. Monocyte diversity in myocardial infarction.
Shantsila E, Lip GY.
J Am Coll Cardiol. 2009 Jul 7;54(2):139-42. doi: 10.1016/j.jacc.2009.03.047. No abstract available.
935. Renin-angiotensin-aldosterone system blockade in atrial fibrillation and left atrial remodelling.
Krishnamoorthy S, Lip GY.
Int J Clin Pract. 2009 Jul;63(7):982-5. doi: 10.1111/j.1742-1241.2009.02083.x. No abstract available.
936. Mitral regurgitation reduces systemic coagulation activity in rheumatic heart disease: using
fibrin D-dimer as a biomarker of thrombogenesis.
Tay KH, Khoo CW, Lip GY.
J Heart Valve Dis. 2009 May;18(3):276-7. No abstract available.
937. Defibrillation testing in patients with atrial fibrillation.
Lim HS, Lip GY.
Europace. 2009 Aug;11(8):1108-9. doi: 10.1093/europace/eup157. Epub 2009 Jun 23.
938. Antithrombotic therapy use for patients with atrial fibrillation undergoing percutaneous
coronary intervention: new data in an area of limited evidence.
Marín F, Kirchhof P, Lip GY.
Europace. 2009 Jul;11(7):842-3. doi: 10.1093/europace/eup161. No abstract available.
939. How safe is the antiarrhythmic drug therapy in atrial fibrillation?
Krishnamoorthy S, Lip GY.
Europace. 2009 Jul;11(7):837-9. doi: 10.1093/europace/eup170. No abstract available.
940. Bleeding rates in elderly patients on vitamin K antagonist therapy for nonvalvular atrial
fibrillation.
Tay KH, Lip GY, Lane DA.
Blood Coagul Fibrinolysis. 2009 Jul;20(5):392-3. doi: 10.1097/MBC.0b013e32832aec47. No abstract
available.
941. Early and comprehensive management of atrial fibrillation: executive summary of the
proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'.
Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R, Cosio F, Crijns H, Diener
HC, Goette A, Israel CW, Kuck KH, Lip GY, Nattel S, Page RL, Ravens U, Schotten U, Steinbeck G,
Vardas P, Waldo A, Wegscheider K, Willems S, Breithardt G.
Eur Heart J. 2009 Dec;30(24):2969-77c. doi: 10.1093/eurheartj/ehp235. Epub .
942. Early and comprehensive management of atrial fibrillation: proceedings from the 2nd
AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial
fibrillation'.
Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R, Cosio F, Crijns H, Diener
HC, Goette A, Israel CW, Kuck KH, Lip GY, Nattel S, Page RL, Ravens U, Schotten U, Steinbeck G,
Vardas P, Waldo A, Wegscheider K, Willems S, Breithardt G.
98
Europace. 2009 Jul;11(7):860-85. doi: 10.1093/europace/eup124. Epub 2009 Jun 16. No abstract
available.
943. Glycemic status underlies increased arterial stiffness and impaired endothelial function in
migrant South Asian stroke survivors compared to European Caucasians: pathophysiological insights
from the West Birmingham Stroke Project.
Gunarathne A, Patel JV, Kausar S, Gammon B, Hughes EA, Lip GY.
Stroke. 2009 Jul;40(7):2298-306. doi: 10.1161/STROKEAHA.109.548388. Epub 2009 Jun 11.
944. Obstructive sleep apnea and cardiovascular disease.
Butt M, Dwivedi G, Khair O, Lip GY.
Int J Cardiol. 2010 Feb 18;139(1):7-16. doi: 10.1016/j.ijcard.2009.05.021. Epub 2009 Jun 7. Review.
945. Hypertension to heart failure: a pathophysiological spectrum relating blood pressure, drug
treatments and stroke.
Subramaniam V, Lip GY.
Expert Rev Cardiovasc Ther. 2009 Jun;7(6):703-13. doi: 10.1586/erc.09.43.
946. Fondaparinux: an overview.
Nadar SK, Goyal D, Shantsila E, Banerjee P, Lip GY.
Expert Rev Cardiovasc Ther. 2009 Jun;7(6):577-85. doi: 10.1586/erc.09.19.
947. Assessment of endothelial function: implications for hypertension and cardiovascular disorders.
Butt M, Dwivedi G, Khair O, Lip GY.
Expert Rev Cardiovasc Ther. 2009 Jun;7(6):561-3. doi: 10.1586/erc.09.36. No abstract available.
948. Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and
management.
Shantsila E, Lip GY, Chong BH.
Chest. 2009 Jun;135(6):1651-64. doi: 10.1378/chest.08-2830. Review.
949. Peripheral arterial disease and Virchow's triad.
Bennett PC, Silverman SH, Gill PS, Lip GY.
Thromb Haemost. 2009 Jun;101(6):1032-40. Review.
950. Endothelial function and endothelial progenitors: possible mediators of the benefits from
physical exercise?
Shantsila E, Lip GY.
Eur J Cardiovasc Prev Rehabil. 2009 Aug;16(4):401-3. doi: 10.1097/HJR.0b013e32832d3c76. No
abstract available.
951. Antithrombotic therapy use after percutaneous coronary intervention and stent implantation in
patients taking chronic oral anticoagulation.
Ruiz-Nodar JM, Marín F, Lip GY.
JACC Cardiovasc Interv. 2008 Jun;1(3):329; author reply 330-1. doi: 10.1016/j.jcin.2008.03.016. No
abstract available.
952. Evidence guided antiplatelet treatment: time to move from bench to bedside.
Apostolakis S, Shantsila E, Lip GY.
Thromb Res. 2009 Dec;124(6):649-50. doi: 10.1016/j.thromres.2009.04.020. Epub 2009 May 14. No
abstract available.
99
953. Performing repeated noninvasive bedside measures of volume response to intravenous
furosemide in acute pulmonary edema: a feasibility assessment.
Ng Kam Chuen MJ, Lip GY, Macfadyen RJ.
Cardiovasc Ther. 2009 Summer;27(2):89-95. doi: 10.1111/j.1755-5922.2009.00080.x.
954. Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone.
Krishnamoorthy S, Lip GY.
Expert Rev Cardiovasc Ther. 2009 May;7(5):473-81. doi: 10.1586/erc.09.14. Review.
955. Female gender is a risk factor for stroke and thromboembolism in atrial fibrillation patients.
Lane DA, Lip GY.
Thromb Haemost. 2009 May;101(5):802-5. No abstract available. Erratum in: Thromb Haemost.2010
Sep;104(3):653.
956. Indications for the use of diagnostic implantable and external ECG loop recorders.
Task Force members, Brignole M, Vardas P, Hoffman E, Huikuri H, Moya A, Ricci R, Sulke N, Wieling
W; EHRA Scientific Documents Committee, Auricchio A, Lip GY, Almendral J, Kirchhof P, Aliot E,
Gasparini M, Braunschweig F; Document Reviewers, Lip GY, Almendral J, Kirchhof P, Botto GL; EHRA
Scientific Documents Committee.
Europace. 2009 May;11(5):671-87. doi: 10.1093/europace/eup097. Review. No abstract available.
Erratum in: Europace. 2009 Jun;11(6):836.
957. New antiplatelet drugs: beyond aspirin and clopidogrel.
Siddique A, Butt M, Shantsila E, Lip GY.
Int J Clin Pract. 2009 May;63(5):776-89. doi: 10.1111/j.1742-1241.2009.02058.x. Review.
958. Ischemic stroke in South Asians: a review of the epidemiology, pathophysiology, and ethnicityrelated clinical features.
Gunarathne A, Patel JV, Gammon B, Gill PS, Hughes EA, Lip GY.
Stroke. 2009 Jun;40(6):e415-23. doi: 10.1161/STROKEAHA.108.535724. Epub 2009 Apr 23. Review.
959. Clinical outcomes of acute stroke patients with atrial fibrillation.
Khoo CW, Lip GY.
Expert Rev Cardiovasc Ther. 2009 Apr;7(4):371-4. doi: 10.1586/erc.09.11.
960. Unraveling the paradoxical link between obesity and heart failure: the role of adipocytokines.
Patel JV, Tracey I, Hughes EA, Lip GY.
Expert Rev Cardiovasc Ther. 2009 Apr;7(4):337-40. doi: 10.1586/erc.09.12. No abstract available.
961. Drug-eluting stents: a comprehensive appraisal.
Butt M, Connolly D, Lip GY.
Future Cardiol. 2009 Mar;5(2):141-57. doi: 10.2217/14796678.5.2.141. Review.
962. Burden of atrial fibrillation.
Khoo CW, Lip GY.
Curr Med Res Opin. 2009 May;25(5):1261-3. doi: 10.1185/03007990902910443 .
963. Markers of thrombosis and hemostasis in acute coronary syndromes: relationship to increased
heart rate and reduced heart-rate variability.
Hamaad A, Sosin MD, Blann AD, Lip GY, MacFadyen RJ.
100
Clin Cardiol. 2009 Apr;32(4):204-9. doi: 10.1002/clc.20321.
964. Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S.
N Engl J Med. 2009 May 14;360(20):2066-78. doi: 10.1056/NEJMoa0901301. Epub 2009 Mar 31.
965. AZD6140 and bleeding: towards safer antiplatelet therapy?
Siddique A, Shantsila E, Lip GY.
Int J Clin Pract. 2009 Apr;63(4):537-9. doi: 10.1111/j.1742-1241.2008.01963.x. No abstract available.
966. Response to Dr Kula: Asymptomatic hypoxia in a young pregnant lady--unusual presentation of
atrial septal defect.
Krishnamoorthy S, Lip GY.
Int J Cardiol. 2010 Oct 29;144(3):428. doi: 10.1016/j.ijcard.2009.03.047. Epub 2009 Mar 26. No
abstract available.
967. Risks of cardiovascular events and effects of routine blood pressure lowering among patients
with type 2 diabetes and atrial fibrillation: results of the ADVANCE study.
Du X, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A, Woodward M, Cooper M, Harrap S,
Hamet P, Poulter N, Lip GY, Patel A; ADVANCE Collaborative Group.
Eur Heart J. 2009 May;30(9):1128-35. doi: 10.1093/eurheartj/ehp055. Epub 2009 Mar 11.
968. The prognostic value of biomarkers after a premature myocardial infarction.
Pineda J, Marín F, Marco P, Roldán V, Valencia J, Ruiz-Nodar JM, Romero DH, Sogorb F, Lip GY.
Int J Cardiol. 2010 Sep 3;143(3):249-54. doi: 10.1016/j.ijcard.2009.02.019. Epub 2009 Mar 17.
969. Atrial fibrillation and stroke risk prevention in real-life clinical practice.
Tay KH, Lip GY, Lane DA.
Thromb Haemost. 2009 Mar;101(3):415-6. No abstract available.
970. Variability of response to antiplatelet therapy: what should we do next?
Shantsila E, Lip GY.
Fundam Clin Pharmacol. 2009 Feb;23(1):19-22. doi: 10.1111/j.1472-8206.2008.00674.x. No abstract
available.
971. Acute management of atrial fibrillation.
Khoo CW, Lip GY.
Chest. 2009 Mar;135(3):849-59. doi: 10.1378/chest.08-2183. Review.
972. Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation.
Ruiz-Nodar JM, Marín F, Sánchez-Payá J, Hurtado JA, Valencia-Martín J, Manzano-Fernández S,
Roldán V, Pérez-Andreu V, Sogorb F, Valdés M, Lip GY.
Eur Heart J. 2009 Apr;30(8):932-9. doi: 10.1093/eurheartj/ehp045. Epub 2009 Feb 26.
973. Illness perceptions, affective response, and health-related quality of life in patients with atrial
fibrillation.
Lane DA, Langman CM, Lip GY, Nouwen A.
J Psychosom Res. 2009 Mar;66(3):203-10. doi: 10.1016/j.jpsychores.2008.10.007.
974. Monocytes in acute coronary syndromes.
Shantsila E, Lip GY.
101
Arterioscler Thromb Vasc Biol. 2009 Oct;29(10):1433-8. doi: 10.1161/ATVBAHA.108.180513. Epub
2009 Feb 19. Review.
975. Effects of coronary artery disease and percutaneous intervention on the cardiac metabolism of
nonesterified fatty acids and insulin: Implications of diabetes mellitus.
Jaumdally RJ, Lip GY, Patel JV, MacFadyen RJ, Varma C.
J Intern Med. 2009 Jun;265(6):689-97. doi: 10.1111/j.1365-2796.2009.02072.x. Epub 2009 Feb 16.
976. Novel oral anticoagulants.
Khoo CW, Tay KH, Shantsila E, Lip GY.
Int J Clin Pract. 2009 Apr;63(4):630-41. doi: 10.1111/j.1742-1241.2009.02011.x. Epub 2009 Feb 16.
Review.
977. Generalized obesity but not that characterized by raised waist-hip ratio is associated with
increased perceived breathlessness during treadmill exercise testing.
Goyal D, Logie IM, Nadar SK, Lip GY, Macfadyen RJ.
Cardiovasc Ther. 2009 Spring;27(1):10-6. doi: 10.1111/j.1755-5922.2008.00067.x.
978. Anticoagulation variability: is it the physician, patient or hospital?
Tay KH, Lip GY, Lane DA.
J Intern Med. 2009 Mar;265(3):303-6. doi: 10.1111/j.1365-2796.2008.02069.x. No abstract available.
979. Circulating biomarkers of angiogenesis as indicators of left ventricular systolic dysfunction
amongst patients with coronary artery disease.
Patel JV, Abraheem A, Chackathayil J, Gunning M, Creamer J, Hughes EA, Lip GY.
J Intern Med. 2009 May;265(5):562-7. doi: 10.1111/j.1365-2796.2008.02057.x. Epub 2009 Jan 31.
980. Plasma indices of angiogenesis in rheumatoid disease: relationship to cardiovascular risk factors
and cardiac function.
Bhatia GS, Sosin MD, Patel JV, Grindulis KA, Khattak FH, Davis RC, Lip GY.
Int J Cardiol. 2010 Dec 3;145(3):e105-8. doi: 10.1016/j.ijcard.2008.12.168. Epub 2009 Jan 29.
981. Atrial fibrillation following cardiac surgery: clinical features and preventative strategies.
Kaireviciute D, Aidietis A, Lip GY.
Eur Heart J. 2009 Feb;30(4):410-25. doi: 10.1093/eurheartj/ehn609. Epub 2009 Jan 27. Review.
982. Circulating levels of adiponectin, leptin, and tumour necrosis factor alpha in hypertension.
Patel JV, Lim HS, Dubb K, Hughes EA, Lip GY.
Ann Med. 2009;41(4):291-300. doi: 10.1080/07853890802672839.
983. A randomized trial of the addition of home-based exercise to specialist heart failure nurse care:
the Birmingham Rehabilitation Uptake Maximisation study for patients with Congestive Heart Failure
(BRUM-CHF) study.
Jolly K, Taylor RS, Lip GY, Davies M, Davis R, Mant J, Singh S, Greenfield S, Ingram J, Stubley J, Bryan S,
Stevens A.
Eur J Heart Fail. 2009 Feb;11(2):205-13. doi: 10.1093/eurjhf/hfn029.
984. Elevated angiogenin levels in chronic heart failure.
Patel JV, Sosin M, Gunarathne A, Hussain I, Davis RC, Hughes EA, Lip GY.
Ann Med. 2008;40(6):474-9. doi: 10.1080/07853890802001419.
102
985. Asymptomatic hypoxia in a young pregnant lady--unusual presentation of atrial septal defect.
Krishnamoorthy S, Butt M, Lip GY.
Int J Cardiol. 2010 Aug 20;143(2):e34-6. doi: 10.1016/j.ijcard.2008.12.039. Epub 2009 Jan 21.
986. Challenges facing anticoagulation among the elderly and frail.
Tay KH, Lane DA, Lip GY.
Age Ageing. 2009 Mar;38(2):140-2. doi: 10.1093/ageing/afn295. Epub 2009 Jan 20. No abstract
available.
987. Circulating endothelial cells and rheumatoid arthritis: relationship with plasma markers of
endothelial damage/dysfunction.
Foster W, Shantsila E, Carruthers D, Lip GY, Blann AD.
Rheumatology (Oxford). 2009 Mar;48(3):285-8. doi: 10.1093/rheumatology/ken486. Epub 2009 Jan
19.
988. Thrombosis prophylaxis in patients with ischaemic (cardioembolic) stroke. How long is long
enough?
Lip GY, Krishnamoorthy S.
Hamostaseologie. 2009 Jan;29(1):96-101. Review.
989. Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical
management and prognosis.
Cambronero F, Marín F, Roldán V, Hernández-Romero D, Valdés M, Lip GY.
Eur Heart J. 2009 Jan;30(2):139-51. doi: 10.1093/eurheartj/ehn538. Epub 2009 Jan 9. Review.
990. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited.
Watson T, Shantsila E, Lip GY.
Lancet. 2009 Jan 10;373(9658):155-66. doi: 10.1016/S0140-6736(09)60040-4. Review.
991. Predicting thrombotic events: creating a complex approach for a complex condition.
Shantsila E, Lip GY.
Thromb Haemost. 2008 Dec;100(6):962-4. No abstract available.
992. Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: is clopidogrel
any safer than aspirin when combined with warfarin?
Tay KH, Lane DA, Lip GY.
Thromb Haemost. 2008 Dec;100(6):955-7. No abstract available.
993. Face to face with basic and clinical research in Thrombosis and Haemostasis.
Preissner KT, Lip GY.
Thromb Haemost. 2009 Jan;101(1):1. No abstract available.
994. Radiofrequency catheter ablation of atrial fibrillation and thromboembolic risk.
Khoo CW, Lip GY.
Eur J Neurol. 2008 Dec;15(12):1261-2. doi: 10.1111/j.1468-1331.2008.02342.x. No abstract available.
995. Quality of life in older people with atrial fibrillation.
Lane DA, Lip GY.
J Interv Card Electrophysiol. 2009 Jun;25(1):37-42. doi: 10.1007/s10840-008-9318-y. Epub 2008 Nov
26. Review.
103
996. What "drives" the link between the renin-angiotensin-aldosterone system and the
prothrombotic state in hypertension?
Tay KH, Lip GY.
Am J Hypertens. 2008 Dec;21(12):1278-9. doi: 10.1038/ajh.2008.315. No abstract available.
PMID:
997. The endothelium, arterial stiffness, and von Willebrand factor levels in hypertensive women:
effects of ethnicity.
Butt M, Lip GY.
Am J Hypertens. 2008 Dec;21(12):1275-6. doi: 10.1038/ajh.2008.303. No abstract available.
998. Hypertension, stroke and the impact of atrial fibrillation.
Krishnamoorthy S, Lip GY.
Expert Rev Cardiovasc Ther. 2008 Nov;6(10):1287-9. doi: 10.1586/14779072.6.10.1287. No abstract
available.
999.Impact of chronic kidney disease on major bleeding complications and mortality in patients with
indication for oral anticoagulation undergoing coronary stenting.
Manzano-Fernández S, Marín F, Pastor-Pérez FJ, Caro C, Cambronero F, Lacunza J, Pinar E, PascualFigal DA, Valdés M, Lip GY.
Chest. 2009 Apr;135(4):983-90. doi: 10.1378/chest.08-1425. Epub 2008 Nov 18.
1000. Management of acute myocardial infarction in patients presenting with persistent ST-segment
elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction
of the European Society of Cardiology.
Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K,
Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M; ESC Committee for
Practice Guidelines (CPG).
Eur Heart J. 2008 Dec;29(23):2909-45. doi: 10.1093/eurheartj/ehn416. Epub 2008 Nov 12. No
abstract available.
1001. Is thrombogenesis related to residual platelet function in ischaemic heart disease?
Pastor-Pérez FJ, Marín F, Manzano-Fernández S, Lip GY.
Eur Heart J. 2008 Dec;29(24):3065; author reply 3065-6. doi: 10.1093/eurheartj/ehn472. Epub 2008
Oct 25. No abstract available.
1002. Ethnicity and peripheral artery disease.
Bennett PC, Silverman S, Gill PS, Lip GY.
QJM. 2009 Jan;102(1):3-16. doi: 10.1093/qjmed/hcn140. Epub 2008 Oct 23. Review.
1003. Gender and the response to blood pressure-lowering treatment.
Lip GY, Butt M.
Eur Heart J. 2008 Nov;29(21):2585-6. doi: 10.1093/eurheartj/ehn451. Epub 2008 Oct 13. No abstract
available.
1004. The endothelium and atrial fibrillation. The prothrombotic state revisited.
Freestone B, Lip GY.
Hamostaseologie. 2008 Oct;28(4):207-12. Review.
104
1005. Circulating serum adiponectin levels in patients with coronary artery disease: relationship to
atherosclerotic burden and cardiac function.
Patel JV, Abraheem A, Dotsenko O, Creamer J, Gunning M, Hughes EA, Lip GY.
J Intern Med. 2008 Dec;264(6):593-8. doi: 10.1111/j.1365-2796.2008.02007.x. Epub 2008 Sep 10.
1006. Managing the anticoagulated patient with atrial fibrillation at high risk of stroke who needs
coronary intervention.
Lip GY.
BMJ. 2008 Sep 12;337:a840. doi: 10.1136/bmj.39533.570602.BE. No abstract available. Erratum in:
BMJ. 2008;337:a1721.
1007. Hemoxygenase-1 in cardiovascular disease.
Idriss NK, Blann AD, Lip GY.
J Am Coll Cardiol. 2008 Sep 16;52(12):971-8. doi: 10.1016/j.jacc.2008.06.019. Review.
1008. Candidate circulating biomarkers for the cardiovascular disease continuum.
Dotsenko O, Chackathayil J, Patel JV, Gill PS, Lip GY.
Curr Pharm Des. 2008;14(24):2445-61. Review.
1009. The relationship of circulating endothelial cells to plasma indices of endothelial
damage/dysfunction and apoptosis in acute coronary syndromes: implications for prognosis.
Boos CJ, Balakrishnan B, Blann AD, Lip GY.
J Thromb Haemost. 2008 Nov;6(11):1841-50. doi: 10.1111/j.1538-7836.2008.03148.x. Epub 2008 Aug
28.
1010. 'Aspirin resistance' or treatment non-compliance: which is to blame for cardiovascular
complications?
Shantsila E, Lip GY.
J Transl Med. 2008 Aug 29;6:47. doi: 10.1186/1479-5876-6-47.
1011. Apixaban, an oral, direct inhibitor of activated Factor Xa.
Shantsila E, Lip GY.
Curr Opin Investig Drugs. 2008 Sep;9(9):1020-33. Review.
1012. The impact of statin use on atrial fibrillation.
Sánchez-Quiñones J, Marín F, Roldán V, Lip GY.
QJM. 2008 Nov;101(11):845-61. doi: 10.1093/qjmed/hcn101. Epub 2008 Aug 24. Review.
1013. Effects of atorvastatin 80 mg daily on indices of matrix remodelling in 'high-risk' patients with
ischemic heart disease.
López-Cuenca A, Marín F, Roldán V, Climent VE, Valdés M, Lip GY.
Int J Cardiol. 2010 Feb 18;139(1):95-7. doi: 10.1016/j.ijcard.2008.06.076. Epub 2008 Aug 22.
1014. Patients' experience of home and hospital based cardiac rehabilitation: a focus group study.
Jones MI, Greenfield S, Jolly K; BRUM Trial Steering Committee.
Eur J Cardiovasc Nurs. 2009 Mar;8(1):9-17. doi: 10.1016/j.ejcnurse.2008.06.001. Epub 2008 Aug 21.
1015. [Guidelines for cardiac pacing and cardiac resynchronization therapy].
Vardas PE, Auricchio A, Blanc JJ, Daubert JC, Drexler H, Ector H, Gasparini M, Linde C, Morgado FB,
Oto A, Sutton R, Trusz-Gluza M; Grupo de Trabalho para Pacing Cardíaco e Terapia de
Ressincronização Cardíaca da European Society of Cardiology; European Heart Rhythm Association,
105
Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I,
Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Priori SG,
Blomström-Lundqvist C, Brignole M, Terradellas JB, Camm J, Castellano P, Cleland J, Farre J, Fromer
M, Le Heuzey JY, Lip GY, Merino JL, Montenero AS, Ritter P, Schalij MJ, Stellbrink C.
Rev Port Cardiol. 2008 May;27(5):639-87. Portuguese. No abstract available.
1016. Relationships between endothelial, inflammatory and angiogenesis markers in rheumatoid
arthritis: implications for cardiovascular pathophysiology.
Foster W, Carruthers D, Lip GY, Blann AD.
Thromb Res. 2009 Feb;123(4):659-64. doi: 10.1016/j.thromres.2008.06.014. Epub 2008 Aug 8. No
abstract available.
1017. Initiation and persistence of warfarin or aspirin as thromboprophylaxis in chronic atrial
fibrillation in general practice.
Khoo CW, Lip GY.
J Thromb Haemost. 2008 Oct;6(10):1622-4. doi: 10.1111/j.1538-7836.2008.03115.x. Epub 2008 Aug
1. Review. No abstract available.
1018. Anaemia as predictor of gastrointestinal bleeding in atrial fibrillation patients undergoing
percutaneous coronary artery stenting.
Manzano-Fernández S, Marin F, Martinez JA, Cambronero F, Valdés M, Ruiz-Nodar JM, Pérez-Berbel
P, Lip GY.
QJM. 2008 Sep;101(9):749-51. doi: 10.1093/qjmed/hcn082. Epub 2008 Jul 29. No abstract available.
1019. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines (8th Edition).
Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GY, Manning WJ; American College
of Chest Physicians.
Chest. 2008 Jun;133(6 Suppl):546S-592S. doi: 10.1378/chest.08-0678.
1020. Soluble CD40 ligand, platelet surface CD40 ligand, and total platelet CD40 ligand in atrial
fibrillation: relationship to soluble P-selectin, stroke risk factors, and risk factor intervention.
Choudhury A, Chung I, Panja N, Patel J, Lip GY.
Chest. 2008 Sep;134(3):574-81. doi: 10.1378/chest.07-2745. Epub 2008 Jul 18.
1021. Increased major bleeding complications related to triple antithrombotic therapy usage in
patients with atrial fibrillation undergoing percutaneous coronary artery stenting.
Manzano-Fernández S, Pastor FJ, Marín F, Cambronero F, Caro C, Pascual-Figal DA, Garrido IP, Pinar
E, Valdés M, Lip GY.
Chest. 2008 Sep;134(3):559-67. doi: 10.1378/chest.08-0350.
1022. Premature coronary artery disease in young (age <45) subjects: interactions of lipid profile,
thrombophilic and haemostatic markers.
Pineda J, Marín F, Marco P, Roldán V, Valencia J, Ruiz-Nodar JM, Sogorb F, Lip GY.
Int J Cardiol. 2009 Aug 14;136(2):222-5. doi: 10.1016/j.ijcard.2008.04.020. Epub 2008 Jul 14.
1023. Soluble, platelet-bound, and total P-selectin as indices of platelet activation in congestive heart
failure.
Chung I, Choudhury A, Patel J, Lip GY.
Ann Med. 2009;41(1):45-51. doi: 10.1080/07853890802227089.
106
1024. Paroxysmal atrial fibrillation, stroke risk and thromboprophylaxis.
Lip GY.
Thromb Haemost. 2008 Jul;100(1):11-3. doi: 10.1160/TH08-05-0331. No abstract available.
1025. Beyond glucose levels in diabetic patients with coronary artery disease: platelet activity and
non-responsiveness to antiplatelet therapy.
Shantsila E, Lip GY.
Thromb Haemost. 2008 Jul;100(1):7-8. doi: 10.1160/TH08-06-0342. No abstract available.
1026. Thrombosis and Haemostasis: volume 100 and going strong ...
Preissner KT, Lip GY.
Thromb Haemost. 2008 Jul;100(1):1-2. doi: 10.1160/TH08-06-0359. No abstract available.
1027. Ventricular optimization of biventricular pacing: a systematic review.
Lim SH, Lip GY, Sanderson JE.
Europace. 2008 Aug;10(8):901-6. doi: 10.1093/europace/eun177. Epub 2008 Jul 8. Review.
1028. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary
artery stenting. An expert consensus document with focus on atrial fibrillation.
Rubboli A, Halperin JL, Airaksinen KE, Buerke M, Eeckhout E, Freedman SB, Gershlick AH, Schlitt A,
Tse HF, Verheugt FW, Lip GY.
Ann Med. 2008;40(6):428-36. doi: 10.1080/07853890802089786. Review.
1029. Factor VII -323 decanucleotide D/I polymorphism in atrial fibrillation: implications for the
prothrombotic state and stroke risk.
Roldán V, Marín F, González-Conejero R, García-Honrubia A, Martí S, Alfaro A, Valdés M, Corral J,Lip
GY, Vicente V.
Ann Med. 2008;40(7):553-9. doi: 10.1080/07853890802108412.
1030. Risk factors and stroke risk stratification for atrial fibrillation: limitations and new possibilities.
Lip GY.
Am Heart J. 2008 Jul;156(1):1-3. doi: 10.1016/j.ahj.2008.02.020. Epub 2008 May 5. No abstract
available.
1031. Vital exhaustion and cardiovascular disease: are circulating fibrinogen and D-dimer levels a
plausible link?
Bennett PC, Lane DA, Lip GY.
Stress. 2008 Jul;11(4):247-9. doi: 10.1080/10253890701833029.
1032. Endothelium and fibrinolysis in hypertension: important facets of a prothrombotic state?
Lip GY, Blann AD.
Hypertension. 2008 Aug;52(2):218-9. doi: 10.1161/HYPERTENSIONAHA.108.114876. Epub 2008 Jun
23. No abstract available.
1033. Measurement of stiffness index by digital volume pulse analysis technique: clinical utility in
cardiovascular disease risk stratification.
Gunarathne A, Patel JV, Hughes EA, Lip GY.
Am J Hypertens. 2008 Aug;21(8):866-72. doi: 10.1038/ajh.2008.207. Epub 2008 Jun 12.
1034. Impact of mean arterial blood pressure on higher arterial stiffness indices in South Asians
compared to white Europeans.
107
Gunarathne A, Patel JV, Gammon B, Hughes EA, Lip GY.
J Hypertens. 2008 Jul;26(7):1420-6. doi: 10.1097/HJH.0b013e3282ffb42a.
1035. The left atrium and diastolic dysfunction in hypertensive left ventricular hypertrophy: a
consideration of size and function?
Dwivedi G, Lip GY.
J Hypertens. 2008 Jul;26(7):1310-2. doi: 10.1097/HJH.0b013e328302ee20. No abstract available.
1036. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M,
Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen
CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F.
N Engl J Med. 2008 Jun 12;358(24):2560-72. doi: 10.1056/NEJMoa0802987. Epub 2008 Jun 6.
1037. Interleukin-8 and atrial fibrillation.
Melenovsky V, Lip GY.
Europace. 2008 Jul;10(7):784-5. doi: 10.1093/europace/eun154. Epub 2008 Jun 3. No abstract
available.
1038. Premature coronary artery disease: an inferred cardiovascular variant or a South Asian genetic
disorder?
Patel JV, Dwivedi S, Hughes EA, Lip GY.
Thromb Haemost. 2008 Jun;99(6):991-2. doi: 10.1160/TH08-05-0286. No abstract available.
1039. Arterial stiffness: beyond pulse wave velocity and its measurement.
Lim HS, Lip GY.
J Hum Hypertens. 2008 Oct;22(10):656-8. doi: 10.1038/jhh.2008.47. No abstract available.
1040. Antithrombotic treatment in atrial fibrillation.
Lip GY, Boos CJ.
Postgrad Med J. 2008 May;84(991):252-8. doi: 10.1136/hrt.2005.066944. Review.
1041. Plasma indices of endothelial and platelet activation in Rheumatoid Disease: relationship to
cardiovascular co-morbidity.
Bhatia GS, Sosin MD, Patel JV, Grindulis KA, Khattak FH, Davis RC, Lip GY.
Int J Cardiol. 2009 May 1;134(1):97-103. doi: 10.1016/j.ijcard.2008.01.038. Epub 2008 May 23.
1042. Statins and inflammation: reciprocal effectors to endothelial progenitors?
Shantsila E, Watson T, Lip GY.
Thromb Res. 2008;123(1):1-4. doi: 10.1016/j.thromres.2008.03.021. Epub 2008 May 15. No abstract
available.
1043. Asymptomatic atrial fibrillation on device interrogation.
Lim HS, Lip GY.
J Cardiovasc Electrophysiol. 2008 Aug;19(8):891-3. doi: 10.1111/j.1540-8167.2008.01194.x. Epub
2008 May 9. Review. No abstract available.
1044. Circulating matrix metalloproteinase-9 levels in atherosclerotic vascular disease: a possible
measurement of systemic or specific disease pathophysiology?
Lim HS, Lip GY.
108
J Intern Med. 2008 Jun;263(6):620-2. doi: 10.1111/j.1365-2796.2008.01937.x. Review. No abstract
available.
1045. The role of aspirin in cardiovascular prevention: implications of aspirin resistance.
Gasparyan AY, Watson T, Lip GY.
J Am Coll Cardiol. 2008 May 13;51(19):1829-43. doi: 10.1016/j.jacc.2007.11.080. Review.
1046. The potential impact of periodontal disease on general health: a consensus view.
Williams RC, Barnett AH, Claffey N, Davis M, Gadsby R, Kellett M, Lip GY, Thackray S.
Curr Med Res Opin. 2008 Jun;24(6):1635-43. doi: 10.1185/03007990802131215. Epub 2008 Apr 30.
Review.
1047. Consensus document on antithrombotic therapy in the setting of electrophysiological
procedures.
Blanc JJ, Almendral J, Brignole M, Fatemi M, Gjesdal K, González-Torrecilla E, Kulakowski P, Lip GY,
Shah D, Wolpert C; Scientific Initiatives Committee of the European Heart Rhythm Association.
Europace. 2008 May;10(5):513-27. doi: 10.1093/europace/eun104. No abstract available.
1048. Circulating endothelial cells in health and disease: how do we best quantify them?
Shantsila E, Lip GY.
J Thromb Haemost. 2008 Jun;6(6):1021-4. doi: 10.1111/j.1538-7836.2008.02985.x. Epub 2008 Apr
18. No abstract available.
1049. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular
atrial fibrillation.
Stroke Risk in Atrial Fibrillation Working Group.
Stroke. 2008 Jun;39(6):1901-10. doi: 10.1161/STROKEAHA.107.501825. Epub 2008 Apr 17. Review.
1050. Anticoagulation in atrial fibrillation: the trials and tribulations of keeping within therapeutic
range.
Taggar JS, Lip GY.
Curr Med Res Opin. 2008 May;24(5):1455-8. doi: 10.1185/030079908X301875 . Epub 2008 Apr 9.
PMID:
1051. Obstructive sleep apnoea and metabolic syndrome: two sides of the same coin?
Dwivedi G, Khair O, Lip GY.
J Hum Hypertens. 2008 Jun;22(6):377-9. doi: 10.1038/jhh.2008.14. Epub 2008 Apr 3. No abstract
available.
1052. Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension.
Patel JV, Lim HS, Varughese GI, Hughes EA, Lip GY.
Ann Med. 2008;40(3):215-22. doi: 10.1080/07853890701779586.
1053. Implantable cardioverter defibrillator following acute myocardial infarction: the '48-hour' and
'40-day' rule.
Lim HS, Lip GY, Tse HF.
Europace. 2008 May;10(5):536-9. doi: 10.1093/europace/eun070. Epub 2008 Mar 26. Review.
1054. New approaches to therapy with omega-3 fatty acids.
Kakar P, Watson T, Lip GY.
Curr Atheroscler Rep. 2008 Feb;10(1):79-87. Review.
109
1055. Plasma metalloproteinase-9 in age-related macular degeneration.
Blann AD, Lip GY.
Eye (Lond). 2009 Feb;23(2):494-5; author reply 495. doi: 10.1038/eye.2008.71. Epub 2008 Mar 21.
No abstract available.
1056. Left ventricular ejection fraction: are the revised cut-off points for defining systolic dysfunction
sufficiently evidence based?
Mahadevan G, Davis RC, Frenneaux MP, Hobbs FD, Lip GY, Sanderson JE, Davies MK.
Heart. 2008 Apr;94(4):426-8. doi: 10.1136/hrt.2007.123877. Review. No abstract available.
1057. Biomarkers of endothelial dysfunction are elevated and related to prognosis in chronic heart
failure patients with diabetes but not in those without diabetes.
Kistorp C, Chong AY, Gustafsson F, Galatius S, Raymond I, Faber J, Lip GY, Hildebrandt P.
Eur J Heart Fail. 2008 Apr;10(4):380-7. doi: 10.1016/j.ejheart.2008.02.012. Epub 2008 Mar 17.
1058. Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation
receiving anticoagulation.
Lip GY.
BMJ. 2008 Mar 15;336(7644):614-5. doi: 10.1136/bmj.39351.706586.AD. Review. No abstract
available.
1059. Influence of atrial fibrillation on plasma von willebrand factor, soluble E-selectin, and Nterminal pro B-type natriuretic peptide levels in systolic heart failure.
Freestone B, Gustafsson F, Chong AY, Corell P, Kistorp C, Hildebrandt P, Lip GY.
Chest. 2008 May;133(5):1203-8. doi: 10.1378/chest.07-2557. Epub 2008 Mar 13.
1060. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal
atrial fibrillation?
Nieuwlaat R, Dinh T, Olsson SB, Camm AJ, Capucci A, Tieleman RG, Lip GY, Crijns HJ; Euro Heart
Survey Investigators.
Eur Heart J. 2008 Apr;29(7):915-22. doi: 10.1093/eurheartj/ehn101. Epub 2008 Mar 10.
1061. The Birmingham Rehabilitation Uptake Maximisation study (BRUM): a randomised controlled
trial comparing home-based with centre-based cardiac rehabilitation.
Jolly K, Lip GY, Taylor RS, Raftery J, Mant J, Lane D, Greenfield S, Stevens A.
Heart. 2009 Jan;95(1):36-42. doi: 10.1136/hrt.2007.127209. Epub 2008 Mar 10.
1062. Mortality in patients with atrial fibrillation: improving or not?
Taggar JS, Marín F, Lip GY.
Europace. 2008 Apr;10(4):389-90. doi: 10.1093/europace/eun054. Epub 2008 Mar 8. No abstract
available.
1063. [Guidelines in cardiac pacing and resynchronization therapy].
Grupa Robocza Europejskiego Towarzystwa Kardiologicznego ds. stymulacji serca i resynchronizacji
we współpracy; Europejskim Towarzystwem Rytmu Serca, Vardas PE, Auricchio A, Blanc JJ, Daubert
JC, Drexler H, Ector H, Gasparini M, Linde C, Morgado FB, Oto A, Sutton R, Trusz-Gluza M, Vahanian A,
Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Filippatos G, Hellemans I, Kristensen
SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Priori SG, BlomströmLundqvist C, Brignole M, Terradellas JB, Camm J, Castellano P, Cleland J, Farre J, Fromer M, Le Heuzey
JY, Lip GY, Merino JL, Montenero AS, Ritter P, Schlij MJ, Stellbrink C; European Cardiac Society.
110
Kardiol Pol. 2007 Dec;65(12):1449-87; discussion 1488-9. Polish. No abstract available.
1064. The balance between stroke prevention and bleeding risk in atrial fibrillation: a delicate
balance revisited.
Lip GY.
Stroke. 2008 May;39(5):1406-8. doi: 10.1161/STROKEAHA.107.506832. Epub 2008 Mar 6. No abstract
available.
1065. Endothelial progenitor cells, endothelial dysfunction, inflammation, and oxidative stress in
hypertension.
Watson T, Goon PK, Lip GY.
Antioxid Redox Signal. 2008 Jun;10(6):1079-88. doi: 10.1089/ars.2007.1998. Review.
1066. Letter by Roldán et al regarding article, "Plasminogen activator inhibitor-1 as a predictor of
postoperative atrial fibrillation after cardiopulmonary bypass".
Roldán V, Marín F, Lip GY.
Circulation. 2008 Feb 26;117(8):e169; author reply e170. doi:
10.1161/CIRCULATIONAHA.107.746461. No abstract available.
1067. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing
percutaneous coronary intervention and stent implantation implications for bleeding risk and
prognosis.
Ruiz-Nodar JM, Marín F, Hurtado JA, Valencia J, Pinar E, Pineda J, Gimeno JR, Sogorb F, Valdés M, Lip
GY.
J Am Coll Cardiol. 2008 Feb 26;51(8):818-25. doi: 10.1016/j.jacc.2007.11.035.
1068. Assessment of endothelial damage/dysfunction: a focus on circulating endothelial cells.
Boos CJ, Blann AD, Lip GY.
Methods Mol Med. 2007;139:211-24.
'
1069. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors,
risk stratification schema and cost effectiveness data.
Hughes M, Lip GY; Guideline Development Group, National Clinical Guideline for Management of
Atrial Fibrillation in Primary and Secondary Care, National Institute for Health and Clinical Excellence.
Thromb Haemost. 2008 Feb;99(2):295-304. doi: 10.1160/TH07-08-0508. Review.
'
1070. Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation.
Lip GY, Frison L, Grind M; SPORTIF Investigators.
J Intern Med. 2008 Jul;264(1):50-61. doi: 10.1111/j.1365-2796.2007.01909.x. Epub 2008 Feb 4.
1071. New insights on endothelial progenitor cell subpopulations and their angiogenic properties.
Shantsila E, Watson T, Tse HF, Lip GY.
J Am Coll Cardiol. 2008 Feb 12;51(6):669-71. doi: 10.1016/j.jacc.2007.09.057. No abstract available.
1072. Self-care and adherence to medication: a survey in the hypertension outpatient clinic.
Gohar F, Greenfield SM, Beevers DG, Lip GY, Jolly K.
BMC Complement Altern Med. 2008 Feb 8;8:4. doi: 10.1186/1472-6882-8-4.
1073. The effects of maximal treadmill graded exercise testing on haemorheological, haemodynamic
and flow cytometry platelet markers in patients with systolic or diastolic heart failure.
Chung I, Goyal D, Macfadyen RJ, Lip GY.
111
Eur J Clin Invest. 2008 Mar;38(3):150-8. doi: 10.1111/j.1365-2362.2008.01909.x.
1074. Influence of electrical cardioversion on inflammation and indexes of structural remodeling, in
persistent atrial fibrillation.
Climent V, Marín F, Mainar L, Roldán V, García A, Martínez JG, Lip GY.
Int J Cardiol. 2009 Feb 20;132(2):227-32. doi: 10.1016/j.ijcard.2007.11.044. Epub 2008 Jan 30.
1075. Experiences of living with congestive heart failure: a qualitative study.
Thornhill K, Lyons AC, Nouwen A, Lip GY.
Br J Health Psychol. 2008 Feb;13(Pt 1):155-75. doi: 10.1348/135910706X170983.
.
1076. Circulating endothelial cells: from bench to clinical practice.
Shantsila E, Blann AD, Lip GY.
J Thromb Haemost. 2008 May;6(5):865-8. doi: 10.1111/j.1538-7836.2008.02918.x. Epub 2008 Jan 25.
Review. No abstract available.
1077. Imaging of the unstable plaque.
Tan KT, Lip GY.
Int J Cardiol. 2008 Jul 4;127(2):157-65. doi: 10.1016/j.ijcard.2007.11.054. Epub 2008 Jan 22. Review.
1078. Ethnic differences in myocardial infarction in patients with hypertension: effects of diabetes
mellitus.
Patel JV, Lim HS, Gunarathne A, Tracey I, Durrington PN, Hughes EA, Lip GY.
QJM. 2008 Mar;101(3):231-6. doi: 10.1093/qjmed/hcm151. Epub 2008 Jan 19.
1079. Risk predictors for lone atrial fibrillation.
Taggar JS, Lip GY.
Europace. 2008 Jan;10(1):6-8. doi: 10.1093/europace/eum274. No abstract available.
1080. Inflammation and atrial fibrillation: cause or effect?
Boos CJ, Lip GY.
Heart. 2008 Feb;94(2):133-4. doi: 10.1136/hrt.2007.119651. No abstract available.
1081. Endothelial progenitor cells: from pathophysiology to clinical practice.
Goon PK, Watson T, Stonelake PS, Lip GY.
Int J Clin Pract. 2008 Jan;62(1):4-6. doi: 10.1111/j.1742-1241.2007.01555.x. No abstract available.
1082. The QRISK was less likely to overestimate cardiovascular risk than the Framingham or ASSIGN
equations.
Taggar JS, Lip GY.
ACP J Club. 2008 Jan-Feb;148(1):25. No abstract available.
1083. Atrial fibrillation (chronic).
Boos CJ, Lane DA, Lip GY.
BMJ Clin Evid. 2008 Apr 30;2008. pii: 0217.
1084. Atrial fibrillation (acute onset).
Lip GY, Watson T.
BMJ Clin Evid. 2008 May 2;2008. pii: 0210.
112
1085. Stroke prevention.
Lip GY, Kalra L.
BMJ Clin Evid. 2008 Sep 3;2008. pii: 0207.
1086. Can patients with atrial fibrillation be optimally risk stratified for stroke and
thromboembolism?
Taggar JS, Watson T, Lip GY.
Stroke. 2008 Feb;39(2):e24-5; author reply e26. Epub 2007 Dec 27. No abstract available.
1087. Measurement of C-reactive protein and natriuretic peptides for cardiovascular risk assessment:
the need for age and gender-specific thresholds.
Dotsenko O, Chackathayil J, Lip GY.
J Hypertens. 2008 Jan;26(1):11-3. No abstract available.
1088. Soluble CD40L, platelet surface CD40L and total platelet CD40L in congestive heart failure:
relationship to platelet volume, mass and granularity.
Chung I, Choudhury A, Patel J, Lip GY.
J Intern Med. 2008 Mar;263(3):313-21. Epub 2007 Dec 10.
1089. Soluble P-selectin and vascular endothelial growth factor in steady state sickle cell disease:
relationship to genotype.
Blann AD, Mohan JS, Bareford D, Lip GY.
J Thromb Thrombolysis. 2008 Apr;25(2):185-9. Epub 2007 Dec 14.
1090. Effects of percutaneous coronary intervention on peripheral venous blood circulating
endothelial cells and plasma indices of endothelial damage/dysfunction.
Boos CJ, Balakrishnan B, Jessani S, Blann AD, Lip GY.
Chest. 2007 Dec;132(6):1920-6.
1091. Relationship of soluble CD40 ligand to vascular endothelial growth factor, angiopoietins, and
tissue factor in atrial fibrillation: a link among platelet activation, angiogenesis, and thrombosis?
Choudhury A, Freestone B, Patel J, Lip GY.
Chest. 2007 Dec;132(6):1913-9.
1092. Identifying AF patients at risk of stroke: can prothrombotic indices improve things?
Watson T, Lip GY.
Int J Cardiol. 2008 Jun 6;126(3):299-301. Epub 2008 Feb 20. No abstract available.
1093. Atrial fibrillation: Rate control and digoxin.
Lip GY, Rudolf M; Guideline development group for the NICE clinical guideline for the management of
atrial fibrillation.
BMJ. 2007 Dec 8;335(7631):1169-70. No abstract available.
1094. Is soluble CD40 ligand a mediator of angiogenesis in patients with coronary artery disease?
Lim HS, Tayebjee MH, Tan KT, Patel JV, Macfadyen RJ, Lip GY.
Thromb Res. 2008;122(3):307-13. Epub 2007 Dec 3.
1095. Barriers to anticoagulation in patients with atrial fibrillation: changing physician-related
factors.
Lane DA, Lip GY.
113
Stroke. 2008 Jan;39(1):7-9. Epub 2007 Nov 29. No abstract available.
1096. Widening access to cardiovascular healthcare: community screening among ethnic minorities
in inner-city Britain - the Healthy Hearts Project.
Patel JV, Gunarathne A, Lane D, Lim HS, Tracey I, Panja NC, Lip GY, Hughes EA.
BMC Health Serv Res. 2007 Nov 23;7:192.
1097. Increased 5-year mortality in the migrant South Asian stroke patients with diabetes mellitus in
the United Kingdom: the West Birmingham Stroke Project.
Gunarathne A, Patel JV, Potluri R, Gammon B, Jessani S, Hughes EA, Lip GY.
Int J Clin Pract. 2008 Feb;62(2):197-201. Epub 2007 Nov 23.
1098. Cardiac biomarkers: myths, facts and future horizons.
Dotsenko O, Chackathayil J, Lip GY.
Expert Rev Mol Diagn. 2007 Nov;7(6):693-7. Review. No abstract available.
1099. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial
arrhythmias.
Shantsila E, Watson T, Lip GY.
Europace. 2007 Sep;9 Suppl 4:iv37-44. Review.
1100. Circulating endothelial cells, arterial stiffness, and cardiovascular risk stratification in
hypertension.
Boos CJ, Lane DA, Karpha M, Beevers DG, Haynes R, Lip GY.
Chest. 2007 Nov;132(5):1540-7.
1101. mpaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial
fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels.
Freestone B, Chong AY, Nuttall S, Lip GY.
Thromb Res. 2008;122(1):85-90. Epub 2007 Nov 8.
1102. A multimarker risk stratification approach to non-ST elevation acute coronary syndrome:
implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels.
Tello-Montoliu A, Marín F, Roldán V, Mainar L, López MT, Sogorb F, Vicente V, Lip GY.
J Intern Med. 2007 Dec;262(6):651-8. Epub 2007 Nov 7.
1103. Plasma angiogenin levels in acute coronary syndromes: implications for prognosis.
Tello-Montoliu A, Marín F, Patel J, Roldán V, Mainar L, Vicente V, Sogorb F, Lip GY.
Eur Heart J. 2007 Dec;28(24):3006-11. Epub 2007 Nov 2.
1104. Post-stenting antithrombotic drug therapy in patients with atrial fibrillation.
Lip GY.
Am J Med. 2007 Nov;120(11):920-2. No abstract available.
1105. Cardioversion and remodelling in atrial fibrillation: Insights beyond the prothrombotic state.
Shantsila E, Watson T, Lip GY.
Thromb Res. 2008;121(4):443-5. Epub 2007 Oct 24. No abstract available.
1106. Atrial fibrillation and stroke prevention.
Lip GY, Lim HS.
Lancet Neurol. 2007 Nov;6(11):981-93. Review.
114
1107. Elevated lipoprotein (a) and apolipoprotein B to AI ratio in South Asian patients with ischaemic
stroke.
Sharobeem KM, Patel JV, Ritch AE, Lip GY, Gill PS, Hughes EA.
Int J Clin Pract. 2007 Nov;61(11):1824-8.
1108. Atherosclerotic renal artery stenosis--do we really know what to do?
Srivastava S, Lip GY.
Blood Press. 2007;16(5):288-90. Review. No abstract available.
1109. Indices of angiogenesis, platelet activation, and endothelial damage/dysfunction in relation to
ethnicity and coronary artery disease: differences in central versus peripheral levels.
Jaumdally RJ, Varma C, Blann AD, Macfadyen RJ, Lip GY.
Ann Med. 2007;39(8):628-33.
1110. The effects of exercise stress testing on soluble E-selectin, von Willebrand factor, and
circulating endothelial cells as indices of endothelial damage/dysfunction.
Boos CJ, Balakrishnan B, Lip GY.
Ann Med. 2008;40(1):66-73.
1111. A systematic review of the prothrombotic effects of an acute change in posture: a possible
mechanism underlying the morning excess in cardiovascular events?
Thrall G, Lane D, Carroll D, Lip GY.
Chest. 2007 Oct;132(4):1337-47. Review.
1112. Platelet activation in coronary artery disease: intracardiac vs peripheral venous levels and the
effects of angioplasty.
Jaumdally RJ, Varma C, Blann AD, MacFadyen RJ, Lip GY.
Chest. 2007 Nov;132(5):1532-9. Epub 2007 Oct 1.
PMID:
17908707
1113. Anticoagulation for elderly patients with atrial fibrillation: not to be neglected.
Taggar JS, Lip GY.
Europace. 2008 Jan;10(1):1-2. Epub 2007 Sep 28. No abstract available.
1114. Repeated assessment of physical biomeasures or blood biomarkers for the definition of
volume status and cardiac loading in LVSD.
Chuen MJ, Lip GY, MacFadyen RJ.
Biomark Med. 2007 Oct;1(3):355-74. doi: 10.2217/17520363.1.3.355.
1115. Outcome parameters for trials in atrial fibrillation: recommendations from a consensus
conference organized by the German Atrial Fibrillation Competence NETwork and the European
Heart Rhythm Association.
Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G, Hohnloser S,
Kappenberger L, Kuck KH, Lip GY, Olsson B, Meinertz T, Priori S, Ravens U, Steinbeck G, Svernhage E,
Tijssen J, Vincent A, Breithardt G.
Europace. 2007 Nov;9(11):1006-23. Epub 2007 Sep 25.
1116. Outcome parameters for trials in atrial fibrillation: executive summary.
115
Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G, Hohnloser S,
Kappenberger L, Kuck KH, Lip GY, Olsson B, Meinertz T, Priori S, Ravens U, Steinbeck G, Svernhage E,
Tijssen J, Vincent A, Breithardt G.
Eur Heart J. 2007 Nov;28(22):2803-17. Epub 2007 Sep 25.
1117. From diabetes to metabolic syndrome: a viewpoint on an evolving concept.
Lim HS, Lip GY.
Curr Pharm Des. 2007;13(25):2580-3. Review.
1118. Hypertension in pregnancy: pathophysiology and management strategies.
Karthikeyan VJ, Lip GY.
Curr Pharm Des. 2007;13(25):2567-79. Review.
1119. Management of hypertension in relation to acute coronary syndromes and revascularisation.
Kühl M, Lip GY, Varma C.
Curr Pharm Des. 2007;13(25):2556-66. Review.
1120. Hypertension, anti-hypertensive therapy and neoplasia.
Goon PK, Stonelake PS, Lip GY.
Curr Pharm Des. 2007;13(25):2539-44. Review.
1121. Comparative dose titration responses to the introduction of bisoprolol or carvedilol in stable
chronic systolic heart failure.
Hamaad A, Lip GY, Nicholls D, MacFadyen RJ.
Cardiovasc Drugs Ther. 2007 Dec;21(6):437-44.
1122. Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body
nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and
permanent atrial fibrillation.
Freestone B, Chong AY, Nuttall S, Blann AD, Lip GY.
Chest. 2007 Oct;132(4):1253-8. Epub 2007 Sep 21.
1123. Endothelial colony forming units: are they a reliable marker of endothelial progenitor cell
numbers?
Shantsila E, Watson T, Tse HF, Lip GY.
Ann Med. 2007;39(6):474-9.
1124. Platelet adhesion in congestive heart failure.
Chung I, Choudhury A, Lip GY.
Thromb Res. 2008;121(6):885-8. Epub 2007 Sep 17. No abstract available.
1125. Risk factors for anticoagulation-related bleeding complications in patients with atrial
fibrillation: a systematic review.
Hughes M, Lip GY; Guideline Development Group for the NICE national clinical guideline for
management of atrial fibrillation in primary and secondary care.
QJM. 2007 Oct;100(10):599-607. Epub 2007 Sep 10. Review.
.
1126. Endotoxemia, inflammation, and atrial fibrillation.
Boos CJ, Lip GY, Jilma B.
Am J Cardiol. 2007 Sep 15;100(6):986-8. Epub 2007 Jul 2.
1127. The Birmingham Rehabilitation Uptake Maximisation Study (BRUM). Home-based compared
with hospital-based cardiac rehabilitation in a multi-ethnic population: cost-effectiveness and patient
adherence.
116
Jolly K, Taylor R, Lip GY, Greenfield S, Raftery J, Mant J, Lane D, Jones M, Lee KW, Stevens A.
Health Technol Assess. 2007 Sep;11(35):1-118. Review.
1128. Alpha 1-microglobulin: a further insight into inflammation in hypertension?
Karthikeyan VJ, Lip GY.
Am J Hypertens. 2007 Sep;20(9):1022-3. No abstract available.
.
1129. Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac
Pacing and Cardiac Resynchronization Therapy of the European 1130. Society of Cardiology.
Developed in collaboration with the European Heart Rhythm Association.
Vardas PE, Auricchio A, Blanc JJ, Daubert JC, Drexler H, Ector H, Gasparini M, Linde C, Morgado FB,
Oto A, Sutton R, Trusz-Gluza M; European Society of Cardiology; European Heart Rhythm Association.
Eur Heart J. 2007 Sep;28(18):2256-95. Epub 2007 Aug 28. No abstract available.
1131. Effects of white European, African Caribbean and South Asian ethnicity on homocysteine levels
in patients with systolic heart failure.
Sosin MD, Patel JV, Bhatia GS, Hughes EA, Davis RC, Lip GY.
Int J Cardiol. 2008 Sep 16;129(1):69-75. Epub 2007 Aug 23.
1132. Combining antiplatelet drugs and oral anticoagulant therapy in atrial fibrillation: acute
coronary syndromes and/or percutaneous coronary intervention/stenting revisited.
Watson T, Lip GY.
Stroke. 2007 Oct;38(10):e107-8. Epub 2007 Aug 23. No abstract available.
1133. Management of atrial fibrillation.
Lip GY, Tse HF.
Lancet. 2007 Aug 18;370(9587):604-18. Review.
1134. Endothelial progenitor cells, endothelial cell dysfunction and much more: observations from
cardiac syndrome X.
Goon PK, Lip GY.
Heart. 2007 Sep;93(9):1020-1. No abstract available.
1135. Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to
functional data and prognosis.
Jordán A, Roldán V, García M, Monmeneu J, de Burgos FG, Lip GY, Marín F.
J Intern Med. 2007 Sep;262(3):385-92.
1136. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial
fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised
controlled trial.
Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E; BAFTA investigators; Midland
Research Practices Network (MidReC).
Lancet. 2007 Aug 11;370(9586):493-503.
.
1137. Common carotid artery intima-media thickness and intracranial pulsatility index in non-STelevation acute coronary syndromes.
Tello-Montoliu A, Moltó JM, López-Hernández N, García-Medina A, Roldán V, Sogorb F, Lip GY, Marín
F.
Cerebrovasc Dis. 2007;24(4):338-42. Epub 2007 Aug 9.
1138. Secular trends in the cardiovascular risk profile and mortality of stroke admissions in an inner
city, multiethnic population in the United Kingdom (1997-2005).
Gunarathne A, Patel JV, Potluri R, Gill PS, Hughes EA, Lip GY.
J Hum Hypertens. 2008 Jan;22(1):18-23. Epub 2007 Aug 2.
1139. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over:
cluster randomised controlled trial.
Fitzmaurice DA, Hobbs FD, Jowett S, Mant J, Murray ET, Holder R, Raftery JP, Bryan S, Davies M,Lip
GY, Allan TF.
117
BMJ. 2007 Aug 25;335(7616):383. Epub 2007 Aug 2.
1140. Depression, anxiety, and quality of life in patients with atrial fibrillation.
Thrall G, Lip GY, Carroll D, Lane D.
Chest. 2007 Oct;132(4):1259-64. Epub 2007 Jul 23.
1141. 'DNA' may not mean 'did not participate': a qualitative study of reasons for non-adherence at
home- and centre-based cardiac rehabilitation.
Jones M, Jolly K, Raftery J, Lip GY, Greenfield S; BRUM Steering Committee.
Fam Pract. 2007 Sep;24(4):343-57. Epub 2007 Jul 13.
1142. Coronary artery disease and ischemic stroke in atrial fibrillation.
Lip GY.
Chest. 2007 Jul;132(1):8-10. No abstract available.
1143. Measuring soluble CD40 ligand:interleukin-10 ratio as a prognostic marker in acute myocardial
infarction: yet another prognostic biomarker?
Jessani S, Lip GY.
Thromb Res. 2007;121(3):289-91. Epub 2007 Jul 3. Review. No abstract available.
.
1144. New frontiers in cardiovascular disease: circulating endothelial cells and endothelial progenitor
cells as cellular biomarkers.
Goon PK, Watson T, Lip GY.
Clin Lab. 2007;53(5-6):297-9. No abstract available.
1145. Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners
and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the
elderly (SAFE) trial.
Mant J, Fitzmaurice DA, Hobbs FD, Jowett S, Murray ET, Holder R, Davies M, Lip GY.
BMJ. 2007 Aug 25;335(7616):380. Epub 2007 Jun 29.
1146. Management of atrial fibrillation.
Kakar P, Boos CJ, Lip GY.
Vasc Health Risk Manag. 2007;3(1):109-16. Review.
1147. Thromboprophylaxis in acute ischaemic stroke: how can we PREVAIL?
Lim HS, Lip GY.
Lancet Neurol. 2007 Jul;6(7):578-9. No abstract available.
1148. Stroke prevention in atrial fibrillation--things can only get better.
Lip GY, Watson T.
Br J Clin Pharmacol. 2007 Nov;64(5):575-7. Epub 2007 Jun 19. No abstract available.
1149. The effects of coronary artery disease severity on time-dependent changes in platelet
activation indices in stored whole blood.
Boos CJ, Balakrishnan B, Lip GY.
J Thromb Thrombolysis. 2008 Apr;25(2):135-40. Epub 2007 Jun 16.
1150. Ethnic differences in cancer incidence and mortality: the Birmingham Factory Screening
Project.
Lane DA, Lip GY, Beevers DG.
QJM. 2007 Jul;100(7):423-31. Epub 2007 Jun 12.
.
118
1151. Statin therapy in South-Asian patients: clinical implications beyond lipid lowering?
Jaumdally JR, Varma C, Lip GY.
Expert Opin Pharmacother. 2007 Jun;8(9):1235-43. Review.
1152. Systemic and intracardiac vascular endothelial growth factor and angiopoietin-1 and -2 levels
in coronary artery disease: effects of angioplasty.
Jaumdally RJ, Varma C, Blann AD, MacFadyen RJ, Lip GY.
Ann Med. 2007;39(4):298-305.
1153. Soluble CD40 ligand and atrial fibrillation: relationship to platelet activation, and endothelial
damage/dysfunction.
Blann AD, Choudhury A, Freestone B, Patel J, Lip GY.
Int J Cardiol. 2008 Jun 23;127(1):135-7. Epub 2007 Jun 6.
1154. The quest for circulating endothelial cell standardization: the peril of platelets.
Goon PK, Watson T, Stonelake PS, Lip GY.
Cytometry B Clin Cytom. 2007 Sep;72(5):416. No abstract available.
1155.
Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to
outcomes in anticoagulated patients with atrial fibrillation.
Lip GY, Frison L, Grind M.
J Intern Med. 2007 Jun;261(6):577-86.
1156. Circulating endothelial cells in obstructive sleep apnea: an important methodological lesson.
Goon PK, Watson T, Lip GY.
Am J Respir Crit Care Med. 2007 Jun 15;175(12):1346; author reply 1347. No abstract available.
1157. Guideline-adherent antithrombotic treatment is associated with improved outcomes
compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on
Atrial Fibrillation.
Nieuwlaat R, Olsson SB, Lip GY, Camm AJ, Breithardt G, Capucci A, Meeder JG, Prins MH, Lévy S,
Crijns HJ; Euro Heart Survey Investigators.
Am Heart J. 2007 Jun;153(6):1006-12.
1158. An analysis of factors that predict patient consent to take part in a randomized controlled trial.
Fletcher K, Mant J, Holder R, Fitzmaurice D, Lip GY, Hobbs FD.
Fam Pract. 2007 Sep;24(4):388-94. Epub 2007 May 29.
1159. Effects of "newer" and "older" antihypertensive drugs on hemorrheological, platelet, and
endothelial factors. A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.
Spencer CG, Felmeden DC, Blann AD, Lip GY.
Am J Hypertens. 2007 Jun;20(6):699-704.
1160. Physical fitness and the relationship between hypertension and markers of atherothrombosis.
Jessani S, Lip GY.
Am J Hypertens. 2007 Jun;20(6):676-7. No abstract available.
1161. Cardioversion for atrial fibrillation: does inflammation matter?
Watson T, Kakar P, Lip GY.
Am J Cardiol. 2007 Jun 1;99(11):1617-8. Epub 2007 Apr 17. No abstract available.
119
1162. Peripheral artery disease and hypertension: the relation between ankle-brachial index and
mortality.
Karthikeyan VJ, Lip GY.
J Hum Hypertens. 2007 Oct;21(10):762-5. Epub 2007 May 17. No abstract available.
1163. Platelet surface CD62P and CD63, mean platelet volume, and soluble/platelet P-selectin as
indexes of platelet function in atrial fibrillation: a comparison of "healthy control subjects" and
"disease control subjects" in sinus rhythm.
Choudhury A, Chung I, Blann AD, Lip GY.
J Am Coll Cardiol. 2007 May 15;49(19):1957-64. Epub 2007 Apr 30.
1164. Maintaining therapeutic anticoagulation: the importance of keeping "within range".
Lane DA, Lip GY.
Chest. 2007 May;131(5):1277-9. No abstract available.
1165. Cardioversion of atrial fibrillation: from guidelines to contemporary clinical practice.
Lip GY.
Int J Clin Pract. 2007 May;61(5):714-6. No abstract available.
1166. Hypertension: endothelial dysfunction, the prothrombotic state and antithrombotic therapy.
Kakar P, Lip GY.
Expert Rev Cardiovasc Ther. 2007 May;5(3):441-50. Review.
1167. Involvement of circulating endothelial progenitor cells and vasculogenic factors in the
pathogenesis of diabetic retinopathy.
Goon PK, Lip GY.
Eye (Lond). 2007 Jun;21(6):838-9; author reply 838. Epub 2007 Apr 20. No abstract available.
1168. Relationship between circulating endothelial cells and the predicted risk of cardiovascular
events in acute coronary syndromes.
Boos CJ, Soor SK, Kang D, Lip GY.
Eur Heart J. 2007 May;28(9):1092-101. Epub 2007 Apr 21.
1169. Oral anticoagulation in atrial fibrillation: A pan-European patient survey.
Lip GY, Agnelli G, Thach AA, Knight E, Rost D, Tangelder MJ.
Eur J Intern Med. 2007 May;18(3):202-8.
1170. Atrial fibrillation--the growing epidemic.
Lip GY, Kakar P, Watson T.
Heart. 2007 May;93(5):542-3. No abstract available.
.
1171. Stroke prevention in atrial fibrillation: antiplatelet therapy revisited.
Lip GY, Watson T.
Eur Heart J. 2007 Apr;28(8):926-8. Epub 2007 Apr 12. No abstract available.
.
1172. Reproducibility and safety of the incremental shuttle walking test for cardiac rehabilitation.
Jolly K, Taylor RS, Lip GY, Singh S; BRUM Steering Committee.
Int J Cardiol. 2008 Mar 28;125(1):144-5. Epub 2007 Apr 3.
1173. Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X.
120
Kakar P, Watson T, Lip GY.
Curr Opin Investig Drugs. 2007 Mar;8(3):256-65. Review.
1174. Standardization of circulating endothelial cell enumeration by the use of human umbilical vein
endothelial cells.
Goon PK, Watson T, Shantsila E, Boos CJ, Lip GY.
J Thromb Haemost. 2007 Apr;5(4):870-2. No abstract available.
.
1175. Coronary sinus blood sampling: an insight into local cardiac pathophysiology and treatment?
Jaumdally R, Varma C, Macfadyen RJ, Lip GY.
Eur Heart J. 2007 Apr;28(8):929-40. Epub 2007 Mar 29. Review.
1176. Should oral glucose tolerance testing be mandatory following acute myocardial infarction?
Jessani S, Gangopadhyay K, Patel JV, Lip GY, Millane T.
Int J Clin Pract. 2007 Apr;61(4):680-3.
1177. Prognostic value of plasma soluble P-selectin and von Willebrand factor as indices of platelet
activation and endothelial damage/dysfunction in high-risk patients with hypertension: a sub-study
of the Anglo-Scandinavian Cardiac Outcomes Trial.
Varughese GI, Patel JV, Tomson J, Blann AD, Hughes EA, Lip GY.
J Intern Med. 2007 Apr;261(4):384-91.
1178. Rivaroxaban.
Kakar P, Watson T, Lip GY.
Drugs Today (Barc). 2007 Mar;43(3):129-36. Review.
1178. Assessment of platelet activation indices using the ADVIATM 120 amongst 'high-risk' patients
with hypertension.
Boos CJ, Beevers GD, Lip GY.
Ann Med. 2007;39(1):72-8.
1180. Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin
and antithrombotic therapy.
Choudhury A, Chung I, Blann AD, Lip GY.
Chest. 2007 Mar;131(3):809-15.
1181. Ethnic disparities in malignant hypertension: further observations.
Karthikeyan VJ, Beevers DG, Lip GY.
J Hypertens. 2007 Apr;25(4):895; author reply 896. No abstract available.
1182. Modern management of atrial fibrillation.
Watson T, Shanstila E, Lip GY.
Clin Med (Lond). 2007 Jan-Feb;7(1):28-34. Review.
1183. Home-based exercise rehabilitation in addition to specialist heart failure nurse care: design,
rationale and recruitment to the Birmingham Rehabilitation Uptake Maximisation study for patients
with congestive heart failure (BRUM-CHF): a randomised controlled trial.
Jolly K, Tayor RS, Lip GY, Greenfield SM, Davies MK, Davis RC, Mant JW, Singh SJ, Ingram JT, Stubley J,
Stevens AJ.
BMC Cardiovasc Disord. 2007 Mar 7;7:9.
121
1184. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and
platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk
factors, stroke risk stratification schema, and prognosis.
Lip GY, Patel JV, Hughes E, Hart RG.
Stroke. 2007 Apr;38(4):1229-37. Epub 2007 Mar 1.
1185. Subclinical atherosclerosis and risk of atrial fibrillation: the rotterdam study.
Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Rooij FJ, Lip GY, Witteman JC.
Arch Intern Med. 2007 Feb 26;167(4):382-7.
1186. Statins and intra-plaque angiogenesis in carotid artery disease.
Karthikeyan VJ, Lip GY.
Atherosclerosis. 2007 Jun;192(2):455-6. Epub 2007 Feb 26. No abstract available.
1187. A systematic review of the effects of acute psychological stress and physical activity on
haemorheology, coagulation, fibrinolysis and platelet reactivity: Implications for the pathogenesis of
acute coronary syndromes.
Thrall G, Lane D, Carroll D, Lip GY.
Thromb Res. 2007;120(6):819-47. Epub 2007 Feb 23. Review.
1188. Antioxidant protection: yet another function of endothelial progenitor cells?
Shantsila E, Watson T, Lip GY.
J Hum Hypertens. 2007 May;21(5):343-6. Epub 2007 Feb 22. No abstract available.
.
1189. Is it the post-challenge hyperglycaemic spike or arterial stiffness we should be screening for?
Jessani S, Lip GY.
Int J Clin Pract. 2007 Mar;61(3):356-8. No abstract available.
1190. Endothelial progenitor cells in cardiovascular disorders.
Shantsila E, Watson T, Lip GY.
J Am Coll Cardiol. 2007 Feb 20;49(7):741-52. Review.
1191. Ethnicity and cardiovascular disease prevention in the United Kingdom: a practical approach to
management.
Lip GY, Barnett AH, Bradbury A, Cappuccio FP, Gill PS, Hughes E, Imray C, Jolly K, Patel K.
J Hum Hypertens. 2007 Mar;21(3):183-211. Review.
.
1192. Effect of hypertension on anticoagulated patients with atrial fibrillation.
Lip GY, Frison L, Grind M; SPORTIF Invetigators.
Eur Heart J. 2007 Mar;28(6):752-9. Epub 2007 Feb 8.
1193. New insights into complement C3 and inflammation in hypertension.
Nadar SK, Lip GY.
J Hum Hypertens. 2007 Apr;21(4):261-3. Epub 2007 Feb 8. No abstract available.
1194. Platelet activation in acute, decompensated congestive heart failure.
Chung I, Choudhury A, Lip GY.
Thromb Res. 2007;120(5):709-13. Epub 2007 Feb 6.
122
.
1195. The JBS-2 guidelines on prevention of cardiovascular disease in clinical practice: an opportunity
missed.
Jessani S, Lip GY, Barnett A, Millane T.
QJM. 2007 Feb;100(2):121-4. No abstract available.
1196. Cross-cultural adaptation into Punjabi of the English version of the Hospital Anxiety and
Depression Scale.
Lane DA, Jajoo J, Taylor RS, Lip GY, Jolly K; Birmingham Rehabilitation Uptake Maximisation (BRUM)
Steering Committee.
BMC Psychiatry. 2007 Jan 26;7:5.
1197. Platelet adhesion in atrial fibrillation.
Choudhury A, Chung I, Blann A, Lip GY.
Thromb Res. 2007;120(4):623-9. Epub 2007 Jan 23.
1197. Significant decrease in angiopoietin-1 and angiopoietin-2 after radical prostatectomy in
prostate cancer patients.
Caine GJ, Ryan P, Lip GY, Blann AD.
Cancer Lett. 2007 Jun 28;251(2):296-301. Epub 2007 Jan 19.
1198. Management of atrial fibrillation: the NICE guidelines.
Lip GY, Rudolf M, Kakar P.
Int J Clin Pract. 2007 Jan;61(1):9-11. No abstract available.
1199. Stroke risk stratification in atrial fibrillation: something to EXAMINE more closely.
Watson T, Kakar P, Lip GY.
Int J Clin Pract. 2007 Jan;61(1):6-9. No abstract available. Erratum in: Int J Clin Pract. 2007
Mar;61(3):534.
1200. Haemorheological, platelet and endothelial indices in relation to global measures of
cardiovascular risk in hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes
Trial.
Spencer CG, Felmeden DC, Blann AD, Lip GY.
J Intern Med. 2007 Jan;261(1):82-90.
1201. Effects of low osmolar contrast (iomeprol) on haemorheology and platelet activation in
patients with coronary artery disease.
Jaumdally RJ, Varma C, MacFadyen RJ, Lip GY.
J Thromb Thrombolysis. 2007 Jun;23(3):189-94. Epub 2007 Jan 13.
1202. Review: Angiotensin converting enzyme inhibitors and angiotensin receptor blockers prevent
atrial fibrillation.
Karthikeyan VJ, Lip GY.
1203. Evid Based Med. 2006 Feb;11(1):15. No abstract available.
Raised leptin concentrations among South Asian patients with chronic heart failure.
Patel JV, Sosin M, Lim HS, Chung I, Panja N, Davis RC, Hughes EA, Lip GY.
Int J Cardiol. 2007 Oct 31;122(1):34-40. Epub 2006 Dec 21.
1204. N-terminal pro-brain natriuretic peptide and coronary artery disease.
123
Karthikeyan VJ, Lip GY.
Eur J Clin Invest. 2007 Jan;37(1):1-7. No abstract available.
1205. Stroke: ethnic differences do exist.
Kakar P, Gunarathne A, Lip GY.
Expert Rev Neurother. 2006 Dec;6(12):1769-71. No abstract available.
1206. Management of atrial fibrillation.
Watson T, Lip GY.
Herz. 2006 Dec;31(9):849-56. Review.
1207. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing
percutaneous coronary intervention: the need for consensus and a management guideline.
Lip GY, Karpha M.
Chest. 2006 Dec;130(6):1823-7.
1208. Circulating endothelial cells and von Willebrand factor as indices of endothelial
damage/dysfunction in coronary artery disease: a comparison of central vs. peripheral levels and
effects of coronary angioplasty.
Boos CJ, Jaumdally RJ, MacFadyen RJ, Varma C, Lip GY.
J Thromb Haemost. 2007 Mar;5(3):630-2. Epub 2006 Nov 30. No abstract available.
1209. Oxidative stress and hypertension.
Karthikeyan VJ, Lip GY.
Int J Clin Pract. 2006 Dec;60(12):1525-7. No abstract available.
1210. Bleeding risk stratification models in deciding on anticoagulation in patients with atrial
fibrillation: a useful complement to stroke risk stratification schema.
Kakar P, Lane D, Lip GY.
Chest. 2006 Nov;130(5):1296-9. No abstract available.
1211. Oral omega n3-PUFA therapy (Omacor) has no impact on indices of heart rate variability in
stable post myocardial infarction patients.
Hamaad A, Kaeng Lee W, Lip GY, MacFadyen RJ.
Cardiovasc Drugs Ther. 2006 Oct;20(5):359-64.
1212. Atrial fibrillation and stroke prevention.
Kakar P, Lip GY.
Expert Rev Neurother. 2006 Oct;6(10):1523-30. Review.
1213. Aortic elasticity, left ventricular geometry and diastolic dysfunction in hypertension.
Karthikeyan VJ, Lip GY.
Int J Clin Pract. 2006 Nov;60(11):1337-40. No abstract available.
1214. Antihypertensive treatment, adiponectin and cardiovascular risk.
Karthikeyan VJ, Lip GY.
J Hum Hypertens. 2007 Jan;21(1):8-11. Epub 2006 Oct 26. Review. No abstract available.
1215. Fibrin D-dimer levels and thromboembolic events in patients with atrial fibrillation.
Watson T, Shantsila E, Lip GY.
Int J Cardiol. 2007 Aug 9;120(1):123-4; author reply 125-6. Epub 2006 Oct 19. No abstract available.
124
1216. Assessment of mean platelet volume in coronary artery disease - what does it mean?
Boos CJ, Lip GY.
Thromb Res. 2007;120(1):11-3. Epub 2006 Oct 12. No abstract available.
1217. Circulating endothelial cells in cardiovascular disease.
Boos CJ, Lip GY, Blann AD.
J Am Coll Cardiol. 2006 Oct 17;48(8):1538-47. Epub 2006 Sep 26. Review.
1218. Death or heart failure post acute myocardial infarction? The role of cardiac biomarkers.
Jessani S, Lip GY.
J Card Fail. 2006 Oct;12(8):641-3. Review. No abstract available.
1219. Platelets and heart failure.
Chung I, Lip GY.
Eur Heart J. 2006 Nov;27(22):2623-31. Epub 2006 Oct 6. Review.
1220. Plasma von Willebrand factor and soluble E-selectin levels in stable outpatients with systolic
heart failure: the Frederiksberg heart failure study.
Chong AY, Freestone B, Lim HS, Kistorp C, Gustafsson F, Hildebrandt P, Lip GY.
Int J Cardiol. 2007 Jun 25;119(1):80-2. Epub 2006 Oct 5.
1221. Platelet activation and cardiovascular outcomes in acute coronary syndromes.
Boos CJ, Lip GY.
J Thromb Haemost. 2006 Dec;4(12):2542-3. Epub 2006 Oct 5. No abstract available.
1222. Aspirin resistance: what, why and when?
Shantsila E, Watson T, Lip GY.
Thromb Res. 2007;119(5):551-4. Epub 2006 Sep 27. Review. No abstract available.
1223. Proteomics, metabolomics and circulating endothelial progenitor cells in acute coronary
syndromes.
Goon PK, Lip GY.
J Thromb Thrombolysis. 2006 Oct;22(2):155-6. No abstract available.
1224. Temporal and venepuncture-related decline in circulating endothelial cell capture from mixed
venous blood.
Boos CJ, Lane DA, Kang D, Goon PK, Blann AD, Lip GY.
J Thromb Thrombolysis. 2006 Oct;22(2):125-31.
1225. Effects of blood pressure on the prothrombotic risk in 1235 patients with non-valvular atrial
fibrillation.
Varughese GI, Patel JV, Tomson J, Lip GY.
Heart. 2007 Apr;93(4):495-9. Epub 2006 Sep 27.
1226. Anticoagulation for stroke prevention: high effectiveness, more cost benefit?
Shantsila E, Watson T, Lip GY.
Pharmacoeconomics. 2006;24(10):1035-8. No abstract available.
1227. C-reactive protein and lone atrial fibrillation: potential confounders.
Boos CJ, Lip GY.
125
Am J Cardiol. 2006 Oct 1;98(7):991-2. Epub 2006 Jul 26. No abstract available.
1228. Role of metabolically active hormones in the insulin resistance associated with short-term
glucocorticoid treatment.
Patel JV, Cummings DE, Girod JP, Mascarenhas AV, Hughes EA, Gupta M, Lip GY, Reddy S, Brotman
DJ.
J Negat Results Biomed. 2006 Sep 11;5:14.
1229. Rhythm control and cardioversion.
Sulke N, Sayers F, Lip GY; Guideline Development Group for the NICE clinical guideline for the
management of atrial fibrillation.
Heart. 2007 Jan;93(1):29-34. Epub 2006 Sep 8. Review. No abstract available.
1230. Angiogenin: a review of the pathophysiology and potential clinical applications.
Tello-Montoliu A, Patel JV, Lip GY.
J Thromb Haemost. 2006 Sep;4(9):1864-74. Review.
1231. Identification, diagnosis and assessment of atrial fibrillation.
Dewar RI, Lip GY; Guidelines Development Group for the NICE clinical guideline for the management
of atrial fibrillation.
Heart. 2007 Jan;93(1):25-8. Epub 2006 Sep 4. Review. No abstract available.
1232. Rate control in the medical management of atrial fibrillation.
Camm AJ, Savelieva I, Lip GY; Guideline Development Group for the NICE clinical guideline for the
management of atrial fibrillation.
Heart. 2007 Jan;93(1):35-8. Epub 2006 Sep 4. Review. No abstract available.
1233. Antithrombotic treatment in atrial fibrillation.
Kalra L, Lip GY; Guideline Development Group for the NICE clinical guideline for the management of
atrial fibrillation.
Heart. 2007 Jan;93(1):39-44. Epub 2006 Sep 4. Review. No abstract available.
1234. Acute management of atrial fibrillation with acute haemodynamic instability and in the
postoperative setting.
Mann CJ, Kendall S, Lip GY; Guideline Development Group for the NICE clinical guideline for the
management of atrial fibrillation.
Heart. 2007 Jan;93(1):45-7. Epub 2006 Sep 4. Review. No abstract available.
1235. Patient care pathway, implementation and audit criteria for patients with atrial fibrillation.
Davis M, Rodgers S, Rudolf M, Hughes M, Lip GY; Guideline Development Group for the NICE clinical
guideline for the management of atrial fibrillation.
Heart. 2007 Jan;93(1):48-52. Epub 2006 Sep 4. Review. No abstract available.
1236. The new NICE guideline on atrial fibrillation management.
Lip GY, Rudolf M.
Heart. 2007 Jan;93(1):23. Epub 2006 Sep 4. No abstract available.
1237. Effects of aspirin on intra-platelet vascular endothelial growth factor, angiopoietin-1, and pselectin levels in hypertensive patients.
Nadar S, Blann AD, Lip GY.
Am J Hypertens. 2006 Sep;19(9):970-7; discussion 978.
126
1238. Towards understanding the aetiology and pathophysiology of human hypertension: where are
we now?
Kakar P, Lip GY.
J Hum Hypertens. 2006 Nov;20(11):833-6. Epub 2006 Aug 24. No abstract available.
1239. Towards improving the clinical assessment and management of human hypertension: An
overview from this Journal.
Kakar P, Lip GY.
J Hum Hypertens. 2006 Dec;20(12):913-6. Epub 2006 Aug 24. Review. No abstract available.
1240. Vasculoprotective effects of angiotensin receptor blockers: beyond the renin-angiotensinaldosterone system?
Karthikeyan VJ, Lip GY.
J Hypertens. 2006 Sep;24(9):1715-7. No abstract available.
1241. Endotoxemia enhances circulating endothelial cells in humans.
Boos CJ, Mayr FB, Lip GY, Jilma B.
J Thromb Haemost. 2006 Nov;4(11):2509-11. Epub 2006 Aug 14. No abstract available.
1242. Arterial disease and venous thromboembolism: a modern paradigm?
Goon PK, Lip GY.
Thromb Haemost. 2006 Aug;96(2):111-2. No abstract available.
1243. Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors
following surgery for breast cancer.
Caine GJ, Stonelake PS, Lip GY, Blann AD.
Cancer Lett. 2007 Apr 8;248(1):131-6. Epub 2006 Aug 7.
1244. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of
patients with atrial fibrillation.
Lip GY, Lane D, Van Walraven C, Hart RG.
Stroke. 2006 Sep;37(9):2294-300. Epub 2006 Aug 3. Erratum in: Stroke. 2006 Sep;37(9):2444.
1245. A cross-sectional study of hypertension in an elderly population (75 years and over) with atrial
fibrillation: secondary analysis of data from the Birmingham Atrial Fibrillation in the Aged (BAFTA)
randomised controlled trial.
Hurley V, Ireson R, Fletcher K, Lip GY, Hobbs FD, Mant J; BAFTA Investigators.
Int J Cardiol. 2007 Apr 25;117(2):152-6. Epub 2006 Aug 2.
1246. Hypertension and breast cancer: an association revisited?
Goon PK, Messerli FH, Lip GY.
J Hum Hypertens. 2006 Oct;20(10):722-4. Epub 2006 Aug 3. No abstract available.
1247. Adiponectin and hypertension: a putative link between adipocyte function and atherosclerotic
risk?
Patel JV, Lim HS, Hughes EA, Lip GY.
J Hum Hypertens. 2007 Jan;21(1):1-4. Epub 2006 Jul 27. Review. No abstract available.
1248. Atrial fibrillation post-cardiac surgery: changing perspectives.
Shantsila E, Watson T, Lip GY.
127
Curr Med Res Opin. 2006 Aug;22(8):1437-41. Review.
1249. Antithrombotic therapy: standard therapy in essential hypertension?
Lip GY.
Prog Cardiovasc Dis. 2006 Jul-Aug;49(1):11-5. Review. No abstract available.
1250. Viewpoint: the prothrombotic state in heart failure: a maladaptive inflammatory response?
Chong AY, Lip GY.
Eur J Heart Fail. 2007 Feb;9(2):124-8. Epub 2006 Jul 21. Review.
1251. Management of atrial fibrillation.
Lip GY, Tello-Montoliu A.
Heart. 2006 Aug;92(8):1177-82. Review. No abstract available.
1252. A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial
fibrillation: the Rotterdam Study 1990-1999.
Heeringa J, Conway DS, van der Kuip DA, Hofman A, Breteler MM, Lip GY, Witteman JC.
J Thromb Haemost. 2006 Sep;4(9):1944-9. Epub 2006 Jul 5.
1253. Anticoagulation for stroke prevention in atrial fibrillation: is gender important?
Lip GY, Watson T, Shantsila E.
Eur Heart J. 2006 Aug;27(16):1893-4. Epub 2006 Jul 4. No abstract available.
1254. Detection and quantification of mature circulating endothelial cells using flow cytometry and
immunomagnetic beads: a methodological comparison.
Goon PK, Boos CJ, Stonelake PS, Blann AD, Lip GY.
Thromb Haemost. 2006 Jul;96(1):45-52.
1255. Plasma haemostatic markers, endothelial function and ambulatory blood pressure changes
with home versus hospital cardiac rehabilitation: the Birmingham Rehabilitation Uptake
Maximisation Study.
Lee KW, Blann AD, Jolly K, Lip GY; BRUM Investigators.
Heart. 2006 Dec;92(12):1732-8. Epub 2006 Jun 28.
1256. 'Association of platelet function in hypertensive patients with left ventricular hypertrophy'.
Lip GY, Blann AD.
Platelets. 1999;10(1):71-2. No abstract available.
1257. Effects of omega-3 polyunsaturated fatty acids on metabolically active hormones in patients
post-myocardial infarction.
Patel JV, Lee KW, Tomson J, Dubb K, Hughes EA, Lip GY.
Int J Cardiol. 2007 Jan 31;115(1):42-5. Epub 2006 Jun 15.
1258. Prevention of cardiovascular disease in clinical practice: The Joint British Societies' (JBS 2)
guidelines.
Jessani S, Watson T, Cappuccio FP, Lip GY.
J Hum Hypertens. 2006 Sep;20(9):641-5. Epub 2006 Jun 1. No abstract available.
1259. Pharmacotherapy for atrial fibrillation: is rhythm control achievable?
Watson T, Shantsila E, Lip GY.
Expert Opin Pharmacother. 2006 Jun;7(9):1105-7.
128
1260. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart
Survey on Atrial Fibrillation.
Nieuwlaat R, Capucci A, Lip GY, Olsson SB, Prins MH, Nieman FH, López-Sendón J, Vardas PE, Aliot E,
Santini M, Crijns HJ; Euro Heart Survey Investigators.
Eur Heart J. 2006 Dec;27(24):3018-26. Epub 2006 May 26.
1261. Is hypertension an inflammatory process?
Boos CJ, Lip GY.
Curr Pharm Des. 2006;12(13):1623-35. Review.
1262. Traditional risk factors for coronary atherosclerosis in Indo Asians: the need for a reappraisal.
Jaumdally JR, Lip GY, Varma C.
Curr Pharm Des. 2006;12(13):1611-21. Review.
1263. Novel concepts of statin therapy for cardiovascular risk reduction in hypertension.
Varughese GI, Patel JV, Lip GY, Varma C.
Curr Pharm Des. 2006;12(13):1593-609. Review.
1264. Target organ damage in hypertension: pathophysiology and implications for drug therapy.
Nadar SK, Tayebjee MH, Messerli F, Lip GY.
Curr Pharm Des. 2006;12(13):1581-92. Review.
1265. The role of hyperglycaemia and the hypercoagulable state in the pathogenesis of
cardiovascular events in diabetes mellitus: implications for hypertension management.
Lim HS, MacFadyen RJ, Bakris G, Lip GY.
Curr Pharm Des. 2006;12(13):1567-79. Review.
1266. Aspirin for prevention of stroke in atrial fibrillation.
Lip GY.
Stroke. 2006 Jul;37(7):1640. Epub 2006 May 25. No abstract available.
1267. Anticoagulation control with vitamin K antagonists: how well are we doing?
Lane DA, Boos CJ, Lip GY.
Chest. 2006 May;129(5):1122-4. No abstract available.
1268. Quality of life in patients with atrial fibrillation: a systematic review.
Thrall G, Lane D, Carroll D, Lip GY.
Am J Med. 2006 May;119(5):448.e1-19. Review.
1269. Urotensin and cardiovascular risk among patients with end-stage renal disease: fact or fiction?
Boos CJ, Lip GY.
Am J Hypertens. 2006 May;19(5):511-2. Review. No abstract available.
1270. Platelet microparticles and platelet adhesion: therapeutic implications for the prevention and
treatment of stroke.
Tan KT, Lip GY.
Curr Treat Options Cardiovasc Med. 2006 May;8(3):251-8.
1271. Ximelagatran: an eulogy.
Boos CJ, Lip GY.
129
Thromb Res. 2006;118(3):301-4. Epub 2006 Apr 19. No abstract available.
1272. Does smoking status influence the effect of physical exercise on fibrinolytic function in healthy
volunteers?
Tello-Montoliu A, Roldán V, Climent VE, Sogorb F, Lip GY, Marín F.
J Thromb Thrombolysis. 2006 Apr;21(2):163-6.
1273. Atrial fibrillation (recent onset).
Lip GY.
Clin Evid. 2005 Dec;(14):71-89. Review. No abstract available.
1274. Do the National Institute of Clinical Excellence guidelines apply to 'real world' use of Abciximab
in percutaneous coronary intervention in a teaching hospital setting?
Khan JM, Watson RD, Varma C, Millane T, Lip GY.
Int J Clin Pract. 2006 Apr;60(4):498-9. No abstract available.
1275. Blood pressure control in the setting of diabetes mellitus: new targets, new hope for
improvement?
Varughese GI, Patel JV, Lip GY.
J Hum Hypertens. 2006 Sep;20(9):635-7. Epub 2006 Apr 13. No abstract available.
1276. Blood pressure measurement in atrial fibrillation: goodbye mercury?
Watson T, Lip GY.
J Hum Hypertens. 2006 Sep;20(9):638-40. Epub 2006 Apr 13. No abstract available.
1277. Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in
cancer.
Goon PK, Lip GY, Boos CJ, Stonelake PS, Blann AD.
Neoplasia. 2006 Feb;8(2):79-88. Review.
1278. South Asian or Afro-Caribbean ethnicity is not associated with altered 1 min heart rate
recovery estimates in suspected coronary artery disease patients.
Goyal D, Tayebjee M, Lip GY, MacFadyen RJ.
Int J Cardiol. 2007 Jan 8;114(2):261-4. Epub 2006 Mar 6.
.
1279. Growth hormone therapy and the heart.
Climent VE, Picó A, Sogorb F, Aznar S, Lip GY, Marín F.
Am J Cardiol. 2006 Apr 1;97(7):1097-102. Epub 2006 Feb 23.
1280. Circulating endothelial cells in malignant disease.
Goon PK, Boos CJ, Stonelake PS, Lip GY.
Future Oncol. 2005 Dec;1(6):813-20. Review.
1281. Left ventricular systolic dysfunction in rheumatoid disease: an unrecognized burden?
Bhatia GS, Sosin MD, Patel JV, Grindulis KA, Khattak FH, Hughes EA, Lip GY, Davis RC.
J Am Coll Cardiol. 2006 Mar 21;47(6):1169-74. Epub 2006 Feb 23.
1282. Abnormal circulating neutrophil linked matrix metalloproteinase -9 in stable coronary artery
disease.
Tayebjee MH, Lip GY, Tan KT, MacFadyen RJ.
130
Thromb Haemost. 2006 Jan;95(1):202-4. No abstract available.
1283. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study.
Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip GY,
Witteman JC.
Eur Heart J. 2006 Apr;27(8):949-53. Epub 2006 Mar 9.
1284. Lip GY.
Circulation. 2006 Mar 7;113(9):f33-4. No abstract available.
1285. Ximelagatran.
Choudhury A, Goyal D, Lip GY.
Drugs Today (Barc). 2006 Jan;42(1):3-19. Review.
1286. Thromboprophylaxis in atrial fibrillation: why, how, when and how can we do better?
Watson T, Lip GY.
Int J Clin Pract. 2006 Mar;60(3):252-5. No abstract available.
1287. Endothelial activation, dysfunction, and damage in congestive heart failure and the relation to
brain natriuretic peptide and outcomes.
Chong AY, Freestone B, Patel J, Lim HS, Hughes E, Blann AD, Lip GY.
Am J Cardiol. 2006 Mar 1;97(5):671-5. Epub 2006 Jan 10.
1288. Prevention of atrial fibrillation by angiotensin-converting enzyme inhibitors and angiotensin II
receptor blockers.
Boos CJ, Lip GY.
J Am Coll Cardiol. 2006 Feb 21;47(4):889-90; author reply 890-1. Epub 2006 Jan 26. No abstract
available.
1289. Reactive oxygen species production by circulating monocytes: insights from pathophysiology to
clinical hypertension.
Lim HS, Patel JV, Lip GY.
J Hum Hypertens. 2006 May;20(5):307-9. No abstract available.
1290. Blood pressure control and prevention of stroke.
Karthikeyan VJ, Lip GY.
Expert Rev Neurother. 2006 Feb;6(2):203-12.
1291.Endothelial progenitor cells in the vascular pathophysiology of hypertension: arterial stiffness,
ageing and more.
Boos CJ, Goon PK, Lip GY.
J Hum Hypertens. 2006 Jul;20(7):475-7. Epub 2006 Feb 2. No abstract available.
1292. Pulse pressure and carotid atherosclerosis: an important link revisited?
Karthikeyan VJ, Lip GY.
Int J Clin Pract. 2006 Feb;60(2):127-30. No abstract available.
1293. Venous thromboembolism.
Blann AD, Lip GY.
BMJ. 2006 Jan 28;332(7535):215-9. Review. No abstract available.
131
1294. White blood cell count and hypertension.
Karthikeyan VJ, Lip GY.
J Hum Hypertens. 2006 May;20(5):310-2. No abstract available.
1295. Matrix metalloproteinases and hypertension: a link between left ventricular hypertrophy and
diastolic dysfunction?
Karthikeyan VJ, Lip GY.
Tohoku J Exp Med. 2006 Feb;208(2):93-7. No abstract available.
1296. Assessment of hemostatic risk factors in predicting arterial thrombotic events.
Boos CJ, Lip GY.
Arterioscler Thromb Vasc Biol. 2006 Feb;26(2):e18. No abstract available.
1297. The endothelium, inflammation, and coagulation in sepsis.
Boos CJ, Goon PK, Lip GY.
Clin Pharmacol Ther. 2006 Jan;79(1):20-2. Review. No abstract available.
1298. Sudden death is less common than might be expected in underprivileged ethnic minorities at
high cardiovascular risk.
Hamaad A, Ghattas A, Hirani F, Lip GY, MacFadyen RJ.
Int J Cardiol. 2006 Feb 15;107(2):235-40.
1299. Antithrombotic therapy for congestive heart failure.
Chung I, Lip GY.
Int J Clin Pract. 2006 Jan;60(1):36-47. Review.
1300. Markers of inflammation in acute coronary syndromes: association with increased heart rate
and reductions in heart rate variability.
Hamaad A, Sosin M, Blann AD, Patel J, Lip GY, MacFadyen RJ.
Clin Cardiol. 2005 Dec;28(12):570-6.
1301. Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet
microparticle levels.
Tan KT, Tayebjee MH, Lim HS, Lip GY.
Diabet Med. 2005 Dec;22(12):1657-62.
1302. What role do extracellular matrix changes contribute to the cardiovascular disease burden of
diabetes mellitus?
Tayebjee MH, Lip GY, MacFadyen RJ.
Diabet Med. 2005 Dec;22(12):1628-35. Review.
1303. Managing acute and recent-onset atrial fibrillation.
Freestone B, Lip GY.
Evid Based Cardiovasc Med. 2003 Sep;7(3):111-6. No abstract available.
1304. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting.
Marín F, Pascual DA, Roldán V, Arribas JM, Ahumada M, Tornel PL, Oliver C, Gómez-Plana J, Lip GY,
Valdés M.
Am J Cardiol. 2006 Jan 1;97(1):55-60. Epub 2005 Nov 7.
1305. The assessment of platelet activation in antiplatelet drug development.
132
Tan KT, Lip GY.
Curr Med Chem. 2005;12(26):3117-25. Review.
1306. Plasma markers of endothelial damage/dysfunction, inflammation and thrombogenesis in
relation to TIMI risk stratification in acute coronary syndromes.
Lee KW, Blann AD, Lip GY.
Thromb Haemost. 2005 Nov;94(5):1077-83.
1307. Plasma markers of angiogenesis in pregnancy induced hypertension.
Nadar SK, Karalis I, Al Yemeni E, Blann AD, Lip GY.
Thromb Haemost. 2005 Nov;94(5):1071-6.
1308. Circulating endothelial progenitor cells.
Boos CJ, Goon PK, Lip GY.
N Engl J Med. 2005 Dec 15;353(24):2613-6; author reply 2613-6. No abstract available.
1309. The prothrombotic risk of diabetes mellitus in atrial fibrillation and heart failure.
Varughese GI, Patel JV, Tomson J, Lip GY.
J Thromb Haemost. 2005 Dec;3(12):2811-3. No abstract available.
1310.Blood oxygen saturation during atrio-ventricular dissociation with wide-QRS complex
tachycardias.
Marinskis G, Lip GY, Aidietis A, Jurkuvenas P, Kaireviciūte D, Jezov V, Bagdonas K, Serpytis P,
Laucevicius A.
Int J Cardiol. 2006 Feb 8;107(1):134-5. Erratum in: Int J Cardiol. 2008 Jan 11;123(2):217. Adietis,
Audrius [corrected to Aidietis, Audrius].
1311. Abnormal soluble CD40 ligand and C-reactive protein concentrations in hypertension:
relationship to indices of angiogenesis.
Patel JV, Lim HS, Nadar S, Tayebjee M, Hughes EA, Lip GY.
J Hypertens. 2006 Jan;24(1):117-21.
1312. Inter-relationships of indices of endothelial damage/dysfunction [circulating endothelial cells,
von Willebrand factor and flow-mediated dilatation] to tissue factor and interleukin-6 in acute
coronary syndromes.
Lee KW, Blann AD, Lip GY.
Int J Cardiol. 2006 Aug 10;111(2):302-8. Epub 2005 Dec 1.
1313. The effects of direct current cardioversion for persistent atrial fibrillation on indices of
endothelial damage/dysfunction.
Freestone B, Chong AY, Blann AD, Lip GY.
Thromb Res. 2006;118(4):479-85. Epub 2005 Nov 28.
1314. Home-based cardiac rehabilitation compared with centre-based rehabilitation and usual care:
a systematic review and meta-analysis.
Jolly K, Taylor RS, Lip GY, Stevens A.
Int J Cardiol. 2006 Aug 28;111(3):343-51. Epub 2005 Nov 28. Review.
1315. Is an advanced age an additive risk factor to the prothrombotic or hypercoagulable state in
atrial fibrillation?
Roldán V, Marín F, García A, Tello-Montoliu A, Lip GY.
133
Int J Cardiol. 2006 Jun 16;110(2):265-6. Epub 2005 Nov 28. No abstract available.
1316. Serum adiponectin in coronary heart disease: ethnic differences and relation to coronary
artery disease severity.
Lim HS, Tayebjee MH, Tan KT, Patel JV, Macfadyen RJ, Lip GY.
Heart. 2005 Dec;91(12):1605-6. No abstract available.
1317. Circulating endothelial cells: markers of vascular dysfunction.
Goon PK, Boos CJ, Lip GY.
Clin Lab. 2005;51(9-10):531-8. Review.
1318. Is atrial fibrillation an inflammatory disorder?
Boos CJ, Anderson RA, Lip GY.
Eur Heart J. 2006 Jan;27(2):136-49. Epub 2005 Nov 8. Review.
1319. Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological
links.
Lip GY, Varughese GI.
Int J Cardiol. 2005 Dec 7;105(3):319-21.
1320. Anticoagulation plus aspirin following acute myocardial infarction: yes or no ... and if the latter,
why not?
Lip GY, Varma C.
Thromb Res. 2006;118(4):429-32. Epub 2005 Nov 7. Review. No abstract available.
1321. Circulating endothelial cells in acute ischaemic stroke.
Nadar SK, Lip GY, Lee KW, Blann AD.
Thromb Haemost. 2005 Oct;94(4):707-12.
1322. Circulating endothelial cells in atrial fibrillation with and without acute cardiovascular disease.
Freestone B, Lip GY, Chong AY, Nadar S, Lee KW, Blann AD.
Thromb Haemost. 2005 Oct;94(4):702-6.
1323. The potential role of platelet microparticles in atherosclerosis.
Tan KT, Lip GY.
Thromb Haemost. 2005 Sep;94(3):488-92. Review.
1324. Biomarkers in atrial fibrillation: further observations on biologic plausibility, cause and effect.
Boos CJ, Lip GY.
J Thromb Thrombolysis. 2005 Dec;20(3):189-90. No abstract available.
1325. Ethnic differences in arterial responses, inflammation, and metabolic profiles: possible insights
into ethnic differences in cardiovascular disease and stroke.
Lip GY, Boos CJ.
Arterioscler Thromb Vasc Biol. 2005 Nov;25(11):2240-2. No abstract available.
134
1326. Endothelial function and its assessment.
Felmeden DC, Lip GY.
Expert Opin Investig Drugs. 2005 Nov;14(11):1319-36. Review.
1327. Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an
educational intervention programme. The West Birmingham Atrial Fibrillation Project.
Lane DA, Ponsford J, Shelley A, Sirpal A, Lip GY.
Int J Cardiol. 2006 Jun 28;110(3):354-8. Epub 2005 Oct 25.
1328. Alcohol and hypertension: an old relationship revisited.
Tomson J, Lip GY.
Alcohol Alcohol. 2006 Jan-Feb;41(1):3-4. Epub 2005 Oct 20. No abstract available.
1329. Targeting the renin-angiotensin-aldosterone-system in atrial fibrillation: a shift from electrical
to structural therapy?
Choudhury A, Varughese GI, Lip GY.
Expert Opin Pharmacother. 2005 Oct;6(13):2193-207. Review.
1330. Impaired tissue Doppler diastolic function in patients with coronary artery disease: relationship
to endothelial damage/dysfunction and platelet activation.
Lee KW, Blann AD, Lip GY.
Am Heart J. 2005 Oct;150(4):756-66.
1331. Rheumatoid disease and ischaemic heart disease: insights from pathophysiology and vascular
biology.
Bhatia GS, Sosin MD, Khattak FH, Davis RC, Lip GY.
Int J Cardiol. 2005 Oct 20;105(1):1-10. Review.
1332. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial
fibrillation: a systematic review and meta-analysis.
Lip GY, Edwards SJ.
Thromb Res. 2006;118(3):321-33. Epub 2005 Sep 29. Review.
1333. How far can population epidemiology contribute to defining the relationship between
hypertension and left ventricular systolic dysfunction?
MacFadyen RJ, Goyal D, Lip GY.
J Hum Hypertens. 2005 Dec;19(12):919-22. No abstract available.
1334. Elevated platelet microparticles in stable coronary artery disease are unrelated to disease
severity or to indices of inflammation.
Tan KT, Tayebjee MH, Macfadyen RJ, Lip GY, Blann AD.
Platelets. 2005 Sep;16(6):368-71.
1335. Increased circulating endothelial cells in acute heart failure: comparison with von Willebrand
factor and soluble E-selectin.
Chong AY, Lip GY, Freestone B, Blann AD.
Eur J Heart Fail. 2006 Mar;8(2):167-72. Epub 2005 Sep 26.
1336. Angiogenic factors in atrial fibrillation: a possible role in thrombogenesis?
Freestone B, Chong AY, Lim HS, Blann A, Lip GY.
Ann Med. 2005;37(5):365-72.
135
1337. Anticoagulation as thromboprophylaxis for atrial fibrillation: implications in the 'real world' and
the need for risk stratification.
Lane DA, Lip GY.
Blood Coagul Fibrinolysis. 2005 Oct;16(7):461-4. No abstract available.
1338. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth
factor levels in hypertension: relationship to target organ damage [a sub-study of the AngloScandinavian Cardiac Outcomes Trial (ASCOT)].
Nadar SK, Blann A, Beevers DG, Lip GY.
J Intern Med. 2005 Oct;258(4):336-43.
1339. Antithrombotic treatment in atrial fibrillation.
Lip GY, Boos CJ.
Heart. 2006 Feb;92(2):155-61. Epub 2005 Sep 13. Review.
1340. Effects of omega-3 polyunsaturated fatty acids on plasma indices of thrombogenesis and
inflammation in patients post-myocardial infarction.
Lee KW, Blann AD, Lip GY.
Thromb Res. 2006;118(3):305-12. Epub 2005 Sep 8.
1341. Blood clotting, inflammation, and thrombosis in cardiovascular events: perspectives.
Boos CJ, Lip GY.
Front Biosci. 2006 Jan 1;11:328-36. Review.
1342. Short-term adjuvant atorvastatin improves frequency domain indices of heart rate variability in
stable systolic heart failure.
Hamaad A, Sosin M, Lip GY, MacFadyen RJ.
Cardiovasc Drugs Ther. 2005 May;19(3):183-7.
1343. Failed reperfusion with thrombolysis--the effect of a local environment?
Varma C, Lip GY.
Thromb Res. 2006;118(2):185-7. Epub 2005 Aug 31. No abstract available.
1344. Ximelagatran in the clinic: practical management of patients.
Schulman S, Lip GY.
Semin Vasc Med. 2005 Aug;5(3):301-7. Review.
1345. Platelet activation in pregnancy-induced hypertension.
Karalis I, Nadar SK, Al Yemeni E, Blann AD, Lip GY.
Thromb Res. 2005;116(5):377-83. Epub 2005 Feb 24.
1346. Percutaneous coronary interventions for coronary artery disease: the long and short of
optimizing medical therapy.
Jaumdally R, Lip GY, Varma C.
Int J Clin Pract. 2005 Sep;59(9):1070-81. Review.
1347. Interleukin-15 in hypertension: further insights into inflammation and vascular disease.
Lim HS, Lip GY.
Am J Hypertens. 2005 Aug;18(8):1017-8. No abstract available.
136
1348. Targeting the renin-angiotensin-aldosterone system in atrial fibrillation: from pathophysiology
to clinical trials.
Boos CJ, Lip GY.
J Hum Hypertens. 2005 Nov;19(11):855-9. No abstract available.
1349. Differences in the platelet reactivity response to mental stress in cardiac syndrome X patients
compared to known coronary artery disease patients: concepts, explanations and methodological
weaknesses.
Thrall G, Lane D, Lip GY.
Thromb Res. 2006;117(3):351-2. Epub 2005 Aug 9. No abstract available.
1350. Ximelagatran: a clinical perspective.
Boos CJ, Hinton A, Lip GY.
Eur J Intern Med. 2005 Aug;16(4):267-78.
1351. Antihypertensive therapy in diabetes mellitus: insights from ALLHAT and the Blood PressureLowering Treatment Trialists' Collaboration meta-analysis.
Varughese GI, Lip GY.
J Hum Hypertens. 2005 Nov;19(11):851-3. No abstract available.
1352. Blood pressure changes in acute haemorrhagic stroke.
Tomson J, Lip GY.
1353. Ximelagatran for stroke prevention in atrial fibrillation.
Boos CJ, Lip GY.
Expert Rev Cardiovasc Ther. 2005 Jul;3(4):551-63. Review.
1354. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand
levels in patients with stable coronary artery disease.
Tayebjee MH, Lip GY, Tan KT, Patel JV, Hughes EA, MacFadyen RJ.
Am J Cardiol. 2005 Aug 1;96(3):339-45.
1355. Platelet P-selectin and platelet mass, volume and component in sickle cell disease: relationship
to genotype.
Mohan JS, Lip GY, Bareford D, Blann AD.
Thromb Res. 2006;117(6):623-9. Epub 2005 Jul 27.
1356. Correlation of plasma von Willebrand factor levels, an index of endothelial
damage/dysfunction, with two point-based stroke risk stratification scores in atrial fibrillation.
Roldán V, Marín F, García-Herola A, Lip GY.
Thromb Res. 2005;116(4):321-5. Epub 2005 Feb 8.
1357. Antiplatelet and anticoagulant therapy in patients with advanced heart failure.
Lip GY, Chung I.
Thromb Res. 2005;116(4):275-7. Epub 2005 Feb 8. No abstract available.
1358. Atrial fibrillation post-myocardial infarction: frequency, consequences, and management.
Bhatia GS, Lip GY.
Curr Heart Fail Rep. 2004 Dec;1(4):149-55. Review.
1359. The role of inflammation in atrial fibrillation.
137
Boos CJ, Lip GY.
Int J Clin Pract. 2005 Aug;59(8):870-2. No abstract available.
1360. Relation of platelet activation to coronary angiographic severity and collateralization.
Tan KT, Tayebjee MH, Macfadyen RJ, Lip GY.
Am J Cardiol. 2005 Jul 15;96(2):208-10.
1361. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers.
Brotman DJ, Girod JP, Posch A, Jani JT, Patel JV, Gupta M, Lip GY, Reddy S, Kickler TS.
Thromb Res. 2006;118(2):247-52. Epub 2005 Jul 11.
1362. Is there an association between hypertension and the development of coronary collateral
flow?
Tayebjee MH, Lip GY, Macfadyen RJ.
J Hum Hypertens. 2005 Oct;19(10):757-9. Review. No abstract available.
1363. Peripheral arterial disease: a high risk - but neglected - disease population.
Tomson J, Lip GY.
BMC Cardiovasc Disord. 2005 Jun 22;5(1):15.
1364. The angiopoietin/Tie-2 system in proliferative sickle retinopathy: relation to vascular
endothelial growth factor, its soluble receptor Flt-1 and von Willebrand factor, and to the effects of
laser treatment.
Mohan JS, Lip PL, Blann AD, Bareford D, Lip GY.
Br J Ophthalmol. 2005 Jul;89(7):815-9.
1365. Type 2 diabetes mellitus: a cardiovascular perspective.
Varughese GI, Tomson J, Lip GY.
Int J Clin Pract. 2005 Jul;59(7):798-816. Review.
1366. Hemodynamic, hemostatic, and endothelial reactions to psychological and physical stress in
coronary artery disease patients.
Bacon SL, Ring C, Hee FL, Lip GY, Blann AD, Lavoie KL, Carroll D.
Biol Psychol. 2006 Feb;71(2):162-70. Epub 2005 Jun 14.
1367. Darusentan (Abbott Laboratories).
Lip GY.
IDrugs. 2001 Nov;4(11):1284-92.
1368. Ethnic differences in cardiovascular and all-cause mortality in Birmingham, England: the
Birmingham Factory Screening Project.
Lane DA, Lip GY, Beevers DG.
J Hypertens. 2005 Jul;23(7):1347-53.
1369. Cardioversion and the endothelium in atrial fibrillation.
Lip GY, Freestone B.
Thromb Res. 2006;117(3):231-3. Epub 2005 May 31. No abstract available.
1370. Is hypertension a prothrombotic state?
Varughese GI, Lip GY.
Curr Hypertens Rep. 2005 Jun;7(3):168-73. Review.
138
1371. Effects of antiplatelet therapy and oral anticoagulation on indices of endothelial
damage/dysfunction in patients with systolic heart failure in sinus rhythm.
Chong AY, Chin BS, Blann AD, Lip GY.
Thromb Res. 2005;116(2):181-3. Epub 2005 Jan 18. No abstract available.
1372. Exercise and hypertension.
Choudhury A, Lip GY.
J Hum Hypertens. 2005 Aug;19(8):585-7. No abstract available.
1373. Elevated high-sensitive C-reactive protein, large arterial stiffness and atherosclerosis: a
relationship between inflammation and hypertension?
Boos CJ, Lip GY.
J Hum Hypertens. 2005 Jul;19(7):511-3. Review. No abstract available.
1374. Aspirin and endothelial function in hypertension.
Felmeden D, Nadar SK, Lip GY.
J Hum Hypertens. 2005 Sep;19(9):663-5. Review. No abstract available.
1375. Recruitment of ethnic minority patients to a cardiac rehabilitation trial: the Birmingham
Rehabilitation Uptake Maximisation (BRUM) study [ISRCTN72884263].
Jolly K, Lip GY, Taylor RS, Mant JW, Lane DA, Lee KW, Stevens AJ; BRUM Steering Committee.
BMC Med Res Methodol. 2005 May 17;5:18.
1376. Platelet microparticles and soluble P selectin in peripheral artery disease: relationship to
extent of disease and platelet activation markers.
Tan KT, Tayebjee MH, Lynd C, Blann AD, Lip GY.
Ann Med. 2005;37(1):61-6.
\
1377. Platelet adhesion in hypertension: application of a novel assay of platelet adhesion.
Nadar SK, Caine GJ, Blann AD, Lip GY.
Ann Med. 2005;37(1):55-60.
1378. Effects of congestive heart failure on plasma von Willebrand factor and soluble P-selectin
concentrations in patients with non-valvar atrial fibrillation.
Lip GY, Pearce LA, Chin BS, Conway DS, Hart RG.
Heart. 2005 Jun;91(6):759-63.
1379. Heterotopic heart transplantation.
Tayebjee MH, Lip GY.
Int J Cardiol. 2005 May 25;101(2):311-2. No abstract available.
1380. Vascular endothelial growth factor and angiogenesis in heart failure.
Lip GY, Chung I.
J Card Fail. 2005 May;11(4):285-7. No abstract available.
1381. Stroke prevention.
Lip GY, Rothwell P, Sudlow C.
Clin Evid. 2004 Dec;(12):253-84. Review. No abstract available. Update in: Clin Evid. 2005
Dec;(14):173-97.
139
1382. A prophylactically implanted cardioverter defibrillator did not reduce all-cause mortality after a
recent myocardial infarction.
Lip GY, Choudhury A.
ACP J Club. 2005 May-Jun;142(3):58. No abstract available.
.
1383. Factors predicting the development of metabolic syndrome and type II diabetes against a
background of hypertension.
Lim HS, Lip GY, Beevers DG, Blann AD.
Eur J Clin Invest. 2005 May;35(5):324-9.
1384. Matrix metalloproteinases in coronary artery disease: clinical and therapeutic implications and
pathological significance.
Tayebjee MH, Lip GY, MacFadyen RJ.
Curr Med Chem. 2005;12(8):917-25. Review.
1385. Plasma von Willebrand factor levels and surrogates of atherosclerosis.
Lip GY, Foster W, Blann AD.
J Thromb Haemost. 2005 Apr;3(4):659-61. No abstract available.
1386. Hormone replacement use and cardiovascular function and structure in postmenopausal
women.
Tomson J, Os I, Lip GY.
Blood Press. 2005;14(1):3-5. No abstract available.
1387. Soluble vascular endothelial growth factor, soluble VEGF receptor Flt-1 and endothelial
function in healthy smokers.
Schmidt-Lucke C, Belgore F, Reinhold D, Ansorge S, Klein HU, Schmidt-Lucke JA, Lip GY.
Int J Cardiol. 2005 Apr 20;100(2):207-12.
1388. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control,
endothelial damage/dysfunction and atherosclerosis.
Lim HS, Lip GY, Blann AD.
Atherosclerosis. 2005 May;180(1):113-8. Epub 2004 Dec 21.
1389. Are there ethnic differences in the circadian variation in onset of acute myocardial infarction?
A comparison of 3 ethnic groups in Birmingham, UK and Alicante, Spain.
López F, Lee KW, Marín F, Roldán V, Sogorb F, Caturla J, Lip GY.
Int J Cardiol. 2005 Apr 8;100(1):151-4.
1390. Hypertension in patients with type-II diabetes: relation to urinary albumin excretion,
endothelial function and inflammation.
Varughese GI, Lip GY.
J Hum Hypertens. 2005 Jun;19(6):421-4. Review. No abstract available.
1391. Preventing stroke in atrial fibrillation: the SPORTIF programme.
Lip GY.
Pathophysiol Haemost Thromb. 2005;34 Suppl 1:25-30. Review.
1392. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2
levels in gestational hypertension.
140
Tayebjee MH, Karalis I, Nadar SK, Beevers DG, MacFadyen RJ, Lip GY.
Am J Hypertens. 2005 Mar;18(3):325-9.
1393. Plasma levels of tissue factor and soluble E-selectin in sickle cell disease: relationship to
genotype and to inflammation.
Mohan JS, Lip GY, Wright J, Bareford D, Blann AD.
Blood Coagul Fibrinolysis. 2005 Apr;16(3):209-14.
1394. Genetic polymorphisms and thromoembolic risk in atrial fibrillation.
Marín F, Roldán V, Tello A, Lip GY.
J Thromb Thrombolysis. 2004 Oct;18(2):151-2. No abstract available.
1395. Comparison of brain natriuretic peptide and left ventricular diastolic function determined by
tissue Doppler in patients with diabetes mellitus, patients with hypertension without diabetes, and in
healthy subjects.
Lim HS, Patel JV, Nadar S, Hughes EA, Lip GY.
Am J Cardiol. 2005 Apr 1;95(7):905-8.
1396. Relation of interleukin-6 levels and prothrombin fragment 1+2 to a point-based score for
stroke risk in atrial fibrillation.
Roldán V, Marín F, Martínez JG, García-Herola A, Sogorb F, Lip GY.
Am J Cardiol. 2005 Apr 1;95(7):881-2.
1397. Incremental shuttle walking is associated with activation of haemostatic and haemorheological
markers in patients with coronary artery disease: the Birmingham rehabilitation uptake maximization
study (BRUM).
Lee KW, Blann AD, Ingram J, Jolly K, Lip GY; BRUM Investigators.
Heart. 2005 Nov;91(11):1413-7. Epub 2005 Mar 17.
1398. Depression, indirect clinical markers of cardiac disease severity, and mortality following
myocardial infarction.
Lane D, Ring C, Lip GY, Carroll D.
Heart. 2005 Apr;91(4):531-2. No abstract available.
1399. How good is anticoagulation control in non-valvar atrial fibrillation? Observations on the
elderly, ethnicity, patient perceptions, and understanding of AF thromboprophylaxis.
Choudhury A, Lip GY.
Heart. 2005 Apr;91(4):425-6.
1400. Effects of short-term glucocorticoids on cardiovascular biomarkers.
Brotman DJ, Girod JP, Garcia MJ, Patel JV, Gupta M, Posch A, Saunders S, Lip GY, Worley S, Reddy S.
J Clin Endocrinol Metab. 2005 Jun;90(6):3202-8. Epub 2005 Mar 15.
1401. Hormone replacement therapy and cardiovascular risk.
Chong AY, Lip GY.
Treat Endocrinol. 2002;1(2):95-103. Review.
1402. Atrial fibrillation, the prothrombotic state, inflammation, and gender.
Conway DS, Lip GY.
Am J Cardiol. 2005 Mar 15;95(6):819. No abstract available.
141
1403. Positive pressure ventilation in the management of acute and chronic cardiac failure: a
systematic review and meta-analysis.
Nadar S, Prasad N, Taylor RS, Lip GY.
Int J Cardiol. 2005 Mar 18;99(2):171-85. Review.
1404. Goodbye mercury? Blood pressure measurement and its future.
Varughese GI, Lip GY.
J R Soc Med. 2005 Mar;98(3):89-90. No abstract available.
1405. Soluble CD40L in peripheral artery disease. Relationship with disease severity, platelet markers
and the effects of angioplasty.
Blann AD, Tan KT, Tayebjee MH, Davagnanam I, Moss M, Lip GY.
Thromb Haemost. 2005 Mar;93(3):578-83.
1406. Fondaparinux.
Tan KT, Lip GY.
Curr Pharm Des. 2005;11(4):415-9. Review.
1407. Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet
activation and angiogenesis in patients with advanced cancer.
Caine GJ, Harris AL, Christodoulos K, Lip GY, Blann AD.
Cancer Lett. 2005 Mar 10;219(2):163-7.
1408. Hibernating myocardium in heart failure.
Bhatia G, Sosin M, Leahy JF, Connolly DL, Davis RC, Lip GY.
Expert Rev Cardiovasc Ther. 2005 Jan;3(1):111-22. Review.
1409. The effect of multi-factorial intervention on plasma von Willebrand factor, soluble E-selectin
and tissue factor in diabetes mellitus: implications for atherosclerotic vascular disease.
Lim HS, Chong AY, Freestone B, Blann AD, Lip GY.
Diabet Med. 2005 Mar;22(3):249-55.
1410. Circulating endothelial cells. Biomarker of vascular disease.
Blann AD, Woywodt A, Bertolini F, Bull TM, Buyon JP, Clancy RM, Haubitz M, Hebbel RP, Lip GY,
Mancuso P, Sampol J, Solovey A, Dignat-George F.
Thromb Haemost. 2005 Feb;93(2):228-35. Review.
1411. Thrombotic complications and thromboprophylaxis in breast and gynaecological malignancies.
Goyal D, Choudhury A, Lip GY.
Curr Opin Obstet Gynecol. 2005 Feb;17(1):13-20. Review.
1412. Rheumatoid disease and the heart: from epidemiology to echocardiography.
Bhatia GS, Sosin MD, Grindulis KA, Davis RC, Lip GY.
Expert Opin Investig Drugs. 2005 Jan;14(1):65-76. Review.
1413. Ambulatory blood pressure monitoring in heart failure: a systematic review.
Goyal D, Macfadyen RJ, Watson RD, Lip GY.
Eur J Heart Fail. 2005 Mar 2;7(2):149-56. Review.
1414. Virchow's triad revisited: blood constituents.
Chung I, Lip GY.
142
Pathophysiol Haemost Thromb. 2003 Sep-2004 Dec;33(5-6):449-54. Review.
1415. Atrial fibrillation and the hypercoagulable state: from basic science to clinical practice.
Choudhury A, Lip GY.
Pathophysiol Haemost Thromb. 2003 Sep-2004 Dec;33(5-6):282-9. Review. No abstract available.
1416. High pulse pressure and nondipping circadian blood pressure in patients with coronary artery
disease: Relationship to thrombogenesis and endothelial damage/dysfunction.
Lee KW, Blann AD, Lip GY.
Am J Hypertens. 2005 Jan;18(1):104-15.
1417. Exercise and the prothrombotic state: a paradox of cardiovascular prevention or an enhanced
prothrombotic state?
Thrall G, Lip GY.
Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):265-6. No abstract available.
1418. Recent developments in atrial fibrillation.
Iqbal MB, Taneja AK, Lip GY, Flather M.
BMJ. 2005 Jan 29;330(7485):238-43. Review. No abstract available.
1419. Psychological interventions for depression in heart failure.
Lane DA, Chong AY, Lip GY.
Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003329. Review.
1420. Antithrombotic therapy in hypertension: a Cochrane Systematic review.
Felmeden DC, Lip GY.
J Hum Hypertens. 2005 Mar;19(3):185-96. Review.
1421. Atrial fibrillation (acute).
Freestone B, Lip GY.
Clin Evid. 2004 Jun;(11):76-97. Review. No abstract available.
1422. Blood pressure demographics: nature or nurture ... ... genes or environment?
Tomson J, Lip GY.
BMC Med. 2005 Jan 7;3:3.
1423. Tissue inhibitor of metalloproteinse-1 is a marker of diastolic dysfunction using tissue doppler
in patients with type 2 diabetes and hypertension.
Tayebjee MH, Lim HS, Nadar S, MacFadyen RJ, Lip GY.
Eur J Clin Invest. 2005 Jan;35(1):8-12.
1424. A pharmacogenetic effect of factor XIII valine 34 leucine polymorphism on fibrinolytic therapy
for acute myocardial infarction.
Marín F, González-Conejero R, Lee KW, Corral J, Roldán V, López F, Sogorb F, Caturla J, Lip GY, Vicente
V.
J Am Coll Cardiol. 2005 Jan 4;45(1):25-9.
1425. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix
metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix
metalloproteinases (TIMP)-1 and -2.
Tayebjee MH, Lip GY, Blann AD, Macfadyen RJ.
143
Thromb Res. 2005;115(3):205-10.
1426. Haemoconcentration and the hypercoagulable state associated with mental stress.
Thrall G, Lip GY.
Thromb Res. 2005;115(3):171-3. No abstract available.
1427. Abnormal circulating levels of metalloprotease 9 and its tissue inhibitor 1 in angiographically
proven peripheral arterial disease: relationship to disease severity.
Tayebjee MH, Tan KT, MacFadyen RJ, Lip GY.
J Intern Med. 2005 Jan;257(1):110-6.
1428. Anti-thrombotic therapy for atrial fibrillation and patients' preferences for treatment.
Lane D, Lip GY.
Age Ageing. 2005 Jan;34(1):1-3. No abstract available.
1429. Platelet morphology, soluble P selectin and platelet P-selectin in acute ischaemic stroke. The
West Birmingham Stroke Project.
Nadar SK, Lip GY, Blann AD.
Thromb Haemost. 2004 Dec;92(6):1342-8.
1430. Angiotensin II-mediated vascular inflammation: the balance between vascular endothelial
growth factor and angiopoietins.
Lim HS, Felmeden D, Lip GY.
Hypertension. 2005 Feb;45(2):e3. No abstract available.
1431. Antihypertensive therapy and endothelial function.
Nadar S, Blann AD, Lip GY.
Curr Pharm Des. 2004;10(29):3607-14. Review.
1432. Endothelial dysfunction: methods of assessment and application to hypertension.
Nadar S, Blann AD, Lip GY.
Curr Pharm Des. 2004;10(29):3591-605. Review.
1433. Drug development and the importance of ethnicity: lessons from heart failure management
and implications for hypertension.
Sosin MD, Bhatia GS, Lip GY, Davis RC.
Curr Pharm Des. 2004;10(29):3569-77. Review.
1434. Novel therapies for the prevention of stroke.
Boos CJ, Lip GY.
Expert Opin Investig Drugs. 2004 Dec;13(12):1615-30. Review.
1435. Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes:
implications for cardiovascular risk and effects of multifactorial intervention.
Lim HS, Blann AD, Chong AY, Freestone B, Lip GY.
Diabetes Care. 2004 Dec;27(12):2918-24.
1436. Heart failure--the importance of ethnicity.
Sosin MD, Bhatia GS, Davis RC, Lip GY.
Eur J Heart Fail. 2004 Dec;6(7):831-43. Review.
144
1437. Stroke prevention.
Freestone B, Lip GY, Rothwell P, Sudlow C.
Clin Evid. 2003 Dec;(10):246-72. Review. No abstract available. Update in: Clin Evid. 2004
Dec;(12):253-84.
1438. Atrial fibrillation (acute).
Freestone B, Lip GY.
Clin Evid. 2003 Dec;(10):76-94. Review. No abstract available. Update in: Clin Evid. 2004 Jun;(11):7697.
1439. Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor
tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade.
Lip PL, Chatterjee S, Caine GJ, Hope-Ross M, Gibson J, Blann AD, Lip GY.
Br J Ophthalmol. 2004 Dec;88(12):1543-6.
1440. Acute coronary syndromes presenting solely with heart failure symptoms: are they under
recognised?
Hamaad A, Lip GY, MacFadyen RJ.
Eur J Heart Fail. 2004 Oct;6(6):683-6.
1441. Pushing the envelope too far?
Connolly DL, Lip GY, Lo TS.
J Am Coll Cardiol. 2004 Nov 16;44(10):2094-5; author reply 2095. No abstract available.
1442. Plasma von Willebrand factor and the development of the metabolic syndrome in patients with
hypertension.
Lim HS, Lip GY, Blann AD.
J Clin Endocrinol Metab. 2004 Nov;89(11):5377-81.
1443. Platelet morphology and plasma indices of platelet activation in essential hypertension: effects
of amlodipine-based antihypertensive therapy.
Nadar S, Blann AD, Lip GY.
Ann Med. 2004;36(7):552-7.
1444. Heart rate variability estimates of autonomic tone: relationship to mapping pathological and
procedural stress responses in coronary disease.
Hamaad A, Lip GY, MacFadyen RJ.
Ann Med. 2004;36(6):448-61. Review.
1445. Circulating levels of VEGF-A, VEGF-D and soluble VEGF-A receptor (sFIt-1) in human breast
cancer.
Hoar FJ, Lip GY, Belgore F, Stonelake PS.
Int J Biol Markers. 2004 Jul-Sep;19(3):229-35.
1446. Echocardiographic changes in patients with malignant phase hypertension: the West
Birmingham Malignant Hypertension Register.
Nadar S, Beevers DG, Lip GY.
J Hum Hypertens. 2005 Jan;19(1):69-75.
1447. Inflammation, arrhythmia burden and the thrombotic consequences of atrial fibrillation.
Conway DS, Lip GY.
145
Eur Heart J. 2004 Oct;25(19):1761. No abstract available.
1448. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial
fibrillation.
Conway DS, Buggins P, Hughes E, Lip GY.
Am Heart J. 2004 Sep;148(3):462-6.
1449. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference
on Antithrombotic and Thrombolytic Therapy.
Clagett GP, Sobel M, Jackson MR, Lip GY, Tangelder M, Verhaeghe R.
Chest. 2004 Sep;126(3 Suppl):609S-626S. Review.
1450. Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients
with acute coronary syndromes.
Lee KW, Lip GY, Tayebjee M, Foster W, Blann AD.
Blood. 2005 Jan 15;105(2):526-32. Epub 2004 Sep 16.
1451. Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in
acute onset non-rheumatic atrial fibrillation.
Marín F, Roldán V, Climent VE, Ibáñez A, García A, Marco P, Sogorb F, Lip GY.
Heart. 2004 Oct;90(10):1162-6.
1452. Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in
hypertension: effects of antihypertensive therapy.
Nadar SK, Blann AD, Lip GY.
J Intern Med. 2004 Oct;256(4):331-7.
1453. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated
dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic
peptide.
Chong AY, Blann AD, Patel J, Freestone B, Hughes E, Lip GY.
Circulation. 2004 Sep 28;110(13):1794-8. Epub 2004 Sep 13.
1454. Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart.
Lim HS, MacFadyen RJ, Lip GY.
Arch Intern Med. 2004 Sep 13;164(16):1737-48. Review.
1455. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with
hypertension Relationship to tissue Doppler indices of diastolic relaxation.
Tayebjee MH, Nadar SK, MacFadyen RJ, Lip GY.
Am J Hypertens. 2004 Sep;17(9):770-4.
1456. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and
their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac
Outcomes Trial (ASCOT).
Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY.
Am J Hypertens. 2004 Sep;17(9):764-9.
1457. Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state
associated with atrial fibrillation.
Marín F, Corral J, Roldán V, González-Conejero R, del Rey ML, Sogorb F, Lip GY, Vicente V.
146
J Mol Cell Cardiol. 2004 Sep;37(3):699-704.
1458. Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion
of persistent atrial fibrillation.
Conway DS, Buggins P, Hughes E, Lip GY.
Am J Cardiol. 2004 Aug 15;94(4):508-10.
1459. Diabetes, the renin-angiotensin system and heart disease.
Lim HS, Lip GY.
Curr Vasc Pharmacol. 2003 Jun;1(2):225-38. Review.
1460. The endothelium and platelets in cardiovascular disease: potential targets for therapeutic
intervention.
Tan KT, Watson SP, Lip GY.
Curr Med Chem Cardiovasc Hematol Agents. 2004 Apr;2(2):169-78. Review.
1461. Left ventricular systolic dysfunction and atrial fibrillation in older people in the community: the
need for identification, as well as appropriate management.
Choudhury A, Lip GY.
Age Ageing. 2004 Sep;33(5):434-6. No abstract available.
1462. Clinical review: clinical management of atrial fibrillation - rate control versus rhythm control.
Lim HS, Hamaad A, Lip GY.
Crit Care. 2004 Aug;8(4):271-9. Epub 2004 Feb 19. Review.
1463. Platelet adhesion in breast cancer: development and application of a novel assay.
Caine GJ, Nadar SK, Lip GY, Stonelake PS, Blann AD.
Blood Coagul Fibrinolysis. 2004 Sep;15(6):513-8.
1464. Ethnic differences in patient perceptions of heart failure and treatment: the West Birmingham
heart failure project.
Lip GY, Khan H, Bhatnagar A, Brahmabhatt N, Crook P, Davies MK; West Birmingham heart failure
project.
Heart. 2004 Sep;90(9):1016-9.
1465. The unifying role of matrix metalloproteinases in atheroma and vascular stroke.
Tayebjee MH, Lip GY, MacFadyen RJ.
Stroke. 2004 Oct;35(10):2239. Epub 2004 Aug 12. No abstract available.
1466. Effects of dietary fat intake in sudden death: reduction of death with omega-3 fatty acids.
Lee KW, Hamaad A, MacFadyen RJ, Lip GY.
Curr Cardiol Rep. 2004 Sep;6(5):371-8. Review.
1467. Plasma angiopoietin-1, angiopoietin-2, angiopoietin receptor tie-2, and vascular endothelial
growth factor levels in acute coronary syndromes.
Lee KW, Lip GY, Blann AD.
Circulation. 2004 Oct 19;110(16):2355-60. Epub 2004 Aug 9.
1468. An 8-year follow-up study of acute admissions with heart failure in a multiethnic population.
Sosin MD, Bhatia GS, Zarifis J, Davis RC, Lip GY.
Eur J Heart Fail. 2004 Aug;6(5):669-72.
147
1469. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 and -2 in type 2
diabetes: effect of 1 year's cardiovascular risk reduction therapy.
Tayebjee MH, Lim HS, MacFadyen RJ, Lip GY.
Diabetes Care. 2004 Aug;27(8):2049-51. No abstract available.
1470. Metabolic syndrome: a definition in progress.
Lim HS, Patel JV, Lip GY.
Circulation. 2004 Jul 27;110(4):e35; author reply e35. No abstract available.
1471. Antiplatelet agents and anticoagulants for hypertension.
Lip GY, Felmeden DC.
Cochrane Database Syst Rev. 2004;(3):CD003186. Review. Update in: Cochrane Database Syst Rev.
2011;(12):CD003186.
1472. Diastolic heart failure: recognition, diagnosis and management.
Goyal D, Choudhary A, Lip GY, MacFadyen RJ.
Expert Opin Pharmacother. 2004 Aug;5(8):1745-54. Review.
1473. Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a
substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Nadar SK, Blann AD, Kamath S, Beevers DG, Lip GY.
J Am Coll Cardiol. 2004 Jul 21;44(2):415-22.
1474. Salt intake and Helicobacter pylori infection.
Beevers DG, Lip GY, Blann AD.
J Hypertens. 2004 Aug;22(8):1475-7.
1475. Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer:
further evidence for a role of platelets in tumour angiogenesis.
Caine GJ, Lip GY, Blann AD.
Ann Med. 2004;36(4):273-7.
1476. Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma.
Caine GJ, Lip GY, Stonelake PS, Ryan P, Blann AD.
Thromb Haemost. 2004 Jul;92(1):185-90.
1477. Antiarrhythmic drugs in atrial fibrillation: an overview of new agents, their mechanisms of
action and potential clinical utility.
Choudhury A, Lip GY.
Expert Opin Investig Drugs. 2004 Jul;13(7):841-55. Review.
1478. Autonomic reflexes in heterotopic heart transplantation.
Tayebjee MH, Singh SP, Lip GY.
Int J Clin Pract. 2004 May;58(5):520-2.
1479. Further insights into the prothrombotic state in mitral stenosis and atrial flutter.
Conway DS, Lip GY.
Chest. 2004 Jun;125(6):2361-2; author reply 2362-3. No abstract available.
148
1480. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial
fibrillation.
Conway DS, Buggins P, Hughes E, Lip GY.
J Am Coll Cardiol. 2004 Jun 2;43(11):2075-82.
1481. Comparison of outcomes of patients with symptomatic peripheral artery disease with and
without atrial fibrillation (the West Birmingham Atrial Fibrillation Project).
Conway DS, Lip GY.
Am J Cardiol. 2004 Jun 1;93(11):1422-5, A10.
1482. Relation of interleukin-6, C-reactive protein, and the prothrombotic state to transesophageal
echocardiographic findings in atrial fibrillation.
Conway DS, Buggins P, Hughes E, Lip GY.
Am J Cardiol. 2004 Jun 1;93(11):1368-73, A6.
1483. Platelet activation in the hypertensive disorders of pregnancy.
Nadar S, Lip GY.
Expert Opin Investig Drugs. 2004 May;13(5):523-9. Review.
1484. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus:
relationships to cardiovascular disease and risk factor intervention.
Lim HS, Blann AD, Lip GY.
Circulation. 2004 Jun 1;109(21):2524-8. Epub 2004 May 10.
1485. Is depression following acute myocardial infarction an independent risk for mortality?
Lane D, Lip GY, Carroll D.
Am J Cardiol. 2004 May 15;93(10):1333-4. No abstract available.
1486.Thrombogenesis, atherogenesis and angiogenesis in vascular disease: a new 'vascular triad'.
Lip GY, Blann AD.
Ann Med. 2004;36(2):119-25. Review.
1487. Thrombomodulin, von Willebrand factor and E-selectin as plasma markers of endothelial
damage/dysfunction and activation in pregnancy induced hypertension.
Nadar SK, Al Yemeni E, Blann AD, Lip GY.
Thromb Res. 2004;113(2):123-8.
1488. Dual chamber versus single chamber ventricular pacemakers for sick sinus syndrome and
atrioventricular block.
Dretzke J, Toff WD, Lip GY, Raftery J, Fry-Smith A, Taylor R.
Cochrane Database Syst Rev. 2004;(2):CD003710. Review.
1489. Collateralization and the response to obstruction of epicardial coronary arteries.
Tayebjee MH, Lip GY, MacFadyen RJ.
QJM. 2004 May;97(5):259-72. Review.
1490. Relationship of homocysteine to markers of platelet and endothelial activation in "high risk"
hypertensives: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.
Spencer CG, Martin SC, Felmeden DC, Blann AD, Beevers GD, Lip GY.
Int J Cardiol. 2004 Apr;94(2-3):293-300.
149
1491. Ethnic differences in left ventricular size and the prevalence of left ventricular hypertrophy
among hypertensive patients vary with electrocardiographic criteria.
Spencer CG, Beevers DG, Lip GY.
J Hum Hypertens. 2004 Sep;18(9):631-6.
1492. Atrial fibrillation: should we target platelets or the coagulation pathway?
Tan KT, Lip GY.
Card Electrophysiol Rev. 2003 Dec;7(4):370-1. Review.
1493. Impaired fasting glycaemia vs. impaired glucose tolerance: two sides of the same coin with
implications for cardiovascular risk.
Lim HS, Lip GY.
Diabet Med. 2004 Apr;21(4):303-4. No abstract available.
1494. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of
circulating endothelial cells. Relationship with von Willebrand factor and tissue factor.
Makin AJ, Blann AD, Chung NA, Silverman SH, Lip GY.
Eur Heart J. 2004 Mar;25(5):371-6.
1495. Compliance with pharmacological therapy in hypertension: can we do better, and how?
Thrall G, Lip GY, Lane D.
J Hum Hypertens. 2004 Sep;18(9):595-7. No abstract available.
1496. A randomized trial of aspirin on the risk of embolic events in patients with infective
endocarditis.
Connolly DL, Choudhury A, Davis RC, Lip GY.
J Am Coll Cardiol. 2004 Mar 17;43(6):1134-5; author reply 1135. No abstract available.
1497. Acute versus habitual exercise, thrombogenesis and exercise intensity.
Lee KW, Lip GY.
Thromb Haemost. 2004 Mar;91(3):416-9. No abstract available.
1498. Plasma angiopoietin-1, angiopoietin-2, and angiopoietin receptor tie-2 levels in congestive
heart failure.
Chong AY, Caine GJ, Freestone B, Blann AD, Lip GY.
J Am Coll Cardiol. 2004 Feb 4;43(3):423-8.
1499. Hormone replacement therapy and cardiovascular disease: does route of administration and
formulation matter?
Foster W, Lip GY.
Br J Haematol. 2004 Mar;124(6):836-40. No abstract available.
1500. Current anticoagulation therapy--a GP guide.
Tan KT, Lip GY.
Practitioner. 2004 Feb;248(1655):87-8, 92-4, 97-8. No abstract available.
1501. Tedisamil: a new novel antiarrhythmic.
Freestone B, Lip GY.
Expert Opin Investig Drugs. 2004 Feb;13(2):151-60.
150
1502. Localisation of members of the vascular endothelial growth factor (VEGF) family and their
receptors in human atherosclerotic arteries.
Belgore F, Blann A, Neil D, Ahmed AS, Lip GY.
J Clin Pathol. 2004 Mar;57(3):266-72.
1503. Arterial stiffness in diabetes and hypertension.
Lim HS, Lip GY.
J Hum Hypertens. 2004 Jul;18(7):467-8. Review. No abstract available.
1504. Angiopoietin/tie-2 as mediators of angiogenesis: a role in congestive heart failure?
Chong AY, Caine GJ, Lip GY.
Eur J Clin Invest. 2004 Jan;34(1):9-13.
1505. Virchow's triad revisited.
Brotman DJ, Deitcher SR, Lip GY, Matzdorff AC.
South Med J. 2004 Feb;97(2):213-4. No abstract available.
1506. The renin-angiotensin-aldosterone system in atrial fibrillation: a new therapeutic target?
Freestone B, Beevers DG, Lip GY.
J Hum Hypertens. 2004 Jul;18(7):461-5. Review. No abstract available.
1507. Increases in lipids and immune cells in response to exercise and mental stress in patients with
suspected coronary artery disease: effects of adjustment for shifts in plasma volume.
Bacon SL, Ring C, Lip GY, Carroll D.
Biol Psychol. 2004 Feb;65(3):237-50.
1508. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney
disease: the chronic renal impairment in Birmingham (CRIB) study.
Landray MJ, Wheeler DC, Lip GY, Newman DJ, Blann AD, McGlynn FJ, Ball S, Townend JN, Baigent C.
Am J Kidney Dis. 2004 Feb;43(2):244-53.
1509. Management of hypertension in pregnancy.
Chung NA, Beevers DG, Lip GY.
Am J Cardiovasc Drugs. 2001;1(4):253-62. Review.
1510. Matrix metalloproteinases in atrial fibrillation.
Marín F, Roldán V, Climent V, Lip GY.
J Am Coll Cardiol. 2004 Jan 7;43(1):152; author reply 152-3. No abstract available.
1511. Unheralded sudden cardiac death: do autonomic tone and thrombosis interact as key factors in
aetiology?
Hamaad A, Lip GY, MacFadyen RJ.
Ann Med. 2003;35(8):592-604. Review.
1512. White coat hypertension: not so benign after all?
Chung I, Lip GY.
J Hum Hypertens. 2003 Dec;17(12):807-9. No abstract available.
1513. Thrombogenesis and endothelial damage/dysfunction in peripheral artery disease.
Relationship to ethnicity and disease severity.
Makin AJ, Chung NA, Silverman SH, Lip GY.
151
Thromb Res. 2003;111(4-5):221-6.
1514. Platelet and haemorheological markers in 'high risk' hypertensives are improved by tighter
blood pressure control and cardiovascular risk management: a substudy of the Anglo-Scandinavian
Cardiac Outcomes Trial (ASCOT).
Spencer CG, Gurney D, Felmeden DC, Blann AD, Beevers DG, Lip GY.
J Intern Med. 2004 Jan;255(1):59-67.
1515. Mortality in congestive heart failure complicated by atrial fibrillation.
Sosin M, Davis RC, Lip GY.
Eur Heart J. 2004 Jan;25(1):97-8; author reply 98. No abstract available.
1516. The prothrombotic state in atrial fibrillation: the atrium, the endothelium... And tissue factor?
Lip GY.
Thromb Res. 2003;111(3):133-5. No abstract available.
1517. Ethnicity in relation to atrial fibrillation and stroke (the West Birmingham Stroke Project).
Conway DS, Lip GY.
Am J Cardiol. 2003 Dec 15;92(12):1476-9.
1518. Is angiotensin receptor blockade antithrombotic?
Lim HS, Lip GY.
Arch Intern Med. 2003 Dec 8-22;163(22):2790-1; author reply 2792-3. No abstract available.
1519. Restenosis after coronary stenting: the 'gender paradox'.
Alfonso F, Tayebjee MH, Lip GY.
Eur Heart J. 2003 Dec;24(24):2239. No abstract available.
1520. The adhesion molecule P-selectin and cardiovascular disease.
Blann AD, Nadar SK, Lip GY.
Eur Heart J. 2003 Dec;24(24):2166-79. Review. Erratum in: Eur Heart J. 2006 Feb;27(4):501.
1521. Extracellular matrix biology: a new frontier in linking the pathology and therapy of
hypertension?
Tayebjee MH, MacFadyen RJ, Lip GY.
J Hypertens. 2003 Dec;21(12):2211-8. Review.
1522. Soluble E-selectin in cardiovascular disease and its risk factors. A review of the literature.
Roldán V, Marín F, Lip GY, Blann AD.
Thromb Haemost. 2003 Dec;90(6):1007-20. Review.
1523. Psychosocial functioning of adults with congenital heart disease: a neglected area.
Tayebjee MH, Lip GY.
Eur Heart J. 2003 Dec;24(23):2159; author reply 2159-60. No abstract available.
1524. Anxiety, depression, and prognosis after myocardial infarction: is there a causal association?
Lane D, Carroll D, Lip GY.
J Am Coll Cardiol. 2003 Nov 19;42(10):1808-10. No abstract available.
1525. Congestive heart failure and Virchow's triad: a neglected association.
Sosin MD, Bhatia G, Davis RC, Lip GY.
152
Wien Med Wochenschr. 2003;153(19-20):411-6. Review.
1526. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue
factor and vascular endothelial growth factor levels in congestive heart failure.
Chin BS, Blann AD, Gibbs CR, Chung NA, Conway DG, Lip GY.
Eur J Clin Invest. 2003 Nov;33(11):941-8.
1527. Indices of thrombogenesis, endothelial damage and platelet function following percutaneous
peripheral artery angiography and angioplasty for peripheral vascular disease.
Makin AJ, Chung NA, Silverman SH, Moss MS, Lip GY.
Pathophysiol Haemost Thromb. 2003 Mar-Apr;33(2):102-8.
1528. Angiogenesis, thrombogenesis, endothelial dysfunction and angiographic severity of coronary
artery disease.
Chung NA, Lydakis C, Belgore F, Li-Saw-Hee FL, Blann AD, Lip GY.
Heart. 2003 Dec;89(12):1411-5.
1529. Red vs white thrombi: treating the right clot is crucial.
Tan KT, Lip GY.
Arch Intern Med. 2003 Nov 10;163(20):2534-5; author reply 2535. No abstract available.
1530. The prevalence and persistence of depression and anxiety following myocardial infarction.
Lane D, Carroll D, Ring C, Beevers DG, Lip GY.
Br J Health Psychol. 2002 Feb;7(Pt 1):11-21.
1531. LIFE: losartan versus atenolol.
Chong AY, Lip GY.
Lancet. 2003 Oct 25;362(9393):1416. No abstract available.
1532. Platelets, atherosclerosis and the endothelium: new therapeutic targets?
Tan KT, Lip GY.
Expert Opin Investig Drugs. 2003 Nov;12(11):1765-76. Review.
1533. Treatment of hypertension in peripheral arterial disease.
Lip GY, Makin AJ.
Cochrane Database Syst Rev. 2003;(4):CD003075. Review. Update in: Cochrane Database Syst Rev.
2009;(4):CD003075.
1534. Effects of lifestyle on hemostasis, fibrinolysis, and platelet reactivity: a systematic review.
Lee KW, Lip GY.
Arch Intern Med. 2003 Oct 27;163(19):2368-92. Review.
1535.More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease
and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA,
ValHEFT, HOPE-TOO and SYST-EUR2).
Lip GY, Beevers DG.
J Hum Hypertens. 2003 Nov;17(11):747-50. Review. No abstract available.
1536. Admissions with atrial fibrillation in a multiracial population in Kuala Lumpur, Malaysia.
Freestone B, Rajaratnam R, Hussain N, Lip GY.
Int J Cardiol. 2003 Oct;91(2-3):233-8.
153
1537. Coagulopathic complications in breast cancer.
Caine GJ, Stonelake PS, Rea D, Lip GY.
Cancer. 2003 Oct 15;98(8):1578-86. Review.
1538. Acute coronary syndromes: Virchow's triad revisited.
Lee KW, Lip GY.
Blood Coagul Fibrinolysis. 2003 Oct;14(7):605-25. Review.
1539. Thromboembolism associated with new anti-cancer treatment strategies in combination with
conventional chemotherapy: new drugs, old risks?
Caine GJ, Lip GY.
Thromb Haemost. 2003 Oct;90(4):567-9. No abstract available.
1540.Plasma angiopoietin-1, angiopoietin-2 and Tie-2 in breast and prostate cancer: a comparison
with VEGF and Flt-1.
Caine GJ, Blann AD, Stonelake PS, Ryan P, Lip GY.
Eur J Clin Invest. 2003 Oct;33(10):883-90.
1541. Basic fibrobrast growth factor induces the secretion of vascular endothelial growth factor by
human aortic smooth muscle cells but not by endothelial cells.
Belgore F, Lip GY, Blann AD.
Eur J Clin Invest. 2003 Oct;33(10):833-9.
1542. Primary hyperaldosteronism.
Nadar S, Lip GY, Beevers DG.
Ann Clin Biochem. 2003 Sep;40(Pt 5):439-52. Review.
1543. Fibrinogen: biochemistry, epidemiology and determinants.
Kamath S, Lip GY.
QJM. 2003 Oct;96(10):711-29. Review. No abstract available.
1544. Heart failure: treatment and ethnic origin.
Sosin MD, Bhatia GS, Davis RC, Connolly DL, Lip GY.
Lancet. 2003 Sep 13;362(9387):919-20. No abstract available.
1545. Home-based versus hospital-based cardiac rehabilitation after myocardial infarction or
revascularisation: design and rationale of the Birmingham Rehabilitation Uptake Maximisation Study
(BRUM): a randomised controlled trial [ISRCTN72884263].
Jolly K, Lip GY, Sandercock J, Greenfield SM, Raftery JP, Mant J, Taylor R, Lane D, Lee KW, Stevens AJ.
BMC Cardiovasc Disord. 2003 Sep 10;3:10. Epub 2003 Sep 10.
1546. Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure:
relationship to treatment and prognosis.
Chin BS, Conway DS, Chung NA, Blann AD, Gibbs CR, Lip GY.
Blood Coagul Fibrinolysis. 2003 Sep;14(6):515-21.
1547. Effects of C-reactive protein on the release of von Willebrand factor, E-selectin,
thrombomodulin and intercellular adhesion molecule-1 from human umbilical vein endothelial cells.
Blann AD, Lip GY.
Blood Coagul Fibrinolysis. 2003 Jun;14(4):335-40.
154
1548. Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA): a randomised
controlled trial of warfarin versus aspirin for stroke prevention in the management of atrial
fibrillation in an elderly primary care population [ISRCTN89345269].
Mant JW, Richards SH, Hobbs FD, Fitzmaurice D, Lip GY, Murray E, Banting M, Fletcher K, Rahman J,
Allan T, Raftery J, Bryan S; Midlands Research Consortium of General Practice.
BMC Cardiovasc Disord. 2003 Aug 26;3:9. Epub 2003 Aug 26.
1549. Homocysteine and the risk of stroke and thromboembolism in atrial fibrillation: an uncertain
role.
Nadar S, Lip GY.
Stroke. 2003 Sep;34(9):e143; author reply e143-5. Epub 2003 Aug 21. No abstract available.
1550. Platelet activation, haemorheology and thrombogenesis in acute atrial fibrillation: a
comparison with permanent atrial fibrillation.
Kamath S, Blann AD, Chin BS, Lip GY.
Heart. 2003 Sep;89(9):1093-5. No abstract available.
1551. Heart failure in a multiethnic population in Kuala Lumpur, Malaysia.
Chong AY, Rajaratnam R, Hussein NR, Lip GY.
Eur J Heart Fail. 2003 Aug;5(4):569-74.
1552. Psychological interventions for depression in adolescent and adult congenital heart disease.
Lip GY, Lane DA, Millane TA, Tayebjee MH.
Cochrane Database Syst Rev. 2003;(3):CD004394. Review.
1553. Relation of thrombogenesis in systemic hypertension to angiogenesis and endothelial
damage/dysfunction (a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]).
Felmeden DC, Spencer CG, Chung NA, Belgore FM, Blann AD, Beevers DG, Lip GY.
Am J Cardiol. 2003 Aug 15;92(4):400-5.
1554. The role of omega-3 fatty acids in the secondary prevention of cardiovascular disease.
Lee KW, Lip GY.
QJM. 2003 Jul;96(7):465-80. Review.
1555. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation.
Roldán V, Marín F, Blann AD, García A, Marco P, Sogorb F, Lip GY.
Eur Heart J. 2003 Jul;24(14):1373-80.
1556. The prothrombotic state in hypertension and the effects of antihypertensive treatment.
Nadar S, Lip GY.
Curr Pharm Des. 2003;9(21):1715-32. Review.
1557. Hypertension to heart failure: new developmental strategies do not cross a clinical and
therapeutic divide.
MacFadyen RJ, Lip GY, Davis R.
Curr Pharm Des. 2003;9(21):1665-78. Review.
1558. Homocysteine is unlikely to be associated with the risk of thromboembolic complications in
atrial fibrillation.
Nadar S, Blann A, Lip GY.
155
Blood Coagul Fibrinolysis. 2003 Jul;14(5):513-4. No abstract available.
1559. A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial
cell function in health and in hypertension: relationship to cardiovascular risk and effects of
treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.
Felmeden DC, Blann AD, Spencer CG, Beevers DG, Lip GY.
Blood Coagul Fibrinolysis. 2003 Jul;14(5):425-31.
1560. Fibrin D-dimer levels in atrial fibrillation as an index of thrombogenesis: a possible test to
exclude left atrial thrombus?
Tayebjee MH, Lip GY.
Am J Cardiol. 2003 Jul 1;92(1):47-9. No abstract available.
1561. Neither carvedilol nor bisoprolol in maximally tolerated doses has any specific advantage in
lowering chronic heart failure oxidant stress: implications for beta-blocker selection.
Chin BS, Gibbs CR, Blann AD, Lip GY.
Clin Sci (Lond). 2003 Oct;105(4):507-12.
1562. Fibrinolytic function and atrial fibrillation.
Marín F, Roldán V, Lip GY.
Thromb Res. 2003 Mar 15;109(5-6):233-40. Review.
1563. Salt-loading and nitric oxide inhibition after the menopause.
Tayebjee MH, Lee KW, Lip GY.
J Hypertens. 2003 Jul;21(7):1255-7. Review. No abstract available.
1564. Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery
disease: development and application of an immunoassay.
Chung NA, Makin AJ, Lip GY.
Eur J Clin Invest. 2003 Jul;33(7):529-35.
1565. Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of
endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation.
Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY.
Circulation. 2003 Jul 1;107(25):3141-5. Epub 2003 Jun 9.
1566. Post-stroke inflammatory response: effects of stroke evolution and outcome.
Tan KT, Lip GY, Blann AD.
Curr Atheroscler Rep. 2003 Jul;5(4):245-51. Review.
1567. Pharmacological modulation of platelet function in hypertension.
Blann AD, Nadar S, Lip GY.
Hypertension. 2003 Jul;42(1):1-7. Epub 2003 Jun 2. Review.
1568. Is low-molecular-weight heparin safer than warfarin for secondary prevention of venous
thromboembolism in cancer patients?
Caine GJ, Lip GY.
Arch Intern Med. 2003 May 26;163(10):1243-4; author reply 1244. No abstract available.
1569. Hypertension and the prothrombotic state.
Nadar S, Lip GY.
156
J Am Coll Cardiol. 2003 May 21;41(10):1847; author reply 1847. No abstract available.
1570. Ethnicity and arrhythmias.
Freestone B, Lip GY.
Card Electrophysiol Rev. 2003 Jan;7(1):92-5. Review.
1571. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT):
ALL predictable, and no big surprise out of a HAT?
Beevers DG, Lee KW, Lip GY.
J Hum Hypertens. 2003 Jun;17(6):367-72. No abstract available.
1572. Alterations of thrombogenesis, endothelial damage and oxidative stress with reperfusion
during femoral artery bypass surgery for peripheral vascular disease.
Makin AJ, Chung NA, Silverman SH, Lip GY.
Pathophysiol Haemost Thromb. 2002 Jul-Aug;32(4):158-64.
1573. Insulin resistance and vascular remodelling, in relation to left ventricular mass, geometry and
function: an answer to LIFE?
Lee KW, Lip GY.
J Hum Hypertens. 2003 May;17(5):299-304. No abstract available.
1574. Validity of D-dimer tests for pulmonary embolism: better to diagnose or exclude?
Caine GJ, Lip GY.
Ann Emerg Med. 2003 May;41(5):756; author reply 756-7. No abstract available.
1575. Intravenous water-soluble amiodarone improved 24-hour survival in incessant ventricular
tachycardia.
Hamaad A, Lip GY.
ACP J Club. 2003 May-Jun;138(3):62. No abstract available.
1576. Implications of the LIFE trial.
Nadar S, Lim HS, Lip GY.
Expert Opin Investig Drugs. 2003 May;12(5):871-7. Review.
1577. The METHRO trials.
Hamaad A, Tayebjee MH, Lip GY.
Expert Opin Investig Drugs. 2003 May;12(5):865-70. Review.
1578. Factor X inhibitors.
Tan KT, Makin A, Lip GY.
Expert Opin Investig Drugs. 2003 May;12(5):799-804. Review.
1579. Casebook: dyspnoea.
Lim HS, Lip GY.
Practitioner. 2003 Apr;247(1645):267, 270-3, 275-7. Review. No abstract available.
1580. Patient perceptions of hypertension and its treatment.
Svensson S, Lip GY.
Blood Press. 2003;12(1):5-6. No abstract available.
1581. Patients' understanding of anticoagulant therapy in a multiethnic population.
157
Nadar S, Begum N, Kaur B, Sandhu S, Lip GY.
J R Soc Med. 2003 Apr;96(4):175-9.
1582. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor,
TIMP-1?
Marín F, Roldán V, Climent V, Garcia A, Marco P, Lip GY.
Stroke. 2003 May;34(5):1181-6. Epub 2003 Mar 27.
1583. Angiogenesis: basic pathophysiology and implications for disease.
Felmeden DC, Blann AD, Lip GY.
Eur Heart J. 2003 Apr;24(7):586-603. Review. No abstract available.
1584. Vascular endothelial growth factor and tissue factor in patients with established peripheral
artery disease: a link between angiogenesis and thrombogenesis?
Makin AJ, Chung NA, Silverman SH, Lip GY.
Clin Sci (Lond). 2003 Apr;104(4):397-404.
1585. Assessment of endothelial damage and dysfunction: observations in relation to heart failure.
Chong AY, Blann AD, Lip GY.
QJM. 2003 Apr;96(4):253-67. Review. No abstract available.
1586. Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in
congestive heart failure.
Chin BS, Langford NJ, Nuttall SL, Gibbs CR, Blann AD, Lip GY.
Eur J Heart Fail. 2003 Mar;5(2):171-4.
1587. A case of breathlessness.
Lim HS, Lip GY.
Practitioner. 2003 Mar;247(1644):199-200, 204-7. Review. No abstract available.
1588. Anticoagulation uptake in emergency department patients with atrial fibrillation.
Freestone B, Lip GY.
Stroke. 2003 Mar;34(3):591; author reply 591. Epub 2003 Feb 20. No abstract available.
1589. Low-density lipoprotein subfractions and cardiovascular risk in hypertension: relationship to
endothelial dysfunction and effects of treatment.
Felmeden DC, Spencer CG, Blann AD, Beevers DG, Lip GY.
Hypertension. 2003 Mar;41(3):528-33. Epub 2003 Feb 24.
1590. Brachial plexus injury as an unusual complication of coronary artery bypass graft surgery.
Chong AY, Clarke CE, Dimitri WR, Lip GY.
Postgrad Med J. 2003 Feb;79(928):84-6. Review.
1591. Physical activity in relation to indices of endothelial function and angiogenesis factors in
hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Felmeden DC, Spencer CG, Blann AD, Beevers DG, Lip GY.
J Intern Med. 2003 Jan;253(1):81-91.
1592. Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study.
Conway DS, Heeringa J, Van Der Kuip DA, Chin BS, Hofman A, Witteman JC, Lip GY.
Stroke. 2003 Feb;34(2):413-7.
158
1593. Hypertension, platelets, and the endothelium: the "thrombotic paradox" of hypertension (or
"Birmingham paradox") revisited.
Lip GY.
Hypertension. 2003 Feb;41(2):199-200. No abstract available.
1594. Alcohol and cardiovascular disease--more than one paradox to consider. Alcohol and
hypertension--does it matter? (no!).
Lip GY, Beevers DG.
J Cardiovasc Risk. 2003 Feb;10(1):11-4. Review.
1595. D-dimer tests for assessment of patients with suspected pulmonary embolism.
Caine GJ, Lip GY.
Arch Intern Med. 2003 Jan 27;163(2):243. No abstract available.
1596. In-hospital symptoms of depression do not predict mortality 3 years after myocardial
infarction.
Lane D, Carroll D, Ring C, Beevers DG, Lip GY.
Int J Epidemiol. 2002 Dec;31(6):1179-82.
1597. Anticoagulation in hospitals and general practice.
Blann AD, Fitzmaurice DA, Lip GY.
BMJ. 2003 Jan 18;326(7381):153-6. Review. No abstract available.
1598. Tamoxifen for breast-cancer prevention.
Caine GJ, Blann AD, Stonelake PS, Kehoe ST, Lip GY.
Lancet. 2003 Jan 11;361(9352):177-8; author reply 178. No abstract available.
1599. Lipid lowering in hypertension and heart protection: observations from the Anglo-Scandinavian
Cardiac Outcomes Trial (ASCOT) and the Heart Protection Study.
Nadar S, Lim HS, Beevers DG, Lip GY.
J Hum Hypertens. 2002 Dec;16(12):815-7. No abstract available.
1600. ABC of antithrombotic therapy: Antithrombotic therapy in special circumstances. II-In children,
thrombophilia, and miscellaneous conditions.
Jilma B, Kamath S, Lip GY.
BMJ. 2003 Jan 11;326(7380):93-6. Review. No abstract available.
1601. Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular
risk factors and risk factor management.
Felmeden DC, Spencer CG, Belgore FM, Blann AD, Beevers DG, Lip GY.
Am J Hypertens. 2003 Jan;16(1):11-20.
1602. Antithrombotic therapy in special circumstances. I--pregnancy and cancer.
Jilma B, Kamath S, Lip GY.
BMJ. 2003 Jan 4;326(7379):37-40. Review. No abstract available.
1603. Antithrombotic strategies in acute coronary syndromes and percutaneous coronary
interventions.
Connolly DL, Lip GY, Chin BS.
BMJ. 2002 Dec 14;325(7377):1404-7. Review. No abstract available.
159
1604. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic
paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT]
Study).
Meinertz T, Lip GY, Lombardi F, Sadowski ZP, Kalsch B, Camez A, Hewkin A, Eberle S; ERAFT
Investigators.
Am J Cardiol. 2002 Dec 15;90(12):1300-6.
1605. Dietary prevention of carcinogenesis in smokers.
Caine GJ, Lip GY.
J Intern Med. 2002 Dec;252(6):577-8. No abstract available.
1606. Ethnicity and peripheral vascular disease.
Makin AJ, Silverman SH, Lip GY.
Int J Clin Pract. 2002 Nov;56(9):645-8.
1607. Antithrombotic therapy in acute coronary syndromes.
Watson RD, Chin BS, Lip GY.
BMJ. 2002 Dec 7;325(7376):1348-51. Review. No abstract available.
1608. ABC of antithrombotic therapy: Antithrombotic therapy in myocardial infarction and stable
angina.
Lip GY, Chin BS, Prasad N.
BMJ. 2002 Nov 30;325(7375):1287-9. Review. No abstract available.
1609. Vascular endothelial growth factor and soluble P-selectin in acute and chronic congestive heart
failure.
Chin BS, Chung NA, Gibbs CR, Blann AD, Lip GY.
Am J Cardiol. 2002 Dec 1;90(11):1258-60. No abstract available.
.
1610. Valvar heart disease and prosthetic heart valves.
Goldsmith I, Turpie AG, Lip GY.
BMJ. 2002 Nov 23;325(7374):1228-31. Review. No abstract available.
1611. The role of aspirin in carcinogenesis.
Caine GJ, Kehoe ST, Lip GY.
Br J Cancer. 2002 Nov 18;87(11):1337-8. No abstract available.
1612. Acute ingestion of red wine by men activates platelets but does not influence endothelial
markers: no effect of white wine.
Blann AD, Williams NR, Lip GY, Rajput-Williams J, Howard AN.
Blood Coagul Fibrinolysis. 2002 Oct;13(7):647-51.
1613.A study of platelet activation in paroxysmal, persistent and permanent atrial fibrillation.
Kamath S, Chin BS, Blann AD, Lip GY.
Blood Coagul Fibrinolysis. 2002 Oct;13(7):627-36.
1614. Ongoing trials involving angiotensin-converting enzyme inhibitors.
Nadar S, Lip GY.
Expert Opin Investig Drugs. 2002 Nov;11(11):1633-43. Review.
160
1615. ABC of antithrombotic therapy: Antithrombotic therapy for cerebrovascular disorders.
Lip GY, Kamath S, Hart RG.
BMJ. 2002 Nov 16;325(7373):1161-3. Review. No abstract available.
1616. Ethnic differences in peripheral vascular disease.
Makin A, Silverman S, Lip GY.
Int J Clin Pract. 2002 Oct;56(8):605-8. Review.
1617. Antithrombotic therapy in peripheral vascular disease.
Makin AJ, Silverman SH, Lip GY.
BMJ. 2002 Nov 9;325(7372):1101-4. Review. No abstract available.
1618. Secular trends in cardiovascular disease.
Nadar S, Lip GY.
J Hum Hypertens. 2002 Oct;16(10):663-6. No abstract available.
1619. A study of platelet activation in atrial fibrillation and the effects of antithrombotic therapy.
Kamath S, Blann AD, Chin BS, Lanza F, Aleil B, Cazenave JP, Lip GY.
Eur Heart J. 2002 Nov;23(22):1788-95.
1620. Atrial fibrillation in the elderly: anticoagulation strategies and indications in the very elderly.
Kamath S, Lip GY.
Am J Geriatr Cardiol. 2002 Nov-Dec;11(6):357-62; quiz 363-4. Review.
1621. Changes in von Willebrand factor and soluble ICAM, but not soluble VCAM, soluble E selectin
or soluble thrombomodulin, reflect the natural history of the progression of atherosclerosis.
Blann AD, Lip GY, McCollum CN.
Atherosclerosis. 2002 Dec;165(2):389-91. No abstract available.
1622. Antithrombotic therapy for atrial fibrillation.
Lip GY, Hart RG, Conway DS.
BMJ. 2002 Nov 2;325(7371):1022-5. Review. No abstract available.
1623. The hypercoagulable state of malignancy: pathogenesis and current debate.
Caine GJ, Stonelake PS, Lip GY, Kehoe ST.
Neoplasia. 2002 Nov-Dec;4(6):465-73. Review.
1624. ABC of antithrombotic therapy: Venous thromboembolism: treatment strategies.
Turpie AG, Chin BS, Lip GY.
BMJ. 2002 Oct 26;325(7370):948-50. Review. No abstract available. Erratum in: BMJ. 2003 Jun
21;326(7403):1362. BMJ. 2003 Jan 18;326(7381):156.
1625. Airborne occupational exposure and ABO phenotype: an example of gene-environment
interaction in ischaemic heart disease?
Lee KW, Lip GY.
J Cardiovasc Risk. 2002 Aug;9(4):179-82. No abstract available.
1626. Plasma vascular endothelial growth factor, soluble VEGF receptor FLT-1, and von Willebrand
factor in glaucoma.
Lip PL, Felmeden DC, Blann AD, Matheou N, Thakur S, Cunliffe IA, Lip GY.
161
Br J Ophthalmol. 2002 Nov;86(11):1299-302.
1627. Venous thromboembolism: pathophysiology, clinical features, and prevention.
Turpie AG, Chin BS, Lip GY.
BMJ. 2002 Oct 19;325(7369):887-90. Review. No abstract available.
1628. Hypertension, left ventricular hypertrophy, and sudden death.
Tin LL, Beevers DG, Lip GY.
Curr Cardiol Rep. 2002 Nov;4(6):449-57. Review.
1629. Bleeding risks of antithrombotic therapy.
Fitzmaurice DA, Blann AD, Lip GY.
BMJ. 2002 Oct 12;325(7368):828-31. Review. No abstract available.
1630 Anticoagulants as anticancer agents?
Caine GJ, Lip GY.
Lancet Oncol. 2002 Oct;3(10):591-2. No abstract available.
1631. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and
platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk
factors.
Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY.
Circulation. 2002 Oct 8;106(15):1962-7.
1632. ABC of antithrombotic therapy: An overview of antithrombotic therapy.
Blann AD, Landray MJ, Lip GY.
BMJ. 2002 Oct 5;325(7367):762-5. Review. No abstract available. Erratum in: BMJ 2002 Nov
23;325(7374):1231.
1633. Angiogenesis in myocardial infarction. An acute or chronic process?
Chung NA, Lydakis C, Belgore F, Blann AD, Lip GY.
Eur Heart J. 2002 Oct;23(20):1604-8.
1634. Do protein Z levels influence the prothrombotic state in atrial fibrillation?
Marco P, Marín F, García A, Roldán V, Lip GY.
Thromb Res. 2002 May 15;106(4-5):269-70. No abstract available.
1635. Is the hypercoagulable state in atrial fibrillation mediated by vascular endothelial growth
factor?
Chung NA, Belgore F, Li-Saw-Hee FL, Conway DS, Blann AD, Lip GY.
Stroke. 2002 Sep;33(9):2187-91.
1636. Inflammation, cell adhesion molecules, and stroke: tools in pathophysiology and
epidemiology?
Blann AD, Ridker PM, Lip GY.
Stroke. 2002 Sep;33(9):2141-3. No abstract available.
1637. Hypertension and renal failure.
Nadar S, Beevers DG, Lip GY.
Clin Med (Lond). 2002 Jul-Aug;2(4):378-9. No abstract available.
162
1638. Influence of the risk factors for atherosclerosis on levels of soluble adhesion molecules and
endothelial markers in peripheral vascular disease.
Blann AD, Lip GY, McCollum CN.
Thromb Haemost. 2002 Aug;88(2):366-7. No abstract available.
1639. Endothelin binding and calcium signalling in hypertension.
Tayebjee M, Lip GY.
J Hypertens. 2002 Sep;20(9):1711-2. No abstract available.
1640. Relationship between plasma markers of endothelial cell integrity and the Framingham
cardiovascular disease risk-factor scores in apparently healthy individuals.
Blann AD, McCollum CN, Lip GY.
Blood Coagul Fibrinolysis. 2002 Sep;13(6):513-8.
1641. Tackling malignant hypertension: not so desperate now.
Felmeden DC, Beevers DG, Lip GY.
Am Heart J. 2002 Aug;144(2):E4. No abstract available.
1642. HRT in a general practice population: further observations on the 'healthy cohort' effect.
Lee KW, Freestone B, Harris L, Lip GY.
Int J Clin Pract. 2002 Jul-Aug;56(6):486-7. No abstract available.
1643. Effects of enalapril and losartan on circulating adhesion molecules and monocyte chemotactic
protein-1.
Jilma B, Li-Saw-Hee FL, Wagner OF, Beevers DG, Lip GY.
Clin Sci (Lond). 2002 Aug;103(2):131-6.
1644. A prospective randomized trial of aspirin-clopidogrel combination therapy and dose-adjusted
warfarin on indices of thrombogenesis and platelet activation in atrial fibrillation.
Kamath S, Blann AD, Chin BS, Lip GY.
J Am Coll Cardiol. 2002 Aug 7;40(3):484-90.
1645. A reliable plasma marker of platelet activation: does it exist?
Gurney D, Lip GY, Blann AD.
Am J Hematol. 2002 Jun;70(2):139-44. Review.
1646. Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a
substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Spencer CG, Gurney D, Blann AD, Beevers DG, Lip GY; ASCOT Steering Committee, AngloScandinavian Cardiac Outcomes Trial.
Hypertension. 2002 Jul;40(1):61-6.
1647. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm: a
Cochrane systematic review.
Lip GY, Gibbs CR.
QJM. 2002 Jul;95(7):461-8. Review.
1648. Anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review.
Lip GY, Gibbs CR.
QJM. 2002 Jul;95(7):451-9. Review.
163
1649. Oxidative stress in malignant and non-malignant phase hypertension.
Lip GY, Edmunds E, Nuttall SL, Landray MJ, Blann AD, Beevers DG.
J Hum Hypertens. 2002 May;16(5):333-6.
1650. Losartan and the meaning of LIFE.
Lip GY.
J Hum Hypertens. 2002 May;16(5):289-91. No abstract available.
1651. Cardiomyopathy in practice.
Nadar S, Lip GY.
Practitioner. 2002 Jun;246(1635):416, 420-7. Review. No abstract available.
1652. Quality of life in adults with congenital heart disease.
Lane DA, Lip GY, Millane TA.
Heart. 2002 Jul;88(1):71-5.
1653. Lipid lowering and the assessment of endothelial function.
Lee KW, Felmeden DC, Lip GY.
Cardiovasc Res. 2002 Apr;54(1):191-2; author reply 193-4. No abstract available.
1654. Antiarrhythmics in atrial fibrillation.
Freestone B, Lip GY.
Curr Opin Investig Drugs. 2002 Jan;3(1):84-8. Review.
1655. A case of resistant hypertension in a 69-year-old man.
Chin BS, Chong AY, Lip GY.
J Hum Hypertens. 2002 Jun;16(6):445-7.
1656. Sequential alterations in haemorheology, endothelial dysfunction, platelet activation and
thrombogenesis in relation to prognosis following acute stroke: The West Birmingham Stroke Project.
Lip GY, Blann AD, Farooqi IS, Zarifis J, Sagar G, Beevers DG.
Blood Coagul Fibrinolysis. 2002 Jun;13(4):339-47.
1657. 'You cannot be serious!' compliance and antihypertensive regimens.
Langman CM, Lyons AC, Lip GY.
Int J Clin Pract. 2002 Apr;56(3):164-6. Review. No abstract available.
1658. Baseline abnormalities of endothelial function and thrombogenesis in relation to prognosis in
essential hypertension.
Lip GY, Blann AD, Edmunds E, Beevers DG.
Blood Coagul Fibrinolysis. 2002 Jan;13(1):35-41.
1659. Platelet P-selectin levels in relation to plasma soluble P-selectin and beta-thromboglobulin
levels in atrial fibrillation.
Kamath S, Blann AD, Caine GJ, Gurney D, Chin BS, Lip GY.
Stroke. 2002 May;33(5):1237-42.
1660. Prevalence and risk factors of silent brain infarcts in the population.
Freestone B, Lip GY.
Stroke. 2002 May;33(5):1179-80; author reply 1179-80. No abstract available.
164
1661. Statins and the assessment of endothelial function.
Lee KW, Felmeden DC, Lip GY.
J Intern Med. 2002 May;251(5):452-3; author reply 453-4. No abstract available.
1662 Ethnic differences in blood pressure and the prevalence of hypertension in England.
Lane D, Beevers DG, Lip GY.
J Hum Hypertens. 2002 Apr;16(4):267-73.
1663. Risk factors for mortality in acute myocardial infarction.
Freestone B, Lip GY.
Lancet. 2002 Apr 6;359(9313):1252. No abstract available.
1664 . Peripheral vascular disease and Virchow's triad for thrombogenesis.
Makin A, Silverman SH, Lip GY.
QJM. 2002 Apr;95(4):199-210. Review. No abstract available.
1665. Cancer and ethnic minorities.
Caine GJ, Beevers DG, Lip GY.
Lancet Oncol. 2002 Jan;3(1):9. No abstract available.
1666. Cancer and the prothrombotic state.
Lip GY, Chin BS, Blann AD.
Lancet Oncol. 2002 Jan;3(1):27-34. Review.
1667. Systolic vs diastolic blood pressure and the burden of hypertension.
Tin LL, Beevers DG, Lip GY.
J Hum Hypertens. 2002 Mar;16(3):147-50. No abstract available.
1668. YM-337. Yamanouchi.
Kamath S, Lip GY.
Curr Opin Investig Drugs. 2001 Aug;2(8):1093-6.
1669. The renin-angiotensin-aldosterone system and fibrinolysis.
Felmeden DC, Lip GY.
J Renin Angiotensin Aldosterone Syst. 2000 Sep;1(3):240-4. Review.
1670. Psychological factors in heart failure: a review of the literature.
MacMahon KM, Lip GY.
Arch Intern Med. 2002 Mar 11;162(5):509-16. Review.
1671. Abnormal low-density lipoprotein subfraction profile in patients with untreated hypertension.
Landray MJ, Edmunds E, Li-Saw-Hee FL, Hughes BA, Beevers DG, Kendall MJ, Lip GY.
QJM. 2002 Mar;95(3):165-71.
1672. Soluble adhesion molecules and coronary heart disease.
Blann AD, Lip GY.
Lancet. 2002 Feb 9;359(9305):525-6; author reply 526-7. No abstract available.
1673. Inverse relationship between plasma von Willebrand factor and soluble P selectin in patients
with type 1 but not type 2 von Willebrand disease.
Blann AD, Nitu-Whalley IC, Lee CA, Lip GY.
165
Am J Hematol. 2002 Feb;69(2):135-7.
1674. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with
coronary or peripheral atherosclerosis, or Type II diabetes.
Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY.
Clin Sci (Lond). 2002 Feb;102(2):187-94.
1675. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the
West Birmingham Atrial Fibrillation Project.
Lip GY, Kamath S, Jafri M, Mohammed A, Bareford D.
Stroke. 2002 Jan;33(1):238-42.
1676. The protective effect of blocking angiotensin in both type I and type II diabetics with
nephropathy.
Beevers DG, Lip GY.
J Hum Hypertens. 2001 Dec;15(12):837-9. Review. No abstract available.
1677. ACE inhibitors in vascular disease: some PROGRESS, more HOPE.
Lip GY, Beevers DG.
J Hum Hypertens. 2001 Dec;15(12):833-5. Review. No abstract available.
1678. New pharmacological strategies for the treatment of heart failure.
Chin BS, Lip GY.
Curr Opin Investig Drugs. 2001 Jul;2(7):923-8. Review.
1679. Paroxysmal atrial fibrillation.
Lip GY, Hee FL.
QJM. 2001 Dec;94(12):665-78. Review.
1680. Increased von Willebrand factor in the endocardium as a local predisposing factor for
thrombogenesis in overloaded human atrial appendage.
Lip GY, Conway DS.
J Am Coll Cardiol. 2001 Dec;38(7):2133-5. No abstract available.
1681. Platelets and atrial fibrillation.
Kamath S, Blann AD, Lip GY.
Eur Heart J. 2001 Dec;22(24):2233-42. Review. No abstract available.
1682. Effects of acute exercise on hemorheological, endothelial, and platelet markers in patients with
chronic heart failure in sinus rhythm.
Gibbs CR, Blann AD, Edmunds E, Watson RD, Lip GY.
Clin Cardiol. 2001 Nov;24(11):724-9.
1683. Managing atrial fibrillation in the Accident and Emergency department.
Williams E, Ansari M, Lip GY.
QJM. 2001 Nov;94(11):609-14.
1684. Blood pressure in different ethnic groups.
Lane D, Lip GY.
Am J Cardiol. 2001 Nov 15;88(10):1218-9. No abstract available.
166
.
1685. Calcium antagonists in diabetic hypertension.
Felmeden DC, Lip GY, Beevers G.
Diabetes Obes Metab. 2001 Oct;3(5):311-8. Review. No abstract available.
1686. The impact of coronary heart disease in determining use of hormone replacement therapy in a
general practice population.
Chin BS, Futaba K, Jethwa A, Lip GY.
Int J Clin Pract. 2001 Oct;55(8):515-8.
1687. Partial leptin deficiency and human adiposity.
Farooqi IS, Keogh JM, Kamath S, Jones S, Gibson WT, Trussell R, Jebb SA, Lip GY, O'Rahilly S.
Nature. 2001 Nov 1;414(6859):34-5.
1688. Perceptions and behaviour of hypertensive patients: a divine intervention or a case for
Hippocrates?
Langman CM, Lyons AC, Lip GY.
J Hum Hypertens. 2001 Nov;15(11):751-4. No abstract available.
1689. Anticoagulation for heart failure in sinus rhythm.
Lip GY, Gibbs CR.
Cochrane Database Syst Rev. 2001;(4):CD003336. Review. Update in: Cochrane Database Syst Rev.
2012;6:CD003336.
1690. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm.
Lip GY, Gibbs CR.
Cochrane Database Syst Rev. 2001;(4):CD003333. Review.
1691. Haemorheological, endothelial and platelet function in subjects with hypertension:
relationship to cardiovascular risk and influence of antihypertensive treatment.
Spencer CG, Beevers DG, Lip GY; Anglo-Scandinavian Cardiac Outcomes Trial.
J Hum Hypertens. 2001 Aug;15 Suppl 1:S39-42. No abstract available.
1692. Alcohol and the heart.
Lip GY.
Practitioner. 2001 Oct;245(1627):808-10, 812, 814 passim. Review. No abstract available.
1693. Arrhythmias in adults following repair of tetralogy of Fallot.
Lip GY, Singh SP.
Am J Cardiol. 2001 Oct 15;88(8):936. No abstract available.
1694. Antihypertensive therapy and cancer risk.
Felmeden DC, Lip GY.
Drug Saf. 2001;24(10):727-39. Review.
1695. A prospective study of changes in the quality of life of patients following mitral valve repair and
replacement.
Goldsmith IR, Lip GY, Patel RL.
Eur J Cardiothorac Surg. 2001 Nov;20(5):949-55.
1696. Predictors of attendance at cardiac rehabilitation after myocardial infarction.
167
Lane D, Carroll D, Ring C, Beevers DG, Lip GY.
J Psychosom Res. 2001 Sep;51(3):497-501.
1697. Increased platelet glycoprotein V levels in patients with coronary and peripheral
atherosclerosis--the influence of aspirin and cigarette smoking.
Blann AD, Lanza F, Galajda P, Gurney D, Moog S, Cazenave JP, Lip GY.
Thromb Haemost. 2001 Sep;86(3):777-83.
1698 Regression of left ventricular hypertrophy and improved prognosis: some hope now . . . or
hype?
Lip GY.
Circulation. 2001 Oct 2;104(14):1582-4. No abstract available.
1699. New antiarrhythmic agents for atrial fibrillation.
Conway DS, Lip GY.
Curr Opin Investig Drugs. 2001 Jan;2(1):87-92. Review. No abstract available.
1700. Systemic thromboembolism in atrial fibrillation.
Makin AJ, Conway DS, Lip GY.
Arch Intern Med. 2001 Aug 13-27;161(15):1920-4. No abstract available.
1701. Left internal mammary graft stenosis and restenosis following angioplasty and stenting.
Spencer CG, Lip GY.
Heart. 2001 Sep;86(3):E9.
1702. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent
and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function.
Li-Saw-Hee FL, Blann AD, Gurney D, Lip GY.
Eur Heart J. 2001 Sep;22(18):1741-7.
1703. The prevalence of pre-eclampsia and obstetric outcome in pregnancies of normotensive and
hypertensive women attending a hospital specialist clinic.
Lydakis C, Beevers M, Beevers DG, Lip GY.
Int J Clin Pract. 2001 Jul-Aug;55(6):361-7.
1704. A cross-sectional, diurnal, and follow-up study of platelet activation and endothelial
dysfunction in malignant phase hypertension.
Lip GY, Edmunds E, Hee FL, Blann AD, Beevers DG.
Am J Hypertens. 2001 Aug;14(8 Pt 1):823-8.
1705. Long term anticoagulation or antiplatelet treatment. Inclusion criteria determine results of
review.
Mant J, Fitzmaurice D, Murray E, Lip GY, Hobbs FD.
BMJ. 2001 Jul 28;323(7306):233-4; author reply 235-6. No abstract available.
1706. Platelet activation: assessment and quantification.
Kamath S, Blann AD, Lip GY.
Eur Heart J. 2001 Sep;22(17):1561-71. Review. No abstract available.
1707. Secondary prevention of cardiovascular disease and diabetes: still suboptimal in patients with
myocardial infarction.
168
Chin BS, Kharim S, Ghaffar A, Rehman A, Lip GY.
J Intern Med. 2001 Aug;250(2):180-2. No abstract available.
1708. Atrial fibrillation and stroke: more concepts and controversies.
Conway D, Lip GY.
Stroke. 2001 Aug;32(8):1931-8. No abstract available.
1709. Altered cardiac function.
Makin A, Chin BS, Lip GY.
J R Coll Surg Edinb. 2001 Jun;46(3):190-1. No abstract available.
1710. Further pathophysiological insights into age related macular degeneration.
Lip PL, Lip GY.
Br J Ophthalmol. 2001 Aug;85(8):1013. No abstract available.
1711. A pilot study of homocyst(e)ine levels in essential hypertension: relationship to von Willebrand
factor, an index of endothelial damage.
Lip GY, Edmunds E, Martin SC, Jones AF, Blann AD, Beevers DG.
Am J Hypertens. 2001 Jul;14(7 Pt 1):627-31.
1712. Anticoagulation and atrial fibrillation.
Conway DS, Lip GY.
Postgrad Med J. 2001 Jul;77(909):487; author reply 488. No abstract available.
1713. Peripheral vascular disease and hypertension: a forgotten association?
Makin A, Lip GY, Silverman S, Beevers DG.
J Hum Hypertens. 2001 Jul;15(7):447-54. Review.
1714. Right atrial function in hypertension.
Chung NA, Lip GY.
J Hum Hypertens. 2001 Jul;15(7):439-41. No abstract available.
1715. Abnormal haemorheology, endothelial function and thrombogenesis in relation to
hypertension in acute (ictus < 12 h) stroke patients: the West Birmingham Stroke Project.
Lip GY, Blann AD, Farooqi IS, Zarifis J, Sagar G, Beevers DG.
Blood Coagul Fibrinolysis. 2001 Jun;12(4):307-15.
1716. Unstable angina following acute MI in a patient with bilateral coronary artery fistulae: an
unusual presentation of coronary steal?
Chin B, Spencer CG, Lip GY.
Int J Clin Pract. 2001 Jun;55(5):342-3.
1717. The measurement of blood pressure and the detection of hypertension in children and
adolescents.
Lip GY, Beevers M, Beevers DG, Dillon MJ.
J Hum Hypertens. 2001 Jun;15(6):419-23.
1718. Ethnic differences in hypertension and blood pressure control in the UK.
Lane DA, Lip GY.
QJM. 2001 Jul;94(7):391-6. Review. No abstract available.
169
1719. Thromboprophylaxis for atrial flutter.
Lip GY, Kamath S.
Eur Heart J. 2001 Jun;22(12):984-7. No abstract available.
1720. Plasma levels of vascular endothelial growth factor (VEGF) and its receptor, Flt-1, in
haematological cancers: a comparison with breast cancer.
Belgore FM, Lip GY, Bareford D, Wadley M, Stonelake P, Blann AD.
Am J Hematol. 2001 Jan;66(1):59-61.
1721. Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory
markers in subjects with peripheral artery disease.
Blann AD, Gurney D, Hughes E, Buggins P, Silverman SH, Lip GY.
Am J Cardiol. 2001 Jul 1;88(1):A7-8, 89-92. No abstract available.
1722. Helicobacter pylori as the cause of coronary artery restenosis following angioplasty--is the way
to a man's heart disease through his stomach?
Conway DS, Lip GY.
Dig Liver Dis. 2001 Apr;33(3):214-6. Review. No abstract available.
1723. Atrial fibrillation and abnormalities of hemostatic factors.
Lip GY, Blann AD.
Am J Cardiol. 2001 May 1;87(9):1136-7. No abstract available.
1724. Dyslipidaemia in patients with malignant-phase hypertension.
Edmunds E, Landray MJ, Li-Saw-Hee FL, Hughes BA, Beevers DG, Lip GY.
QJM. 2001 Jun;94(6):327-32.
1725. Diurnal variation in stroke onset in atrial fibrillation.
Lip GY, Tan EK, Lau CK, Kamath S.
Stroke. 2001 Jun;32(6):1443-8. No abstract available.
1726. Angiotensin-II-receptor inhibitors in pregnancy.
Chung NA, Lip GY, Beevers M, Beevers DG.
Lancet. 2001 May 19;357(9268):1620-1. No abstract available.
1727. A prospective study of changes in patients' quality of life after aortic valve replacement.
Goldsmith IR, Lip GY, Patel RL.
J Heart Valve Dis. 2001 May;10(3):346-53.
1728. Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in
essential hypertension: a pilot prospective randomised double-blind parallel group trial.
Li-Saw-Hee FL, Beevers DG, Lip GY.
Int J Cardiol. 2001 May;78(3):241-6.
1729. Case book: palpitations.
Conway D, Lip GY.
Practitioner. 2001 May;245(1622):393-6, 398, 401. Review. No abstract available.
.
1730. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia
and atherosclerosis and the effects of fluvastatin or fenofibrate.
170
Blann AD, Belgore FM, Constans J, Conri C, Lip GY.
Am J Cardiol. 2001 May 15;87(10):1160-3.
1731. Resistant hypertension and the Birmingham Hypertension Square.
Felmeden DC, Lip GY.
Curr Hypertens Rep. 2001 Jun;3(3):203-8. Review.
1732. ABC of hypertension: Blood pressure measurement. Part IV-automated sphygmomanometry:
self blood pressure measurement.
O'Brien E, Beevers G, Lip GY.
BMJ. 2001 May 12;322(7295):1167-70. Review. No abstract available.
1733. Effect of acute exercise on the raised plasma fibrinogen, soluble P-selectin and von Willebrand
factor levels in chronic atrial fibrillation.
Li-Saw-Hee FL, Blann AD, Edmunds E, Gibbs CR, Lip GY.
Clin Cardiol. 2001 May;24(5):409-14.
1734. Targeting patients with atrial fibrillation and improving their anticoagulation management.
Kamath S, Lip GY.
Clin Cardiol. 2001 May;24(5):355-7. No abstract available.
1735. ABC of hypertension. Blood pressure measurement. Part III-automated sphygmomanometry:
ambulatory blood pressure measurement.
O'Brien E, Beevers G, Lip GY.
BMJ. 2001 May 5;322(7294):1110-4. Review. No abstract available.
1736. Renal cell carcinoma and malignant phase hypertension.
Wong PS, Lip GY, Gearty JC, Arkell DG, Howie AJ, Ferreira MA, Beevers DG.
Blood Press. 2001;10(1):16-21.
1737. ABC of hypertension: Blood pressure measurement. Part II-conventional sphygmomanometry:
technique of auscultatory blood pressure measurement.
Beevers G, Lip GY, O'Brien E.
BMJ. 2001 Apr 28;322(7293):1043-7. Review. No abstract available.
1738. Virchow's triad revisited: the importance of soluble coagulation factors, the endothelium, and
platelets.
Blann AD, Lip GY.
Thromb Res. 2001 Feb 15;101(4):321-7. Review. No abstract available.
1739. The ECG and left ventricular hypertrophy in primary care hypertensives.
Conway D, Lip GY.
J Hum Hypertens. 2001 Apr;15(4):215-7. No abstract available.
1740. Blockade of the renin-angiotensin-aldosterone system with combination angiotensin receptor
antagonist and ACE inhibitor therapy: observations from Val-HeFT and CALM.
Chin BS, Lip GY.
J Hum Hypertens. 2001 Feb;15(2):89-92. No abstract available.
1741. Calcium channel blockers in hypertension: the debate reawakens.
Lip GY, Beevers DG.
171
J Hum Hypertens. 2001 Feb;15(2):85-7. No abstract available.
1742. ABC of hypertension. Blood pressure measurement. Part I-sphygmomanometry: factors
common to all techniques.
Beevers G, Lip GY, O'Brien E.
BMJ. 2001 Apr 21;322(7292):981-5. Review. No abstract available.
1743. ABC of hypertension: The pathophysiology of hypertension.
Beevers G, Lip GY, O'Brien E.
BMJ. 2001 Apr 14;322(7291):912-6. Review. No abstract available.
1744. Age-related macular degeneration is associated with increased vascular endothelial growth
factor, hemorheology and endothelial dysfunction.
Lip PL, Blann AD, Hope-Ross M, Gibson JM, Lip GY.
Ophthalmology. 2001 Apr;108(4):705-10.
1745. Measurement of free and complexed soluble vascular endothelial growth factor receptor, Flt1, in fluid samples: development and application of two new immunoassays.
Belgore FM, Blann AD, Lip GY.
Clin Sci (Lond). 2001 May;100(5):567-75.
1746. Effects of balloon mitral valvuloplasty on systemic and regional left atrial levels of prothrombin
fragment 1+2 in mitral stenosis.
Li-Saw-Hee FL, Lip GY.
Clin Sci (Lond). 2001 May;100(5):467-8. No abstract available.
1747. Mortality and quality of life 12 months after myocardial infarction: effects of depression and
anxiety.
Lane D, Carroll D, Ring C, Beevers DG, Lip GY.
Psychosom Med. 2001 Mar-Apr;63(2):221-30.
1748. Should patients with hypertension receive antithrombotic therapy?
Lip GY, Edmunds E, Beevers DG.
J Intern Med. 2001 Mar;249(3):205-14. Review.
1749. Hormone replacement therapy and cardiovascular risk: do abnormalities of coagulation and
fibrinolysis matter?
Lip GY, Felmeden DC.
J Intern Med. 2001 Mar;249(3):201-4. No abstract available.
1750. Abnormalities of hemorheological, endothelial, and platelet function in patients with chronic
heart failure in sinus rhythm: effects of angiotensin-converting enzyme inhibitor and beta-blocker
therapy.
Gibbs CR, Blann AD, Watson RD, Lip GY.
Circulation. 2001 Apr 3;103(13):1746-51.
1751. Soluble P-selectin is influenced by cancer chemotherapy.
Gurney D, Poole C, Kehoe S, Lip GY, Blann AD.
Platelets. 2001 Feb;12(1):37-8. No abstract available.
172
1752. Plasma levels of vascular endothelial growth factor and its soluble receptor (SFlt-1) in essential
hypertension.
Belgore FM, Blann AD, Li-Saw-Hee FL, Beevers DG, Lip GY.
Am J Cardiol. 2001 Mar 15;87(6):805-7, A9.
1753. Cariporide Aventis.
Chin B, Lip GY.
Curr Opin Investig Drugs. 2000 Nov;1(3):340-6. Review.
1754. Cardioversion of atrial fibrillation or flutter: a 'stunning' problem.
Kamath S, Lip GY.
Eur Heart J. 2001 Mar;22(6):520-1. No abstract available.
1755. Increased soluble P-selectin in patients with haematological and breast cancer: a
comparison with fibrinogen, plasminogen activator inhibitor and von Willebrand factor.
Blann AD, Gurney D, Wadley M, Bareford D, Stonelake P, Lip GY.
Blood Coagul Fibrinolysis. 2001 Jan;12(1):43-50.
1756.Do electrophysiological interventions confer a prothrombotic state?
Lip GY, Kamath S.
Pacing Clin Electrophysiol. 2001 Jan;24(1):1-4. No abstract available.
1757. The placebo effect and white coat effect in isolated systolic hypertension and systo-diastolic
hypertension.
Felmeden DC, Lip GY, Beevers M, Beevers DG.
Blood Press. 2000;9(6):335-9.
1758. Myocardial bridging.
Felmeden DC, Lip GY.
Int J Clin Pract. 2000 Oct;54(8):542-3.
1759. Hormone replacement therapy and hypertension.
Felmeden DC, Lip GY.
Blood Press. 2000;9(5):246-9. Review.
PMID:
1760. Atrial fibrillation and stroke in patients admitted to a city centre hospital serving a multiethnic
community.
Lip GY, Zarifis J.
Int J Cardiol. 2000 Sep 15;75(2-3):311-2. No abstract available.
1761. Blood pressure monitoring in atrial fibrillation using electronic devices.
Lip GY, Zarifis J, Beevers DG.
Arch Intern Med. 2001 Jan 22;161(2):294. No abstract available.
1762. Lipoprotein (a) and thrombogenesis in left ventricular dysfunction.
Lip GY.
Eur Heart J. 2001 Jan;22(2):181-2. No abstract available.
1763. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted
warfarin on thrombogenesis in chronic atrial fibrillation.
Li-Saw-Hee FL, Blann AD, Lip GY.
173
Stroke. 2000 Apr;31(4):828-33.
1764. Effect of aortic valve replacement on plasma soluble P-selectin, von Willebrand factor, and
fibrinogen.
Goldsmith IR, Blann AD, Patel RL, Lip GY.
Am J Cardiol. 2001 Jan 1;87(1):107-10, A9.
1765. Diurnal variation and cardiovascular disease.
Kamath S, Yunus F, Ganesalingam R, Lip GY.
Am Heart J. 2001 Jan;141(1):E3. No abstract available.
1766. Thrombogenesis and fibrinolysis in acute coronary syndromes. Important facets of a
prothrombotic or hypercoagulable state?
Lip GY, Blann AD.
J Am Coll Cardiol. 2000 Dec;36(7):2044-6. No abstract available.
1767. Effects of depression and anxiety on mortality and quality-of-life 4 months after myocardial
infarction.
Lane D, Carroll D, Ring C, Beevers DG, Lip GY.
J Psychosom Res. 2000 Oct;49(4):229-38.
1768. Hypertension and the prothrombotic state.
Lip GY.
J Hum Hypertens. 2000 Oct-Nov;14(10-11):687-90. Review.
1769. Anomalous coronary arteries of aortic origin.
Felmeden D, Singh SP, Lip GY.
Int J Clin Pract. 2000 Jul-Aug;54(6):390-4. Review.
1770. Helicobacter pylori seropositivity, lipid concentrations and haemostatic factors.
Lip GY, Blann AD, Beevers DG.
J Intern Med. 2000 Oct;248(4):354-6. No abstract available.
1771. A pilot study of streptokinase-induced endothelial injury and platelet activation following acute
myocardial infarction.
Lip GY, Lydakis C, Nuttall SL, Landray MJ, Watson RD, Blann AD.
J Intern Med. 2000 Oct;248(4):316-8.
1772.Management of pericardial effusion by drainage: a survey of 10 years' experience in a city
centre general hospital serving a multiracial population.
Gibbs CR, Watson RD, Singh SP, Lip GY.
Postgrad Med J. 2000 Dec;76(902):809-13.
1773. Do depression and anxiety predict recurrent coronary events 12 months after myocardial
infarction?
Lane D, Carroll D, Ring C, Beevers DG, Lip GY.
QJM. 2000 Nov;93(11):739-44.
1774. Myocardial infarction complicating hormone replacement therapy in a young woman with
normal coronary arteries.
Steiner MK, Clarkson PB, Lip GY.
174
Int J Clin Pract. 2000 Sep;54(7):475-7.
1775 Atrial endocardial changes in mitral valve disease: a scanning electron microscopy study.
Goldsmith I, Kumar P, Carter P, Blann AD, Patel RL, Lip GY.
Am Heart J. 2000 Nov;140(5):777-84.
1776. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential
hypertension. Relationship to left ventricular mass and anti-hypertensive therapy.
Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GY.
Int J Cardiol. 2000 Aug;75(1):43-7.
1777. Left atrial thrombin generation and prothrombin fragment 1+2.
Blann AD, Lip GY.
Clin Sci (Lond). 2000 Nov;99(5):411-2. No abstract available.
1778. Vascular endothelial growth factor and its receptor, Flt-1, in smokers and non-smokers.
Belgore FM, Lip GY, Blann AD.
Br J Biomed Sci. 2000;57(3):207-13.
1779. Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'?
Lip GY, Felmeden DC, Li-Saw-Hee FL, Beevers DG.
1780. Eur Heart J. 2000 Oct;21(20):1653-65. Review. No abstract available.
sFlt-1, a potential antagonist for exogenous VEGF.
Belgore FM, Blann AD, Lip GY.
Circulation. 2000 Oct 10;102(15):E108-9. No abstract available.
1781. National service framework for coronary heart disease. Many operators and facilities will not
meet standards set out in framework.
Jolly K, rouse A, Lip GY.
BMJ. 2000 Sep 9;321(7261):634-5. No abstract available.
1782. Plasma levels of vascular endothelial growth factor (VEGF) in haematological cancers.
Belgore FM, Lip GY, Bareford D, Blann AD.
Br J Haematol. 2000 Aug;110(2):496-7. No abstract available.
1783. Effect of degree of blood pressure on the hypercoagulable state in chronic atrial fibrillation.
Li-Saw-Hee FL, Blann AD, Lip GY.
Am J Cardiol. 2000 Oct 1;86(7):795-7, A9.
1784. Differences in free and total tissue factor pathway inhibitor, and tissue factor in peripheral
artery disease compared to healthy controls.
Blann AD, Amiral J, McCollum CN, Lip GY.
Atherosclerosis. 2000 Sep;152(1):29-34.
1785. Malnutrition in hospital.
Chin B, Reid M, Alderslade G, Lip GY.
QJM. 2000 Sep;93(9):640-1. No abstract available.
1786. Hormone replacement therapy and intima-media thickness of the common carotid artery: the
Rotterdam study.
175
Edmunds E, Landray M, Lip GY.
Stroke. 2000 Sep;31(9):2273-4. No abstract available.
1787. An independent verdict: does infection with Helicobacter pylori cause ischaemic heart disease?
Edmunds E, Lip GY.
Dig Liver Dis. 2000 Jan-Feb;32(1):69-70. Review. No abstract available.
.
1788. The prothrombotic state in atrial fibrillation: new insights, more questions, and clear answers
needed.
Lip GY.
Am Heart J. 2000 Sep;140(3):348-50. No abstract available.
1789. Managing cardiac arrhythmias. Part II. Management strategies for specific cardiac arrhythmias.
Kamath S, Lip GY.
Practitioner. 2000 Jun;244(1611):568-73. Review. No abstract available.
1790. Managing cardiac arrhythmias. Part I. General principles of investigation and management.
Kamath S, Lip GY.
Practitioner. 2000 Jun;244(1611):559, 560, 563-5. Review. No abstract available.
1791. Do patients with de novo hypertension differ from patients with previously known
hypertension when malignant phase hypertension occurs?
Lip GY, Beevers M, Beevers DG.
Am J Hypertens. 2000 Aug;13(8):934-9.
1792.Successful therapy reduces levels of vascular endothelial growth factor (VEGF) in patients with
hypertension and patients with hypercholesterolemia.
Belgore FM, Lip GY, Blann AD.
Atherosclerosis. 2000 Aug;151(2):599. No abstract available.
1793. Increased platelet activation and endothelial dysfunction in patients with atrial fibrillation
immediately following percutaneous balloon mitral valvuloplasty.
Goldsmith IR, Foo LS, Blann AD, Lip GY.
Clin Cardiol. 2000 Aug;23(8):587-90.
1794. Association between elevated plasma fibrinogen and the small, dense low-density lipoprotein
phenotype among postmenopausal women.
Edmunds E, Landray M, Lip GY.
Am J Cardiol. 2000 Jul 1;86(1):126. No abstract available.
1795. Management of patients with myocardial infarction and hypertension.
Lip GY, Lydakis C, Beevers DG.
Eur Heart J. 2000 Jul;21(14):1125-34. Review. No abstract available.
1796. Reduced indexes of left atrial hypercoagulability in patients with severe mitral regurgitation.
Goldsmith IR, Blann AD, Patel RL, Lip GY.
Am J Cardiol. 2000 Jul 15;86(2):234-6. No abstract available.
1797. Haematocrit and plasma viscosity in atrial fibrillation.
Lip GY, Kamath S, Blann AD.
Int J Cardiol. 2000 Jun 12;74(1):85-8. No abstract available.
176
1798. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to
endothelial dysfunction and laser treatment.
Lip PL, Belgore F, Blann AD, Hope-Ross MW, Gibson JM, Lip GY.
Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2115-9.
1799. Antithrombotic therapy in atrial fibrillation.
Chin B, Lip GY.
J R Soc Med. 2000 May;93(5):278-9. No abstract available.
1800. Cell adhesion molecules in cardiovascular disease and its risk factors--what can soluble levels
tell us?
Blann AD, Lip GY.
J Clin Endocrinol Metab. 2000 May;85(5):1745-7. Review. No abstract available.
1801. A cross-sectional and diurnal study of thrombogenesis among patients with chronic atrial
fibrillation.
Li-Saw-Hee FL, Blann AD, Lip GY.
J Am Coll Cardiol. 2000 Jun;35(7):1926-31.
1802. Haemorheological factors in hypertension.
Spencer CG, Lip GY.
J Hum Hypertens. 2000 May;14(5):291-3. Review. No abstract available.
1803. Do alpha blockers cause heart failure and stroke? Observations from ALLHAT.
Beevers DG, Lip GY.
J Hum Hypertens. 2000 May;14(5):287-9. Review. No abstract available.
1804. von Willebrand factor, fibrinogen, and soluble P-selectin levels after mitral valve replacement
versus mitral valve repair.
Goldsmith IR, Blann AD, Patel RL, Lip GY.
Am J Cardiol. 2000 May 15;85(10):1218-22.
1805. Salt and cardiovascular disease: clinical and epidemiological evidence.
Gibbs CR, Lip GY, Beevers DG.
J Cardiovasc Risk. 2000 Feb;7(1):9-13. Review. No abstract available.
1806. Plasma fibrinogen, soluble P-selectin, and von Willebrand factor in aortic valve disease:
evidence for abnormal haemorheology, platelet activation, and endothelial dysfunction.
Goldsmith IR, Blann AD, Patel RL, Lip GY.
Heart. 2000 May;83(5):577-8. No abstract available.
1807. Takayasu's pulseless disease.
Gibbs CR, Lip GY.
Clin Cardiol. 2000 Apr;23(4):293-4. No abstract available.
1808. Cardiovascular risk in women: the cardiologist's perspective.
Edmunds E, Lip GY.
QJM. 2000 Mar;93(3):135-45. Review. No abstract available.
177
1809. Simplified preparation of human arterial sections for PCR analysis of Chlamydia pneumoniae
and human DNA.
Palfrey D, Cook PJ, Smythe JA, Lip GY, Hine AV.
Mol Pathol. 1999 Oct;52(5):289-94.
1810. Mitral regurgitation and atrial fibrillation: milder the disease, higher the risk?
Kamath S, Lip GY.
Int J Cardiol. 2000 Feb 15;72(3):235-7. No abstract available.
1811. Atrial fibrillation in general practice.
Lip GY.
Practitioner. 1999 Oct;243(1603):746-51. Review. No abstract available.
1812. ABC of heart failure: Heart failure in general practice.
Hobbs FD, Davis RC, Lip GY.
BMJ. 2000 Mar 4;320(7235):626-9. Review. No abstract available.
1813. ABC of heart failure. Management: digoxin and other inotropes, beta blockers, and
antiarrhythmic and antithrombotic treatment.
Gibbs CR, Davies MK, Lip GY.
BMJ. 2000 Feb 19;320(7233):495-8. Review. No abstract available.
1814. Serum urate is associated with baseline renal dysfunction but not survival or deterioration in
renal function in malignant phase hypertension.
Lip GY, Beevers M, Beevers DG.
J Hypertens. 2000 Jan;18(1):97-101.
1815. What has happened to malignant hypertension? A disease no longer vanishing.
Edmunds E, Beevers DG, Lip GY.
J Hum Hypertens. 2000 Mar;14(3):159-61. Review. No abstract available.
1816. Anticoagulation of older patients.
Lip GY, Li-Saw-Hee FL.
Age Ageing. 2000 Jan;29(1):3-4. No abstract available.
.
1817. Lipoprotein(a) in atrial fibrillation.
Lip GY.
Am Heart J. 2000 Mar;139(3):555-6. No abstract available.
1818. ABC of heart failure. Acute and chronic management strategies.
Millane T, Jackson G, Gibbs CR, Lip GY.
BMJ. 2000 Feb 26;320(7234):559-62. Review. No abstract available.
1819. ABC of heart failure. Management: diuretics, ACE inhibitors, and nitrates.
Davies MK, Gibbs CR, Lip GY.
BMJ. 2000 Feb 12;320(7232):428-31. Review. No abstract available.
1820.ABC of heart failure. Non-drug management.
Gibbs CR, Jackson G, Lip GY.
BMJ. 2000 Feb 5;320(7231):366-9. Review. No abstract available.
178
1821. ABC of heart failure.
Davies MK, Gibbs CR, Lip GY.
BMJ. 2000 Jan 29;320(7230):297-300. Review. No abstract available.
1822. Do Indo-Asians have smaller coronary arteries?
Lip GY, Rathore VS, Katira R, Watson RD, Singh SP.
Postgrad Med J. 1999 Aug;75(886):463-6.
1823. Does hypertension confer a prothrombotic state? Virchow's triad revisited.
Lip GY, Blann AD.
Circulation. 2000 Jan 25;101(3):218-20. No abstract available.
1824. ABC of heart failure: aetiology.
Lip GY, Gibbs CR, Beevers DG.
BMJ. 2000 Jan 8;320(7227):104-7. Review. No abstract available.
1825. ABC of heart failure. Clinical features and complications.
Watson RD, Gibbs CR, Lip GY.
BMJ. 2000 Jan 22;320(7229):236-9. Review. No abstract available.
1826. ABC of heart failure. Pathophysiology.
Jackson G, Gibbs CR, Davies MK, Lip GY.
BMJ. 2000 Jan 15;320(7228):167-70. Review. No abstract available.
1827. Target organ damage and the prothrombotic state in hypertension.
Lip GY.
Hypertension. 2000 Dec;36(6):975-7. No abstract available.
1828. Psychology in coronary care.
Lane D, Carroll D, Lip GY.
QJM. 1999 Aug;92(8):425-31. Review.
1829. Reversible anterior ischaemic optic neuropathy in accelerated hypertension.
Lip PL, Lip GY.
Eye (Lond). 1999 Jun;13 ( Pt 3a):391. No abstract available.
1830. Contamination of the surgeon's bare and gloved fingertips in cardiac operations.
Goldsmith I, Lip GY, Khan F, Hutton R, Patel RL.
Int J Clin Pract. 1998 Nov-Dec;52(8):529-32.
1831. ABC of heart failure. History and epidemiology.
Davis RC, Hobbs FD, Lip GY.
BMJ. 2000 Jan 1;320(7226):39-42. Review. No abstract available.
1832.Hospital morbidity and mortality and changes in quality of life following mitral valve surgery in
the elderly.
Goldsmith I, Lip GY, Kaukuntla H, Patel RL.
J Heart Valve Dis. 1999 Nov;8(6):702-7.
1833. Atrial fibrillation and ethnicity.
179
Gibbs CR, Lip GY.
Circulation. 1999 Dec 21;100(25):e153. No abstract available.
1834. White coat hypertension and carotid atherosclerosis.
Landray MJ, Sagar G, Murray S, Beevers M, Beevers DG, Lip GY.
Blood Press. 1999;8(3):134-40.
1835. Angioedema due to ACE inhibitors: increased risk in patients of African origin.
Gibbs CR, Lip GY, Beevers DG.
Br J Clin Pharmacol. 1999 Dec;48(6):861-5.
1836. Recurrent malignant hypertension: a report of two cases and review of the literature.
Spencer CG, Lip GY, Beevers DG.
J Intern Med. 1999 Nov;246(5):513-6. Review.
1837. Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with
stroke among 1531 participants in the stroke prevention in atrial fibrillation III study.
Feinberg WM, Pearce LA, Hart RG, Cushman M, Cornell ES, Lip GY, Bovill EG.
Stroke. 1999 Dec;30(12):2547-53.
1838. Management of pulmonary thrombo-embolism using catheter manipulation: a report of four
cases and review of the literature.
Wong PS, Singh SP, Watson RD, Lip GY.
Postgrad Med J. 1999 Dec;75(890):737-41. Review.
1839. Left ventricular hypertrophy and its regression: the prothrombic state in hypertension may be
involved in its pathophysiology and altered by therapy.
Spencer CG, Lip GY.
Am J Hypertens. 1999 Oct;12(10 Pt 1):1048-9. No abstract available.
1840. Assessment of risk of thromboembolism in atrial fibrillation: which patients should be
anticoagulated?
Lip GY.
Eur Heart J. 1999 Dec;20(23):1757-8. No abstract available.
1841. Percutaneous balloon valvuloplasty for congenital pulmonary valve stenosis in adults.
Lip GY, Singh SP, de Giovanni J.
Clin Cardiol. 1999 Nov;22(11):733-7.
1842. Increased membrane and soluble P-selectin in atrial fibrillation.
Blann AD, Li-Saw-Hee F, Lip GY, Minamino T, Kitakaze M, Sanada S, Asanuma H, Kurotobi T,
Koretsune Y, Fukunami M, Kuzuya T, Hoki N, Hori M.
Circulation. 1999 Oct 26;100(17):e86-7. No abstract available.
1843. Atrial fibrillation and mortality.
Lip GY.
Eur Heart J. 1999 Nov;20(21):1525-7. No abstract available.
1844. Hyperlipidaemia management after primary coronary artery bypass surgery: a survey of
patients and general practitioners.
Goldsmith I, Lip GY, Emsden K, Nugent A, Patel RL.
180
J Cardiovasc Risk. 1999 Aug;6(4):263-7.
1845. Left ventricular hypertrophy in the population.
Edmunds E, Spencer CG, Lip GY.
Eur Heart J. 1999 Oct;20(20):1514-5. No abstract available.
1846. Ethnicity and heart failure.
Gibbs CR, Lip GY.
Eur Heart J. 1999 Oct;20(19):1436-7. No abstract available.
1847. Prothrombotic factors, endothelial function and left ventricular hypertrophy in isolated systolic
hypertension compared with systolic-diastolic hypertension.
Lip GY, Blann AD, Beevers DG.
J Hypertens. 1999 Aug;17(8):1203-7.
1848. Soluble intercelluar adhesion molecule-1, E-selectin, vascular cell adhesion molecule-1 and von
Willebrand factor in stroke.
Blann A, Kumar P, Krupinski J, McCollum C, Beevers DG, Lip GY.
Blood Coagul Fibrinolysis. 1999 Jul;10(5):277-84.
1849. Antihypertensive agents and left ventricular hypertrophy with 'usual' care in the population
setting.
Lip GY.
J Hum Hypertens. 1999 Aug;13(8):497-8. Review. No abstract available.
1850. Changes in renal function with percutaneous transluminal coronary angioplasty.
Lip GY, Rathore VS, Katira R, Singh SP, Watson RD.
Int J Cardiol. 1999 Jul 31;70(2):127-31.
1851. Urinary sodium excretion and blood pressure in chronic psychiatric in-patients.
Lip GY, Douglas M, Gupta A, Beevers DG.
J Hum Hypertens. 1999 Jul;13(7):461-6.
1852 Diuretic therapy for hypertension: a cancer risk?
Lip GY, Ferner RE.
J Hum Hypertens. 1999 Jul;13(7):421-3. Review. No abstract available.
1853. Comparison of primary coronary artery bypass surgery in a British Indo-Asian and white
Caucasian population.
Goldsmith I, Lip GY, Tsang G, Patel RL.
Eur Heart J. 1999 Aug;20(15):1094-100.
1854. The management of hypertensive disease in black patients.
Gibbs CR, Beevers DG, Lip GY.
QJM. 1999 Apr;92(4):187-92. Review.
1855. Atenolol and fetal growth in pregnancies complicated by hypertension.
Lydakis C, Lip GY, Beevers M, Beevers DG.
Am J Hypertens. 1999 Jun;12(6):541-7.
181
1856. Left ventricular hypertrophy and sudden death.
Spencer CG, Lip GY.
J Am Coll Cardiol. 1999 Jun;33(7):2089. No abstract available.
1857. A survey of hospital morbidity, mortality and quality of life following coronary artery bypass
surgery in a UK Indo-Asian population.
Goldsmith IR, Lip GY, Kumar PP, Patel RL.
Int J Clin Pract. 1999 Jan-Feb;53(1):9-14.
1858. Atrial fibrillation, thromboembolism and antithrombotic therapy.
Li-Saw-Hee FL, Lip GY.
Int J Clin Pract. 1999 Mar;53(2):110-7. Review.
1859.Thromboprophylaxis for atrial fibrillation.
Lip GY.
Lancet. 1999 May 8;353(9164):1620-1. No abstract available.
1860. Cell adhesion molecules in cardiovascular disease: what can soluble levels tell us?
Blann AD, Lip GY.
Heart. 1999 Jan;81(1):101-2. No abstract available.
1861.Significance of soluble P-selectin, von Willebrand factor, and other adhesion molecules in
hypercholesterolemia and peripheral artery disease.
Blann AD, Lip GY, Fijnheer R.
Circulation. 1999 May 11;99(18):2478-9. No abstract available.
1862. Indexes of hypercoagulability measured in peripheral blood reflect levels in intracardiac blood
in patients with atrial fibrillation secondary to mitral stenosis.
Li-Saw-Hee FL, Blann AD, Goldsmith I, Lip GY.
Am J Cardiol. 1999 Apr 15;83(8):1206-9.
1863. Does heart failure confer a hypercoagulable state? Virchow's triad revisited.
Lip GY, Gibbs CR.
J Am Coll Cardiol. 1999 Apr;33(5):1424-6. Review.
1864. Evaluation of the Sorin bicarbon bileaflet valve in 488 patients (519 prostheses).
Goldsmith I, Lip GY, Patel RL.
Am J Cardiol. 1999 Apr 1;83(7):1069-74.
1865. Obstetric and neonatal outcome following chronic hypertension in pregnancy among different
ethnic groups.
Lydakis C, Beevers DG, Beevers M, Lip GY.
QJM. 1998 Dec;91(12):837-44.
1866. Thromboprophylaxis for atrial fibrillation.
Lip GY.
Lancet. 1999 Jan 2;353(9146):4-6. No abstract available. Erratum in: Lancet 1999 Jun
5;353(9168):1978.
1867. White coat hypertension: a recognised syndrome with uncertain implications.
Landray MJ, Lip GY.
J Hum Hypertens. 1999 Jan;13(1):5-8. Review. No abstract available.
1868. The 'vasovagal effect' of nitrates: an under-recognised complication of nitrate use.
Lydakis C, Chaudary AY, Lip GY.
182
Int J Clin Pract. 1998 Sep;52(6):418-21. Review.
1869. Why beta-blockers are good for some patients with hypertension: a case study of a
hypertensive patient with adrenergic paroxysmal atrial fibrillation.
Lip GY, Beevers DG.
J Hum Hypertens. 1998 Dec;12(12):867-8. No abstract available.
1870. Beta-blockers in hypertension: to reappraise or to call a halt?
Lip GY.
J Hum Hypertens. 1998 Dec;12(12):799-801. No abstract available.
1871. Raised levels of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in the
plasma of patients with ischaemic heart disease and hyperlipidaemia.
Blann AD, Lip GY.
Atherosclerosis. 1998 Nov;141(1):177-8. No abstract available.
1872. Lack of relationship between left ventricular mass and serum cholesterol in hypertensives.
Lip GY, Edmunds E, Beevers DG.
J Hypertens. 1998 Nov;16(11):1703-4. No abstract available.
1873. Falls in old age: inevitable or preventable?
Li-Saw-Hee FL, Lip GY.
Scott Med J. 1998 Oct;43(5):133-4. No abstract available.
1874. The 'Birmingham Hypertension Square' for the optimum choice of add-in drugs in the
management of resistant hypertension.
Lip GY, Beevers M, Beevers DG.
J Hum Hypertens. 1998 Nov;12(11):761-3. No abstract available.
1875. Antihypertensive therapy before, during, and after stroke.
Mzimba ZS, Beevers DG, Lip GY.
Basic Res Cardiol. 1998;93 Suppl 2:59-62. Review.
1876. Do intraocular angiotensin II levels, plasma prothrombotic factors and endothelial dysfunction
contribute to proliferative diabetic retinopathy?
Lip PL, Jones AF, Price N, Headon M, Beevers DG, Lip GY.
Acta Ophthalmol Scand. 1998 Oct;76(5):533-6.
1877.Is uric acid really an independent cardiovascular risk factor?
Beevers DG, Lip GY.
Lancet. 1998 Nov 7;352(9139):1556. No abstract available.
1878. Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive
men.
Lip GY, Blann AD.
J Hypertens. 1998 Oct;16(10):1557-9. No abstract available.
1879. Coronary spasm in acute myocardial infarction.
Lip GY, Ray KK, Shiu MF.
Heart. 1998 Aug;80(2):197-9.
1880. Antihypertensive drug treatment and fibrinolytic function.
Lip GY, Blann AD.
Am J Hypertens. 1998 Oct;11(10):1266-7. Review. No abstract available.
1881. Anomalous origin of the left coronary artery.
Felmeden D, Lip GY.
Int J Clin Pract. 1998 Jul-Aug;52(5):351.
.
1882. Does hypertension confer a hypercoagulable state?
Lip GY, Li-Saw-Hee FL.
J Hypertens. 1998 Jul;16(7):913-6. Review.
183
1883. Experience with low-dose aspirin as thromboprophylaxis for the Tissuemed porcine aortic
bioprosthesis: a survey of five years' experience.
Goldsmith I, Lip GY, Mukundan S, Rosin MD.
J Heart Valve Dis. 1998 Sep;7(5):574-9.
1884. JNC-VI: a view from the United Kingdom.
Beevers DG, Lip GY.
J Hum Hypertens. 1998 Sep;12(9):649-51. Review. No abstract available.
1885. Aortic coarctation diagnosed after hypertension in pregnancy.
Lip GY, Singh SP, Beevers DG.
Am J Obstet Gynecol. 1998 Sep;179(3 Pt 1):814-5.
1886. Oxidative stress after thrombolysis.
Landray MJ, Nuttall SL, Lydakis C, Martin U, Maxwell SR, Lip GY.
Lancet. 1998 Sep 19;352(9132):960. No abstract available.
1887. Antithrombotics for left-ventricular impairment.
Lip GY, Gibbs CR.
Lancet. 1998 Sep 5;352(9130):817-8. No abstract available.
1888. Association of atherogenic low-density lipoprotein subfractions with carotid atherosclerosis.
Landray MJ, Sagar G, Muskin J, Murray S, Holder RL, Lip GY.
QJM. 1998 May;91(5):345-51.
1889. Microalbuminuria and cardiovascular risk.
Lydakis C, Lip GY.
QJM. 1998 Jun;91(6):381-91. Review.
1890. Ambulatory blood pressure monitoring and stroke: more questions than answers.
Lip GY, Gibbs CR, Beevers DG.
Stroke. 1998 Aug;29(8):1495-7. No abstract available.
1891. Atrial fibrillation amongst the Indo-Asian general practice population. The West Birmingham
Atrial Fibrillation Project.
Lip GY, Bawden L, Hodson R, Rutland E, Snatchfold J, Beevers DG.
Int J Cardiol. 1998 Jul 1;65(2):187-92.
1892. Regression of LVH or improved prognosis (or both): what is the question?
Lip GY, Lydakis C, Zarifis J, Messerli FH.
J Hum Hypertens. 1998 Jul;12(7):423-5. Review. No abstract available.
PMID:
1893. Endothelial integrity, soluble adhesion molecules and platelet markers in type 1 diabetes
mellitus.
Blann AD, Lip GY.
Diabet Med. 1998 Aug;15(8):634-42. Review.
1894. The endothelium in atherothrombotic disease: assessment of function, mechanisms and
clinical implications.
Blann AD, Lip GY.
184
Blood Coagul Fibrinolysis. 1998 Jun;9(4):297-306. Review.
.
1895. Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion:
implications for increased vascular risk.
Lip PL, Blann AD, Jones AF, Lip GY.
Eye (Lond). 1998;12 ( Pt 2):245-51.
1896. Digoxin revisited.
Li-Saw-Hee FL, Lip GY.
QJM. 1998 Apr;91(4):259-64. Review. No abstract available.
1897. Do we still need dipyridamole?
Gibbs CR, Lip GY.
Br J Clin Pharmacol. 1998 Apr;45(4):323-8. Review.
1898. Women's awareness of, and attitudes towards, hormone replacement therapy: ethnic
differences and effects of age and education.
Lydakis C, Kerr H, Hutchings K, Lip GY.
Int J Clin Pract. 1998 Jan-Feb;52(1):7-12.
1899. Up to date review of the secondary preventive measures for recurrent ischaemic stroke and
transient ischaemic episodes.
Gibbs CR, Li-Saw-Hee FL, Lip GY.
Scott Med J. 1998 Feb;43(1):6. No abstract available.
1900. Lipoprotein (a): more than just a bystander in the pathophysiology of hypertension?
Jones AF, Lip GY.
J Hum Hypertens. 1998 Feb;12(2):75-7. No abstract available.
1901. An unusual cause of palpitations requiring atrioventricular node ablation and pacemaker
therapy.
Lydakis C, Hollinrake K, Lip GY.
Blood Press. 1997 Nov;6(6):368-71.
1902. Hyperhomocysteinaemia: a cardiovascular risk factor needing a large intervention trial?
Blann AD, Lip GY.
Int J Cardiol. 1997 Dec 19;62(3):217-9. No abstract available.
.
1903. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and
transient cerebral ischemia: the West Birmingham Stroke Project.
Cook PJ, Honeybourne D, Lip GY, Beevers DG, Wise R, Davies P.
Stroke. 1998 Feb;29(2):404-10.
1904. Atrial fibrillation and the thyroid.
Wong PS, Hee FL, Lip GY.
Heart. 1997 Dec;78(6):623-4. No abstract available.
1905. 'Reverse dipping' on ambulatory blood pressure monitoring.
Lip GY, Beevers DG.
J Hum Hypertens. 1997 Dec;11(12):821-2. No abstract available.
185
1906. Platelets and hypertension: the pressure is on the clot.
Blann AD, Lip GY.
J Hum Hypertens. 1997 Dec;11(12):763-4. No abstract available.
1907. Chlamydia pneumoniae antibodies in severe essential hypertension.
Cook PJ, Lip GY, Davies P, Beevers DG, Wise R, Honeybourne D.
Hypertension. 1998 Feb;31(2):589-94.
1908. Malignant hypertension in young women is related to previous hypertension in pregnancy, not
oral contraception.
Lip GY, Beevers M, Beevers DG.
QJM. 1997 Sep;90(9):571-5.
1909. Microalbuminuria in hypertension: is it up to measure?
Lydakis C, Efstratopoulos A, Lip GY.
J Hum Hypertens. 1997 Nov;11(11):695-7. Review. No abstract available.
1910. Atrial fibrillation in hypertension: under recognised or over diagnosed?
Lip GY.
J Hum Hypertens. 1997 Nov;11(11):691-3. Review. No abstract available.
1911. Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to
ethnicity and left ventricular hypertrophy.
Lip GY, Blann AD, Jones AF, Lip PL, Beevers DG.
Am J Cardiol. 1997 Dec 15;80(12):1566-71.
1912. Thromboembolic risk and pacemakers.
Gibbs C, Blann AD, Lip GY.
Lancet. 1997 Dec 13;350(9093):1780-1. No abstract available.
1913. Does renal function improve after diagnosis of malignant phase hypertension?
Lip GY, Beevers M, Beevers DG.
J Hypertens. 1997 Nov;15(11):1309-15.
1914. Atrial fibrillation begets trouble.
Hee FL, Wong PS, Lip GY.
Heart. 1997 Oct;78(4):421. No abstract available.
1915. Fibromuscular dysplasia.
Felmeden D, Lip GY, Beevers DG.
J Hum Hypertens. 1997 Oct;11(10):687-8. No abstract available.
1916. Angiotensin-converting-enzyme inhibitors in early pregnancy.
Lip GY, Churchill D, Beevers M, Auckett A, Beevers DG.
Lancet. 1997 Nov 15;350(9089):1446-7. No abstract available.
1917. Evidence of platelet activation in hypertension.
Blann AD, Lip GY, Islim IF, Beevers DG.
J Hum Hypertens. 1997 Sep;11(9):607-9.
1918. Free radicals and antioxidants in cardiovascular disease.
186
Maxwell SR, Lip GY.
Br J Clin Pharmacol. 1997 Oct;44(4):307-17. Review.
1919. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial
function in women undergoing surgical menopause: implications for prevention of atherosclerosis.
Lip GY, Blann AD, Jones AF, Beevers DG.
Am Heart J. 1997 Oct;134(4):764-71.
1920. Coronary risk factors, endothelial function, and atherosclerosis: a review.
Blann AD, Lip GY.
Clin Cardiol. 1997 Oct;20(10):822, 824. No abstract available.
Hypothesis: is soluble P-selectin a new marker of platelet activation?
Blann AD, Lip GY.
Atherosclerosis. 1997 Feb 10;128(2):135-8. Review. No abstract available.
1921. The detection of endothelial dysfunction in patients with essential hypertension.
Li-Saw-Hee FL, Blann AD, Lip GY.
Int J Cardiol. 1997 Sep 19;61(2):171-4. No abstract available.
1922. Interpretation of IST and CAST stroke trials. International Stroke Trial. Chinese Acute Stroke
Trial.
Lip GY, Beevers DG.
Lancet. 1997 Aug 9;350(9075):442-3; author reply 443-4. No abstract available.
1923. Can we treat coronary artery disease with antibiotics?
Lip GY, Beevers DG.
Lancet. 1997 Aug 9;350(9075):378-9. No abstract available.
1924. Coarctation of aorta.
Katira R, Rathore VS, Lip GY, Singh SP.
J Hum Hypertens. 1997 Aug;11(8):537-8. No abstract available.
1925. Relation between endothelial-cell activation and infection, inflammation, and infarction.
Blann AD, Lip GY.
Lancet. 1997 Jul 26;350(9073):293-4. No abstract available.
1926. Can we treat hypertensive menopausal women with hormone replacement therapy?
Lip GY.
J Hum Hypertens. 1997 Jul;11(7):397-9. No abstract available.
1927. Exacerbation of atherosclerosis by hypertension: potential mechanisms and clinical
implications.
Lip GY.
Arch Intern Med. 1997 Jun 9;157(11):1265-6. No abstract available.
1928. Fundal changes in malignant hypertension.
Lip PL, Lip GY, Beevers DG.
J Hum Hypertens. 1997 Jun;11(6):395-6. No abstract available.
1929. Angiotensin II receptor antagonists, elite drugs (or not) for patients with heart failure or
hypertension?
Beevers DG, Lip GY.
J Hum Hypertens. 1997 Jun;11(6):329-30. No abstract available.
1930. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers.
Blann AD, Lip GY, Beevers DG, McCollum CN.
Thromb Haemost. 1997 Jun;77(6):1077-80.
1931. Does paroxysmal atrial fibrillation confer a paroxysmal thromboembolic risk?
Lip GY.
187
Lancet. 1997 May 31;349(9065):1565-6. No abstract available.
1932. Effect of atenolol on birth weight.
Lip GY, Beevers M, Churchill D, Shaffer LM, Beevers DG.
Am J Cardiol. 1997 May 15;79(10):1436-8.
1933. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation
Project.
Lip GY, Golding DJ, Nazir M, Beevers DG, Child DL, Fletcher RI.
Br J Gen Pract. 1997 May;47(418):285-9.
1934. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders?
Lip GY, Blann A.
Cardiovasc Res. 1997 May;34(2):255-65. Review.
1935. Hypercoagulability and haemodynamic abnormalities in atrial fibrillation.
Lip GY.
Heart. 1997 May;77(5):395-6. No abstract available.
1936. Hormone replacement therapy with conjugated estrogens and high blood pressure: response
to Dr. Jespersen.
Wong PS, Lip GY, Beevers DG.
Am J Hypertens. 1997 May;10(5 Pt 1):579. No abstract available.
1937. Plasma thrombomodulin in atherosclerosis and its risk factors.
Lip GY, Blann AD.
Am J Med. 1997 Apr;102(4):423-5. No abstract available.
1938. The left atrium in hypertension, an appendage often forgotten.
Lip GY.
J Hum Hypertens. 1997 Mar;11(3):145-7. Review. No abstract available.
1939. Acute admissions with atrial fibrillation in a British multiracial hospital population.
Zarifis J, Beevers G, Lip GY.
Br J Clin Pract. 1997 Mar;51(2):91-6.
1940. Percutaneous balloon valvuloplasty of stenosed mitral bioprosthesis.
Lip GY, Wasfi M, Halim M, Singh H.
Int J Cardiol. 1997 Mar;59(1):97-100. No abstract available.
1941. Hypothesis: is soluble P-selectin a new marker of platelet activation?
Blann AD, Lip GY.
Atherosclerosis. 1997 Feb 10;128(2):135-8. Review. No abstract available.
1942. Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic
options.
Maxwell SR, Lip GY.
Int J Cardiol. 1997 Jan 31;58(2):95-117. Review.
1943. Hypothesis: is soluble P-selectin a new marker of platelet activation?
Blann AD, Lip GY.
Atherosclerosis. 1997 Feb 10;128(2):135-8. Review. No abstract available.
1944. Doctors, nurses, pharmacists and patients--the Rational Evaluation and Choice in Hypertension
(REACH) survey of hypertension care delivery.
Lip GY, Beevers DG.
Blood Press Suppl. 1997;1:6-10.
1945. Ambulatory blood pressure monitoring in acute stroke. The West Birmingham Stroke Project.
Lip GY, Zarifis J, Farooqi IS, Page A, Sagar G, Beevers DG.
Stroke. 1997 Jan;28(1):31-5.
188
1946.Intracardiac thrombus formation in cardiac impairment: the role of anticoagulant therapy.
Lip GY.
Postgrad Med J. 1996 Dec;72(854):731-8. Review.
1947. Ambulatory blood pressure monitoring in patients with single chamber ventricular pacemakers
(VVI pacing mode)
Lip GY, Adeotoye OA, Zarifis J, Singh SP, Watson RD, Beevers DG.
Am J Hypertens. 1996 Dec;9(12 Pt 1):1240-1. No abstract available.
1948.Thrombogenesis in mitral regurgitation and aortic stenosis.
Lip GY, Rumley A, Dunn FG, Lowe GD.
Angiology. 1996 Dec;47(12):1117-25.
1949. Commentary: do angiotensin II receptor antagonists regress left ventricular hypertrophy?
Lip GY.
J Hum Hypertens. 1996 Nov;10(11):725-7. Review. No abstract available.
1950. Ethnic differences in pre-admission levels of physical activity in patients admitted with
myocardial infarction.
Lip GY, Cader MZ, Lee F, Munir SM, Beevers DG.
Int J Cardiol. 1996 Oct 11;56(2):169-75.
1951. Does non-malignant essential hypertension cause renal damage? A clinician's view.
Beevers DG, Lip GY.
J Hum Hypertens. 1996 Oct;10(10):695-9. Review.
1952. Antithrombotic therapy for non-rheumatic atrial fibrillation.
Lip GY.
QJM. 1996 Oct;89(10):799-800; author reply 801-2. No abstract available.
1953. Adverse change in low-density lipoprotein subfractions profile with oestrogen-only hormone
replacement therapy.
Rajman I, Lip GY, Cramb R, Maxwell SR, Zarifis J, Beevers DG, Kendall MJ.
QJM. 1996 Oct;89(10):771-8.
1954. Infectious agents and atherosclerotic vascular disease.
Cook PJ, Lip GY.
QJM. 1996 Oct;89(10):727-35. Review.
1955. Intravenous amiodarone in treatment of recent-onset atrial fibrillation.
Lip GY.
J Am Coll Cardiol. 1996 Oct;28(4):1080-2. No abstract available.
1956. Sarcoid heart disease: a rare cause of chest pain and malignant cardiac arrhythmia in a young
Asian man. A case report.
Lip GY, Gupta J, Gill JS, Singh SP.
Angiology. 1996 Sep;47(9):905-10.
1957.Ambulatory blood pressure monitoring in atrial fibrillation.
Lip GY, Zarifis J, Beevers M, Beevers DG.
Am J Cardiol. 1996 Aug 1;78(3):350-3.
189
1958. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet
activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin.
Lip GY, Lip PL, Zarifis J, Watson RD, Bareford D, Lowe GD, Beevers DG.
Circulation. 1996 Aug 1;94(3):425-31.
1959. Epidemiology of aortic aneurysm and peripheral vascular disease may show ethnic differences.
Lip GY, Beevers DG.
BMJ. 1996 Jul 20;313(7050):173. No abstract available.
1960. Design and baseline characteristics of a hypertension intervention program in a South African
village: patient awareness and understanding of their disease process are important.
Lip GY, Hayter J, Makwana NV.
J Hum Hypertens. 1996 Jul;10(7):499. No abstract available.
1961. Case report: fatal verapamil overdosage despite intensive therapy and use of high dose
intravenous calcium.
Li Saw Hee FL, Lip GY.
J Hum Hypertens. 1996 Jul;10(7):495-6.
Malignant hypertension in association with primary aldosteronism.
Zarifis J, Lip GY, Leatherdale B, Beevers G.
Blood Press. 1996 Jul;5(4):250-4.
1962. Editorial: combination therapy for systemic hypertension (15 September 1995).
Lip GY, Roberts R, Gates S, Beevers M, Orsborn RC, Beevers DG.
Am J Cardiol. 1996 Jul 1;78(1):129-30. No abstract available.
1963. Antagonism to calcium antagonists.
Lip GY, Beevers DG.
Lancet. 1996 Jun 22;347(9017):1761. No abstract available.
1964. Value of ECGs in identifying heart failure due to left ventricular systolic dysfunction. ECGs are
valuable in hospital as well as general practice.
Lip GY, Beevers G, Zarifis J, Singh SP.
BMJ. 1996 May 4;312(7039):1161. No abstract available.
1965. Warfarin and aspirin as thromboprophylaxis in atrial fibrillation.
Lip GY, Lowe GD.
Br J Clin Pharmacol. 1996 May;41(5):369-79. Review.
1966. Are calcium antagonists safe in hypertension?
Lip GY, Beevers DG.
Postgrad Med J. 1996 Apr;72(846):193-4. No abstract available.
1967. Fibrinogen and fibrin D-dimer levels in paroxysmal atrial fibrillation: evidence for intermediate
elevated levels of intravascular thrombogenesis.
Lip GY, Lowe GD, Rumley A, Dunn FG.
Am Heart J. 1996 Apr;131(4):724-30.
1968. Ethnic differences in public health awareness, health perceptions and physical exercise:
implications for heart disease prevention.
190
Lip GY, Luscombe C, McCarry M, Malik I, Beevers G.
Ethn Health. 1996 Mar;1(1):47-53.
1969. Percutaneous balloon dilatation of aortic coarctation in adults.
deGiovanni JV, Lip GY, Osman K, Mohan M, Islim IF, Gupta J, Watson RD, Singh SP.
Am J Cardiol. 1996 Feb 15;77(5):435-9. No abstract available.
1970. Hypertensive retinopathy: a review of existing classification systems and a suggestion for a
simplified grading system.
Dodson PM, Lip GY, Eames SM, Gibson JM, Beevers DG.
J Hum Hypertens. 1996 Feb;10(2):93-8. Review.
1971. Physician variation in the management of patients with atrial fibrillation.
Lip GY, Zarifis J, Watson RD, Beevers DG.
Heart. 1996 Feb;75(2):200-5.
1972. ABC of atrial fibrillation. Atrial fibrillation in general and hospital practice.
Lip GY, Beevers DG, Coope JR.
BMJ. 1996 Jan 20;312(7024):175-8. Review. No abstract available.
1973. ABC of atrial fibrillation. Cardioversion of atrial fibrillation.
Lip GY, Watson RD, Singh SP.
BMJ. 1996 Jan 13;312(7023):112-5. Review. No abstract available.
1974. Quality of service provision for anticoagulation in atrial fibrillation. Many patients are
ineligible.
Lip GY.
BMJ. 1996 Jan 6;312(7022):51. No abstract available.
1975. ABC of atrial fibrillation. Antithrombotic treatment for atrial fibrillation.
Lip GY, Lowe GD.
BMJ. 1996 Jan 6;312(7022):45-9. Review.
1976. Does acetaminophen damage the heart?
Lip GY, Vale JA.
J Toxicol Clin Toxicol. 1996;34(2):145-7. Review. No abstract available.
1977. ABC of atrial fibrillation. Drugs for atrial fibrillation.
Lip GY, Watson RD, Singh SP.
BMJ. 1995 Dec 16;311(7020):1631-4. Review. No abstract available.
1978. ABC of atrial fibrillation. Investigation and non-drug management of atrial fibrillation.
Lip GY, Singh SP, Watson RD.
BMJ. 1995 Dec 9;311(7019):1562-5. Review. No abstract available.
1979. ABC of atrial fibrillation. Differential diagnosis of atrial fibrillation.
Lip GY, Watson RD.
BMJ. 1995 Dec 2;311(7018):1495-8. Review. No abstract available.
1980.Effects of discontinuing hormone replacement therapy in patients with uncontrolled
hypertension.
Zarifis J, Lip GY, Beevers DG.
191
Am J Hypertens. 1995 Dec;8(12 Pt 1):1241-2. No abstract available.
1981. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension:
implications for atherogenesis? A preliminary report.
Lip GY, Blann AD, Zarifis J, Beevers M, Lip PL, Beevers DG.
J Hypertens. 1995 Dec;13(12 Pt 2):1674-8.
1982. von Willebrand factor and its relevance to cardiovascular disorders.
Lip GY, Blann AD.
Br Heart J. 1995 Dec;74(6):580-3. Review.
1983. The coagulation system is activated in idiopathic cardiomyopathy.
Lip GY.
J Am Coll Cardiol. 1995 Dec;26(7):1757-8. No abstract available.
1984. ABC of atrial fibrillation. Aetiology, pathophysiology, and clinical features.
Lip GY, Beevers DG, Singh SP, Watson RD.
BMJ. 1995 Nov 25;311(7017):1425-8. Review. No abstract available.
1985. ABC of atrial fibrillation. History, epidemiology, and importance of atrial fibrillation.
Lip GY, Beevers DG.
BMJ. 1995 Nov 18;311(7016):1361-3. Review. No abstract available. Erratum in: BMJ 1996 Jan
6;312(7022):49.
1986. Does atrial fibrillation confer a hypercoagulable state?
Lip GY.
Lancet. 1995 Nov 18;346(8986):1313-4. Review. No abstract available.
1987. Chlamydia pneumoniae and acute arterial thrombotic disease.
Cook PJ, Honeybourne D, Lip GY, Beevers DG, Wise R.
Circulation. 1995 Nov 15;92(10):3148-9. No abstract available.
.
1988. Severe hypertension with lone bilateral papilloedema: a variant of malignant hypertension.
Lip GY, Beevers M, Dodson PM, Beevers DG.
Blood Press. 1995 Nov;4(6):339-42.
1989. Hormone replacement therapy and cardiovascular risk: the cardiovascular physicians'
viewpoint.
Lip GY, Beevers G, Zarifis J.
J Intern Med. 1995 Nov;238(5):389-99. Review.
1990. Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation: effects of cardioversion
to sinus rhythm.
Lip GY, Rumley A, Dunn FG, Lowe GD.
Int J Cardiol. 1995 Oct;51(3):245-51.
1991. Poisoning with anti-hypertensive drugs: methyldopa and clonidine.
Zarifis J, Lip GY, Ferner RE.
J Hum Hypertens. 1995 Oct;9(10):787-90. Review.
1992. Poisoning with anti-hypertensive drugs: angiotensin converting enzyme inhibitors.
192
Lip GY, Ferner RE.
J Hum Hypertens. 1995 Sep;9(9):711-5. Review.
1993. Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor, and fibrin D-dimer in
left ventricular dysfunction secondary to coronary artery disease with and without aneurysms.
Lip GY, Lowe GD, Metcalfe MJ, Rumley A, Dunn FG.
Am J Cardiol. 1995 Sep 1;76(7):453-8.
1994. Malignant hypertension in the elderly.
Lip GY, Beevers M, Potter JF, Beevers DG.
QJM. 1995 Sep;88(9):641-7.
1995. Fibrin D-dimer: a useful clinical marker of thrombogenesis?
Lip GY, Lowe GD.
Clin Sci (Lond). 1995 Sep;89(3):205-14. Review. No abstract available.
1996. Complications and survival of 315 patients with malignant-phase hypertension.
Lip GY, Beevers M, Beevers DG.
J Hypertens. 1995 Aug;13(8):915-24.
1997. Recurrent myocardial infarction with angina and normal coronary arteries.
Lip GY, Gupta J, Khan MM, Singh SP.
Int J Cardiol. 1995 Aug;51(1):65-71.
1998. Lipoprotein (a) and vascular disease: thrombogenesis and atherogenesis.
Lip GY, Jones AF.
QJM. 1995 Aug;88(8):529-39. Review.
1999 Cardioversion of atrial fibrillation.
Lip GY.
Postgrad Med J. 1995 Aug;71(838):457-65. Review.
2000. Open access echocardiography. Hospital patients need open access echocardiography.
Zarifis J, Beevers DG, Lip GY.
BMJ. 1995 Jul 29;311(7000):326. No abstract available.
2001.Coagulation activity is increased in the left atrium of patients with mitral stenosis.
Lip GY, Zarifis J.
J Am Coll Cardiol. 1995 Jul;26(1):302-3. No abstract available.
2002. Poisoning with anti-hypertensive drugs: alpha-adrenoceptor antagonists.
Lip GY, Ferner RE.
J Hum Hypertens. 1995 Jul;9(7):523-6. Review.
2003. Is diastolic dysfunction associated with thrombogenesis? A study of circulating markers of a
prothrombotic state in patients with coronary artery disease.
Lip GY, Lowe GD, Metcalfe MJ, Rumley A, Dunn FG.
Int J Cardiol. 1995 Jun 2;50(1):31-42. Erratum in: Int J Cardiol 1995 Sep;51(2):205.
2004. Nitrates and severe aortic stenosis.
Lip GY, Singh SP.
193
Br Heart J. 1995 Jun;73(6):586. No abstract available.
2005. Insulin resistance, high prevalence of diabetes, and cardiovascular risk in immigrant Asians.
Farooqi I, Beevers G, Lip GY.
Br Heart J. 1995 Jun;73(6):584. No abstract available.
2006. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin
treatment.
Lip GY, Lowe GD, Rumley A, Dunn FG.
Br Heart J. 1995 Jun;73(6):527-33.
2007. Poisoning with antihypertensive drugs: diuretics and potassium supplements.
Lip GY, Ferner RE.
J Hum Hypertens. 1995 May;9(5):295-301. Review.
2008. Poisoning with anti-hypertensive drugs: beta-adrenoceptor blocker drugs.
Lip GY, Ferner RE.
J Hum Hypertens. 1995 Apr;9(4):213-21. Review.
2009. Hormone replacement therapy and cardiovascular risk.
Lip GY.
Lancet. 1995 Mar 4;345(8949):585-6. No abstract available.
2010. Dietary fat purchasing habits in whites, blacks and Asian peoples in England--implications for
heart disease prevention.
Lip GY, Malik I, Luscombe C, McCarry M, Beevers G.
Int J Cardiol. 1995 Mar 3;48(3):287-93.
2011. Poisoning with anti-hypertensive drugs: calcium antagonists.
Lip GY, Ferner RE.
J Hum Hypertens. 1995 Mar;9(3):155-61. Review.
2012. Fibrinogen and cardiovascular disorders.
Lip GY.
QJM. 1995 Mar;88(3):155-65. Review.
2013. Alcohol, hypertension, coronary disease and stroke.
Lip GY, Beevers DG.
Clin Exp Pharmacol Physiol. 1995 Mar;22(3):189-94. Review.
2014. Health promotion in general practice. Focus on modification of risk factors and patients'
perception of lifestyle.
Lip GY, Balasubramaniam R, Maurice A, Beevers G.
BMJ. 1995 Feb 25;310(6978):533. No abstract available.
2015. Hormone replacement therapy is not a risk for venous thrombosis.
Lip GY, Beevers M, Zarifis J, Beevers G.
Scott Med J. 1995 Feb;40(1):30. No abstract available.
2016. Seasonal variations in fatal pulmonary embolism. Malignant phase hypertension does not vary
by season.
194
Lip GY, Beevers M, Zarifis J, Beevers G.
BMJ. 1995 Jan 14;310(6972):129-30. No abstract available.
2017. Duration of cough following cessation of ACE inhibitor therapy.
Lip GY, Zarifis J, Beevers M, Beevers DG.
Am J Hypertens. 1995 Jan;8(1):98. No abstract available.
2018. Factors influencing coronary artery bypass graft patency.
Metcalfe MJ, Lip GY, Dargie HJ.
Cardiovasc Surg. 1994 Dec;2(6):679-85. Review.
2019. Evidence of inadequate investigation and treatment of patients with heart failure.
Zarifis J, Beevers DG, Lip GY.
Br Heart J. 1994 Dec;72(6):593. No abstract available.
2020. Sudden infant death syndrome among Asians in Britain.
Farooqi I, Lip GY, Beevers DG.
BMJ. 1994 Nov 5;309(6963):1232. No abstract available.
2021. The failure of malignant hypertension to decline: a survey of 24 years' experience in a
multiracial population in England.
Lip GY, Beevers M, Beevers G.
J Hypertens. 1994 Nov;12(11):1297-305.
2022. A comparative study of risk factors for acute myocardial infarction amongst men of Indo-origin
in Trinidad and the UK.
Farooqi IS, Dar S, Farooqi S, Beevers DG, Lip GY.
Int J Cardiol. 1994 Nov;47(1):45-9.
2023. Have we identified the factors affecting prognosis following coronary artery bypass surgery?
Lip GY, Metcalfe MJ.
Br J Clin Pract. 1994 Nov-Dec;48(6):317-22. Review.
2024. Abnormalities of rheology and coagulation in hypertension.
Lip GY, Beevers DG.
J Hum Hypertens. 1994 Sep;8(9):693-702. Review.
2025.
Hormone replacement therapy. Attitudes of women should be considered.
Air A, Lip GY, Beevers DG.
BMJ. 1994 Jul 16;309(6948):192. No abstract available.
2026. Overdose of diltiazem.
Lip GY, Ferner RE.
BMJ. 1994 Jul 16;309(6948):193. No abstract available.
2027.Hormone replacement therapy and blood pressure in hypertensive women.
Lip GY, Beevers M, Churchill D, Beevers DG.
J Hum Hypertens. 1994 Jul;8(7):491-4.
195
2028. Acute myocardial infarction: a rare complication of the thrombotic tendency in nephrotic
syndrome.
Lip GY, Tean KN, Dunn FG.
Br J Clin Pract. 1994 Jul-Aug;48(4):218-20.
2029. Cardioversion of atrial fibrillation: how important is a long arrhythmia duration?
Lip GY, Hogg KJ.
Scott Med J. 1994 Jun;39(3):78-9.
2030. Hypertension and the heart.
Lip GY, Gammage MD, Beevers DG.
Br Med Bull. 1994 Apr;50(2):299-321. Review.
2031. Bed sharing and smoking in the sudden infant death syndrome.
Farooqi IS, Lip GY, Beevers DG.
BMJ. 1994 Jan 15;308(6922):204-5. No abstract available.
2032. Treatment of atrial fibrillation in a district general hospital.
Lip GY, Tean KN, Dunn FG.
Br Heart J. 1994 Jan;71(1):92-5.
2033. Anticoagulation in patients with atrial fibrillation. No consensus among doctors.
Lip GY.
BMJ. 1993 Dec 4;307(6917):1493. No abstract available.
2034. An audit of emergency echocardiography in a district general hospital.
Balogun MO, Omotoso AB, Bell E, Lip GY, Gemmill JD, Hogg KJ, Dunn FG.
Int J Cardiol. 1993 Aug;41(1):65-8.
2035. Management of paroxysmal atrial fibrillation.
Lip GY, Metcalfe MJ, Rae AP.
Q J Med. 1993 Aug;86(8):467-72. Review.
2036. Unilateral pulmonary artery agenesis: a rare cause of haemoptysis and pleuritic chest pain.
Lip GY, Dunn FG.
Int J Cardiol. 1993 Jul 1;40(2):121-5.
2037. Diagnosis and treatment of digoxin toxicity.
Lip GY, Metcalfe MJ, Dunn FG.
Postgrad Med J. 1993 May;69(811):337-9. Review. No abstract available.
2038. The acute porphyrias.
Lip GY, McColl KE, Moore MR.
Br J Clin Pract. 1993 Jan-Feb;47(1):38-43. Review.
2039. Sudden death in epilepsy: an avoidable outcome?
Lip GY, Brodie MJ.
J R Soc Med. 1992 Oct;85(10):609-11.
2040. Misuse of calcium antagonists after myocardial infarction.
Metcalfe MJ, Lip GY, Dunn FG.
196
Lancet. 1992 Aug 29;340(8818):545. No abstract available.
2041. Adrenaline in allergic emergencies.
Lip GY, Metcalfe MJ.
BMJ. 1992 Aug 8;305(6849):366-7. No abstract available.
2042. Adrenaline in allergic emergencies.
Lip GY, Metcalfe MJ.
BMJ. 1992 May 30;304(6839):1443. No abstract available.
2043. A presentation of anaplastic carcinoma of the thyroid with symptomatic intra-abdominal
metastases.
Lip GY, Jaap AJ, McCruden DC.
Br J Clin Pract. 1992 Summer;46(2):143-4.
2044. Renal artery embolism: a rare cause of renal colic.
Lip GY, Bramwell SP, Paterson PJ.
J R Soc Med. 1991 Dec;84(12):748-9. No abstract available. Erratum in: J R Soc Med 1992
Jul;85(7):433.
2045. Smoking and recurrent attacks of acute intermittent porphyria.
Lip GY, McColl KE, Goldberg A, Moore MR.
BMJ. 1991 Mar 2;302(6775):507. No abstract available.
197